Clinical trial NCT03086343
Conditions: Rheumatoid Arthritis (RA)
Keywords: Musculoskeletal Disease Arthritis Joint Disease Anti-inflammatory agents Antirheumatic agents
Sponsor: AbbVie
Start date: 2017-05-09; Completion date: 2023-06-06
Enrollment: 657 participants; Allocation: RANDOMIZED; Intervention model: PARALLEL

Brief summary:
The study objective of Period 1 was to compare the safety and efficacy of upadacitinib 15 mg once daily (QD) to abatacept on a background of conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) for the treatment of signs and symptoms of rheumatoid arthritis (RA) in biologic disease-modifying antirheumatic drug (bDMARD)-inadequate response or bDMARD-intolerant participants with moderately to severely active RA. The study objective of Period 2 is to evaluate the long-term safety, tolerability, and efficacy of upadacitinib 15 mg QD in participants with RA who had completed Period 1.

Detailed description:
This is a Phase 3 multicenter study with 2 periods. Period 1 was a 24-week, randomized, double-blind, parallel-group, active-controlled period designed to compare the safety and efficacy of upadacitinib 15 mg and abatacept for the treatment of signs and symptoms of participants with moderately to severely active RA who had an inadequate response to or intolerance to bDMARD therapy and were currently on a stable dose of csDMARD(s) and had never received abatacept. Period 2 is an open-label, long-term extension study to evaluate the long-term safety, tolerability, and efficacy of upadacitinib 15 mg once a day (QD) in participants with RA who had completed Period 1.

Arms: arm 1: Period 1: 500 mg (for body weight \<60 kg); 750 mg (for body weight 60-100 kg); and 1000 mg (for body weight \>100 kg) IV infusion at Baseline, Week 2, Week 4, Week 8, Week 12, Week 16 and Week 20. Period 2: open label upadacitinib 15 mg QD for 192 weeks. arm 2: Period 1: One 15 mg upadacitinib oral tablet QD for 24 weeks. Period 2: open label upadacitinib 15 mg QD for 192 weeks. arm 3: Period 1: One upadacitinib 30 mg oral tablet QD for 24 weeks. Period 2: open label upadacitinib 30 mg (reduced to 15 mg per Amendment 5) QD for 192 weeks. arm 4: Period 1: 500 mg (for body weight \<60 kg); 750 mg (for body weight 60-100 kg); and 1000 mg (for body weight \>100 kg) IV infusion at Baseline, Week 2, Week 4, Week 8, Week 12, Week 16 and Week 20. Period 2: open label upadacitinib 30 mg (reduced to 15 mg per Amendment 5) QD for 192 weeks.
Interventions: intervention 1: Abatacept intervention 2: Placebo for abatacept (0.9% Sodium Chloride Injection or Solution for Infusion) intervention 3: Upadacitinib intervention 4: Placebo for upadacitinib
Intervention descriptions: intervention 1: IV infusion intervention 2: IV infusion intervention 3: 15 mg extended release tablet intervention 4: Film-coated tablet

Protocol documents:
Prot_004.pdf: 
Upadacitinib
M15-925 Protocol Amendment 6
EudraCT 2016-000933-37
1
1.0
Title Page
Clinical Study Protocol M15-925
A Phase 3, Randomized, Active-Controlled, 
Double-Blind Study Comparing Upadacitinib 
(ABT-494) to Abatacept in Subjects with Moderately 
to Severely Active Rheumatoid Arthritis with 
Inadequate Response or Intolerance to Biologic 
DMARDs (bDMARDs) on Stable Conventional 
Synthetic Disease Modifying Anti-Rheumatic Drugs 
(csDMARDs)
Incorporating Administrative Changes 1, 2, 3, 4 and 
Amendments 1, 2, 3, 3.01, 4, 5, and 6
AbbVie Investigational
  Product:
Upadacitinib
Date:
04 December 2020
Development Phase:
3
Study Design:
A 24-week randomized, double-blind, parallel-group, 
active-controlled treatment period followed by an open label 
long-term extension period
EudraCT Number:
2016-000933-37
Investigators:
Multicenter Trial (Investigator information is on file at 
AbbVie)
Sponsor:
AbbVie*
1 North Waukegan Road
North Chicago, IL  60064
abbvie 
NCT03086343




Upadacitinib
M15-925 Protocol Amendment 6
EudraCT 2016-000933-37
3
1.1
Protocol Amendment:  Summary of Changes
Previous Protocol Versions 
Protocol 
Date 
Original
27 June 2016
Amendment 1
31 August 2016
Amendment 2
25 January 2017
Amendment 3
28 March 2017
Administrative Change 1
31 May 2017
Amendment 4 (non-VHP countries)
12 October 2017
Amendment 3.01 (VHP countries)
19 January 2018
Administrative Change 2
19 March 2018
Administrative Change 3
10 January 2019
Administrative Change 4
14 March 2019
Amendment 5
12 March 2020
The purpose of this amendment is to:
●
Apply administrative changes throughout protocol.
Rationale:  Revised text to improve consistency and readability, and/or 
provide clarification.
●
Update Section 1.2, Synopsis
Rationale: Revised to be consistent with Amendment 6 revisions.
●
Update Section 1.3, List of Abbreviations
Rationale:  Updated to include new terms, Direct-to Patient (DTP) and 
Coronavirus Disease – 19 (COVID-19)
●
Update Section 3.2, Benefits and Risks
Rationale:  Revised to include the evaluation of the benefit and risk to subjects 
participating in the study relative to COVID-19.
●
Update Section 5.1, Overall Study Design and Plan:  Description
Rationale:  Added provisions for virtual or alternative locations for study 
visits in the event of a pandemic situation like COVID 19 or any state of 
abbvie 


Upadacitinib
M15-925 Protocol Amendment 6
EudraCT 2016-000933-37
4
emergency (e.g., natural disaster, conflict/combat) to ensure the safety of 
subjects and site staff, while maintaining the integrity of the study.
●
Update Section 5.2.3.2, Prohibited Therapy
Rationale: Revised Table 1 to update the list of examples of commonly used 
strong cytochrome 3A inducers.  
●
Update Section 5.3.1, Efficacy and Safety Measurements Assessed and Flow 
Chart
Rationale: Added clarifications on study activities that can be performed by 
phone/video conference or at local clinic/hospital/laboratory or through the 
optional home healthcare service in the event study visits are impacted by any 
state of emergency or pandemic situation like COVID-19 to ensure subjects'
safety and study continuation, as permitted by IRB/IEC.
●
Update Section 5.3.1.1, Study Procedures
○
Outcomes and Questionnaires
Specified that questionnaires are not eligible for completion by virtual 
interview in the event that an onsite visit cannot be performed due to a 
pandemic or state of emergency and will be completed at the next earliest 
feasible visit.
○
TB (tuberculosis) Testing/TB Prophylaxis and Chest X-rays (CXR)
Specified that chest X-rays can be performed at the next earliest feasible 
visit unless the Investigator has determined that a CXR is required to 
ensure that it is safe to continue study drug administration (e.g., subjects 
with seroconversion on an annual TB test). In this case, the Investigator 
should contact the AbbVie Therapeutic Area Medical Director (TA MD) to 
determine if the subject may continue on study drug and CXR should be 
performed as soon as restrictions allow at the study site or local 
hospital/facility. 
○
12-Lead Electrocardiogram (ECG)
Specified that the 12-Lead ECG can be performed at the next earliest 
feasible visit unless the Investigator has determined that an ECG is 
required to ensure that it is safe to continue study drug administration. In 
abbvie 


Upadacitinib
M15-925 Protocol Amendment 6
EudraCT 2016-000933-37
5
this case, the ECG should be performed as soon as restrictions allow at the 
study site or local hospital/facility.
○
Physical Exam
Added provision allowing the complete physical exam to be performed at 
the next earliest feasible visit.
○
Physician Global Assessment of Disease Activity Visual Analog Scale 
(VAS)
Specified that Physician Global Assessment of Disease Activity is not 
eligible for completion by virtual interview in the event that the subject 
cannot perform an onsite visit due to a pandemic or state of emergency and 
will be completed by the physician at the next earliest feasible subject's 
visit.
○
Tender Joint Count (TJC) and Swollen Joint Count (SJC) Assessments
Added provision allowing the TJC and SJC to be performed at the next 
earliest feasible visit by the independent joint assessor, if possible.
○
Pregnancy Test
Added provision allowing the urine pregnancy test to be performed at a 
local laboratory or at home. Removed the reference to contraception 
requirements for male subjects with a partner of childbearing potential for 
consistency with Section 5.2.4 "Contraception Recommendations."
○
Clinical Laboratory Tests
Added provision allowing the laboratory testing at an alternate local 
facility, in the event that a state of emergency or pandemic prevents the 
subject from performing the central laboratory tests and added the 
requirements to allow the study drug dispensation when laboratory tests are 
performed at a local laboratory.
○
Study Drug Dispensing, Dosing and Compliance
Added provision allowing Direct-to-Patient (DTP) shipment of study drug 
and study ancillaries due to state of emergency or pandemic situations.
○
New Section: Optional Home Healthcare Service Due to State of 
Emergency or Pandemic Situation like COVID-19
abbvie 


Upadacitinib
M15-925 Protocol Amendment 6
EudraCT 2016-000933-37
6
○
Added home healthcare visits as an option in case a study visit on site 
cannot be performed due to state of emergency or pandemic-related 
reasons. 
Rationale: To modify study visits and protocol-specific procedures impacted 
by the COVID-19 or any pandemic/state of emergency as necessary, to ensure 
the safety of subjects/site staff and study continuation including alternative 
locations for data collection, as permitted by IRB/IEC.
●
Update Section 5.4.1, Discontinuation of Individual Subjects
Rationale: Revised to clarify that subjects will have to discontinue study drug 
treatment immediately if they develop a gastrointestinal perforation with the 
exception of appendicitis or mechanical injury to be consistent with the 
Section 6.1.7 "Toxicity Management." Clarified that the state of emergency 
and pandemic-related restrictions may allow mitigation strategies to ensure 
subject safety and continuity of care as an alternative to study 
discontinuation/study drug discontinuation and that the AbbVie TA MD should 
be contacted before discontinuing a subject to ensure all acceptable mitigation 
steps have been explored.
●
Update Section 5.5.1, Treatments Administered
Rationale: Added specifications in order to provide the study drug through 
DTP shipment in the event pandemic situation like COVID-19 or state of 
emergency prevent the study drug dispensation to the subject onsite, if 
permitted by local regulations.
●
Update Section 6.1.1.3, Adverse Events of Special Interest
Rationale:  Clarified and updated the list of the adverse events of special 
interest according to the revised sponsor guidelines.
●
Update Section 6.1.4, Adverse Event Collection Period
Rationale: Added supplemental COVID-19 case report forms for missed or 
virtual visits, study drug interruptions or discontinuations, or adverse events 
and instructions to collect safety information related to COVID-19.
●
Update Section 6.1.5, Serious Adverse Event Reporting
Rationale: Updated telephone number to contact the Immunology Safety 
Team for safety concerns.
abbvie 


Upadacitinib
M15-925 Protocol Amendment 6
EudraCT 2016-000933-37
7
●
Update Section 6.1.6, Pregnancy
Rationale: Updated text to define Pregnancy reporting timeline as 24 hours 
from site staff awareness according to the sponsor requirements.
●
Update Section 6.1.7, Toxicity Management
Rationale: Added guidance for investigators on the management of subjects
with suspected or confirmed COVID-19 infection during the study. Clarified 
that the Investigator should also contact the AbbVie TA MD for confirmed ALT 
or AST > 8 × ULN in addition to the immediate study drug interruption. 
●
Update Section 6.2.2, Reporting
Rationale: Updated text to define Product Complaint reporting timeline as 
24 hours from site staff awareness according to the sponsor requirements.
●
Update Section 7.0, Protocol Deviations
Rationale: Added language to include provision for modifications due to 
protocol deviations that may be due to pandemic like COVID-19 or state of 
emergency situations in order to guide investigators to notify IRB/EC when 
deviations occur.
●
Update Section 9.2, Ethical Conduct of the Study
Rationale: Inclusion of information regarding COVID-19 or any 
pandemic/state of emergency-related acceptable protocol modifications.
●
Update Section 9.3, Subject Information and Consent
Rationale:  Added provision that in the event of a pandemic situation or state 
of emergency, verbal consent may be obtained in addition to the study 
informed consent in accordance with local regulations.
●
Update Section 10.1, Source Documents
Rationale: Noted that remote monitoring may be employed as needed, due to 
COVID-19 or any pandemic/state of emergency.
●
Update Appendix A, Responsibilities of the Clinical Investigator
Rationale:  Clarified that clinical research studies sponsored by AbbVie are 
subject to the International Council for Harmonisation of Technical 
Requirements for Pharmaceuticals for Human Use (ICH) Good Clinical 
Practices (GCP).
abbvie 


Upadacitinib
M15-925 Protocol Amendment 6
EudraCT 2016-000933-37
8
●
Update Appendix B, List of Protocol Signatories
abbvie 


Upadacitinib
M15-925 Protocol Amendment 6
EudraCT 2016-000933-37
9
1.2
Synopsis
AbbVie Inc.
Protocol Number:  M15-925
Name of Study Drug:  Upadacitinib
Phase of Development:  3
Name of Active Ingredient:  Upadacitinib
Date of Protocol Synopsis:  04 December 2020
Protocol Title:  A Phase 3, Randomized, Active-Controlled, Double-Blind Study Comparing 
Upadacitinib (ABT-494) to Abatacept in Subjects with Moderately to Severely Active Rheumatoid 
Arthritis with Inadequate Response or Intolerance to Biologic DMARDs (bDMARDs) on Stable 
Conventional Synthetic Disease Modifying Anti-Rheumatic Drugs (csDMARDs)
Objectives:  
Period 1
To compare the safety and efficacy of upadacitinib 15 mg once daily (QD) versus abatacept intravenous 
(IV) for the treatment of signs and symptoms of rheumatoid arthritis (RA) in bDMARD-inadequate 
response (bDMARD-IR) or bDMARD-intolerant subjects with moderately to severely active RA.
Period 2
To evaluate the long-term safety, tolerability, and efficacy of upadacitinib 15 mg QD in subjects with 
RA who have completed Period 1.
Investigators:  Multicenter
Study Sites:  Approximately 200
Study Population:  
Adult female and male subjects who are at least 18 years of age with a diagnosis of RA for ≥ 3 months 
who also fulfill the 2010 ACR/European League Against Rheumatism (EULAR) classification criteria 
for RA.  Subjects who have been treated ≥ 3 months prior to the screening visit with ≥ 1 bDMARD 
therapy and ≥ 3 months with csDMARDs and have never received abatacept, but continue to exhibit 
active RA or had to discontinue due to intolerability or toxicity, irrespective of treatment duration may 
be enrolled.  Eligible study subjects must have ≥ 6 swollen joints (based on 66 joint counts) and ≥ 6 
tender joints (based on 68 joint counts) at Screening and Baseline Visits, and high-sensitivity C-reactive 
protein (hsCRP) ≥ 3 mg/L (central lab) at Screening.  Subjects must have been on a stable dose of 
csDMARD therapy (restricted to methotrexate [MTX], chloroquine, hydroxychloroquine, sulfasalazine, 
or leflunomide) for ≥ 4 weeks prior to the first dose of study drug.
Number of Subjects to be Enrolled:  Approximately 550
Methodology:  
This is a Phase 3, multicenter study that includes two periods.  Period 1 is a 24-week randomized, 
double-blind, parallel-group, active-controlled treatment period designed to compare the safety and 
efficacy of upadacitinib 15 mg QD versus abatacept IV for the treatment of signs and symptoms of 
subjects with moderately to severely active RA who have an inadequate response to or intolerance to 
bDMARD therapies other than abatacept and are currently on a stable dose of csDMARDs.  Period 2 is 
an open-label extension to evaluate the long-term safety, tolerability, and efficacy of upadacitinib 15 mg 
QD in subjects with RA who have completed Period 1.
abbvie 


Upadacitinib
M15-925 Protocol Amendment 6
EudraCT 2016-000933-37
10
Methodology (Continued):
The study duration will include a 35-day maximum screening period; a 24-week randomized, double 
blind, parallel-group, active controlled treatment period, with 30-day and 70-day follow-ups (Period 1); 
an open-label long term extension period (up to 5 years) with a 30-day follow-up call or site visit 
(Period 2);
Subjects who meet eligibility criteria will be randomized in a 1:1 ratio to one of two treatment groups:

Group 1:  upadacitinib 15 mg QD, N = 275 (Period 1) 

Group 2:  Abatacept IV at Day 1, Weeks 2, 4, 8, 12, 16 and 20 (< 60 kg:  500 mg; 60 – 100 kg:  
750 mg; > 100 kg:  1,000 mg, N = 275 (Period 1)
NOTE:  In Period 1, subjects randomized to Group 1 under Amendment 3 received 30 mg QD dose.  
This study began enrolling under Amendment 3.  Starting with Amendment 4 or 3.01, subjects 
randomized to Group 1 will receive 15 mg QD dose.  In Period 2, subjects who enrolled under 
Amendment 3, including subjects randomized to both Group 1 and Group 2, received open-label 
upadacitinib 30 mg QD.  Subjects who enroll under Amendment 4 or 3.01 or later will receive open-
label upadacitinib 15 mg QD.   
Starting with Amendment 5, all subjects will receive open label upadacitinib 15 mg QD dose, including 
those currently on upadacitinib 30 mg QD.
Randomization will be stratified by number of prior bDMARD use (stratum 1:  failed 1 or 2 biologics of 
the same class; stratum 2:  failed ≥ 3 biologics of the same class or failed biologics of multiple classes) 
AND geographic region.  Once 20% of total subjects have been randomized who have not completed 
> 3 months of methotrexate, further screening of such methotrexate inexperienced subjects may be 
suspended.
Subjects must have been on stable csDMARD(s) treatment for ≥ 4 weeks prior to the first dose of study 
drug and must remain on a stable dose until Week 12; the csDMARD dose may be decreased only for 
safety reasons.  Starting at Week 12 (after Week 12 assessments have been performed), initiation of or 
change in corticosteroids, non-steroidal anti-inflammatory drugs (NSAIDs), acetaminophen, or adding or 
increasing doses for up to 2 csDMARDs (concomitant use of up to 2 csDMARDs except the 
combination of MTX and leflunomide) is allowed as per local label.
Rescue therapy will be offered to subjects who meet the following criteria:

Starting at Week 12, subjects who do not achieve ≥ 20% improvement in both TJC and SJC at 
two consecutive visits will be rescued with optimizing (initiate or increase) background RA 
medications:  NSAIDs, corticosteroids, low-potency analgesics, acetaminophen or adding or 
increasing doses in up to 2 csDMARDs (concomitant use of up to 2 csDMARDs except the 
combination of MTX and leflunomide) and, if necessary, a burst of systemic corticosteroids 
(prednisone equivalent ≤ 0.5 mg/kg/day for 3 consecutive days), intra-articular, intramuscular, 
intravenous, trigger point or tender point, intra-bursa, and intra-tendon sheath injections of 
corticosteroids, dosage and frequency per standard of care, are allowed.
Subjects who complete the Week 24 visit (end of Period 1) will enter the open-label long term extension 
portion of the study, Period 2 (192 weeks).  Subjects who are assigned to upadacitinib treatment group in 
Period 1 will continue to receive upadacitinib 15 mg QD per original randomization assignment.  
Subjects who are assigned to abatacept IV in Period 1 will be switched to receive upadacitinib 15 mg 
QD.
An unblinded analysis will be conducted after all subjects have completed Period 1 (Week 24).  Period 2 
is open-label.
abbvie 


Upadacitinib
M15-925 Protocol Amendment 6
EudraCT 2016-000933-37
11
Methodology (Continued):
Study visits may be impacted by state of emergency or pandemic like COVID-19. If visits cannot be 
conducted onsite due to travel restrictions or other pandemic or state of emergency related reasons, 
virtual visits, visits at alternative locations, or changes in the visit frequency and timing of study 
procedures, among others may be performed. Every effort should be made to ensure the safety of 
subjects and site staff, while maintaining the integrity of the study.
Diagnosis and Main Criteria for Inclusion/Exclusion:  
Main Inclusion:  
1.
Adult male or female, at least 18 years old.
2.
Diagnosis of RA for ≥ 3 months who also fulfill the 2010 ACR/EULAR classification criteria for 
RA.
3.
Subjects have been treated for ≥ 3 months with ≥ 1 bDMARD therapy, but continue to exhibit active 
RA or had to discontinue due to intolerability or toxicity, irrespective of treatment duration AND 
have never received abatacept prior to first dose of study drug.
4.
Subjects have been receiving csDMARD therapy ≥ 3 months and on a stable dose for ≥ 4 weeks 
prior to the first dose of study drug:

The following csDMARDs are allowed (stable dose for ≥ 4 weeks prior to the first dose of 
study drug):  oral or parenteral MTX (7.5 to 25 mg/week), sulfasalazine (≤ 3000 mg/day), 
hydroxychloroquine (≤ 400 mg/day), chloroquine (≤ 250 mg/day), and leflunomide
(≤20 mg/day).

A combination of up to two background csDMARDs is allowed EXCEPT the combination of 
MTX and leflunomide.
5.
Subject meets both of the following minimum disease activity criteria:
a.
≥ 6 swollen joints (based on 66 joint counts) and ≥ 6 tender joints (based on 68 joint counts) at 
Screening and Baseline Visits; and
b.
hsCRP ≥ 3 mg/L (central lab) at Screening Visit.
Main Exclusion:  
1.
Prior exposure to any Janus kinase (JAK) inhibitor (including but not limited to upadacitinib, 
tofacitinib, baricitinib, and filgotinib). 
2.
Prior exposure to abatacept.  
3.
History of any arthritis with onset prior to age 17 years or current diagnosis of inflammatory joint 
disease other than RA (including but not limited to gout, systemic lupus erythematosus, psoriatic 
arthritis, axial spondyloarthritis including ankylosing spondylitis and non-radiographic axial 
spondyloarthritis, reactive arthritis, overlap connective tissue diseases, scleroderma, polymyositis, 
dermatomyositis, fibromyalgia [currently with active symptoms], or any arthritis with onset prior to 
age 17 years).  Current diagnosis of secondary Sjogren's Syndrome is permitted.
4.
Laboratory values meeting the following criteria within the Screening period prior to the first dose 
of study drug:  serum aspartate transaminase > 2 × upper limit of normal (ULN); serum alanine 
transaminase > 2 × ULN; estimated glomerular filtration rate by simplified 4-variable Modification 
of Diet in Renal Disease formula < 40 mL/min/1.73 m2; total white blood cell count < 2,500/µL; 
absolute neutrophil count < 1,500/µL; platelet count < 100,000/µL; absolute lymphocyte count 
< 800/µL; and hemoglobin < 10 g/dL.
abbvie 


Upadacitinib
M15-925 Protocol Amendment 6
EudraCT 2016-000933-37
12
Investigational Product:
Upadacitinib
Dose:
15 mg QD
Mode of Administration:
Oral
Reference Therapy:
Period 1 only:  Placebo for upadacitinib 15 mg QD
Dose:
N/A
Mode of Administration:
Oral
Reference Therapy:
Period 1 only:  abatacept
Dose:
< 60 kg:  500 mg; 60 – 100 kg:  750 mg; > 100 kg:  1,000 mg
Mode of Administration:
IV:  Day 1, Weeks 2, 4, 8, 12, 16, and 20
Reference Therapy:
Period 1 only:  Placebo for abatacept (0.9% Sodium Chloride Injection 
or Solution for Infusion)
Dose:
N/A
Mode of Administration:
IV:  Day 1, Weeks 2, 4, 8, 12, 16, and 20
Duration of Treatment:  216 weeks (Period 1:  24 weeks; Period 2:  192 weeks)
Criteria for Evaluation:
Efficacy:
Period 1:

The primary endpoint is the change from baseline in DAS28 (CRP) at Week 12 (non-
inferiority)
Key secondary endpoints are:

Change from baseline in DAS28 (CRP) at Week 12 (superiority)

Proportion of subjects achieving Clinical Remission (CR) at Week 12 (superiority)

CR is defined as Disease Activity Score (DAS)28 (C-reactive protein [CRP]) < 2.6.
Additional endpoints are:

Proportion of subjects achieving low disease activity (LDA) at Week 12 (non-inferiority).
LDA is defined as Disease Activity Score (DAS)28 (C-reactive protein [CRP]) ≤ 3.2.

ACR20/50/70 response rates at all visits;
ACR20 response rate will be determined based on 20% or greater improvement in Tender Joint 
Count (TJC) and Swollen Joint Count (SJC) and ≥ 3 of the 5 measures of Patient's Assessment 
of Pain (Visual Analog Scale [VAS]), Patient's Global Assessment of Disease Activity (VAS), 
Physician's Global Assessment of Disease Activity (VAS), Health Assessment Questionnaire
Disability Index (HAQ-DI), or hsCRP.

Change from baseline in individual components of ACR response at all visits;

Change from baseline in DAS28(CRP) and DAS28 (erythrocyte sedimentation rate [ESR]) at 
all visits;

Change from baseline in SF 36 at Weeks 4, 12 and 24;

Change from baseline in morning stiffness at all visits;
abbvie 


Upadacitinib
M15-925 Protocol Amendment 6
EudraCT 2016-000933-37
13
Criteria for Evaluation (Continued):
Efficacy (Continued):
Period 1 (Continued):

Proportion of subjects achieving LDA or CR based on DAS28 (CRP), DAS28 (ESR), 
Simplified Disease Activity Index (SDAI), and Clinical Disease Activity Index (CDAI) criteria 
(see below) at all visits;

Change from baseline in EQ-5D-5L at Weeks 4, 12 and 24;

Change from baseline in Functional Assessment of Chronic Illness Therapy – fatigue (FACIT-
F) at Weeks 4, 8, 12, 16 and 24;

Change from baseline in Work Productivity and Activity Impairment (WPAI) at Weeks 4, 8, 12 
and 24;

Change from baseline in CDAI and SDAI at all visits;

Proportion of subjects achieving MCID in change from baseline in HAQ-DI (defined as change 
from baseline in HAQ-DI ≤ –0.3) at all visits;

ACR/EULAR Boolean remission at all visits.

Systemic corticosteroid dose (including cumulative dose at serial time points in Period 1)
DAS28 (CRP) and DAS28 (ESR)
SDAI
CDAI
LDA
≤ 3.2
≤ 11.0
≤ 10
CR
< 2.6
≤ 3.3
≤ 2.8
Period 2:
Assessments to evaluate efficacy of treatment in Period 2 will be analyzed for the following measures at 
Weeks 36, 48, and every 12 weeks thereafter through Week 216/PD:

Change from baseline in DAS28 (CRP);

Proportion of subjects achieving CR based on DAS28 (CRP), DAS28 (ESR), SDAI, and CDAI 
criteria (as defined for Period 1);

Proportion of subjects achieving LDA based on DAS28 (CRP), DAS28 (ESR), SDAI, and 
CDAI criteria (as defined for Period 1);

ACR20/50/70 response rates;

Change from baseline in individual ACR components;

Change from baseline in DAS28 (ESR);

Change from baseline in HAQ-DI at all visits;

Change from baseline in SF 36 at all visits;

Change from baseline in morning stiffness;

Concomitant corticosteroid use.

ACR/EULAR Boolean remission
abbvie 


Upadacitinib
M15-925 Protocol Amendment 6
EudraCT 2016-000933-37
14
Criteria for Evaluation (Continued):
Efficacy (Continued):
Period 2 (Continued):
Assessments to evaluate efficacy of treatment in Period 2 will be analyzed for the following measures at 
Week 48 only:

Change from baseline in EQ-5D-5L;

Change from baseline in FACIT-F;

Change from baseline in WPAI RA.
Pharmacokinetic (Period 1 Only):
Blood samples for assay of upadacitinib and possibly other concomitant medications in plasma will be 
collected at Weeks 2, 4, 8, 12, 16, 20 and 24/Premature Discontinuation.
Exploratory Research Variables and Validation Studies (Optional) (Period 1 Only):
Prognostic and predictive biomarker signatures may be evaluated.  Samples for pharmacogenetic, 
epigenetic, transcriptomic, and proteomic and targeted protein investigations will be collected at various 
time points.  Assessments will include but may not be limited to nucleic acids, proteins, metabolites, or 
lipids.
Safety:
Safety evaluations include adverse event (AE) monitoring, physical examinations, vital sign 
measurements, electrocardiogram (ECG), and clinical laboratory testing (hematology, chemistry, and 
urinalysis) as a measure of safety and tolerability for the entire study duration.
Statistical Methods:
Efficacy:
All efficacy analyses will be carried out using the Full Analysis Set population, which includes all 
randomized subjects who receive at least one dose of study drug.
Period 1 Efficacy:
Analysis of the Primary and Key Secondary Endpoints:
The primary efficacy endpoint will be assessed via non-inferiority comparison of upadacitinib to 
abatacept in change from baseline in DAS28 (CRP) at Week 12 using the 95% confidence interval (CI) 
of treatment difference against the pre-specified non-inferiority margin.
The two key secondary efficacy endpoints involve the superiority comparisons of upadacitinib to 
abatacept on change from baseline in DAS28(CRP) at Week 12 as well as the proportion of subjects 
achieving CR based on DAS28 (CRP) at Week 12.  The overall type I error rate of the primary and key 
secondary endpoints will be strongly controlled via sequential testing.
For the binary endpoint of CR, frequencies and percentages will be reported for each treatment group, 
and comparison of upadacitinib to abatacept will be conducted using the Cochran-Mantel-Haenszel test 
adjusting for main stratification factors.  Non-responder imputation will serve as the primary analysis 
approach for missing data handling.
For the continuous endpoint of change from baseline in DAS28 (CRP), the mean, standard deviation, 
median, and range will be reported for each treatment group.  Comparison between upadacitinib and 
abatacept will be carried out using the analysis of covariance model with treatment group as the fixed 
factor, and the corresponding baseline value and the main stratification factors as the covariates.
Multiple imputations will serve as the primary analysis approach for missing data handling.
abbvie 


Upadacitinib
M15-925 Protocol Amendment 6
EudraCT 2016-000933-37
15
Statistical Methods (Continued):
Long-Term Efficacy for Period 1 and Period 2 Combined:
Long-term efficacy by time point will be summarized using descriptive statistics.
Pharmacokinetic:
A non-linear mixed-effects modeling approach will be used to estimate the population central values and 
the empirical Bayesian estimates of the individual values of upadacitinib oral clearance (CL/F) and 
volume of distribution (V/F).  Additional parameters may be estimated if useful in the interpretation of 
the data.
Safety:
Safety analyses will be carried out using the Safety Analysis Set, which includes all subjects who receive 
at least one dose of study drug.  Analyses will be conducted for Period 1 alone, as well as for Period 1 
and Period 2 combined.  Safety will be assessed by AEs, physical examination, laboratory assessments, 
ECG, and vital signs.  Frequency tables and lists of subjects with treatment-emergent AEs by preferred 
term as in the Medical Dictionary for Regulatory Activities dictionary, by system organ class, by 
severity, and by relationship to the study drug as assessed by the Investigator will be provided.  The 
changes from baseline in vital signs, physical examination results, and clinical laboratory values will be 
analyzed in a descriptive manner.  Shift of laboratory values from baseline to defined time points will be 
tabulated.
abbvie 


Upadacitinib
M15-925 Protocol Amendment 6
EudraCT 2016-000933-37
16
1.3
List of Abbreviations and Definition of Terms
Abbreviations
ACR
American College of Rheumatology
AE
adverse event
ALC
absolute lymphocyte count
ALT
alanine transaminase
ANC
absolute neutrophil count
ANCOVA
analysis of covariance
anti-CCP
anti-cyclic citrullinated peptide
AST
aspartate transaminase
AUC
area under the curve
BCG
Bacille Calmette-Guérin
bDMARD
biologic disease-modifying anti-rheumatic drug
bDMARD-IR
biologic disease-modifying anti-rheumatic drug-inadequate response 
BID
twice daily (Latin:  bis in die) 
BUN
blood urea nitrogen
BP
blood pressure
CBC
complete blood count 
CDAI
clinical disease activity index
CI
confidence interval
CL/F
apparent clearance
COVID-19
Coronavirus Disease – 2019
CPK
creatine phosphokinase
CR
clinical remission 
CRF
case report form
CRP
C-reactive protein
csDMARD
conventional synthetic disease-modifying anti-rheumatic drug
CSR
clinical study report
CXR
chest x-ray
CYP
Cytochrome P450
DAS
disease activity score
DMARD
disease-modifying anti-rheumatic drug
DMC
Data Monitoring Committee
abbvie 


Upadacitinib
M15-925 Protocol Amendment 6
EudraCT 2016-000933-37
17
DNA
Deoxyribonucleic acid
DTP
Direct-to-Patient
ECG
electrocardiogram
eCRF
electronic case report form
EDC
electronic data capture
ePRO
electronic patient-reported outcome
EQ-5D-5L
EuroQoL-5D-5L
ESR
erythrocyte sedimentation rate
EULAR
European League Against Rheumatism
FACIT-F
Functional Assessment of Chronic Illness Therapy – Fatigue
FAS
full analysis set
FSH
follicle stimulating hormone
GCP
Good Clinical Practice
GDH-PQQ
glucose dehydrogenase pyrroloquinolinequinone
GFR
glomerular filtration rate
HAQ-DI
Health Assessment Questionnaire – Disability Index
HBc Ab/anti-HBc
Hepatitis B core antibody 
HBs Ab/anti-HBs
Hepatitis B surface antibody
HBs Ag
Hepatitis B surface antigen
HBV
hepatitis B virus
HCV
hepatitis C virus
HCV Ab
Hepatitis C virus antibody
HDL-C
high-density lipoprotein cholesterol
HIV
human immunodeficiency virus
hsCRP
high-sensitivity C-reactive protein
ICH
International Conference On Harmonization
IEC
independent ethics committee
IGRA
interferon-gamma release assay
IMP
investigational medicinal product
INR
international normalized ratio
IR
inadequate response
IRB
institutional review board
IRT
interactive response technology
IUD
intrauterine device
abbvie 


Upadacitinib
M15-925 Protocol Amendment 6
EudraCT 2016-000933-37
18
IUS
intrauterine hormone-releasing system
IV
intravenous
JAK
Janus kinase
LDA
low disease activity
LDL-C
low-density lipoprotein cholesterol
MACE
major adverse cardiovascular event
MCID
Minimal clinically important difference
MDRD
modification of diet in renal disease
MedDRA
Medical Dictionary for Regulatory Activities
MI
multiple imputation
MTX
methotrexate
MTX-IR
methotrexate inadequate responder
NA
no assessment 
NK
natural killer
NMSC
non-melanoma skin cancer
NRI
non-responder imputation
NRS
numerical rating scale
NSAID
non-steroidal anti-inflammatory drug
OC
observed cases
OLE
open-label extension
PCR
polymerase chain reaction
PD
premature discontinuation
PhGA
Physician's Global Assessment of Disease Activity
PK
pharmacokinetic
PPD
purified protein derivative
PRN
as needed (Latin:  pro re nata)
PRO
patient-reported outcome
PT
preferred term
PtGA
Patient's Global Assessment of Disease Activity
QD
once daily (Latin:  quaque die) 
QTcF
QT interval corrected for heart rate using Fridericia's correction formula
RA
rheumatoid arthritis
RAVE®
EDC system from Medidata
RBC
red blood cell
abbvie 


Upadacitinib
M15-925 Protocol Amendment 6
EudraCT 2016-000933-37
19
RCT
randomized controlled trial
RNA
Ribonucleic acid
SAE
serious adverse event
SAP
statistical analysis plan
SDAI
simplified disease activity index
SF-36
Short Form-36
SJC
swollen joint count
SOC
system organ class
SUSAR
suspected unexpected serious adverse reaction
T2T
treat-to-target
TB
tuberculosis
TEAE
treatment-emergent adverse event
TJC
tender joint count
TNF
tumor necrosis factor
TNF-IR
anti-tumor necrosis factor inadequate responder
Tyk2
Tyrosine kinase 2
ULN
upper limit of normal
V/F
apparent volume of distribution
VAS
visual analog scale
VTE
venous thromboembolic events
WBC
white blood cell
abbvie 


Upadacitinib
M15-925 Protocol Amendment 6
EudraCT 2016-000933-37
20
2.0
Table of Contents
1.0
Title Page..................................................................................1
1.1
Protocol Amendment:  Summary of Changes ...........................................3
1.2
Synopsis .....................................................................................................9
1.3
List of Abbreviations and Definition of Terms........................................16
2.0
Table of Contents...................................................................20
3.0
Introduction ...........................................................................26
3.1
Differences Statement..............................................................................28
3.2
Benefits and Risks....................................................................................28
4.0
Study Objectives....................................................................32
5.0
Investigational Plan...............................................................33
5.1
Overall Study Design and Plan:  Description ..........................................33
5.2
Selection of Study Population..................................................................40
5.2.1
Inclusion Criteria .....................................................................................40
5.2.2
Exclusion Criteria ....................................................................................43
5.2.3
Prior, Concomitant, and Prohibited Therapy...........................................46
5.2.3.1
Permitted Background RA Therapy.........................................................47
5.2.3.2
Prohibited Therapy...................................................................................48
5.2.3.3
Rescue Therapy........................................................................................52
5.2.4
Contraception Recommendations ............................................................53
5.3
Efficacy, Pharmacokinetic, Exploratory Research and Validation 
Studies, and Safety Assessments/Variables.............................................56
5.3.1
Efficacy and Safety Measurements Assessed and Flow Chart ................56
5.3.1.1
Study Procedures .....................................................................................58
5.3.1.2
Collection and Handling of Optional Samples for Exploratory 
Research and Validation Studies .............................................................80
5.3.1.2.1
Optional Samples for Exploratory Research and Validation 
Studies......................................................................................................80
5.3.2
Drug Concentration Measurements .........................................................81
5.3.2.1
Collection of Samples for Analysis .........................................................81
5.3.2.2
Measurement Methods.............................................................................82
5.3.3
Efficacy Variables....................................................................................82
abbvie 


Upadacitinib
M15-925 Protocol Amendment 6
EudraCT 2016-000933-37
21
5.3.3.1
Period 1 Variables....................................................................................82
5.3.3.1.1
Primary Variable......................................................................................82
5.3.3.1.2
Key Secondary Variables.........................................................................83
5.3.3.1.3
Additional Variables ................................................................................83
5.3.3.2
Period 2 Variables....................................................................................84
5.3.4
Safety Variables.......................................................................................85
5.3.5
Pharmacokinetic Variables ......................................................................85
5.3.6
Exploratory Research Variables and Validation Studies.........................86
5.3.6.1
Exploratory Research Variables and Validation Studies.........................86
5.4
Removal of Subjects from Therapy or Assessment.................................86
5.4.1
Discontinuation of Individual Subjects....................................................86
5.4.2
Discontinuation of Entire Study...............................................................89
5.5
Treatments................................................................................................89
5.5.1
Treatments Administered.........................................................................89
5.5.2
Identity of Investigational Product...........................................................91
5.5.2.1
Packaging and Labeling...........................................................................92
5.5.2.2
Storage and Disposition of Study Drugs..................................................93
5.5.3
Method of Assigning Subjects to Treatment Groups...............................93
5.5.4
Selection and Timing of Dose for Each Subject......................................94
5.5.5
Blinding....................................................................................................95
5.5.5.1
Blinding of Investigational Product.........................................................95
5.5.5.2
Blinding of Data for Independent Data Monitoring Committee 
(IDMC) ....................................................................................................96
5.5.6
Treatment Compliance.............................................................................97
5.5.7
Drug Accountability.................................................................................97
5.6
Discussion and Justification of Study Design..........................................98
5.6.1
Discussion of Study Design and Choice of Control Groups....................98
5.6.2
Appropriateness of Measurements...........................................................99
5.6.3
Suitability of Subject Population ...........................................................100
5.6.4
Selection of Doses in the Study .............................................................100
6.0
Complaints ...........................................................................101
6.1
Medical Complaints...............................................................................101
6.1.1
Definitions..............................................................................................101
abbvie 


Upadacitinib
M15-925 Protocol Amendment 6
EudraCT 2016-000933-37
22
6.1.1.1
Adverse Event........................................................................................101
6.1.1.2
Serious Adverse Events .........................................................................102
6.1.1.3
Adverse Events of Special Interest ........................................................103
6.1.2
Adverse Event Severity..........................................................................104
6.1.3
Relationship to Study Drug....................................................................104
6.1.4
Adverse Event Collection Period...........................................................105
6.1.5
Adverse Event Reporting.......................................................................107
6.1.6
Pregnancy...............................................................................................108
6.1.7
Toxicity Management ............................................................................109
6.1.8
Data Monitoring Committee..................................................................115
6.1.9
Cardiovascular Adjudication Committee...............................................115
6.2
Product Complaint .................................................................................115
6.2.1
Definition ...............................................................................................115
6.2.2
Reporting................................................................................................116
7.0
Protocol Deviations..............................................................116
8.0
Statistical Methods and Determination of Sample 
Size ........................................................................................117
8.1
Statistical and Analytical Plans..............................................................117
8.1.1
Analysis Populations..............................................................................118
8.1.1.1
Full Analysis Set....................................................................................118
8.1.1.2
Per Protocol Analysis Set.......................................................................118
8.1.1.3
Safety Analysis Set ................................................................................118
8.1.2
Subject Accountability, Disposition and Study Drug Exposure............119
8.1.2.1
Subject Accountability...........................................................................119
8.1.2.2
Subject Disposition ................................................................................119
8.1.2.3
Study Drug Exposure.............................................................................119
8.1.3
Analysis of Demographic and Baseline Characteristics ........................120
8.1.4
Efficacy Analyses ..................................................................................120
8.1.4.1
Efficacy Analysis for Period 1...............................................................120
8.1.4.1.1
Primary Efficacy Variable .....................................................................120
8.1.4.1.2
Key Secondary Efficacy Variables ........................................................121
8.1.4.1.3
Other Efficacy Variables........................................................................122
8.1.4.1.4
Multiplicity Control for Primary and Key Secondary Endpoints ..........122
abbvie 


Upadacitinib
M15-925 Protocol Amendment 6
EudraCT 2016-000933-37
23
8.1.4.1.5
Imputation Methods...............................................................................122
8.1.4.2
Long-Term Efficacy Analysis for Period 1 and Period 2 
Combined...............................................................................................123
8.1.5
Safety Analyses......................................................................................123
8.1.5.1
General Considerations..........................................................................123
8.1.5.2
Analysis of Adverse Events...................................................................124
8.1.5.2.1
Treatment-Emergent Adverse Events (TEAE) ......................................124
8.1.5.2.2
Serious Adverse Events and Death........................................................125
8.1.5.3
Analysis of Laboratory, Vital Sign, and ECG Data...............................125
8.1.6
Pharmacokinetic and Exposure-Response Analyses .............................126
8.1.7
Statistical Analysis of Biomarker Data..................................................128
8.2
Determination of Sample Size ...............................................................128
8.3
Randomization Methods ........................................................................129
9.0
Ethics.....................................................................................129
9.1
Independent Ethics Committee (IEC) or Institutional Review 
Board (IRB) ...........................................................................................129
9.2
Ethical Conduct of the Study .................................................................130
9.3
Subject Information and Consent...........................................................131
10.0
Source Documents and Case Report Form 
Completion ...........................................................................132
10.1
Source Documents .................................................................................132
10.2
Case Report Forms.................................................................................132
11.0
Data Quality Assurance ......................................................135
12.0
Use of Information...............................................................136
13.0
Completion of the Study .....................................................136
14.0
Investigator's Agreement....................................................138
15.0
Reference List ......................................................................139
List of Tables
Table 1.
Examples of Commonly Used Strong CYP3A Inhibitors and 
Inducers....................................................................................................50
Table 2.
Clinical Laboratory Tests.........................................................................74
abbvie 


Upadacitinib
M15-925 Protocol Amendment 6
EudraCT 2016-000933-37
24
Table 3.
Identity of Investigational Product...........................................................91
Table 4.
Specific Toxicity Management Guidelines for Abnormal 
Laboratory Values..................................................................................112
List of Figures
Figure 1.
Period 1 Study Design .............................................................................35
Figure 2.
Period 2 Study Design .............................................................................36
Figure 3.
Criteria for HBV DNA PCR Qualitative Testing ....................................76
Figure 4.
Adverse Event Collection ......................................................................105
List of Appendices
Appendix A.
Responsibilities of the Clinical Investigator..........................................142
Appendix B.
List of Protocol Signatories....................................................................144
Appendix C.
Local Requirements ...............................................................................145
Appendix D.
Study Activities (Period 1).....................................................................151
Appendix E.
Study Activities – Optional Samples for Exploratory Research 
and Validation Studies (Period 1 Only).................................................156
Appendix F.
Study Activities (Period 2).....................................................................157
Appendix G.
Physician's Global Assessment of Disease Activity Example...............160
Appendix H.
Joint Evaluation Worksheet Example....................................................161
Appendix I.
Latent TB Risk Assessment Form Example ..........................................163
Appendix J.
Patient's Global Assessment of Disease Activity Example ...................164
Appendix K.
Patient's Assessment of Pain Example...................................................165
Appendix L.
Health Assessment Questionnaire (HAQ-DI) Example.........................166
Appendix M.
Patient's Assessment of Severity and Duration of Morning 
Stiffness Example ..................................................................................169
Appendix N.
EuroQoL-5D-5L Example .....................................................................170
Appendix O.
Short Form-36 (SF-36™) Health Status Survey Questionnaire 
Example .................................................................................................173
Appendix P.
Functional Assessment of Chronic Illness Therapy – Fatigue 
(FACIT-F) Scale Example.....................................................................179
abbvie 


Upadacitinib
M15-925 Protocol Amendment 6
EudraCT 2016-000933-37
25
Appendix Q.
Work Productivity and Activity Impairment Questionnaire:  
Rheumatoid arthritis V2.0 (WPAI:RA) .................................................180
Appendix R.
Rheumatology Common Toxicity Criteria v.2.0 Example ....................183
abbvie 


Upadacitinib
M15-925 Protocol Amendment 6
EudraCT 2016-000933-37
26
3.0
Introduction
Rheumatoid Arthritis
Rheumatoid arthritis (RA) is a chronic systemic inflammatory disease of unknown 
etiology.  The hallmark feature of RA is an inflammatory process manifested by persistent 
symmetric polyarthritis of synovial joints which can ultimately lead to bone erosions,
deformity, and disability.  Left untreated, or inadequately treated, progressive functional 
impairment with increasing disability occurs leading to a reduction in quality of life.  The 
prevalence of RA in the general population is approximately 1%, and increases with age 
in both genders, with women being more prone to developing RA than men.  Early 
therapy with disease-modifying anti-rheumatic drugs (DMARDs) is the standard of care, 
including conventional synthetic DMARDs (csDMARDs) (e.g., methotrexate [MTX], 
sulfasalazine, hydroxychloroquine, and leflunomide), and biologic DMARDs 
(bDMARDs) (e.g., anti-tumor necrosis factor [TNF] and non-anti-TNF biologics).
The European League Against Rheumatism (EULAR) recommends a Treat-to-Target 
(T2T) approach to initiate therapy immediately after diagnosis of RA with a goal of 
achieving clinical remission (CR) or low disease activity (LDA), as these are associated 
with improved long-term outcomes.1-3  Also, in line with recent advances in early 
diagnosis, new classification criteria have been developed.  The 2010 American College 
of Rheumatology (ACR)/EULAR classification criteria redefined the paradigm of RA by 
focusing on features at earlier stages of disease that are associated with persistent and/or 
erosive disease, rather than defining the disease by its late-stage features.4
JAK Inhibitor
Evidence suggests that inhibition of Janus kinase (JAK)-mediated pathways is a 
promising approach for the treatment of patients with this chronic disease.5  AbbVie is 
developing a small molecule inhibitor of JAK, upadacitinib, that may address the current 
needs.
abbvie 


Upadacitinib
M15-925 Protocol Amendment 6
EudraCT 2016-000933-37
27
The JAK family is composed of 4 family members:  JAK1, 2, 3, and Tyrosine kinase 2 
(Tyk2).  These cytoplasmic tyrosine kinases are associated with membrane cytokine 
receptors such as common gamma-chain receptors and the glycoprotein 130 
transmembrane proteins.6  Activation of JAK pathways initiates expression of survival 
factors, cytokines, chemokines, and other molecules that facilitate leukocyte cellular 
trafficking and cell proliferation which contribute to inflammatory and autoimmune 
disorders.
Hence, the JAK family has evoked considerable interest in the area of inflammatory 
diseases leading to the development of various JAK inhibitors with different selectivity 
profiles against JAK1, JAK2, JAK3, and Tyk2 which have demonstrated efficacy in 
individuals with RA.7-11  Tofacitinib, the first in this class, has been approved in the 
United States and in other countries for treating moderately to severely active RA 
patients.  Although tofacitinib, a non-selective JAK inhibitor, improves the clinical signs 
and symptoms, and inhibits structural progression in RA patients, questions regarding the 
safety profile remain, including serious infections, herpes zoster reactivation, 
malignancies, and hematologic adverse events (AEs).
The second generation of JAK inhibitors, with different selectivity profile s against JAK1, 
JAK2, JAK3, and Tyk2, are in development.5  Upadacitinib is a novel selective JAK1 
inhibitor being developed for the treatment of adult patients with moderately to severely 
active RA.  In an in vitro setting, upadacitinib potently inhibits JAK1 activity, but to a 
lesser degree, inhibits the other isoforms, JAK2 and JAK3.  The enhanced selectivity of 
upadacitinib against JAK1 may offer an improved benefit-risk profile in patients with RA.  
The clinical hypothesis is that upadacitinib should be effective in decreasing joint 
inflammation and damage associated with RA by interfering with JAK1-mediated 
signaling pathways (i.e., interleukin-6) without causing excessive anemia due to its 
reduced activity against JAK2 (IC50 120 nM), which is essential for erythropoietin 
signaling.  Upadacitinib is also less potent against JAK3 (IC50 2.3 µM), an important 
component of lymphocyte activation and function.  As such, treatment with upadacitinib, 
a selective JAK1 inhibitor with reduced JAK3 inhibition, could result in a decreased risk 
abbvie 


Upadacitinib
M15-925 Protocol Amendment 6
EudraCT 2016-000933-37
28
for infection (including viral reactivation) and/or malignancy compared to a pan JAK 
inhibitor or less selective JAK inhibitors.
In vitro studies suggest that upadacitinib is not an inhibitor of cytochrome P450 (CYP) 
1A2, 2B6, 2C8, 2C9, 2C19, 2D6, or 3A4 at concentrations exceeding those relevant 
clinically.  Upadacitinib increased mRNA expression for CYP3A4 and CYP2B6 in vitro 
in a concentration-dependent manner.  However, physiologically-based pharmacokinetic 
modeling suggests that upadacitinib does not affect plasma concentrations of concomitant 
medications that are substrates for CYP3A or CYP2B6 at the relevant clinical doses.
Among subjects with laboratory evidence of systemic inflammation (as evidenced by 
high-sensitivity C-reactive protein [hsCRP] > upper limit of normal [ULN]), treatment 
with lower doses of upadacitinib (3 mg twice daily (BID) and 6 mg BID) was associated 
with improvements in mean hemoglobin relative to placebo.  At higher doses, there was a 
reduction in mean hemoglobin; however, the mean hemoglobin levels remained within 
normal range throughout the treatment period.
3.1
Differences Statement
Study M15-925 differs from other upadacitinib studies as it is the first study to evaluate 
the safety and efficacy of upadacitinib vs. abatacept in subjects with inadequate response 
to or intolerance to bDMARD treatment.
3.2
Benefits and Risks
Despite major progress in the treatment of RA, there still remains a large unmet medical 
need, as only a small percentage of RA patients reach or maintain a status of LDA or CR 
over time and some patients need to discontinue due to safety or tolerability issues.12,13  
Novel therapies are therefore needed to complement the available interventions to address 
the unmet need.12-14
The dose of upadacitinib selected for the Study M15-925 (once-daily formulation 15 mg 
QD) was chosen based on an optimal benefit to risk profile from the first two Phase 3 
abbvie 


Upadacitinib
M15-925 Protocol Amendment 6
EudraCT 2016-000933-37
29
studies from the RA program:  Study M13-549 (csDMARD-IR) and Study M13-542 
(bDMARD-IR).  The data from these studies showed that both the 15 mg and 30 mg QD 
doses achieved superior responses to placebo for all primary and ranked secondary 
endpoints at Week 12 with a safety profile consistent with the known profile from 
Phase 2b studies (Studies M13-537 [MTX-IR:  methotrexate inadequate responder] and 
M13-550 [TNF IR:  anti-tumor necrosis factor inadequate responder]).  
Benefits
Efficacy Results from Phase 2 Studies with Upadacitinib
Data on the benefit of treatment with upadacitinib are available from Phase 2.  The 
Phase 2 program for upadacitinib consisted of 2 randomized controlled trials (RCTs), both 
on stable background MTX therapy, in subjects with moderately to severely active RA 
and one open-label extension (OLE) study (Study M13-538; NCT02049138) for those 
subjects who had completed either one of the RCTs.  Study M13-550 (NCT01960855) 
enrolled subjects who had an inadequate response to anti-TNF therapy and 
Study M13-537 (NCT02066389) enrolled subjects who had shown an inadequate 
response to MTX.  A total of 4 twice daily (BID) and 1 once daily (QD) dose regimens of 
upadacitinib immediate release capsules (3 mg BID, 6 mg BID, 12 mg BID, 18 mg BID, 
and 24 mg QD) were evaluated.
In TNF-inadequate responder (TNF-IR) subjects, who represent the population with the 
greatest unmet need, the primary endpoint of ACR20 response rate at Week 12 was 
significantly greater at all doses of upadacitinib (up to 73%) compared with placebo 
(35%).  In addition, numerically higher proportions of subjects achieved ACR50 and 
ACR70 responses and LDA (based on Disease Activity Score [DAS]28 C-Reactive 
Protein [CRP] and Clinical Disease Activity Index [CDAI]) in the upadacitinib dose 
groups versus placebo.
In MTX-inadequate responder (MTX-IR) subjects, the primary endpoint of ACR20 
response rate at Week 12 was significantly greater (up to 82%) at all but the lowest dose 
abbvie 


Upadacitinib
M15-925 Protocol Amendment 6
EudraCT 2016-000933-37
30
of upadacitinib compared with placebo (50%).  At all doses of upadacitinib compared to 
placebo, significantly higher proportions of subjects achieved LDA and CR at Week 12.
Risks
The results of all genetic toxicology testing indicate that upadacitinib is not genotoxic.
Embryonic and Fetal Development studies were conducted to determine the 
developmental toxicity, including the teratogenic potential and toxicokinetics, of 
upadacitinib when administered to pregnant animals during the period of organogenesis.  
Results of these studies indicate that upadacitinib is teratogenic in both rats and rabbits.  
upadacitinib administration was associated with skeletal malformations in rats at all doses 
in the absence of maternal toxicity and cardiac malformations in rabbits concurrent with 
maternal toxicity (only at the high dose of 25 mg/kg/day).  Based on these findings, all 
women of childbearing potential must agree to use protocol-specified pregnancy 
avoidance measures as outlined in the protocols.
Safety data from the two Phase 2 RCTs described above (N = 575) showed that the types 
and frequencies of AEs during upadacitinib treatment were consistent with subjects with 
moderately to severely active RA receiving immunomodulatory therapy.  The incidences 
of AEs were numerically higher in the upadacitinib dose groups, with a trend toward 
higher rates with higher doses of upadacitinib.  The most frequently reported AEs (≥ 5%) 
in the upadacitinib treated subjects were urinary tract infection, headache, upper 
respiratory tract infection, and nausea.  There were 6 subjects (1.3% of total combined 
populations) with herpes zoster reactivation distributed across the upadacitinib dose 
groups, and 2 subjects (1.9%) in the placebo groups.  In these two 12 week studies, a total 
of 2 subjects in the upadacitinib treatment groups reported malignancies.  One subject 
reported non-melanoma skin cancers (NMSC) (basal cell and squamous cell carcinoma) 
and 1 subject was diagnosed with lung cancer 11 days after the final scheduled visit, and 
subsequently died 14 weeks after study completion.  These events were reported by the 
Investigators as not possibly related to study drug.  No events of gastrointestinal 
perforation were reported.  Elevations of liver function tests were sporadic with no clear 
abbvie 


Upadacitinib
M15-925 Protocol Amendment 6
EudraCT 2016-000933-37
31
dose response relationship observed.  As observed with other JAK inhibitors, treatment 
with upadacitinib resulted in an increase in lipids (low-density lipoprotein cholesterol 
[LDL-C] and high density lipoprotein cholesterol [HDL-C]).  There was a trend for lower 
red blood cell counts especially at the 2 highest doses (12 mg BID and 18 mg BID), lower 
white blood cell counts and reductions in Natural Killer (NK) cells.  
The Phase 2 program with upadacitinib demonstrated efficacy for improvement in signs 
and symptoms of RA and the safety results were consistent with those known to be 
associated with JAK inhibition.13-21  Taken together, the safety and efficacy data from the 
Phase 2 program show a favorable benefit:risk profile for upadacitinib that supports 
further development of upadacitinib in Phase 3 in subjects with RA.
Many adverse events (AEs) (serious infections, herpes zoster reactivation, malignancies, 
and hematologic AEs) observed with pan-JAK inhibition are thought to be a consequence 
of lack of selectivity against the members of the JAK family of proteins.  Upadacitinib is a 
novel selective JAK1 inhibitor with the ability to decrease inflammation mediated by 
JAK1 signaling while having less inhibitory effects on JAK2 and JAK3.  This could 
potentially minimize some of the reported safety concerns with non-selective JAK 
inhibition which are thought to be mediated by inhibition of JAK2 and JAK3 signaling 
pathways. 
The safety profile specific to upadacitinib is evolving with safety results to date consistent 
with those known to be associated with JAK inhibition.  AEs in the categories of infection 
such as urinary tract infection, upper respiratory tract infection and herpes zoster 
reactivation have been reported as well as AEs in the categories of malignancies, and 
gastrointestinal disorders such as gastrointestinal perforation. 
In addition, laboratory changes observed with upadacitinib include elevations of serum 
transaminases, lipids, creatinine and creatine phosphokinase; both increased and reduced 
hemoglobin, depending on baseline inflammatory burden; and reductions in white blood 
cell counts, including Natural Killer (NK) cells.
abbvie 


Upadacitinib
M15-925 Protocol Amendment 6
EudraCT 2016-000933-37
32
The results of all genetic toxicology testing indicate that upadacitinib is not genotoxic, 
however upadacitinib may be teratogenic, which necessitates avoidance of pregnancy in 
women of childbearing potential.
A detailed discussion of the pre-clinical and clinical toxicology, metabolism, 
pharmacology and safety experience with upadacitinib can be found in the current 
Investigator's Brochure.
Taken together, the safety and efficacy data from upadacitinib studies to date show a 
favorable benefit:risk profile for upadacitinib in the treatment of various 
autoimmune/inflammatory disorders and support the continued investigation of 
upadacitinib in patients with various immune mediated inflammatory conditions.
In view of the COVID-19 pandemic, the benefit:risk profile of various 
immunomodulatory therapies on COVID-19 is being evaluated.  At this time, the effects 
of upadacitinib on the course of COVID-19 are not well defined.
4.0
Study Objectives
Period 1
To compare the safety and efficacy of upadacitinib 15 mg QD versus abatacept on a 
background of csDMARD(s) for the treatment of signs and symptoms of RA in 
bDMARD-inadequate response (bDMARD-IR) or bDMARD-intolerant subjects with 
moderately to severely active RA who have never received abatacept.
Period 2
To evaluate the long-term safety, tolerability, and efficacy of upadacitinib 15 mg QD in 
subjects with RA who have completed Period 1.
abbvie 


Upadacitinib
M15-925 Protocol Amendment 6
EudraCT 2016-000933-37
33
5.0
Investigational Plan
5.1
Overall Study Design and Plan:  Description
This is a Phase 3, multicenter study that includes two periods.  Period 1 is the 24-week 
randomized, double-blind, parallel-group, active-controlled treatment period designed to 
compare the safety and efficacy of upadacitinib 15 mg versus abatacept for the treatment 
of signs and symptoms of subjects with moderately to severely active RA who have an 
inadequate response to or intolerance to bDMARD therapy and are currently on a stable 
dose of csDMARDs and have never received abatacept.  Period 2 is an open-label 
long-term extension to evaluate the long-term safety, tolerability, and efficacy of 
upadacitinib 15 mg QD in subjects with RA who have completed Period 1.  Starting with 
Amendment 5, all subjects will receive open-label upadacitinib 15 mg QD, including 
those currently on upadacitinib 30 mg QD.
The study is designed to enroll approximately 550 subjects at approximately 200 study 
centers worldwide to meet scientific and regulatory objectives without enrolling an undue 
number of subjects in alignment with ethical considerations.  Therefore, if the target 
number of subjects has been enrolled, there is a possibility that additional subjects in 
screening may not be enrolled.
The study duration will include a 35-day screening period; a 24-week randomized, 
double-blind, parallel-group, active controlled treatment period with 30 and 70 day 
follow-ups (Period 1); and a 192-week open-label extension period with a 30-day follow-
up call or site visit (Period 2).
Subjects who meet eligibility criteria will be randomized in a 1:1 ratio to one of 
two treatment groups:
●
Group 1:  upadacitinib 15 mg QD, N = 275 (Period 1) 
●
Group 2:  Abatacept IV at Day 1, Weeks 2, 4, 8, 12, 16 and 20 [< 60 kg:  
500 mg; 60 – 100 kg:  750 mg; > 100 kg:  1,000 mg, N = 275 (Period 1)]
abbvie 


Upadacitinib
M15-925 Protocol Amendment 6
EudraCT 2016-000933-37
34
NOTE:  In Period 1, subjects randomized to Group 1 under Amendment 3 received 30 mg 
QD dose.  This study began enrolling under Amendment 3.  Starting with Amendment 4 
or 3.01, subjects randomized to Group 1 will receive 15 mg QD dose.  In Period 2, 
subjects who enrolled under Amendment 3, including subjects randomized to both 
Group 1 and Group 2, will continue to receive open-label upadacitinib 30 mg QD.  
Subjects who enroll under Amendment 4 or 3.01 or later will receive open-label 
upadacitinib 15 mg QD.  Starting with Amendment 5, all subjects will receive open label 
upadacitinib 15 mg QD including those currently on upadacitinib 30 mg QD.
Subjects must have been on a stable dose of csDMARD(s) for ≥ 4 weeks prior to the 
first dose of study drug and must remain on a stable dose until Week 12; the csDMARD 
dose may be decreased only for safety reasons.  Starting at Week 12, subjects who do not 
achieve ≥ 20% improvement in both TJC and SJC at two consecutive visits will be 
rescued with optimizing (initiate or increase) background RA medications:  NSAIDs, 
corticosteroids, low-potency analgesics, acetaminophen, or adding or increasing doses in 
up to 2 csDMARDs (concomitant use of up to 2 csDMARDs except the combination of 
MTX and leflunomide), and, if necessary, a burst of systemic corticosteroids (prednisone 
equivalent ≤ 0.5 mg/kg/day for 3 consecutive days), intra-articular, intramuscular, 
intravenous, trigger point or tender point, intra-bursa, and intra-tendon sheath injections of 
corticosteroids, dosage and frequency per standard of care, are allowed as per local label.
Subjects who complete the Week 24 visit (end of Period 1) will enter the open-label 
long-term extension portion of the study, Period 2 (192 weeks).  Subjects who are 
assigned to upadacitinib in Period 1 will continue to receive upadacitinib 15 mg QD per 
original randomization assignment in an open-label manner.  Subjects who are assigned to 
abatacept for 24 weeks of Period 1 will be switched to receive upadacitinib 15 mg QD in 
Period 2.
An unblinded analysis will be conducted after all subjects have completed Period 1 
(Week 24) for the purpose of regulatory submission.  
abbvie 


Upadacitinib
M15-925 Protocol Amendment 6
EudraCT 2016-000933-37
35
Study design schematics of Period 1 and Period 2 are shown in Figure 1 and Figure 2, 
respectively.
Figure 1.
Period 1 Study Design
csDMARD = conventional synthetic disease modifying anti-rheumatic drug; DMARD = disease modifying 
anti-rheumatic drug; n = number; QD = once daily; RA = rheumatoid arthritis; W = week
*
The follow-up period is only for subjects who do not enter Period 2.
**
Subjects randomized to Group 1 under Amendment 3 received 30 mg QD dose.  Starting with Amendment 4 or 
3.01, subjects randomized to Group 1 will receive 15 mg QD dose.
abbvie 
Screenin1 Period 
PERIOD 1: 24-Week, Randomized, 
Follow-Up Period 
(Up to 35 days) 
Double-Blind, Treatment Period 
(~ 30 days and 70 days)* 
All subjects on background csDMARD(s) 
-
Adu lts wit h 
moderately to 
severely active 
RA who have had 
an Inadequate 
response to 
biologic 
DMARD(s) AND 
have never 
received 
abatacept IV 
f----~-1 &aup 1: Upadacltlnlb 15 MG cu,-• I 
-1 
n-275 
1--------'!111 
.-t 
.-t 
C 
0 
·;::; 
111 
N 
E 
f---......:;.I 
111 
I 
Baseline 
Group 2: Abatacept IV 
n=275 
W12 
I 
t 
I 
Startini. at W12, initiation of, or I 
change in, csDMARDs is allowed 
I 
I 
W24 


Upadacitinib
M15-925 Protocol Amendment 6
EudraCT 2016-000933-37
36
Figure 2.
Period 2 Study Design
QD = once daily; W = week
*
Subjects who enrolled under Amendment 3, including subjects on both upadacitinib and abatacept will continue to 
receive open-label upadacitinib 30 mg QD.  Subjects who enroll under Amendment 4 or 3.01 or later will receive 
open-label upadacitinib 15 mg QD.  Starting with Amendment 5, all subjects will receive open-label 15 mg QD, 
including those currently on upadacitinib 30 mg QD.
Screening Period
Within 35 days prior to the Baseline Visit, subjects will receive a full explanation of the 
study design and study procedures, provide a written informed consent, and undergo the 
screening procedures outlined in Appendix D.  Lab values can be re-tested once during 
the screening period.  If the re-tested lab value(s) remain(s) exclusionary, the subject will 
be considered a screen failure with no additional re-screening possible.  Redrawing 
samples if previous samples were unable to be analyzed would not count as a retest since 
previous result was never obtained.
Subjects that initially screen fail for the study are permitted to re-screen once following 
re-consent.  Lab values can be re-tested once during the rescreening period.  For 
abbvie 
PERIOD 2: 
Follow-Up Period 
End of Period 1 
Open-Label Extension Period (192 Weeks) 
{"' 30 days) 
Group 1: 
-
Upadacltlnlb 15 MG 
-, 
Upadaclllnlb 15 MG 
,. 
QD* 
Group 2: Abatacept 
-
Upadacitinib 15 MG 
- : 
IV 
, . 
QD• 
I 
' 
' 
i 
. 
I 
I 
I 
I 
, 
W24 
W28 
W32 
W36 
(and every 12 weeks) W216 


Upadacitinib
M15-925 Protocol Amendment 6
EudraCT 2016-000933-37
37
additional re-screenings, AbbVie Therapeutic Area Medical Director approval is required.  
All screening procedures with the possible exceptions noted below will be repeated during 
re-screening.  The subject must meet all the inclusion and none of the exclusion criteria at 
the time of re-screening in order to qualify for the study.  There is no minimum period of 
time a subject must wait to re-screen for the study.  If the subject had a complete initial 
screening evaluation including the assessment of an Interferon-Gamma Release Assay 
(IGRA; QuantiFERON Tuberculosis [TB] Gold In Tube test) and/or a purified protein 
derivative (PPD) test (or equivalent) (or both if required per local guidelines), or chest x-
ray and electrocardiogram (ECG), these tests will not be required to be repeated for re-
screening provided the conditions noted in Section 5.2 are met, there are no changes in the 
subject's medical history that would warrant re-testing, and no more than 90 days have 
passed.
Period 1 (24-Week Randomized, Double-Blind Treatment Period)
Period 1 will begin at the Baseline Visit (Day 1) and will end at the Week 24 Visit.  At the 
Baseline Visit, subjects who meet all the inclusion criteria and none of the exclusion 
criteria described in Section 5.2.1 and Section 5.2.2 will be enrolled into the study and 
randomized to double-blind treatment.  During this period of the study, subjects will visit 
the study site at Weeks 2, 4, 8, 12, 16, 20 and 24.  A ± 3 day window is permitted around 
scheduled study visits.  The last dose of oral study drug in Period 1 is taken the day prior 
to the Week 24 visit, and the last dose of intravenous study drug in Period 1 is infused at 
the Week 20 visit.  Subjects who complete Period 1, but decide not to continue in Period 2 
should complete the 30 and 70 day follow-up visits after the last dose of study drug.
●
Starting at Week 12 subjects who do not achieve ≥ 20% improvement in both 
TJC and SJC at two consecutive visits should have background medication(s) 
adjusted or initiated (see below).
●
Starting at Week 12, subjects who demonstrate worsening of joint count (SJC 
or TJC) from baseline at 2 consecutive visits should be discontinued from 
study drug and treated with standard of care at the discretion of the clinician.
abbvie 


Upadacitinib
M15-925 Protocol Amendment 6
EudraCT 2016-000933-37
38
Period 2 (Open Label Long-Term Extension Period [192 Weeks])
●
Period 2 will begin at the Week 24 Visit after all assessments have been 
completed.  During Period 2, subjects will have a study visit at Weeks 28, 32, 
36, 48, and every 12 weeks thereafter through Week 216/PD.  A ± 7 day 
window is permitted around scheduled study visits.  
●
As was started at Week 12, subjects who do not achieve ≥ 20% improvement 
in both TJC and SJC at two consecutive visits should have background 
medication(s) adjusted or initiated. Subjects who demonstrate worsening of 
joint count (SJC or TJC) from baseline at 2 consecutive visits should be 
discontinued from study drug and treated according to standard of care and at 
the discretion of the clinician.
●
Starting at Week 28 and thereafter, subjects who fail to achieve ≥20% 
improvement in both TJC and SJC from baseline at two consecutive visits, 
despite optimization of background RA therapies (see Section 5.2.3.1 for 
permitted background RA therapies) should be discontinued from study drug 
and treated according to standard of care and at the discretion of the clinician. 
●
Starting at Week 28 and thereafter, subjects who achieve ≥ 20% improvement 
in both TJC and SJC from baseline, but fail to achieve CDAI ≤ 10 at 
two consecutive visits, should be given the option (at the discretion of their 
physician) either to continue or discontinue study drug and be treated 
according to standard of care and at the discretion of the clinician.
Discontinuation of Study Drug and Continuation of Study Participation Period 1 
and Period 2)
Subjects may discontinue study drug treatment but may choose to continue to participate 
in the study (refer to Section 5.4.1 for additional details).  Subjects who prematurely 
discontinue study drug should complete a Premature Discontinuation (PD) visit as soon as 
possible, preferably within 2 weeks, and preferably prior to initiation of another therapy.  
To minimize missing data for efficacy and safety assessments, subjects who prematurely 
discontinue study drug treatment should continue to be followed for all regularly 
scheduled visits as outlined in the Activity Schedule (Appendix D and Appendix F), 
unless subjects have decided to discontinue study participation entirely (withdrawal of 
abbvie 


Upadacitinib
M15-925 Protocol Amendment 6
EudraCT 2016-000933-37
39
informed consent).  Subjects should be advised on the continued scientific importance of 
their data even if they discontinue treatment with study drug early.  Following 
discontinuation of study drug, the subject should be treated in accordance with the 
investigator's best clinical judgment irrespective of whether the subject decides to 
continue participation in the study.  As the subject has discontinued study drug, all rescue-
and efficacy-driven discontinuation criteria no longer apply.  This includes the 20% 
TJC/SJC calculations at Week 12 and visits thereafter, as well as the CDAI calculation at 
Week 28, if applicable.  If at any point a subject no longer wants to provide assessments 
(withdrawal of informed consent) following discontinuation of study drug, a second PD 
visit is not required.
Premature Discontinuation of Study (Withdrawal of Informed Consent) (Period 1 
and Period 2)
Subjects may withdraw from the study completely (withdrawal of informed consent) for 
any reason at any time (refer to Section 5.4.1 for additional details).  If a subject 
prematurely discontinues study drug treatment and study participation (withdrawal of 
informed consent), the procedures outlined for the Premature Discontinuation visit (PD 
visit) should be completed as soon as possible, preferably within 2 weeks of study drug 
discontinuation, and preferably prior to initiation of another therapy.  In addition, if the 
subject is willing, a 30-day and a 70-day follow-up visit (or phone call if a visit is not 
possible) may occur in Period 1, and a 30-day follow-up visit (or phone call if a visit is 
not possible) may occur in Period 2, to determine the status of any ongoing adverse 
events/serious adverse events (AEs/SAEs) or the occurrence of any new AEs/SAEs.
Follow-Up Visit
Follow-Up Visits will occur approximately 30 days and 70 days after the last dose of 
study drug in Period 1 and will occur approximately 30 days after the last dose of study 
drug in Period 2, to obtain information on any new or ongoing AE/SAEs, and to collect 
vital signs and clinical laboratory tests.
Subjects will complete the Follow-Up Visit when they have either
abbvie 


Upadacitinib
M15-925 Protocol Amendment 6
EudraCT 2016-000933-37
40
●
Completed the last visit of Period 1 (Week 24), but decided not to participate 
in the extension Period 2; OR
●
Completed the last visit of Period 2; OR
●
Prematurely discontinued study drug and study participation.  This visit may 
be a telephone call if a site visit is not possible.  Vital signs and laboratory test 
may not be required.  The Follow-Up visit is not applicable for subjects who 
discontinued study drug and continued study participation and completed at 
least one study visit at least approximately 70 days after the last dose of study 
drug in Period 1 and 30 days after the last dose of study drug in Period 2.
Protocol Modifications due to State of Emergency or Pandemic like COVID-19
Study visits may be impacted by a pandemic situation (including the COVID-19 
pandemic) or any state of emergency. If visits cannot be conducted onsite due to travel 
restrictions or other pandemic-related reasons, virtual visits, visits at alternative locations, 
or changes in the visit frequency and timing of study procedures, among others may be 
performed. Additional details are provided in the subsequent sections. Every effort 
should be made to ensure the safety of subjects and site staff, while maintaining the 
integrity of the study.
5.2
Selection of Study Population
It is anticipated that approximately 550 subjects with moderately to severely active RA 
will be randomized at approximately 200 study centers, globally.
A subject may be enrolled in this study provided that he/she has met all of the inclusion 
criteria specified in Section 5.2.1 and none of the exclusion criteria specified in 
Section 5.2.2 of this protocol.
5.2.1
Inclusion Criteria
1.
Adult male or female, at least 18 years old.
2.
Diagnosis of RA for ≥ 3 months who also fulfill the 2010 ACR/EULAR 
classification criteria for RA.
abbvie 


Upadacitinib
M15-925 Protocol Amendment 6
EudraCT 2016-000933-37
41
3.
Subjects have been treated for ≥ 3 months prior to the screening visit with 
≥1 bDMARD therapy, but continue to exhibit active RA or had to dis continue due 
to intolerability or toxicity, irrespective of treatment duration AND have never 
received abatacept prior to first dose of study drug.
4.
Subjects have been receiving csDMARD therapy ≥ 3 months and on a stable dose 
for ≥ 4 weeks prior to the first dose of study drug.
●
The following csDMARDs are allowed (stable dose for ≥ 4 weeks prior to the 
first dose of study drug):  oral or parenteral MTX (7.5 to 25 mg/week), 
sulfasalazine (≤ 3000 mg/day), hydroxychloroquine (≤ 400 mg/day), 
chloroquine (≤ 250 mg/day), and leflunomide (≤ 20 mg/day).
●
A combination of up to two background csDMARDs is allowed EXCEPT the 
combination of MTX and leflunomide.
5.
Subject meets both of the following disease activity criteria:
a.
≥ 6 swollen joints (based on 66 joint counts) and ≥ 6 tender joints (based on 
68 joint counts) at Screening and Baseline Visits; and
b. hsCRP ≥ 3 mg/L (central lab) at Screening Visit.
6.
Stable dose of non-steroidal anti-inflammatory drugs (NSAIDs) and 
acetaminophen/paracetamol must have been at a stable dose ≥ 1 week prior to the 
first dose of study drug; oral corticosteroids (equivalent to prednisone ≤ 10 mg/day) 
or inhaled corticosteroids for stable medical conditions are allowed but must have 
been at a stable dose ≥ 4 weeks prior to the first dose of study drug.
7.
Subjects must have discontinued all bDMARDs prior to the first dose of study 
drug.  The washout period for bDMARDs prior to the first dose of study drug is 
specified below or should be at least five times the mean terminal elimination 
half-life of a drug:
●
≥ 4 weeks for etanercept;
●
≥ 8 weeks for adalimumab, infliximab, certolizumab, golimumab, and 
tocilizumab;
abbvie 


Upadacitinib
M15-925 Protocol Amendment 6
EudraCT 2016-000933-37
42
●
≥ 1 year for rituximab OR ≥ 6 months if B cells have returned to pretreatment 
level or normal reference range (central lab) if pretreatment levels are not 
available.
8.
Subjects must have discontinued all high-potency opiates at least 1 week and oral 
traditional Chinese medicine for at least 4 weeks prior to the first dose of study 
drug (refer to Section 5.2.3.2 for prohibited medications).
9.
Women of childbearing potential (refer to Section 5.2.4), must not have a positive 
serum pregnancy test at the Screening Visit and must have a negative urine 
pregnancy test at the Baseline Visit prior to study drug dosing.  
Note:  Subjects with borderline serum pregnancy tests at Screening must have a 
serum pregnancy test ≥ 3 days later to document continued lack of a positive result.  
10.
If female, subject must be either postmenopausal, OR permanently surgically 
sterile OR for women of childbearing potential practicing at least one protocol 
specified method of birth control (refer to Section 5.2.4), that is effective from 
Study Day 1 through at least 98 days (Period 1)/30 days (Period 2) after the last 
dose of study drug.
●
Additional local requirements may apply.  Refer to Appendix C for local 
requirements.
11.
If male, and subject is sexually active with female partner(s) of childbearing 
potential, he must agree, from Study Day 1 through 30 days after the last dose of 
study drug, to practice the protocol-specified contraception (refer to Section 5.2.4)
●
Additional local requirements may apply.  Refer to Appendix C for local 
requirements.
12.
Subjects must voluntarily sign and date an informed consent, approved by an 
Independent Ethics Committee (IEC)/Institutional Review Board (IRB), prior to 
the initiation of any screening or study-specific procedures.
abbvie 


Upadacitinib
M15-925 Protocol Amendment 6
EudraCT 2016-000933-37
43
Rationale for Inclusion Criteria
1 – 8
To select the appropriate subject population
9 – 11
Upadacitinib is teratogenic in both rats and rabbits.  The effect of 
upadacitinib on human pregnancy and reproduction is unknown
12
In accordance with harmonized Good Clinical Practice (GCP)
5.2.2
Exclusion Criteria
1.
Prior exposure to any JAK inhibitor (including but not limited to upadacitinib, 
tofacitinib, baricitinib, and filgotinib).
2.
Prior exposure to abatacept.
3.
History of any arthritis with onset prior to age 17 years or current diagnosis of 
inflammatory joint disease other than RA (including but not limited to gout, 
systemic lupus erythematosus, psoriatic arthritis, axial spondyloarthritis including 
ankylosing spondylitis and non-radiographic axial spondyloarthritis, reactive 
arthritis, overlap connective tissue diseases, scleroderma, polymyositis, 
dermatomyositis, fibromyalgia [currently with active symptoms], or any arthritis 
with onset prior to age 17 years).  Current diagnosis of secondary Sjogren's 
Syndrome is permitted.
4.
Has been treated with intra-articular, intramuscular, intravenous, trigger point or 
tender point, intra-bursa, or intra-tendon sheath corticosteroids in the preceding 
8 weeks prior to the first dose of study drug.
5.
Has been treated with any investigational drug within 30 days or five half-lives of 
the drug (whichever is longer) prior to the first dose of study drug or is currently 
enrolled in another clinical study.
6.
Female who is pregnant, breastfeeding, or is considering becoming pregnant during 
the study or for approximately 98 days (Period 1)/30 days (Period 2) after the last 
dose of study drug.
abbvie 


Upadacitinib
M15-925 Protocol Amendment 6
EudraCT 2016-000933-37
44
7.
Male who is considering fathering a child or donating sperm during the study or for 
approximately 30 days after the last dose of study drug.
8.
Any active, chronic or recurrent viral infection that, based on the Investigator's 
clinical assessment, makes the subject an unsuitable candidate for the study, 
including hepatitis B virus (HBV) or hepatitis C virus (HCV), recurrent or 
disseminated (even a single episode) herpes zoster, disseminated (even a single 
episode) herpes simplex, or human immunodeficiency virus (HIV).  Active HBV, 
HCV and HIV are defined as:
●
HBV:  hepatitis B surface antigen (HBs Ag) positive (+) or detected sensitivity 
on the HBV deoxyribonucleic acid (DNA) polymerase chain reaction (PCR) 
qualitative test for Hepatitis B core antibody (HBc Ab) positive (+) subjects;
●
HCV:  HCV ribonucleic acid (RNA) detectable in any subject with anti-HCV 
antibody (HCV Ab).
●
HIV:  confirmed positive anti-HIV antibody (HIV Ab) test.
9.
Subject has active TB or meets TB exclusionary parameters (refer to 
Section 5.3.1.1 for specific requirements for TB testing).
10.
Systemic use of known strong cytochrome P450 (CYP)3A inhibitors or strong 
CYP3A inducers from Screening through the end of the study (refer to Table 1 for 
examples of commonly used strong CYP3A inhibitors and inducers).
11.
Receipt of any live vaccine within 4 weeks prior to the first dose of study drug, or 
expected need of live vaccination during study participation including at least 
12 weeks after the last dose of IV study drug and 4 weeks after the last dose of oral 
study drug.
12.
History of any malignancy except for successfully treated NMSC or localized 
carcinoma in situ of the cervix.
13.
History of clinically significant (per Investigator's judgment) drug or alcohol abuse 
within the last 6 months.
abbvie 


Upadacitinib
M15-925 Protocol Amendment 6
EudraCT 2016-000933-37
45
14.
History of gastrointestinal perforation (other than appendicitis or penetrating 
injury), diverticulitis or significantly increased risk for GI perforation per 
investigator judgement.
15.
Conditions that could interfere with drug absorption including but not limited to 
short bowel syndrome.
16.
Subject has been a previous recipient of an organ transplant.
17.
History of clinically significant medical conditions or any other reason that in the 
opinion of the Investigator would interfere with the subject's participation in this 
study or would make the subject an unsuitable candidate to receive study drug.
18.
Active infection(s) requiring treatment with parenteral anti-infectives within 
30 days, or oral anti-infectives within 14 days prior to the first dose of study drug.
19.
History of an allergic reaction or significant sensitivity to constituents of the study 
drugs (and its excipients) and/or other products in the same class.
20.
Laboratory values meeting the following criteria within the Screening period prior 
to the first dose of study drug:
●
Serum aspartate transaminase (AST) > 2 × ULN;
●
Serum alanine transaminase (ALT) > 2 × ULN;
●
Estimated glomerular filtration rate (GFR) by simplified 4-variable 
Modification of Diet in Renal Disease (MDRD) formula 
< 40 mL/min/1.73 m2;
●
Total white blood cell (WBC) count < 2,500/µL;
●
Absolute neutrophil count (ANC) < 1,500/µL;
●
Platelet count < 100,000/µL;
●
Absolute lymphocyte count < 800/µL;
●
Hemoglobin < 10 g/dL.
21.
History of any of the following cardiovascular conditions:
●
Moderate to severe congestive heart failure (New York Heart Association 
class III or IV)
abbvie 


Upadacitinib
M15-925 Protocol Amendment 6
EudraCT 2016-000933-37
46
●
Recent history (within past 6 months) cerebrovascular accident (CVA), 
myocardial infarction, coronary stenting
●
Uncontrolled hypertension as defined by a persistent systolic blood pressure 
(BP) > 160 mmHg or diastolic BP > 100 mmHg.  For subjects with known 
hypertension, the subject's BP must be stable for at least 4 weeks on current, 
stable anti-hypertensive medications.
●
Any other condition which, in the opinion of the Investigator, would put the 
subject at risk by participating in the protocol.
22.
Clinically relevant or significant ECG abnormalities, including ECG with QT 
interval corrected for heart rate (QTc) using Fridericia's correction formula (QTcF) 
> 500 msec.  The QTcF criterion does not apply in patients with a pacemaker or 
any conduction abnormality such as bundle branch block.
Rationale for Exclusion Criteria
1 – 4
To select the appropriate subject population
6, 7
Upadacitinib is teratogenic in both rats and rabbits.  The impact of 
upadacitinib on human pregnancies is unknown
5, 8 – 22
To ensure safety of the subjects throughout the study
5.2.3
Prior, Concomitant, and Prohibited Therapy
Any medication or vaccine (including over-the-counter or prescription medicines, 
vitamins and/or herbal supplements including folic acid) that the subject is receiving 
within 28 days prior to Screening, or receives during the study, must be recorded along 
with the reason for use, date(s) of administration including start and end dates, and dosage 
information including dose, route, and frequency on the appropriate electronic case report 
form (eCRF).  Also, medications including but not limited to DMARDs taken for RA 
since date of RA diagnosis (based on subject recollection and available medical records) 
should be entered into the appropriate eCRF.
abbvie 


Upadacitinib
M15-925 Protocol Amendment 6
EudraCT 2016-000933-37
47
The AbbVie Therapeutic Area Medical Director should be contacted if there are any 
questions regarding concomitant or prior therapies.
5.2.3.1
Permitted Background RA Therapy
Subjects should continue on their stable (≥ 4 weeks prior to the first dose of study drug) 
background csDMARD therapy (restricted to oral or parenteral MTX, [7.5 to 
25 mg/week;], sulfasalazine [≤ 3000 mg/day], hydroxychloroquine, [≤ 400 mg/day], 
chloroquine [≤ 250 mg/day], and leflunomide [≤ 20 mg/day]) up to Week 12.  At any 
time, the csDMARD dose may be decreased only for safety reasons.  Subjects taking 
MTX should take a dietary supplement of oral folic acid (or equivalent, such as folinic 
acid) throughout study participation.  Folic acid dosing and timing of regimen should be 
followed according to Investigator's instructions.  AbbVie will not provide the 
csDMARDs (or folic acid, if taking MTX).
Subjects should continue on their stable doses of NSAIDs, acetaminophen/paracetamol, 
oral corticosteroids (equivalent to prednisone ≤ 10 mg/day), or inhaled corticosteroids.
●
If taking any of the above on a scheduled basis, they should continue to take 
them as they did at study entry with no change in dose or frequency, including 
on study visit days
●
If not taking any of the above at baseline, these must not be initiated except 
where permitted by protocol (specific time period or protocol-defined rescue)
●
If taking any of the above, including low potency analgesics, i.e., tramadol, 
codeine, hydrocodone, or propoxyphene at baseline on an as-needed basis 
(PRN), they should continue to use them for the same reason and same dose 
each time but they should not be taken within the 24 hours prior to any study 
visit to avoid bias in outcome measurements.
In the event of tolerability (or other safety) issues, in Period 1, the doses of these 
medications may be decreased or discontinued with substitution of another permitted 
medication from that class (see Section 5.2.3.2 for prohibited therapies).  
abbvie 


Upadacitinib
M15-925 Protocol Amendment 6
EudraCT 2016-000933-37
48
PRN use of inhaled corticosteroids is permitted at any time.
●
Starting at Week 12 (after Week 12 assessments have been performed) and 
thereafter, intra-articular, intramuscular, intravenous, trigger point or tender 
point, intra-bursa, and intra-tendon sheath injections of corticosteroids, dosage 
and frequency per standard of care, are allowed.  To avoid confounding effects 
of systemic absorption of intra-articular corticosteroids, joint injections should 
be avoided, if possible, within 21 days prior to the next scheduled study visit.  
For the analysis of the TJC and SJC, injected joints will be considered "not 
assessable" for 3 months from the time of the intra-articular injection.  For RA 
flare treatment, no more than 3 consecutive days of systemic corticosteroids 
(maximum dose of 0.5 mg/kg of prednisone or its equivalent) is allowed, after 
which subject should resume their usual daily oral corticosteroid dose.
●
In addition, in Period 2, starting at Week 24 (after Week 24 assessments have 
been performed), initiation, change or discontinuation of corticosteroids, 
NSAIDs, acetaminophen/paracetamol or csDMARDs (restricted to oral or 
parenteral MTX, sulfasalazine, hydroxychloroquine, chloroquine and 
leflunomide except the combination of MTX and leflunomide) is allowed per 
local label.
5.2.3.2
Prohibited Therapy
JAK Inhibitor
Prior exposure to JAK inhibitors and concurrent use during the study (including but not 
limited to tofacitinib [Xeljanz®], baricitinib, and filgotinib) is not allowed.
Corticosteroids
Oral corticosteroids > 10 mg prednisone/day or equivalent and intra-articular, 
intramuscular, intravenous, trigger point or tender point, intra-bursa, and intra-tendon 
sheath corticosteroids are NOT allowed in Period 1 except as described in Section 5.2.3.1
for treatment of an RA flare.
abbvie 


Upadacitinib
M15-925 Protocol Amendment 6
EudraCT 2016-000933-37
49
Any csDMARD/Immunosuppressive Not Listed in Section 5.2.3.1
Biologic Therapies
All biologic therapies related to RA treatment, with the exception of blinded abatacept, 
are prohibited during the study (i.e., Periods 1 and 2).
Subjects must have discontinued the bDMARD prior to the first dose of study drug as 
specified in the washout procedures (Inclusion Criterion 7, Section 5.2.1).  For all other 
bDMARDs, contact the Therapeutic Area Medical Director for the washout period 
required prior to the first dose of study drug.
Examples of biologic therapies include but are not limited to the following:
●
Humira® (adalimumab)
●
Enbrel® (etanercept)
●
Remicade® (infliximab)
●
Kineret® (anakinra)
●
Rituxan® (rituximab)
●
Cimzia® (certolizumab pegol)
●
Simponi® (golimumab)
●
Actemra® (tocilizumab)
●
Raptiva® (efalizumab)
●
Tysabri® (natalizumab)
●
Stelara® (ustekinumab)
●
Benlysta® (belimumab)
●
Dupixent® (dupilumab)
●
Taltz® (ixekizumab)
●
Cosentyx® (secukinumab)
●
Entyvio® (vedolizumab)
abbvie 


Upadacitinib
M15-925 Protocol Amendment 6
EudraCT 2016-000933-37
50
Strong CYP3A Inhibitors or Inducers
Systemic use of known strong CYP3A inhibitors or strong CYP3A inducers is excluded 
from the Screening Visit through the end of the study (i.e., end of Period 2).  The most 
common strong CYP3A inhibitors and inducers are listed in Table 1.
Table 1.
Examples of Commonly Used Strong CYP3A Inhibitors and 
Inducers
Strong CYP3A Inhibitors
Strong CYP3A Inducers
Boceprevir
Cobicistat
Clarithromycin
Conivaptan
Grapefruit (fruit or juice)
Indinavir
Itraconazole
Ketoconazole
Lopinavir/Ritonavir
Mibefradil
Nefazodone
Nelfinavir
Posaconazole
Ritonavir
Saquinavir
Telaprevir
Telithromycin
Troleandomycin
Voriconazole
Avasimibe
Carbamazepine
Phenytoin
Rifampin
Rifapentine
St. John's Wort
Opiates
High potency opiates are not permitted during the study (i.e., Periods 1 and 2), with the 
exception of analgesic care related to AEs or SAEs, and subjects must have discontinued 
high potency opiates at least 1 week prior to the first dose of study drug, including (but 
not limited to):
●
oxycodone
●
oxymorphone
abbvie 


Upadacitinib
M15-925 Protocol Amendment 6
EudraCT 2016-000933-37
51
●
fentanyl
●
levorphanol
●
buprenorphine
●
methadone
●
hydromorphone
●
morphine
●
meperidine
Investigational Drugs
Subjects who have been treated with any investigational drug within 30 days or 
five half-lives of the drug (whichever is longer) prior to the first dose of study drug are 
excluded from participation in this study.  Investigational drugs are also prohibited during 
the study.
Vaccines
Although not mandated by the protocol, vaccines recommended by local guidelines 
should be considered.  If the subject and investigator choose to administer live vaccines, 
these vaccines must be completed (per local label) 4 weeks before the first dose of study 
drug with appropriate precautions and is not allowed during study participation (in 
Period 1) including at least 12 weeks after the last dose of IV study drug and at least 
4 weeks after last dose of oral study drug.  
Examples of live vaccines include, but are not limited to, the following:
●
Monovalent live influenza A (H1N1) (intranasal);
●
Seasonal trivalent live influenza (intranasal);
●
Zostavax (herpes zoster, live attenuated);
●
Rotavirus;
●
Varicella (chicken pox);
●
Measles-mumps-rubella or measles mumps rubella varicella;
abbvie 


Upadacitinib
M15-925 Protocol Amendment 6
EudraCT 2016-000933-37
52
●
Oral polio vaccine;
●
Smallpox;
●
Yellow fever;
●
Bacille Calmette-Guérin (BCG);
●
Typhoid.
In Period 2, if a live vaccine must be administered during study participation, study drug 
must be held for at least 30 days prior to the vaccination and at least 30 days after the 
vaccination (or longer if required locally).
If the live herpes zoster vaccine is to be administered and there is no known history of 
primary varicella (chicken pox), preexisting immunity to varicella should be confirmed 
with antibody testing prior to administration of the herpes zoster vaccine.  If varicella 
antibody testing is negative, the live herpes zoster vaccine should not be administered.
Administration of inactivated (non-live) vaccines is permitted during the study according 
to local practice guidelines.  Examples of common vaccines that are inactivated, toxoid or 
biosynthetic, include but are not limited to:  injectable influenza vaccine, pneumococcal, 
Shingrix (zoster vaccine, recombinant, adjuvanted) and, pertussis (Tdap) vaccines).
Traditional Chinese Medicine
Traditional oral Chinese medicine is not permitted during the study as these may interfere 
with upadacitinib metabolism and exposure and may impact efficacy and safety of 
upadacitinib treatment.  Subjects must have discontinued traditional Chinese medicine at 
least 4 weeks prior to the first dose of study drug.
5.2.3.3
Rescue Therapy
Rescue therapy will be offered to subjects who meet the following criteria from Week 12 
to Week 24:
abbvie 


Upadacitinib
M15-925 Protocol Amendment 6
EudraCT 2016-000933-37
53
Starting at Week 12 and thereafter, subjects who do not achieve ≥ 20% improvement in 
both TJC and SJC as compared to baseline at two consecutive visits will be rescued by 
optimizing (initiate or increase) background RA medications.  
●
Initiation of or change in csDMARDs (concomitant use of up to 2 csDMARDs 
except the combination of MTX and leflunomide; see Inclusion Criterion 4) is 
allowed as per local label.  
●
Initiation or change in NSAIDs, acetaminophen, corticosteroids, low-potency 
analgesics, and, if necessary, a burst of systemic corticosteroids (prednisone 
equivalent ≤ 0.5 mg/kg/day for 3 consecutive days) intra-articular, 
intramuscular, intravenous, trigger point or tender point, intra-bursa, and intra-
tendon sheath injections of corticosteroids, dosage and frequency per standard 
of care, are allowed as per local label.
Starting at Week 12 and thereafter, subjects who demonstrate worsening of joint count 
(SJC or TJC) from baseline at 2 consecutive visits should be discontinued from study drug 
and treated according to standard of care and at the discretion of the clinician.
5.2.4
Contraception Recommendations
Contraception Recommendation for Females
A woman who is postmenopausal or permanently surgically sterile (bilateral 
oophorectomy, bilateral salpingectomy or hysterectomy) is not considered to be a woman 
of childbearing potential and is not required to follow contraception recommendations.  
Postmenopausal is defined as:
●
Age ≥ 55 years with no menses for 12 or more months without an alternative 
medical cause; or
●
Age < 55 years with no menses for 12 or more months without an alternative 
medical cause AND a follicle stimulating hormone (FSH) level > 40 mIU/mL.
If the female subject is < 55 years of age:
abbvie 


Upadacitinib
M15-925 Protocol Amendment 6
EudraCT 2016-000933-37
54
AND has had no menses for ≥ 12 months AND has no history of permanent surgical 
sterilization (defined above), FSH should be tested at Screening.
●
If FSH is not tested, it is assumed that the subject is of childbearing potential 
and protocol-specified contraception is required.
●
If the FSH is tested and the result is consistent with post-menopausal status,
contraception is not required.
●
If the FSH is tested and the result is consistent with pre-menopausal status, 
contraception is required, and a serum pregnancy test must be performed (see 
Section 5.3.1.1, pregnancy test).
For a female subject at any age:
●
Female subjects with menses within the past 12 months are of childbearing 
potential and FSH is therefore not required but contraception is required.
●
Female subjects who are surgically sterile (defined above) are not of 
childbearing potential and therefore no FSH testing or contraception is 
required.
A woman who does not meet the definition of postmenopausal or permanently surgically 
sterile is considered of childbearing potential and is required to practice at least one of the 
following highly effective methods of birth control that is effective from Study Day 1 (or 
earlier) through at least 98 days (Period 1)/30 days (Period 2) after the last dose of study 
drug.
●
Combined (estrogen and progestogen containing) hormonal contraception 
(oral, intravaginal, transdermal, injectable) associated with the inhibition of 
ovulation, initiated at least 30 days prior to Study Day 1.
●
Progestogen-only hormonal contraception (oral, injectable, implantable) 
associated with inhibition of ovulation, initiated at least 1 month prior to Study 
Day 1.
●
Bilateral tubal occlusion/ligation.
abbvie 


Upadacitinib
M15-925 Protocol Amendment 6
EudraCT 2016-000933-37
55
●
Vasectomized partner(s), provided the vasectomized partner verbally confirms 
receipt of medical assessment of the surgical success, and is the sole sexual 
partner of the WOCBP trial participant.
●
Intrauterine device (IUD).
●
Intrauterine hormone-releasing system (IUS).
●
True abstinence (if acceptable per local requirements):  Refraining from 
heterosexual intercourse when this is in line with the preferred and usual 
lifestyle of the subject [periodic abstinence (e.g., calendar, ovulation, 
symptothermal, post-ovulation methods) and withdrawal are not acceptable].
If required per local practices, male or female condom with or without spermicide OR 
cap, diaphragm or sponge with spermicide should be used in addition to one of the highly 
effective birth control methods listed above (excluding true abstinence).
If during the course of the study a woman becomes surgically sterile or post-menopausal 
(defined above) and complete documentation is available, contraceptive measures as 
defined above are no longer required.
It is important to note that contraception requirements described above are specifically 
intended to prevent pregnancy during exposure to the investigational therapy upadacitinib.  
The concomitant csDMARDs (i.e., methotrexate, sulfasalazine, etc.) have been prescribed 
per standard of care prior to study entry and are allowed to be continued during the study.  
Contraception should continue while the subject is on the concomitant csDMARD(s) and 
that duration of contraception after discontinuation of the csDMARD(s) should be based 
on the local label.
Additional local requirements may apply.  Refer to Appendix C for additional local 
requirements.
Contraception Recommendation for Males
There are no contraception requirements for male subjects receiving upadacitinib or their 
female partner(s).
abbvie 


Upadacitinib
M15-925 Protocol Amendment 6
EudraCT 2016-000933-37
56
The concomitant csDMARDs (i.e., methotrexate, sulfasalazine, etc.) have been prescribed 
per standard of care prior to study entry and are allowed to be continued during the study.  
Contraception should continue while the subject is on the concomitant csDMARD(s) and 
that duration of contraception and the requirement not to donate sperm after 
discontinuation of the csDMARD(s) should be based on the local label.
Additional local requirements may apply.  Refer to Appendix C for local requirements.
5.3
Efficacy, Pharmacokinetic, Exploratory Research and 
Validation Studies, and Safety Assessments/Variables
5.3.1
Efficacy and Safety Measurements Assessed and Flow 
Chart
Study procedures described are listed in the following section of this protocol and are 
summarized in tabular format in Appendix D, Appendix E, and Appendix F.
Study visits may be impacted by state of emergency or pandemic situations like COVID-
19. This may include changes such as virtual visits, visits at alternative locations, or 
changes in the visit frequency and timing of study procedures, among others.  Additional 
details are provided in Section 5.3.1.1.
Every effort should be made to ensure the safety of subjects and site staff, while 
maintaining the integrity of the study.
Supplemental study case report forms should be completed in the event of missed/virtual 
visits, or study drug interruptions or discontinuations related to COVID-19.
Study Visits and/or activities should be performed as scheduled whenever possible. 
During a state of emergency or pandemic situation, if it is not possible for all study 
procedures to be performed as specified due to travel restrictions or other reasons, the 
following modifications are allowed:
●
If permitted by local regulations, the IRB/IEC and the subject, study visits may 
be conducted in a subject's home residence (see Section 5.3.1.1 – Sub-Section 
abbvie 


Upadacitinib
M15-925 Protocol Amendment 6
EudraCT 2016-000933-37
57
"Optional Home Healthcare Service Due to State of Emergency or Pandemic 
Situation like COVID-19"). 
●
The following study activities may be performed virtually by phone/video 
conference:
○
Adverse event assessment
○
Concomitant therapy assessment including compliance to contraception 
requirements, if applicable
○
Latent TB risk assessment 
○
Communication of in-home urine pregnancy test result
○
Dispense study drug and subject dosing diary (see Section 5.3.1.1 - Sub-
Section "Study Drug Dispensing, Dosing, and Compliance" for details
about the Direct-to-Patient shipment)
○
Review of subject dosing diary, compliance to IP administrations
●
During a virtual visit, the following activities should not be performed:
○
Patient questionnaires
○
Vital signs and body weight
○
Physical exam
○
Physician Global Assessment (PhGA)
○
TJC68/SJC66
●
The following study activities may be performed by a local 
clinic/hospital/laboratory:
○
QuantiFERON-TB Gold test or equivalent (and/or local PPD skin test)
○
Chest x-ray, if the Investigator has determined, based on clinical 
judgement, that a CXR is required to ensure that it is safe to continue study 
drug administration (e.g., subjects with seroconversion on an annual TB 
test).
In this case, CXR should be performed as soon as restrictions allow at the 
study site or local hospital/facility. Otherwise, the CXR will be performed 
at the next earliest feasible visit.
○
12-lead ECG, if the Investigator has determined, based on clinical 
judgement, that an ECG is required to ensure that it is safe to continue 
abbvie 


Upadacitinib
M15-925 Protocol Amendment 6
EudraCT 2016-000933-37
58
study drug administration. In this case, ECG should be performed as soon 
as restrictions allow at the study site or local hospital/facility. Otherwise, 
the ECG will be performed at the next earliest feasible visit.
○
Local urine pregnancy test
○
Lab tests (blood chemistry, hematology, urinalysis)
○
ESR
All procedures performed at local facilities must be performed by 
appropriately qualified personnel.
●
Lab draws should be obtained as close as possible to the scheduled visit.  
●
The study site should keep records of all visits/study activities performed 
virtually by phone/video or through the optional Home Healthcare Service or 
by a local clinic/hospital/laboratory.
5.3.1.1
Study Procedures
The study procedures outlined in Appendix D and Appendix F are discussed in detail in 
this section, with the exception of exploratory research and validation studies (discussed 
in Section 5.3.1.2.1), drug concentration measurements (discussed in Section 5.3.2), the 
collection of prior and concomitant medication information (discussed in Section 5.2.3), 
and the collection of AE information (discussed in Section 6.0).  All study data will be 
recorded in source documents and on the appropriate eCRFs.
Informed Consent
At the Screening visit, the subject will sign and date a study specific, IEC/IRB approved, 
informed consent form for the study (i.e., includes both Periods 1 and 2) before any study 
procedures are performed or any medications are withheld from the subject in order to 
participate in this study.  Separate written consent will be required for each subject in 
order to participate in the optional exploratory research and validation studies.  The 
separate written consent may be part of the main consent form.  Subjects can withdraw 
informed consent at any time.
abbvie 


Upadacitinib
M15-925 Protocol Amendment 6
EudraCT 2016-000933-37
59
Details regarding how informed consent will be obtained and documented are provided in 
Section 9.3.
Inclusion/Exclusion Criteria
Subjects will be evaluated to ensure they meet all inclusion criteria and have none of the 
exclusion criteria at both Screening and Baseline Visits.
Medical and Surgical History
A complete non-RA-related medical and surgical history, including history of alcohol and 
nicotine use, will be taken from each subject during the Screening Visit.  Additionally, a 
list of each subject's specific RA-related medical and surgical history will be recorded at 
Screening.  History of herpes zoster, herpes zoster vaccination, and hepatitis B 
vaccination status will be recorded as part of the medical history.  An updated medical 
history will be obtained prior to study drug administration at Baseline, to ensure the 
subject is still eligible for enrollment.
A detailed medical history with respect to TB risk factors will be documented in the study 
source documentation.  This information will include BCG vaccination, cohabitation with 
individuals who have had TB, and travel to, residence in, or work in TB endemic 
locations.
Patient Questionnaires
Subjects will complete the following questionnaires as specified in Appendix D and 
Appendix F; a validated translation will be provided in their local language, as applicable:
Period 1
●
Patient's Global Assessment of Disease Activity Visual Analog Scale (VAS) 
(Appendix J)
●
Patient's Assessment of Pain VAS (Appendix K)
abbvie 


Upadacitinib
M15-925 Protocol Amendment 6
EudraCT 2016-000933-37
60
●
Health Assessment Questionnaire – Disability Index (HAQ-DI) to assess the 
physical function and health-related quality of life of each subject 
(Appendix L)
●
Patient's Assessment of Severity and Duration of Morning Stiffness NRS 
(Appendix M)
●
EuroQoL-5D-5L (EQ-5D-5L) (Appendix N)
●
Short Form-36 (SF-36) (Appendix O)
●
FACIT-F (Appendix P)
●
WPAI RA (Appendix Q) 
Period 2
●
Patient's Global Assessment of Disease Activity VAS (Appendix J)
●
Patient's Assessment of Pain VAS (Appendix K)
●
HAQ-DI to assess the physical function and health-related quality of life of 
each subject (Appendix L)
●
Morning Stiffness Rating Scale (NRS) (Appendix M)
●
EQ-5D-5L (Appendix N) 
●
SF-36 (Appendix O) 
●
FACIT-F (Appendix P)
●
WPAI RA (Appendix Q) 
All patient-reported outcomes (PROs) collected electronically.
The subject should complete the questionnaires before site personnel perform any clinical 
assessments and before any interaction with site personnel has occurred to avoid biasing 
the subject's response.
Due to a state of emergency or pandemic situation like COVID-19, subject visits may be 
conducted via phone or video conference.  In these situations, questionnaires will be 
completed by the subject at the next feasible visit.
abbvie 


Upadacitinib
M15-925 Protocol Amendment 6
EudraCT 2016-000933-37
61
TB Testing/TB Prophylaxis
The TB screening tests are diagnostic test results to be interpreted in the context of the 
subject's epidemiology, history, exam findings, etc., and it is the responsibility of the 
Investigator to determine if a subject has previous, active, or latent TB.  Expert 
consultation for the evaluation and/or management of TB may be considered per 
Investigator discretion. 
At screening, all subjects will be assessed for evidence of increased risk for TB by a risk 
assessment form (Appendix I) and tested for TB infection by QuantiFERON-TB Gold 
test.  The PPD Skin Test should be utilized only when a QuantiFERON-TB Gold Test is 
not possible for any reason (unless both tests are required per local guidelines).  The site 
staff will complete the TB risk assessment form and enter the data into an appropriate 
eCRF.  TB risk assessment form will be completed annually for all subjects, regardless of 
TB test results.
If a subject had a negative QuantiFERON-TB Gold (and/or PPD) test (or IGRA 
equivalent such as T-SPOT TB test) within 90 days prior to Screening and source 
documentation is available, the test does not need to be repeated, provided nothing has 
changed in the subject's medical history to warrant a repeat test.  These cases may be 
discussed with the AbbVie Therapeutic Area Medical Director.  The results of the TB 
test(s) will be retained at the site as the original source documentation.
Subjects with a negative TB test and chest x-ray (CXR) not suggestive of active TB or 
prior TB exposure may be enrolled.
Subjects with a positive TB test must be assessed for evidence of active TB versus latent 
TB, including signs and symptoms and CXR.  Subjects with no signs or symptoms and a 
CXR not suggestive of active TB may be enrolled after initiation of TB prophylaxis (see 
below).  
Subjects with evidence of active TB must not be enrolled. 
abbvie 


Upadacitinib
M15-925 Protocol Amendment 6
EudraCT 2016-000933-37
62
For subjects with a negative TB test result at Screening or most recent evaluation, an 
annual TB follow-up test will be performed.  If an annual TB test is newly positive 
(seroconversion), a chest x-ray (CXR) needs to be performed as soon as possible to aid in 
distinguishing active versus latent TB.  Any positive TB screen after the patient has 
started the study, should be reported as an adverse event of latent TB or active TB (as 
applicable). 
For subjects with seroconversion on an annual TB test, if a CXR cannot be done due to
state of emergency or pandemic situation like COVID-19, the Investigator should contact 
the AbbVie TA MD to determine if the subject may continue on study drug.  CXR should 
be performed as soon as restrictions allow at the study site or local hospital/facility.   
If the subject is experiencing signs or symptoms suspicious for TB or something has 
changed in the subject's medical history to warrant a repeat test before the next scheduled 
annual TB re-test, the case (including the TB test results) must be discussed with the 
AbbVie TA MD.
TB test:
●
Subjects with documentation of prior positive result of QuantiFERON-TB 
Gold Test (or equivalent) and/or PPD are not required to repeat either test at 
Screening or during the study and should be considered positive.
●
For regions that require both PPD and QuantiFERON-TB Gold testing, both 
will be performed.  If either PPD or QuantiFERON-TB Gold is positive, the 
TB test is considered positive.
●
The PPD Skin Test (also known as a TB Skin Test or Mantoux Test) should be 
utilized only when a QuantiFERON-TB Gold Test is not possible for any 
reason (unless both tests are required per local guidelines).
●
If only a PPD is placed at screening, then the TB test should be used for the 
remainder of the study for that subject is the PPD.  Similarly, if a subject 
enters the study with a QuantiFERON-TB Gold test (or equivalent) alone, then 
the subject should have their annual TB test performed with a QuantiFERON-
TB Gold test.
abbvie 


Upadacitinib
M15-925 Protocol Amendment 6
EudraCT 2016-000933-37
63
●
If the QuantiFERON-TB Gold Test is NOT possible (or if both the 
QuantiFERON-TB Gold Test and the PPD Skin Test are required per local 
guidelines):  the PPD Skin Test (also known as a TB Skin Test) will be 
performed.  The TB Skin Test should be read by a licensed healthcare 
professional between 48 and 72 hours after administration.  A subject who 
does not return within 72 hours will need to be rescheduled for another skin 
test.  The reaction will be measured in millimeters (mm) of induration and 
induration ≥ 5 mm for RA subjects is considered a positive reaction.  The 
absence of induration will be recorded as "0 mm" not "negative."  Subjects 
who have had an ulcerating reaction to the TB Skin Test in the past should not 
be re-exposed and the TB Skin Test should be considered positive, with no 
requirement for subsequent testing with either PPD or QuantiFERON-TB Gold 
Plus.
●
If the QuantiFERON-TB Gold test is indeterminate, then the investigator
should perform a local QuantiFERON-TB Gold test (or through the central 
laboratory if not locally available) to rule out a positive test result.  If testing 
remains indeterminate or is positive, then the subject is considered to be 
positive for the purpose of this study.  If the testing result is negative, then the 
patient is considered to be negative.
●
Interpretation of a positive annual TB test in low risk subjects:  In cases where 
the QuantiFERON-TB Gold Plus test by the central laboratory is positive and 
the investigator considers the subject at low risk for TB and has no clinical 
suspicion of TB, the investigator may perform a local QuantiFERON-TB Gold 
Plus test (or repeat testing through the central laboratory if not locally 
available) to confirm the positive test result.  If the repeat testing result is 
negative, the investigator may consider the test to be negative based on his/her 
clinical judgment; if the repeat testing result is positive or indeterminate, the 
test is considered positive.
●
An equivalent Interferon Gamma Release Assay (IGRA) (such as T-SPOT TB 
test) may be substituted for the QuantiFERON-TB Gold Plus.
abbvie 


Upadacitinib
M15-925 Protocol Amendment 6
EudraCT 2016-000933-37
64
TB prophylaxis:
At screening, if the subject has evidence of latent TB, prophylactic treatment must be 
initiated at least 2 weeks prior to administration of study drug (or per local guidelines, 
whichever is longer); At least 6 months of prophylaxis needs to be completed to remain in 
the study.
Of note:  Rifampicin or Rifapentine is not allowed for TB prophylaxis.
Subjects with a prior history of latent TB that have documented completion of a full 
course of anti-TB therapy will be allowed to enter the study provided nothing has changed 
in the subject's medical history to warrant repeat treatment.  For subjects with completion 
of a full course of anti-TB therapy, but insufficient documentation, the investigator should 
consult with the AbbVie TA MD.
Newly initiated prophylactic treatment should be captured in the eCRF and in the source 
documents.  Prior therapy should be captured in the eCRF.
During the study, subjects with new evidence of latent TB should initiate prophylactic 
treatment immediately per local guidelines and complete at least 6 months of prophylaxis.  
TB prophylaxis should be initiated and study drug(s) should not be withheld.  2 to 
4 weeks later, the subject should be re-evaluated (unscheduled visit) for signs and 
symptoms as well as laboratory assessment of toxicity to TB prophylaxis.
Chest X-Ray (CXR)
A CXR (posterior-anterior and lateral views) is required:
●
For all subjects at Screening to rule out the presence of TB or other clinically 
relevant findings.  The CXR will not be required if the subject had a previous 
normal CXR (posterior-anterior and lateral views) within 90 days of 
Screening, provided all source documentation is available at the site, as 
outlined below and provided nothing has changed in the subject's medical 
history to warrant a repeat test.
abbvie 


Upadacitinib
M15-925 Protocol Amendment 6
EudraCT 2016-000933-37
65
●
Every 48 weeks for subjects with newly identified TB risk factors as 
determined by the TB risk assessment form (Appendix I), or for subjects living 
in areas endemic for TB or for subjects with newly positive PPD and/or 
QuantiFERON-TB Gold test.
Due to a state of emergency or pandemic situation like COVID-19, subject visits may be 
conducted via phone or video conference.  In these situations, if a visit requires 
completion of a CXR, the CXR will be performed at the next earliest feasible visit, unless 
the Investigator has determined, based on clinical judgement, that a CXR is required to 
ensure that it is safe to continue study drug administration. In this case, CXR should be 
performed as soon as restrictions allow at the study site or local hospital/facility.   
Subjects can have a repeat CXR at any time during the study as warranted, based on the 
opinion of the Investigator.
A radiologist or pulmonologist must perform an assessment of the CXR.  The Principal 
Investigator will indicate the clinical significance of any findings and will sign and date 
the report.  In the assessment of the CXR, the Principal Investigator or their delegate must 
indicate the presence or absence of (1) calcified granulomas, (2) pleural 
scarring/thickening, and (3) signs of active TB.  If the CXR demonstrates changes 
suggestive of previous TB (e.g., calcified nodule, fibrotic scar, apical or basilar pleural 
thickening) or other findings that are clinically significant, the Principal Investigator 
should contact the AbbVie Medical Monitor before enrolling the subject.
12-Lead ECG
For all subjects, a resting 12-lead ECG will be performed at screening, Week 48 and every 
48 weeks thereafter, as specified in Appendix D and Appendix F.  For subjects who do 
not enter Period 2 or prematurely discontinue from study, an ECG will be performed at 
their final visit as indicated in Appendix D and Appendix F.  A qualified physician will 
interpret the clinical significance of any abnormal finding, sign, and date each ECG.  ECG 
with QT interval corrected for heart rate using Fridericia's correction formula (QTcF) 
should be reported (or calculated) and documented in the source documents and later 
abbvie 


Upadacitinib
M15-925 Protocol Amendment 6
EudraCT 2016-000933-37
66
transcribed on to the appropriate eCRF if QTcF prolongation is observed.  A valid QTcF 
cannot be calculated in subjects who have a pacemaker or supraventricular or ventricular 
conduction abnormalities.  In cases of QTcF prolongation, the baseline QTcF will need to 
be entered into the appropriate eCRF for comparison as well.  In addition, any clinically 
significant findings will be documented in the source documents and later transcribed on 
to the appropriate eCRF.  Each signed original ECG will be monitored by the responsible 
site monitor and kept with subject's source documents onsite.
For subjects with a normal ECG taken within 90 days of Screening, a repeat ECG at 
Screening will not be required, provided source documentation is available and provided 
nothing has changed in the subject's medical history to warrant a repeat test.  If there are 
other findings that are clinically significant, the Investigator must contact the AbbVie 
Therapeutic Area Medical Director before enrolling the subject.
Subjects can have a repeat ECG at any time during the study as warranted, based on the 
opinion of the Investigator.
Due to a state of emergency or pandemic situation like COVID-19, subject visits may be 
conducted via phone or video conference.  In these situations, if a visit requires 
completion of an ECG, the ECG will be performed at the next earliest feasible visit, 
unless the Investigator has determined, based on clinical judgement, that an ECG is 
required to ensure that it is safe to continue study drug administration. In this case, the 
ECG should be performed as soon as restrictions allow at the study site or local 
hospital/facility. 
Height and Weight
Height will be measured at the Screening Visit only (with shoes off).  Body weight will be 
measured at all scheduled visits, as specified in Appendix D and Appendix F.  All 
measurements will be recorded in metric units where applicable.
abbvie 


Upadacitinib
M15-925 Protocol Amendment 6
EudraCT 2016-000933-37
67
Vital Signs
Vital sign determinations of systolic and diastolic blood pressure in sitting position, pulse 
rate, respiratory rate, and body temperature will be obtained at visits specified in 
Appendix D and Appendix F.  Blood pressure, pulse rate, body temperature, and 
respiratory rate should be performed before blood draws are performed.
Physical Examination
A complete physical examination will be performed at the designated study visits as 
specified in Appendix D and Appendix F.  The physical examination at the Baseline Visit 
will serve as the baseline physical examination for the entire study.  Physical examination 
abnormalities noted by the Investigator at Baseline prior to the first dose of study drug 
will be recorded in the subject's medical history; abnormalities noted after the first dose of 
study drug will be evaluated and documented by the Investigator as to whether or not the 
abnormality is an AE (see Section 6.1.1.1 for AE definition).  All findings, whether 
related to an AE or part of each subject's medical history, will be captured on the 
appropriate eCRF page.
Due to a state of emergency or pandemic situation like COVID-19, subject visits may be 
conducted via phone or video conference.  In these situations, if a visit by phone or video 
conference occurs at one of the designated study visits specified to complete physical 
examination, the complete physical examination will be performed at the next feasible 
visit.
At any time, a symptom-directed physical examination can be performed as deemed 
necessary by the Investigator.
Physician Global Assessment of Disease Activity VAS
At visits specified in Appendix D and Appendix F, the Physician will rate global 
assessment of subject's current disease activity ranging from 0 to 100 independent of the 
subject's self-assessment using the VAS, which consists of a horizontal 100 mm line 
abbvie 


Upadacitinib
M15-925 Protocol Amendment 6
EudraCT 2016-000933-37
68
anchored at either end by opposite adjectives reflecting the spectrum/severity of the 
parameters assessed (Appendix G).
Due to a state of emergency or pandemic situation like COVID-19, subject visits may be 
conducted via phone or video conference.  In these situations, the Physician Global 
Assessment of Disease Activity will be completed by the physician at the next feasible 
visit.
TJC and SJC Assessment
TJC Assessment
An assessment of 68 joints (Appendix H) will be done for tenderness by pressure 
manipulation on physical examination at visits specified in Appendix D and Appendix F.  
Joint pain/tenderness will be classified as:  present ("1"), absent ("0"), replaced ("9") or no 
assessment ("NA").
SJC Assessment
An assessment of 66 joints (Appendix H) will be done by directed physical examination at 
visits specified in Appendix D and Appendix F.  The joints to be examined for swelling 
are the same as those examined for tenderness, except the hip joints are excluded.  Joint 
swelling will be classified as present ("1"), absent ("0"), replaced ("9") or no assessment 
("NA").
Any injected joints will be considered as "not assessed" ("NA") for 3 months from the 
time of the intra-articular injection.
If possible, the TJC and SJC should be performed by an independent and blinded joint 
assessor who should not perform any other study related procedures.
In order to minimize variability, the same independent joint assessor should evaluate the 
subject at each visit for the duration of the trial as much as possible.  A back-up 
independent joint assessor should be identified.  The independent joint assessors should 
abbvie 


Upadacitinib
M15-925 Protocol Amendment 6
EudraCT 2016-000933-37
69
be a qualified medical professional (e.g., nurse, physician's assistant, physician).  Any 
other joint assessor must be trained and competent in performing such assessments.  It is 
the responsibility of the Investigator to ensure that all assessors are qualified and trained 
to perform joint assessments.  If the independent assessor is not available, the pre-
identified back-up assessor should perform such assessments.
Due to a state of emergency or pandemic situation like COVID-19, subject visits may be 
conducted via phone or video conference.  In these situations, the TJC and SJC will be 
performed at the next feasible visit by the independent joint assessor, if possible.
CDAI
The CDAI calculation is required to determine if a subject fails to achieve low disease 
activity and will be performed at the Week 28 visit.  An Interactive Response Technology 
(IRT) will calculate CDAI with input from site personnel on joint counts and the subject's 
and physician's Global Assessment PtGA and phGA) of RA Disease Activity score.
The calculation used to determine CDAI score at Week 28 is as follows:  
CDAI = TJC28 + SJC28 + PtGA (cm) + PhGA (cm)
NOTE:  Investigator should optimize background RA therapies (as rescue) in subjects 
who failed to achieve a 20% reduction in both tender and swollen joint count.
Pregnancy Test
A serum pregnancy test will be performed for all women of childbearing potential at the 
Screening Visit.  The serum pregnancy test will be sent to and performed by the central 
laboratory.  If the serum pregnancy test is positive the subject is considered a screen 
failure.  If the serum pregnancy test is borderline, it should be repeated ≥ 3 days later to 
determine eligibility.  If the repeat serum pregnancy test is:
●
Positive, the subject is considered a screen failure;
●
Negative, the subject can be enrolled into the trial;
abbvie 


Upadacitinib
M15-925 Protocol Amendment 6
EudraCT 2016-000933-37
70
●
Still borderline ≥ 3 days later, this will be considered documentation of 
continued lack of a positive result and the subject can be enrolled into the trial 
in the absence of clinical suspicion of pregnancy and other pathological causes 
of borderline results.
In Period 1, a urine pregnancy test will be performed for all women of childbearing 
potential at the Baseline Visit prior to the first dose of study drug and at all subsequent 
visits.  More frequent pregnancy tests will be performed throughout the study if required 
per local/country requirements.
●
If the baseline urine pregnancy test performed at the site is negative, then 
dosing with study drug may begin.  If the baseline urine pregnancy test 
performed at the site is positive, dosing with study drug must be withheld and 
a serum pregnancy test is required.  The serum pregnancy test will be sent to 
and performed by the central laboratory.  If the serum pregnancy test is 
negative, study drug may be started.  If the serum pregnancy test is positive, 
study drug must be permanently discontinued.  In the event a serum pregnancy 
test comes back borderline, a repeat test is required (≥ 3 days later) to 
document continued lack of a positive result.
●
If a urine pregnancy test at post-baseline is positive, study drug needs to be 
temporarily discontinued and a serum pregnancy test is required.  The serum 
pregnancy test will be sent to and performed by the central laboratory.  If the 
serum pregnancy test is negative, study drug may be restarted.  If the serum 
pregnancy test is positive, study drug must be permanently discontinued.  In 
the event a serum pregnancy test comes back borderline, a repeat test is 
required (≥ 3 days later) to document continued lack of a positive result.
In Period 2, for women of childbearing potential, a urine pregnancy test will be performed 
at all visits and monthly at home between scheduled study visits.  The results of the 
monthly at home tests will be communicated to the site.  If a urine pregnancy test is 
positive, the subject must stop dosing, return to the study site and have blood drawn for a 
serum pregnancy test that will be analyzed at the central laboratory.
abbvie 


Upadacitinib
M15-925 Protocol Amendment 6
EudraCT 2016-000933-37
71
In the event a urine pregnancy test may not be performed at the protocol specified visits
due to study modifications related to a state of emergency or pandemic situation like 
COVID-19, it can be performed by subjects at a local laboratory or it is possible for the 
Investigator to arrange a shipment from the study site directly to the subject's home of 
urine pregnancy test kits to have the urine pregnancy test done at home (see 
Section 5.3.1.1 - Sub-Section "Study Drug Dispensing, Dosing, and Compliance" for 
details). Home urine pregnancy test should be performed monthly, regardless of ability to 
obtain other laboratory samples.
At each visit, the study staff should review the pregnancy avoidance recommendations 
with each woman of childbearing potential and document this discussion in the subject's 
source records.
If during the course of the study a woman becomes surgically sterile or post-menopausal 
and complete documentation as described in Section 5.2.4 is available, pregnancy testing 
is no longer required.
A pregnant or breastfeeding female will not be eligible for participation in this study or 
continuation on study drug.
Clinical Laboratory Tests
Samples will be obtained for the clinical laboratory tests listed in Table 2.  Unscheduled 
clinical labs may be obtained at any time during the study if deemed appropriate per 
Investigator's discretion.  A certified central laboratory will be utilized to process and 
provide results for the clinical laboratory tests.  All abnormal laboratory tests that are 
considered clinically significant by the Investigator will be followed to a satisfactory 
resolution.
The central laboratory chosen for this study will provide instructions regarding the 
collection, processing, and shipping of these samples.
abbvie 


Upadacitinib
M15-925 Protocol Amendment 6
EudraCT 2016-000933-37
72
If travel restrictions or other changes in local regulations due to state of emergency or 
pandemic situation like COVID-19 prevent the subject from having blood drawn for 
laboratory testing at the study site, it is possible for the Investigator to arrange for subjects 
to have laboratory work done at a local lab, hospital, or other facility to ensure the safety 
assessments are conducted per protocol. Local lab results should be obtained along with 
reference ranges and kept within the subjects' source documentation.  Local lab results 
should be reviewed by the investigator or designee as soon as possible and documented in 
the eCRF.
If laboratory samples cannot be obtained, study drug administration may be continued 
provided labs have been obtained within the prior 3 months, the investigator has reviewed 
the laboratory results and confirmed and discussed with the subject that there is no safety 
concern for the subject to continue use of the study drug in the absence of current lab 
results.  The subject should be scheduled for laboratory draws as soon as feasible and no 
later than the next scheduled visit in order to continue the study drug administration.
If laboratory results are not available within the prior 3 months/two consecutive 12-week 
intervals, study drug dispensation is not allowed until the required laboratory tests are 
completed to ensure the safety assessments are conducted per protocol. 
Blood samples will be obtained for the laboratory tests at visits specified in Appendix D
and Appendix F.  Blood draws should be performed only after all questionnaires (HAQ 
DI, Patient's Assessment of Pain, etc.), clinical assessments, and vital sign determinations 
are obtained.
For clinic visits where samples for serum chemistry tests are collected, subjects should be 
fasting (a minimum 8-hour fast) whenever possible.  If a subject is not able to fast when 
necessary, due to unforeseen circumstances, the non-fasting status will be recorded in 
study source documentation.
Urine samples will be obtained for urinalysis testing at visits specified in Appendix D and 
Appendix F.  The central laboratory will be responsible for performing a macroscopic 
abbvie 


Upadacitinib
M15-925 Protocol Amendment 6
EudraCT 2016-000933-37
73
urinalysis (urine dipstick) on the collected urine specimens.  Specified abnormal 
macroscopic urinalyses defined as leukocytes, nitrite, protein, ketones, or blood greater 
than negative, or glucose greater than normal will be followed up with a microscopic 
analysis at the central laboratory.
For any laboratory test value outside the reference range that the Investigator considers to 
be clinically significant, the Investigator should apply the standard of care for medical 
evaluation and treatment per local guidelines:
●
The Investigator will repeat the test to verify the out-of-range value.
●
The Investigator will follow the out-of-range value to a satisfactory clinical 
resolution.
A laboratory test value that requires a subject to be discontinued from study drug or 
requires a subject to receive treatment will be recorded as an AE.  
abbvie 


Upadacitinib
M15-925 Protocol Amendment 6
EudraCT 2016-000933-37
74
Table 2.
Clinical Laboratory Tests
Hematology 
(Central Lab)
Clinical Chemistrya
(Central Lab)
Urinalysisb
(Central Lab)
Other Laboratory 
Tests
Hematocrit 
Hemoglobin
RBC count
WBC count
Neutrophils
Bands Lymphocytes 
Monocytes
Basophils 
Eosinophils
Platelet count
BUN
Creatinine
Total bilirubin
INR (reflex only)c
ALT
AST
Alkaline phosphatase
CPK 
Sodium Potassium
Chloride
Bicarbonate
Calcium
Inorganic phosphate
Uric acid Cholesterol
LDL-C
HDL-C
Total protein
Glucose
Triglycerides
Albumin
Specific gravity
Ketones
pH
Protein
Blood
Glucose
Urobilinogen
Bilirubin
Leukocytes
Nitrites
Microscopic examination,
if needed
Central Lab Tests:  
Serum pregnancy 
(bHCG) testd
HBs Age
HBs Abe
HBc Abe
HBV DNA PCR 
(reflex only)e
HCV Abf HCV RNA 
(reflex only)e
HIV Abj
QuantiFERON-TB 
Goldf
Rheumatoid Factore
Anti-CCP 
autoantibodiese
hs-CRPg
FSHh
MRB Panelk
Local Lab Tests: 
Urine pregnancy testi
ESR 
ALT = alanine aminotransferase; AST = aspartate aminotransferase; bHCG = beta human chorionic gonadotropin; 
BUN = blood urea nitrogen; CCP = cyclic citrullinated peptide; CK-MB = creatine kinase-MB isozymes; 
CPK = creatine phosphokinase; DNA = deoxyribonucleic acid; ESR = erythrocyte sedimentation rate; FSH = follicle 
stimulating hormone; HBc Ab = hepatitis B core antibody; HBs Ab = hepatitis B surface antibody; HBs 
Ag = hepatitis B surface antigen; HBV = hepatitis B virus; HCV Ab = hepatitis C virus antibody; HDL-C = high-density 
lipoprotein cholesterol; HIV = human immunodeficiency virus; hsCRP = high-sensitivity C-reactive protein; 
INR = international normalized ratio; LDL-C = low-density lipoprotein cholesterol; PCR = polymerase chain reaction; 
RBC = red blood cell; RNA = ribonucleic acid; TB = tuberculosis; WBC = white blood cell
a.
Minimum 8-hour fast.  If a subject is not able to fast when necessary, due to unforeseen circumstances, the 
non-fasting status will be recorded in study source documentation.
b.
A urine dipstick macroscopic urinalysis will be completed by the central laboratory at all required visits.  A 
microscopic analysis will be performed in the event the dipstick results show leukocytes, nitrite, protein, ketones, 
or blood greater than negative or glucose greater than normal.
c.
INR will only be measured if ALT and/or AST > 3 × ULN.
d.
A serum pregnancy test will be performed for all women of childbearing potential at the Screening Visit and if 
postbaseline urine pregnancy test turns positive.
abbvie 


Upadacitinib
M15-925 Protocol Amendment 6
EudraCT 2016-000933-37
75
Table 2.
Clinical Laboratory Tests (Continued)
e.
At Screening only.
f.
If PPD not performed.
g.
In Period 1, the central lab hsCRP results starting from Baseline (Day 1) will not be reported to the Sponsor, 
Investigator, study site personnel, and the subject.  Results of hsCRP may be blunted in subjects taking a JAK 
inhibitor, thereby limiting its clinical utility in the setting of a possible safety assessment or adverse event 
management.  Any local hsCRP or CRP tests should not be reported to the investigator until treatment allocation is 
unblinded or subject is known to be receiving upadacitinib.  In Period 2, the central lab hsCRP results will remain 
blinded to the Investigator, study site personnel, and the subject.  Starting with Amendment 5, at a timepoint 
specified by the Sponsor in Period 2, central laboratory hsCRP results will be reported to the Investigator/study site 
personnel.  After treatment assignment is unblinded, local hsCRP or CRP tests are allowed.
h.
At screening for female subjects < 55 years old AND has had no menses for ≥ 12 months AND has no history of 
permanent surgical sterilization (defined in Section 5.2.4) an FSH should be tested.
i.
A urine pregnancy test will be performed for all female subjects of childbearing potential at the Baseline Visit prior 
to the first dose of study drug and all subsequent visits.  If the baseline urine pregnancy test performed at the site is 
negative, then dosing with study drug may begin.  If the baseline urine pregnancy test performed at the site is 
positive, dosing with study drug must be withheld and a serum pregnancy test is required.  The serum pregnancy 
test will be sent to and performed by the central laboratory.  If the serum pregnancy test is positive, study drug 
must be permanently discontinued.  In the event a pregnancy test comes back borderline, a repeat test is required.  
If a urine pregnancy test postbaseline is positive, study drug needs to be temporarily discontinued and a serum 
pregnancy test is required.  The serum pregnancy test will be sent to and performed by the central laboratory. If 
serum pregnancy test is negative, study drug may be restarted.  If the serum pregnancy test is positive, study drug 
must be permanently discontinued.
j.
Anti-HIV Ab will be performed at Screening, unless prohibited by local regulations.  The Investigator must discuss 
any local reporting requirements to local health agencies with the subject.  The site will report confirmed positive 
results to their health agency per local regulations, if necessary.  If a subject has a confirmed positive result, the 
Investigator must discuss with the subject the potential implications to the subject's health and subject should 
receive or be referred for clinical care promptly.  A subject will not be eligible for study participation if test results 
indicate a positive HIV infection.  AbbVie will not receive results from the testing and will not be made aware of 
any positive result.
k.
If needed to assess B cell counts in subjects who have discontinued rituximab, see Inclusion Criterion 7.
Hepatitis Screen
All subjects will be tested for the presence of HBV and HCV at Screening.
Hepatitis B Virus (HBV):
Subjects will be tested for the presence of HBV at screening using the following tests:
●
HBs Ag (Hepatitis B surface antigen)
abbvie 


Upadacitinib
M15-925 Protocol Amendment 6
EudraCT 2016-000933-37
76
●
HBc Ab/anti-HBc (Hepatitis B core antibody)
●
HBs Ab/anti-HBs (Hepatitis B surface antibody)
A positive result for HBs Ag will be exclusionary.
A negative result for HBs Ag will be tested (automatic reflex testing) for core antibodies 
(HBc Ab) and surface antibodies (HBs Ab).
●
A negative test result for HBc Ab does not require HBV DNA PCR qualitative 
testing and the subject may be enrolled (Figure 3, Scenarios A and B).  For a 
subject who has had a HBV vaccination (should document in the medical 
history), a positive test result for HBs Ab is expected and the subject may be 
enrolled (Figure 3, Scenario B).*
●
A positive test result for HBc Ab requires HBV DNA PCR testing (automatic 
reflex testing) (Figure 3, Scenarios C and D).
○
A positive result for HBV DNA or a result that exceeds detection 
sensitivity will be exclusionary.
○
A subject with a negative result for HBV DNA may be enrolled.
Figure 3.
Criteria for HBV DNA PCR Qualitative Testing
*
For subjects who have had a HBV vaccination (should document in the medical history), a positive test result for 
HBs Ab is expected and these subjects may be enrolled.
abbvie 
Scenario 
A 
B 
C 
D 
Surface Antigen 
(HBsAg) l 
Negative 
Positive 
Exclusionary 
Core Antibody 
Surface Antibody 
(HBcAb) 
(HBsAb) 
Negative 
Negative 
Negative 
Positive• 
Positive 
Positive 
Positive 
Negative 
I HBV DNA PCR I Positive 
Exclusionary 


Upadacitinib
M15-925 Protocol Amendment 6
EudraCT 2016-000933-37
77
Hepatitis C Virus (HCV):
Blood samples for Hepatitis C serology will be obtained at the Screening Visit.  A 
positive HCV Ab will trigger an HCV RNA test.  A subject will not be eligible for study 
participation if test results indicate active Hepatitis C (HCV RNA detectable in any 
subject with anti HCV Ab).
HIV
Subjects with HIV infection are excluded from study participation.  HIV testing will be 
performed at Screening, unless prohibited by local regulations.  The Investigator must 
discuss any local reporting requirements to local health agencies with the subject.  The 
site will report confirmed positive results to their health agency per local regulations, if 
necessary.  If a subject has a confirmed positive result, the Investigator must discuss with 
the subject the potential implications to the subject's health and subject should receive or 
be referred for clinical care promptly.  A subject will not be eligible for study 
participation if test results indicate a positive HIV infection.  AbbVie will not receive 
results from the testing and will not be made aware of any positive result.
Randomization/Drug Assignment
All Screening laboratory results must be reviewed, signed, and dated by the Principal 
Investigator or Sub-investigator prior to the Baseline Visit.  Subjects will not be enrolled 
into the study if laboratory or other Screening result abnormalities are deemed clinically 
significant by the Principal Investigator or Sub-investigator.
Subjects will be eligible for randomization if they continue to meet all of the selection 
criteria (Section 5.2) at Baseline and are willing to continue in the study.
Subjects will be randomized in a 1:1 ratio using interactive response technology (IRT) to 
receive double-blind study drug in one of the following treatment groups:
●
Group 1:  upadacitinib 15 mg QD, N = 275 (Period 1) 
●
Group 2:  Abatacept, N = 275 (Period 1)
abbvie 


Upadacitinib
M15-925 Protocol Amendment 6
EudraCT 2016-000933-37
78
Randomization will be stratified by number of prior bDMARD use (stratum 1:  failed 1 or 
2 biologics of the same class; stratum 2:  failed multiple classes of biologics or 
≥3 biologics of the same class) and geographic region.  Once 35% of the total subjects 
have been randomized in stratum 2, further screening of subjects who meet stratum 
2 criteria may be suspended.  Once 20% of total subjects have been randomized who have 
not completed > 3 months of methotrexate, further screening of such methotrexate 
inexperienced subjects may be suspended.
See Section 5.5.3 for details.
Study Drug Dispensing, Dosing, and Compliance
Study drug will be dispensed to subjects beginning at Baseline (Day 1) and as specified in 
Appendix D and Appendix F.  The first dose of study drug will be administered after all 
other Baseline (Day 1) procedures are completed.  Subjects will maintain a dosing diary 
for all study drug administered outside of the study visit (i.e., at home) to capture dosing 
dates and times.  At visits specified in Appendix D and Appendix F, the site personnel 
will review and retain a copy of the dosing diary, returned study drug kits, and empty 
study drug packaging to verify compliance.
All relevant dosing information will be entered into the eCRF at each visit.  (Refer to 
Section 5.5 for additional information).
Study drug may be shipped from the study site directly to the study subject's home due to 
study modifications related to a state of emergency or pandemic situation like COVID-19 
if all the following criteria are met:
●
Direct-to-patient (DTP) shipment of study drug is allowed by local regulations 
and the relevant ethics committee
●
Subject agrees to have the study drug shipped directly to their home
●
Shipments may also include other study supplies (e.g., drug dosing diaries, in-
home urine pregnancy test kits,).  Instructions will be provided by AbbVie as 
to how a study site can initiate a DTP shipment using Marken, a global vendor 
abbvie 


Upadacitinib
M15-925 Protocol Amendment 6
EudraCT 2016-000933-37
79
selected by AbbVie to provide this service when necessary.  Shipments of 
study drugs from the study site to a subject's home will be appropriately 
temperature controlled (qualified shipper or temperature monitoring) within 
the labeled storage conditions.  Signature is required upon delivery; due to 
COVID-19 related social distancing, this may be provided by the courier after 
delivery.  Documentation of the shipment is to be retained by the clinical site.
●
AbbVie will not receive subject identifying information related to these 
shipments, as the site will work directly with the courier.
The study site is responsible for meeting IRB/IEC reporting requirements related to DTP 
shipments of study drug, and for obtaining consent to provide delivery information to the 
courier and documenting this consent in source documents.
Optional Home Healthcare Service Due to State of Emergency or Pandemic 
Situation like COVID-19
Subjects may be offered the option of home healthcare visits provided by a study nurse or 
third-party vendor.  Study procedures conducted in the home setting may include vital 
signs and body weight, physical exam, blood and urine samples collection, urine 
pregnancy test, adverse event and concomitant therapy assessment including compliance 
to contraception requirements if applicable, latent TB risk assessment form, review of 
subject dosing diary, TJC and SJC performed by the same independent joint assessor, if 
possible, to minimize variability.
This option can only be offered in countries and sites that comply with local regulatory 
and IRB/IEC requirements for homecare.  Any pre-requisite submissions or notifications 
to the site IRB/IEC and local competent health authority should be made, and approvals 
must be obtained prior to implementation.
The investigator should be available via phone call if a consultation is necessary.
abbvie 


Upadacitinib
M15-925 Protocol Amendment 6
EudraCT 2016-000933-37
80
It is recommended that medical personnel entering a subject's home adhere to local health 
regulations during the COVID-19 pandemic, such as the use of Personal Protective 
Equipment (PPE), as required.
If the home visits will not be performed by site personnel, the site may be responsible for 
selecting a vendor, contracting with a vendor, and for ensuring continued compliance with 
the terms of the Clinical Study Agreement.
Individuals performing home visits need to be added to the delegation log.
5.3.1.2
Collection and Handling of Optional Samples for 
Exploratory Research and Validation Studies
5.3.1.2.1
Optional Samples for Exploratory Research and Validation 
Studies
In Period 1, subjects will have the option to provide samples for exploratory research and 
validation studies.  Subjects may still participate in the study even if they decide not to 
participate in this optional exploratory research/validation study.  The procedures for 
obtaining and documenting informed consent are discussed in Section 9.3.
Exploratory research can help to improve our understanding of how individuals respond 
to drugs and our ability to predict which subjects would benefit from receiving specific 
therapies.  In addition, exploratory research may help to improve our understanding of 
how to diagnose and assess/monitor RA by assessing associations between disease 
characteristics, outcomes data, and biomarkers of interest.
Validation studies, including those related to the development of potential in vitro 
diagnostic tests, may be carried out retrospectively in order to assess associations between 
events of interest (i.e., efficacy and/or safety events) and candidate biomarkers.
AbbVie (or people or companies working with AbbVie) will store the exploratory 
research/validation studies samples in a secure storage space with adequate measures to 
protect confidentiality.  The samples will be retained while research on upadacitinib (or 
abbvie 


Upadacitinib
M15-925 Protocol Amendment 6
EudraCT 2016-000933-37
81
drugs of this class) or RA and related conditions continues, but for no longer than 
20 years after the completion of the study.
All subjects are preferred to have been fasting for a minimum of 8 hours prior to sample 
collection.  If a subject is not able to fast when necessary, due to unforeseen 
circumstances, the non-fasting status will be recorded in study documentation.  The 
following samples will be collected according to Appendix E from each subject who 
consents to provide samples for exploratory research/validation studies:
●
DNA samples for pharmacogenetic or epigenetic analyses
●
RNA samples for transcriptomic and/or epigenetic analyses
●
Serum and plasma samples for systemic analyses including, but not limited to, 
proteomics and metabolomics
Samples will be shipped to AbbVie or a designated laboratory for DNA/RNA extraction, 
if applicable, and/or analyses or long-term storage.  Instructions for the preparation and 
shipment of the samples will be provided in the laboratory manual.
5.3.2
Drug Concentration Measurements
5.3.2.1
Collection of Samples for Analysis
Blood samples for assay of upadacitinib will be collected as follows:
●
Week 2 prior to dosing;
●
Weeks 4, 8, 12, 16, 20 and 24/PD at any time during the visit.
On the Week 2 visit day, if possible, subjects should take the study drug dose at the clinic 
after collecting the PK blood sample, except if the subjects regularly take the study drug 
dose at night.  Those subjects who regularly take the study drug dose at night should 
continue to take study drug according to their normal schedule.  For all other visits, 
subjects can take the study drug dose on visit days at their regular schedule and not 
necessarily at the clinic.
abbvie 


Upadacitinib
M15-925 Protocol Amendment 6
EudraCT 2016-000933-37
82
The date and accurate time of the PK sample collection will be recorded on the lab 
requisition form.  The date and accurate time of the last two study drug doses will be 
recorded on the eCRF to the nearest minute.
Refer to the study specific laboratory manual for detailed instructions on sample 
collection, processing, and shipment.
5.3.2.2
Measurement Methods
Plasma concentrations of upadacitinib will be determined by the Drug Analysis 
Department at AbbVie using a validated liquid chromatography/mass spectrometry 
method.
5.3.3
Efficacy Variables
5.3.3.1
Period 1 Variables
5.3.3.1.1
Primary Variable
The primary endpoint is the change from baseline in DAS28 (CRP) at Week 12 (non-
inferiority).
DAS28 (CRP) score will be determined based on a continuous scale of combined 
measures of TJC, SJC, Patient's Global Assessment of Disease Activity (PtGA) (in mm), 
and hsCRP (in mg/L) at Week 12.
DAS28 (CRP) = 0.56 × √(TJC28*) + 0.28 × √(SJC28**) + 0.36 × ln(hsCRP& + 1) + 
0.014 × PtGA» + 0.96
*
TJC28 refers to the Subject's total Tender Joint Count out of the provided 28 evaluated joints.
**
SJC28 refers to the Subject's total Swollen Joint Count out of the provided 28 evaluated joints.
&
hsCRP refers to the high-sensitivity c-reactive protein lab value.  hsCRP unit in the DAS28 (CRP) equation is 
expressed as mg/L.
»
PtGA refers to the Patient's Global Assessment of Disease Activity.  Where √is square root and ln is natural log.
abbvie 


Upadacitinib
M15-925 Protocol Amendment 6
EudraCT 2016-000933-37
83
5.3.3.1.2
Key Secondary Variables
Key secondary endpoints in Period 1 are:
1.
Change from baseline in DAS28 (CRP) at Week 12 (superiority);
2.
Proportion of subjects achieving Clinical Remission (CR) at Week 12 (superiority); 
CR is defined as Disease Activity Score (DAS)28 (C-reactive protein [CRP]) < 2.6 
(superiority).
5.3.3.1.3
Additional Variables
Additional endpoints are:
●
Proportion of subjects achieving low disease activity (LDA) at Week 12 (non-
inferiority).  LDA is defined as Disease Activity Score (DAS)28 (C-reactive 
protein [CRP]) ≤ 3.2.
●
ACR20/50/70 response rates at all visits (non-inferiority); ACR20 response 
rate will be determined based on 20% or greater improvement in Tender Joint 
Count (TJC) and Swollen Joint Count (SJC) and ≥ 3 of the 5 measures of 
Patient's Assessment of Pain (Visual Analog Scale [VAS]), Patient's Global 
Assessment of Disease Activity (VAS), Physician's Global Assessment of 
Disease Activity (VAS), Health Assessment Questionnaire Disability Index 
(HAQ-DI), or hsCRP;
●
Change from baseline in individual components of ACR response at all visits;
●
Change from baseline in DAS28 (CRP) and DAS28 (erythrocyte 
sedimentation rate [ESR]) at all visits;
●
Change from baseline in morning stiffness at all visits;
●
Proportion of subjects achieving LDA or CR based on DAS28 (CRP), DAS28 
(ESR), Simplified Disease Activity Index (SDAI), and CDAI criteria (see 
below) at all visits;
●
Change from baseline in CDAI and SDAI at all visits;
●
Proportion of subjects achieving MCID in change from baseline in HAQ-DI 
(defined as change from baseline in HAQ-DI ≤ –0.3 ) at all visits;
abbvie 


Upadacitinib
M15-925 Protocol Amendment 6
EudraCT 2016-000933-37
84
●
ACR/EULAR Boolean remission at all visits.
●
Systemic corticosteroid dose (including cumulative dose at serial time points 
in Period 1)
DAS28 (CRP) and DAS28 (ESR)
SDAI
CDAI
LDA
≤ 3.2
≤ 11.0
≤ 10
CR
< 2.6
≤ 3.3
≤ 2.8
ACR20/50/70 response rates will be determined based on 20%/50%/70% or greater 
improvement in TJC and SJC and ≥ 3 of the 5 measures of Patient's Assessment of Pain 
(VAS), Patient's Global Assessment of Disease Activity (VAS), Physician's Global 
Assessment of Disease Activity (VAS), HAQ-DI, or hsCRP.
Additional endpoints are:
●
Change from baseline in SF-36 (at Weeks 4, 12 and 24);
●
Change from baseline in EQ-5D-5L (at Weeks 4, 12 and 24);
●
Change from baseline in FACIT-F (at Weeks 4, 8, 12, 16 and 24);
●
Change from baseline in WPAI RA (at Weeks 4, 8, 12 and 24).
5.3.3.2
Period 2 Variables
Assessments to evaluate efficacy of treatment in Period 2 will be analyzed for the 
following measures at Weeks 36, 48, and every 12 weeks thereafter through 
Week 216/PD:
●
Change from baseline in DAS28 (CRP);
●
Proportion of subjects achieving CR based on DAS28 (CRP), DAS28 (ESR), 
SDAI, and CDAI criteria (as defined for Period 1);
●
Proportion of subjects achieving LDA based on DAS28 (CRP), DAS28 (ESR), 
SDAI, and CDAI criteria (as defined for Period 1).
●
ACR20/50/70 response rates;
●
Change from baseline in individual ACR components;
abbvie 


Upadacitinib
M15-925 Protocol Amendment 6
EudraCT 2016-000933-37
85
●
Change from baseline in DAS28 (ESR);
●
Change from baseline in SF-36 at all visits
●
Change from baseline in morning stiffness;
●
Concomitant corticosteroid use;
●
ACR/EULAR Boolean remission.
Assessments to evaluate efficacy of treatment in Period 2 will be analyzed for the 
following measures at Week 48 only:
●
Change from baseline in EQ-5D-5L;
●
Change from baseline FACIT-F 
●
Change from baseline WPAI RA
5.3.4
Safety Variables
Safety evaluations include adverse event monitoring, physical examinations, vital sign 
measurements, ECG, and clinical laboratory testing (hematology, chemistry, and 
urinalysis) as a measure of safety and tolerability for the entire study duration.
5.3.5
Pharmacokinetic Variables
Plasma upadacitinib concentrations will be obtained at the times indicated in Appendix D.  
A non-linear mixed-effects modeling approach will be used to estimate the population 
central values and the empirical Bayesian estimates of the individual values of 
upadacitinib oral clearance (CL/F) and volume of distribution (V/F).  Additional 
parameters may be estimated if useful in the interpretation of the data.
abbvie 


Upadacitinib
M15-925 Protocol Amendment 6
EudraCT 2016-000933-37
86
5.3.6
Exploratory Research Variables and Validation Studies
5.3.6.1
Exploratory Research Variables and Validation Studies
Optional samples may be collected to conduct exploratory investigations into known and 
novel biomarkers.  The types of biomarkers to be analyzed may include, but are not 
limited to nucleic acids, proteins, lipids, or metabolites.
Biomarker assessments may be used to assess and generate prognostic, predictive, or 
surrogate biomarker signatures.  These assessments may be explored in the context of RA 
or related conditions and/or upadacitinib or drugs of similar classes.  The results from 
these analyses are exploratory in nature and may not be included with the clinical study 
report.
The samples may also be used to develop new therapies, research methods or 
technologies.  In addition, samples from this study may be banked for future use.  
Samples may then be used to validate putative biomarker signatures obtained from a 
prospective study, leading to the development of diagnostic tests.
5.4
Removal of Subjects from Therapy or Assessment
5.4.1
Discontinuation of Individual Subjects
Subjects can request to be discontinued from participating in the study at any time for any 
reason including but not limited to disease progression or lack of response to treatment.  
The Investigator may discontinue any subject's participation for any reason, including an 
AE, safety concerns, lack of efficacy, or failure to comply with the protocol.  See 
Section 6.1.7 for toxicity management criteria.
Subjects will have study drug discontinued immediately if any of the following occur:
●
Clinically significant abnormal laboratory results or AEs, which rule out 
continuation of the study drug, as determined by the Investigator or the 
AbbVie Therapeutic Area Medical Director.
abbvie 


Upadacitinib
M15-925 Protocol Amendment 6
EudraCT 2016-000933-37
87
●
Serious infections (e.g., sepsis) which cannot be adequately controlled within 
2 weeks by anti-infective treatment or would put the subject at risk for 
continued participation in the trial as determined by the Investigator.
●
The Investigator believes it is in the best interest of the subject.
●
The subject requests withdrawal from the study.
●
Inclusion or exclusion criteria violation was noted after the subject started 
study drug, when continuation of the study drug would place the subject at risk 
as determined by the AbbVie Therapeutic Area Medical Director.
●
Introduction of prohibited medications or dosages when continuation of the 
study drug would place the subject at risk, as determined by the AbbVie 
Therapeutic Area Medical Director.
●
Subject is non-compliant with TB prophylaxis (if applicable) or develops 
active TB at any time during the study.
●
The subject becomes pregnant while on study drug.
●
Malignancy, except for localized NMSC or carcinoma in-situ of the cervix.
●
Subject is significantly non-compliant with study procedures which would put 
the subject at risk for continued participation in the trial as determined by the 
Investigator or the AbbVie Therapeutic Area Medical Director.
●
Subject develops a gastrointestinal perforation (other than due to appendicitis 
or mechanical injury.)
●
Confirmed diagnosis of deep vein thrombosis, pulmonary embolus or non-
cardiac, non-neurologic arterial thrombosis.
●
Beginning at Week 12, subject has a TJC or SJC worse than baseline at 
two consecutive visits (scheduled or unscheduled).
●
Starting at Week 28 and thereafter, subject fails to show at least 20% 
improvement in TJC and SJC compared to baseline at 2 consecutive visits, 
despite optimization of background RA therapies.
●
Starting at 28 weeks and thereafter, subjects who achieve ≥ 20% improvement 
in both TJC and SJC from baseline but fail to achieve CDAI ≤ 10 at 
two consecutive visits will be given the option, at the discretion of the 
investigator, either to continue or discontinue study drug and be treated 
according to standard of care and at the discretion of the investigator.
abbvie 


Upadacitinib
M15-925 Protocol Amendment 6
EudraCT 2016-000933-37
88
In order to minimize missing data for efficacy and safety assessments, subjects who 
prematurely discontinue study drug treatment should continue to be followed for all 
regularly scheduled visits, unless they have decided to discontinue the study participation 
entirely (withdrawal informed consent).  Subjects should be advised on the continued 
scientific importance of their data even if they discontinue treatment with study drug 
early.
If a subject is discontinued from study drug, the procedures outlined for the Premature 
Discontinuation visit (PD visit) should be completed as soon as possible, preferably 
within 2 weeks of study drug discontinuation.  In addition, if subject is willing, a 30-day 
(and 70-day if within Period 1) follow-up phone call (or visit) after the last dose of study 
drug may be completed to ensure all treatment emergent AEs/SAEs have been resolved.  
Subjects who discontinue the study prematurely after randomization will not be replaced.
All attempts must be made to determine the date of the last study drug dose and the 
primary reason for discontinuation of study drug or study participation.  The information 
will be recorded on the appropriate eCRF page.  However, these procedures should not 
interfere with the initiation of any new treatments or therapeutic modalities that the 
Investigator feels are necessary to treat the subject's condition.  Following discontinuation 
of study drug, the subject will be treated in accordance with the Investigator's best clinical 
judgment irrespective of whether the subject decides to continue participation in the study.
During the COVID 19 pandemic, it has been necessary to employ mitigation strategies to 
enable the investigator to ensure subject safety and continuity of care. 
During a state of emergency or pandemic situation like COVID-19, the investigator 
should contact the sponsor medical contact before discontinuing a subject from the study
or study drug for a reason other than "planned per protocol," to ensure all acceptable 
mitigation steps have been explored.
abbvie 


Upadacitinib
M15-925 Protocol Amendment 6
EudraCT 2016-000933-37
89
Lost to Follow-Up
For subjects to be considered lost to follow-up, reasonable attempts must be made to 
obtain information on the final status of the subject.  At a minimum, two phone calls must 
be made and one certified letter must be sent and documented in the subject's source 
documentation.
5.4.2
Discontinuation of Entire Study
AbbVie may terminate this study prematurely, either in its entirety or at any study site, for 
reasonable cause provided that written notice is submitted in advance of the intended 
termination.  The Investigator may also terminate the study at his/her site for reasonable 
cause, after providing written notice to AbbVie in advance of the intended termination.  
Advance notice is not required by either party if the study is stopped due to safety 
concerns.  If AbbVie terminates the study for safety reasons, AbbVie will immediately 
notify the Investigator by telephone and subsequently provide written instructions for 
study termination.
5.5
Treatments
5.5.1
Treatments Administered
There are two active study drugs in Period 1.  The first is daily upadacitinib and the 
second is abatacept IV.
Upadacitinib, or matching placebo, will be taken orally once daily (QD), beginning on 
Day 1 (Baseline), and should be taken at approximately the same time each day.  
Abatacept or placebo (0.9% Sodium Chloride Injection, or Solution for Infusion 100 mL) 
will be administered by intravenous infusion.  The study drug can be taken with or 
without food.  Subjects will continue their weekly stable background therapy of 
csDMARD(s).  AbbVie will not supply csDMARD(s) (nor folic acid or equivalent, such 
as folinic acid, for subjects who are on MTX).
abbvie 


Upadacitinib
M15-925 Protocol Amendment 6
EudraCT 2016-000933-37
90
Abatacept, or placebo (0.9% Sodium Chloride Injection, or Solution for Infusion 
100 mL), will be given intravenously (IV) on Day 1, Week 2, Week 4, then every 4 weeks 
(q4) thereafter, with the last dose at Week 20.  Dosing for abatacept is as follows:  
< 60 kg:  500 mg; 60 – 100 kg:  750 mg; >100 kg:  1,000 mg.  The entire, fully diluted 
abatacept solution should be administered over a period of 30 minutes and must be 
administered with an infusion set and a sterile, non-pyrogenic, low-protein-binding filter 
(pore size of 0.2 to 1.2 μm).  Abatacept requires reconstitution with sterile water as well 
as dilution prior to infusion with 0.9% Sodium Chloride Injection or Solution for Infusion 
100 mL.  Sites are to follow the commercially available preparation instructions for 
reconstitution and dilution of abatacept and only use silicone-free syringes.  AbbVie will 
supply abatacept and the silicone-free syringes.  Other preparation materials will be 
provided by the sites.
The maltose that is contained in the abatacept formulation can interfere with the readings 
of blood glucose monitors that use test strips with glucose dehydrogenase 
pyrroloquinolinequinone (GDH-PQQ).  The GDH-PQQ based glucose monitoring 
systems may react with the maltose present in abatacept, resulting in falsely elevated 
blood glucose readings on the day of infusion.  On study visit days where blinded 
abatacept is infused, patients that require blood glucose monitoring should be advised to 
consider methods that do not react with maltose, such as those based on glucose 
dehydrogenase nicotine adenine dinucleotide (GDH-NAD), glucose oxidase, or glucose 
hexokinase test methods.
Subjects will be dispensed with oral study drug QD (either upadacitinib 15 mg or 
matching placebo) and receive IV study drug infusions on Day 1, Week 2, Week 4, then 
q4 thereafter (either abatacept or matching placebo). 
Starting at Week 24 (after all assessments have been completed), subjects will be 
dispensed study drug (upadacitinib 15 mg QD) in an open-label fashion until the 
completion of Period 2.
abbvie 


Upadacitinib
M15-925 Protocol Amendment 6
EudraCT 2016-000933-37
91
If a subject is unable to come to the study site to pick up their study drug due to state of 
emergency or any pandemic like COVID-19, a direct-to-patient (DTP) study drug 
shipment can be made from the study site to the subject if allowed by local regulations.  
AbbVie will submit any required notifications to the regulatory authority as applicable.  
Refer to Section 5.3.1.1 for details on DTP shipment of study drug.
5.5.2
Identity of Investigational Product
The individual study drug information is presented in Table 3.
Table 3.
Identity of Investigational Product
Investigational Product
Mode of 
Administration
Formulation
Strength
Manufacturer
Upadacitinib (ABT-494)
Oral
Film-coated Tablet
15 mg
AbbVie
Upadacitinib (ABT-494)
Oral
Film-coated Tablet
30 mg
AbbVie
Placebo for upadacitinib 
(ABT-494)
Oral
Film-coated Tablet
NA
AbbVie
Abatacept
Infusion
Powder
250 mg
Bristol-Myers 
Squibb
Placebo for abatacept
Infusion
0.9 Sodium Chloride 
Injection or Solution 
for Infusion 100 mL
NA
Various**
**
Can be sourced from approved marketed products from various commercial manufacturers depending on 
availability.
0.9% Sodium Chloride (saline) Injection or Solution for Infusion 100 mL will be supplied 
with commercially available and locally sourced material.  Sites are responsible for 
obtaining 0.9% Sodium Chloride Injection or Solution for Infusion 100 mL intravenous 
infusion bags/bottles to be used as diluent and as a vehicle of administration for abatacept 
from a licensed pharmacy or wholesaler.  0.9% Sodium Chloride Injection or Solution for 
Infusion will be administered to those subjects not receiving active abatacept as well as 
those subjects receiving active abatacept.  AbbVie may provide 0.9% Sodium Chlroide 
Injection or Solution for Infusion 100 mL if necessary based on local requirements.  
abbvie 


Upadacitinib
M15-925 Protocol Amendment 6
EudraCT 2016-000933-37
92
Each site will be responsible for maintaining drug accountability records including 
product description, manufacturer, and/or lot numbers for 0.9% Sodium Chloride 
Injection or Solution for Infusion 100 mL.
5.5.2.1
Packaging and Labeling
Upadacitinib and matching placebo will be packaged in bottles with quantities sufficient 
to accommodate study design.  Each kit label will contain a unique kit number.  This kit 
number is assigned to a subject via IRT and encodes the appropriate study drug to be 
dispensed at the subject's corresponding study visit.  Each kit will be labeled as required 
per country requirements.  Labels must remain affixed to the kits.  All blank spaces on the 
label will be completed by the site staff prior to dispensing to the subjects.
Abatacept will be packaged 1 vial per kit.  Silicone-free syringes will also be provided.  
Only silicone-free syringes should be used when preparing doses of abatacept.  Each kit 
label will contain a unique kit number.  This kit number is assigned to a subject via IRT 
and encodes the appropriate study drug to be dispensed at the subject's corresponding 
study visit.  Each kit will be labeled as required per country requirements.  Labels must 
remain affixed to the kits.  All blank spaces on the label will be completed by the site staff 
prior to dispensing to the subjects.
The commercially sourced 0.9% Sodium Chloride Injection or Solution for Infusion 
(100 mL) will not be labeled as an Investigational Medicinal Product (IMP) prior to the 
handling by the unblinded pharmacist or qualified designee.  0.9% Sodium Chloride 
Injection or Solution for Infusion (100 mL) will instead be labeled with a blinded 
dispensing label by the unblinded pharmacist or qualified designee as required.  
Dispensing labels must remain affixed to the material.  If an IMP label on the 0.9% 
Sodium Chloride Injection or Solution for Infusion is mandated by local agencies, labels 
may be applied on the overwrap and will be removed by the unblinded pharmacist or 
qualified designee prior to administration.
abbvie 


Upadacitinib
M15-925 Protocol Amendment 6
EudraCT 2016-000933-37
93
5.5.2.2
Storage and Disposition of Study Drugs
Upadacitinib, or placebo, must be stored at controlled room temperature (15° to 25°C/59° 
to 77°F).  Abatacept must be stored at refrigerated temperature (2° to 8°C/36° to 46°F) 
and protected from light.  0.9% Sodium Chloride Injection or Solution for Infusion should 
be stored per the locally approved commercial label, SmPC or packaging insert.  Study 
drug must not be frozen at any time.  The investigational products are for investigational 
use only and are to be used only within the context of this study.  The study drug supplied 
for this study must be maintained under adequate security and stored under the conditions 
specified on the label until dispensed for subject use or destroyed as appropriate.
5.5.3
Method of Assigning Subjects to Treatment Groups
All subjects will be randomized using IRT.  Before the study is initiated, IRT directions 
will be provided to each site.
All subjects will be assigned a unique identification number by the IRT at the Screening 
Visit.  For subjects that re-screen, the Screening number assigned by the IRT at the initial 
Screening visit should be used; a new Screening number should not be requested.
Subjects will be eligible for randomization if they continue to meet all of the selection 
criteria (Section 5.2) at Baseline and are willing to continue in the study.
Subjects will be randomized in a 1:1 ratio using interactive response technology (IRT) to 
receive double-blind study drug in one of the following treatment groups:
●
Group 1:  Upadacitinib 15 mg QD, N = 275 (Period 1)
●
Group 2:  Abatacept approximately 10 mg/kg IV, N = 275 (Period 1)
Randomization will be stratified by number of prior bDMARD use (stratum 1:  failed 1 or 
2 biologics of the same class; stratum 2:  failed ≥ 3 biologics of the same class or failed 
biologics of multiple classes), and geographic region.  Once 35% of the total subjects 
have been randomized in stratum 2, further screening of subjects who meet stratum 2 
abbvie 


Upadacitinib
M15-925 Protocol Amendment 6
EudraCT 2016-000933-37
94
criteria may be suspended.  Once 20% of total subjects have been randomized who have 
not completed > 3 months of methotrexate, further screening of such methotrexate 
inexperienced subjects may be suspended.
The IRT will assign a randomization number that will encode the subject's treatment 
group assignment according to the randomization schedule generated by the Statistics 
Department at AbbVie.
IRT will provide the appropriate study drug kit number(s) to dispense to each subject.  
Study drug will be administered at the study visits as summarized in Section 5.3.1.1.  
Returned study drug should not be re-dispensed to any subject.
5.5.4
Selection and Timing of Dose for Each Subject
Subjects should take study drug as outlined in Section 5.5.1.
On dosing days that occur on study visit days, subjects should follow the regular dosing 
schedule (refer to Section 5.3.2.1 regarding Week 2 visit).
Each subject's dosing schedule should be closely monitored by the site at each study visit 
by careful review of the subject's dosing diary.  This will ensure that all subjects enrolled 
into the study maintain their original dosing schedule beginning with the first dose of 
study drug (Baseline/Day 1).
If a subject should forget to take their upadacitinib (or matching placebo) dose at their 
regularly scheduled dosing time, they should take the forgotten dose as soon as they 
remember the dose was missed as long as it is at least 10 hours before their next scheduled 
dose.  If a subject only remembers the missed dose within 10 hours before next scheduled 
dose, the subject should skip the missed dose and take the next dose at the scheduled time.  
If the subject experiences a study drug interruption for > 7 consecutive days during 
Weeks 1 through 24 (Period 1) or > 30 consecutive days after Week 24 (Period 2), they 
should notify the Investigator, and the Investigator will determine if study drug should be 
restarted.
abbvie 


Upadacitinib
M15-925 Protocol Amendment 6
EudraCT 2016-000933-37
95
In Period 1, the last dose of oral study drug should be taken the day before the Week 24 
visit, and the last dose of intravenous study drug will be dispensed at the Week 20 visit.
5.5.5
Blinding
5.5.5.1
Blinding of Investigational Product
All AbbVie personnel with direct oversight of the conduct and management of the trial 
(with the exception of AbbVie Drug Supply Management Team and unblinded monitors 
conducting study drug accountability), the Investigator, study site personnel, and the 
subject will remain blinded to each subject's treatment throughout the study.  An 
unblinded pharmacist (or designated unblinded personnel) will be used for the receiving 
and preparation of the blinded doses across the treatment groups.  Upadacitinib tablets 
(active and placebo) will be identical in appearance.  Upadacitinib study drug will be 
delivered to the study drug preparation designee or pharmacist in a blinded label format.  
Abatacept and 0.9% Sodium Chloride Injection or Solution for Infusion (if applicable) 
will be delivered to the unblinded study drug preparation designee or unblinded 
pharmacist (or designated unblinded personnel) in an open-label format.  The unblinded 
pharmacist (or designated unblinded personnel) will prepare the dosing of abatacept, or 
placebo, (in a blinded manner) following the commercially available preparation 
instructions as appropriate based on the subject's assigned treatment group and then 
provide to blinded site personnel.  The blinded site personnel will administer infusions to 
subjects.
The IRT will provide access to unblinded subject treatment information in the case of 
medical emergency.
In the event of a medical situation that requires unblinding of the study drug assignment, 
the Investigator is requested to contact the AbbVie Therapeutic Area Medical Director 
prior to breaking the blind.  However, if an urgent therapeutic intervention is necessary 
which warrants breaking the blind prior to contacting the AbbVie Therapeutic Area 
Medical Director, the Investigator can directly access the IRT system to break the blind 
abbvie 


Upadacitinib
M15-925 Protocol Amendment 6
EudraCT 2016-000933-37
96
without AbbVie notification or agreement.  Unblinding is available in the IRT system via 
the Unblind Subject transaction, which is available only to the Investigator.  If the IRT 
system is unavailable, unblinding may occur by contacting EndPoint technical support via 
either phone (preferred) or email (support@endpointclinical.com).  For country-specific 
phone numbers, please see the following website:  http://www.endpointclinical.com/help-
desk/.  In the event that the blind is broken before notification to the AbbVie Therapeutic 
Area Medical Director, we request that the AbbVie Therapeutic Area Medical Director be 
notified within 24 hours of the blind being broken.  The date and reason that the blind was 
broken must be conveyed to AbbVie and recorded on the appropriate eCRF.
An unblinded analysis will be conducted after all subjects have completed Period 1 
(Week 24).  Study sites and subjects will remain blinded for the duration of Period 1.
5.5.5.2
Blinding of Data for Independent Data Monitoring 
Committee (IDMC)
An external Data Monitoring Committee (DMC) comprised of persons independent of 
AbbVie and with relevant expertise in their field will review unblinded safety data from 
the ongoing study.  The primary responsibility of the DMC will be to protect the safety of 
the subjects participating in this study.
A separate DMC charter will be prepared outside of the protocol and will describe the 
roles and responsibilities of the DMC members, frequency of data reviews, and relevant 
safety data to be assessed.
Communications from the DMC to the Study Teams will not contain information that 
could potentially unblind the team to subject treatment assignments.
As of September 2019, with all subjects having reached the end of Period 1, and after 
final review of unblinded safety data, the DMC concluded its oversight of this study.
abbvie 


Upadacitinib
M15-925 Protocol Amendment 6
EudraCT 2016-000933-37
97
5.5.6
Treatment Compliance
The Investigator or his/her designated and qualified representatives will 
administer/dispense study drug only to subjects enrolled in the study in accordance with 
the protocol.  The study drug must not be used for reasons other than that described in the 
protocol.
Subject dosing will be recorded on a subject dosing diary.  Subjects will be instructed to 
return all drug containers (even if empty) to the study site personnel at each clinic visit.  
The study site personnel will document compliance in the study source documents.
5.5.7
Drug Accountability
The Investigator or his/her representative will verify that study drug supplies are received 
intact and in the correct amounts.  This will be documented by signing and dating the 
Proof of Receipt or similar document and by registering the arrival of drug through the 
IRT.  The original Proof of Receipt Note and the IRT confirmation sheet will be kept in 
the site files as a record of what was received.
In addition, an IRT will be used to document investigational product accountability 
including but not limited to date received, the lot number, kit number(s), date dispensed, 
subject number, and the identification of the person dispensing the drug.
All empty/used study drug packaging will be inventoried by the site.  Empty/used study 
drug packaging should be returned by the subject at each visit for accountability and 
compliance purposes and new packaging issued as necessary.  Site staff will complete 
study drug accountability via IRT, by using source documents, subject dosing diaries, and 
by visually inspecting the packaging whenever possible.  After drug accountability and 
monitor reconciliation has been completed, used packaging and unused study drug will be 
destroyed on site according to local procedures or regulations or returned to the 
destruction depot by the site staff (for those sites that do not meet AbbVie's 
documentation requirements for on-site destruction).  The use of a third party vendor for 
drug destruction must be pre-approved by AbbVie.  For sites performing on-site drug 
abbvie 


Upadacitinib
M15-925 Protocol Amendment 6
EudraCT 2016-000933-37
98
destruction or using a third party vendor for drug destruction, a copy of the destruction 
methodology and date of destruction should be maintained at the site's facility.
Monitors will reconcile the site's processes, source documents, subject's dosing diaries, 
IRT or site accountability record, and destruction records to assure site compliance.
5.6
Discussion and Justification of Study Design
5.6.1
Discussion of Study Design and Choice of Control Groups
This study includes two periods:
Period 1 is a 24-week, randomized, double-blind, active-treatment period to compare 
safety and efficacy of upadacitinib versus abatacept in subjects with moderately to 
severely active RA who have an inadequate response to or intolerance to bDMARD 
therapy (EXCEPT abatacept) and who are on a stable dose of csDMARDs.  Period 1 is 
designed to test non-inferiority of upadacitinib versus abatacept for achieving the primary 
endpoint change from baseline in DAS28(CRP) at Week 12, and other secondary efficacy 
parameters.  Although primary outcome will be assessed at Week 12, the blinded 
comparator study will continue until Week 24. 
All subjects initially assigned to abatacept will have the option to enter Period 2 and to 
receive upadacitinib from Week 24 onwards.  Previous studies with both upadacitinib and 
abatacept have demonstrated robust and statistically significant improvement in disease 
activity at 12 week compared to placebo with moderate additional improvement observed 
with abatacept at 24 compared to 12 weeks.  In a clinical trial with Abatacept in a TNF 
inadequate responder population, near-maximal improvements were noted at Week 12 
(abatacept SmPC),17 and thus comparison of upadacitinib to Abatacept at Week 12 should 
be a valid reflection of relative efficacy of upadacitinib vs. Abatacept.  Durability of the 
comparison will be performed at 24 weeks as a secondary outcome.
abbvie 


Upadacitinib
M15-925 Protocol Amendment 6
EudraCT 2016-000933-37
99
Starting at Week 12 (after the 12 Week assessment), if subjects do not show a 20% 
improvement in tender and swollen joint count two consecutive visits, then they will be 
rescued per Section 5.2.3.3.  
Subjects not responding to therapy can discontinue study drug (or withdraw from study) 
at any time for any reason during the study in order to receive standard of care.  For 
subjects who demonstrate no response to therapy beginning at Week 12 through the 
period prior to Week 24, discontinuation of study drug is advised for subjects who 
demonstrate worsening of TJC or SJC from baseline on 2 consecutive visits.  If at 
28 weeks, subjects fail to achieve ≥ 20% improvement from baseline in both TJC and SJC 
at two consecutive visits, study drug should be discontinued.  Beginning at 28 weeks, 
subjects who achieve ≥20% improvement in both TJC and SJC but who fail to achieve a 
CDAI ≤ 10 at two consecutive visits, the option will be given, at the discretion of the 
investigator, either to continue study drug or discontinue study drug and initiate standard 
of care as determined by the investigator.
The purpose of Period 2 is to evaluate the long-term safety, tolerability, and efficacy of 
upadacitinib 15 mg QD in subjects with RA who have completed Period 1.  Subjects will 
continue to receive upadacitinib 15 mg QD in an open-label manner.
Starting with Amendment 5, all subjects will receive upadacitinib 15 mg, including those 
currently on upadacitinib 30 mg, QD.
5.6.2
Appropriateness of Measurements
Standard statistical, clinical, and laboratory procedures will be utilized in this study.  All 
efficacy measurements in this study are standard for assessing disease activity in subjects 
with RA.  All clinical and laboratory procedures in this study are standard and generally 
accepted.
abbvie 


Upadacitinib
M15-925 Protocol Amendment 6
EudraCT 2016-000933-37
100
5.6.3
Suitability of Subject Population
The intended study population is moderately to severely active RA patients who have had 
an inadequate response to or intolerance to prior bDMARD treatment.  Key entry criteria 
are to enroll adult female and male subjects who are at least 18 years of age with a 
diagnosis of RA for ≥ 3 months who also fulfill the 2010 ACR/EULAR classification 
criteria for RA.  Eligible study subjects must have ≥ 6 swollen joints (based on 66 joint 
counts) and ≥ 6 tender joints (based on 68 joint counts) at Screening and Baseline Visits, 
and hsCRP level ≥ 3 mg/L (above ULN, central lab) at Screening.  Subjects who have 
been treated ≥ 3 months prior to the screening visit with ≥ 1 bDMARD therapy, but 
continue to exhibit active RA or had to discontinue due to intolerability or toxicity, 
irrespective of treatment duration AND have never received abatacept may be enrolled.  
Subjects must have been on a stable background of csDMARD therapy (restricted to 
MTX, chloroquine, hydroxychloroquine, sulfasalazine, or leflunomide) for ≥ 4 weeks 
prior to the first dose of study drug.
5.6.4
Selection of Doses in the Study
One dose of the once-daily formulation of upadacitinib will be evaluated:  upadacitinib 
15 mg QD.  The dose selection in this study is based on analyses of data from two Phase 2 
studies in RA subjects (Studies M13-537 and M13-550) as well as results from the 
first two Phase 3 studies in the RA program:  Study M13-549 (csDMARD-IR) and 
Study M13-542 (bDMARD-IR).  The dose selected for Study M15-925, upadacitinib 
15 mg QD, dosed for up to 216 weeks, is expected to be efficacious with an acceptable 
safety profile.
Results from Studies M13-549 (csDMARD-IR) and M13-542 (bDMARD-IR) showed 
that both the 15 and 30 mg QD doses of upadacitinib achieved superior responses to 
placebo for all primary and ranked secondary endpoints at Week 12 and demonstrated a 
safety profile consistent with the known profile of upadacitinib from Phase 2 studies.  
Therefore, upadacitinib 15 mg was selected for comparison to abatacept in this Phase 3 
abbvie 


Upadacitinib
M15-925 Protocol Amendment 6
EudraCT 2016-000933-37
101
trial in RA patients who are intolerant or inadequate responders to prior biologic 
DMARDs.
6.0
Complaints
A Complaint is any written, electronic, or oral communication that alleges deficiencies 
related to the physical characteristics, identity, quality, purity, potency, durability, 
reliability, safety, effectiveness, or performance of a product/device after it is released for 
distribution.
Complaints associated with any component of this investigational product must be 
reported to the Sponsor (Section 6.2.2).  For AEs, please refer to Section 6.1.  For product 
complaints, please refer to Section 6.2.
6.1
Medical Complaints
The Investigator will monitor each subject for clinical and laboratory evidence of AEs on 
a routine basis throughout the study.  The Investigator will assess and record any AE in 
detail including the date of onset, event diagnosis (if known) or sign/symptom, severity, 
time course (end date, ongoing, intermittent), relationship of the AE to study drug, and 
any action(s) taken.  For SAEs considered as having "no reasonable possibility" of being 
associated with study drug, the Investigator will provide other cause(s) of the event.  For 
AEs to be considered intermittent, the events must be of similar nature and severity.  AEs, 
whether in response to a query, observed by site personnel, or reported spontaneously by 
the subject will be recorded.
All AEs will be followed to a satisfactory conclusion.
6.1.1
Definitions
6.1.1.1
Adverse Event
An AE is defined as any untoward medical occurrence in a patient or clinical investigation 
subject administered a pharmaceutical product and which does not necessarily have a 
abbvie 


Upadacitinib
M15-925 Protocol Amendment 6
EudraCT 2016-000933-37
102
causal relationship with this treatment.  An AE can therefore be any unfavorable and 
unintended sign (including an abnormal laboratory finding), symptom, or disease 
temporally associated with the use of a medicinal (investigational) product, whether or not 
the event is considered causally related to the use of the product.
Such an event can result from use of the drug as stipulated in the protocol or labeling, as 
well as from accidental or intentional overdose, drug abuse, or drug withdrawal.  Any 
worsening of a pre-existing condition or illness is considered an AE.  Worsening in 
severity of a reported AE should be reported as a new AE.  Laboratory abnormalities and 
changes in vital signs are considered to be AEs only if they result in discontinuation from 
the study drug, necessitate therapeutic medical intervention, and/or if the investigator 
considers them to be AEs.
An elective surgery/procedure scheduled to occur during the study will not be considered 
an AE if the surgery/procedure is being performed for a pre-existing condition and the 
surgery/procedure has been pre-planned prior to study entry.  However, if the pre-existing 
condition deteriorates unexpectedly during the study (e.g., surgery performed earlier than 
planned), then the deterioration of the condition for which the elective surgery/procedure 
is being done will be considered an AE.
6.1.1.2
Serious Adverse Events
If an AE meets any of the following criteria, it is to be reported to AbbVie as an SAE 
within 24 hours of the site being made aware of the SAE.
Death of Subject
An event that results in the death of a subject.
Life-Threatening
An event that, in the opinion of the investigator, would have 
resulted in immediate fatality if medical intervention had not 
been taken.  This does not include an event that would have 
been fatal if it had occurred in a more severe form.
abbvie 


Upadacitinib
M15-925 Protocol Amendment 6
EudraCT 2016-000933-37
103
Hospitalization or 
Prolongation of 
Hospitalization
An event that results in an admission to the hospital for any 
length of time or prolongs the subject's hospital stay.  This 
does not include an emergency room visit or admission to an 
outpatient facility.
Congenital Anomaly
An anomaly detected at or after birth, or any anomaly that 
results in fetal loss.
Persistent or 
Significant 
Disability/Incapacity
An event that results in a condition that substantially 
interferes with the activities of daily living of a study subject.  
Disability is not intended to include experiences of relatively 
minor medical significance such as headache, nausea, 
vomiting, diarrhea, influenza, and accidental trauma 
(e.g., sprained ankle).
Important Medical 
Event Requiring 
Medical or Surgical 
Intervention to 
Prevent Serious 
Outcome
An important medical event that may not be immediately 
life-threatening or result in death or hospitalization, but 
based on medical judgment may jeopardize the subject and 
may require medical or surgical intervention to prevent any 
of the outcomes listed above (i.e., death of subject, 
life-threatening, hospitalization, prolongation of 
hospitalization, congenital anomaly, or persistent or 
significant disability/incapacity).  Additionally, any elective 
or spontaneous abortion or stillbirth is considered an 
important medical event.  Examples of such events include 
allergic bronchospasm requiring intensive treatment in an 
emergency room or at home, blood dyscrasias or convulsions 
that do not result in inpatient hospitalization, or the 
development of drug dependency or drug abuse.
For serious adverse events with the outcome of death, the date and cause of death will be 
recorded on the appropriate case report form.
6.1.1.3
Adverse Events of Special Interest
The following AEs of special interest will be monitored during the study (see detailed 
toxicity management in Section 6.1.7):
●
Serious infections
●
Opportunistic infections
abbvie 


Upadacitinib
M15-925 Protocol Amendment 6
EudraCT 2016-000933-37
104
●
Herpes Zoster
●
Active tuberculosis
●
Malignancy (all types);
●
Adjudicated Gastrointestinal Perforations
●
Adjudicated cardiovascular events (e.g., major adverse cardiovascular event 
[MACE])
●
Anemia
●
Neutropenia
●
Lymphopenia
●
Increased serum creatinine and renal dysfunction
●
Hepatic events and increased hepatic transaminases
●
Elevated creatine phosphokinase 
●
Adjudicated embolic and thrombotic events (non-cardiac, non-CNS)
6.1.2
Adverse Event Severity
The Investigator will classify adverse events according to the Rheumatology Common 
Toxicity Criteria v.2.0.22
6.1.3
Relationship to Study Drug
The investigator will use the following definitions to assess the relationship of the adverse 
event to the use of study drug:
Reasonable 
Possibility
After consideration of factors including timing of the event, 
biologic plausibility, clinical judgment, and potential alternative 
causes, there is sufficient evidence (information) to suggest a 
causal relationship.
No Reasonable 
Possibility
After consideration of factors including timing of the event, 
biologic plausibility, clinical judgment, and potential alternative 
causes, there is insufficient evidence (information) to suggest a 
causal relationship.
abbvie 


Upadacitinib
M15-925 Protocol Amendment 6
EudraCT 2016-000933-37
105
For relationship assessments, events assessed as having a reasonable possibility of being 
related to the study drug will be considered "associated." Events assessed as having no 
reasonable possibility of being related to study drug will be considered "not associated."
In addition, when the investigator has not reported a relationship or deemed it not 
assessable, AbbVie will consider the event associated.
If an Investigator's opinion of no reasonable possibility of being related to study drug is 
given, an Other cause of event must be provided by the investigator for the serious 
adverse event.
6.1.4
Adverse Event Collection Period
All AEs reported from the time of study drug administration until up to 70 days following 
discontinuation of study drug administration (depending on if discontinuation occurs in 
Period 1 or Period 2) have elapsed will be collected, whether solicited or spontaneously 
reported by the subject.  Subjects who discontinue study drug treatment but continue to 
participate in the study will have SAEs and nonserious AEs collected for the remainder of 
study participation.  In addition, SAEs and protocol-related nonserious AEs will be 
collected from the time the subject signed the study-specific informed consent.
Adverse event information will be collected as shown in Figure 4.
Figure 4.
Adverse Event Collection
abbvie 
SAEs and 
Protocol-Related 
onseriol!ls AEs 
SAEs and 
onserious AEs 
Elicited and/or Spontaneously Reported 
_ ____ _,A..______ 
_ ________ _,A.._ ________ _ 
r 
- - ---- - ---- - ------ --------
+
-----------------------~--------------------- -
~ 
Consent 
Signed 
Study Dmg 
Start 
Study Drug 
Stopped 
p to 70 Days 
After Smdy 
Drug Stopped 


Upadacitinib
M15-925 Protocol Amendment 6
EudraCT 2016-000933-37
106
Additionally, in order to assist the adjudication process, additional information on any 
potential cardiovascular events including thromboembolic events will be collected, if 
applicable.
In the case of any of the following reported events, the supplemental eCRF should be 
completed:
●
Cardiac events;
●
Myocardial infarction or unstable angina;
●
Heart failure;
●
Cerebral vascular accident and transient ischemic attack;
●
Cardiovascular procedures (SAE Supplemental Procedure eCRF);
●
Embolic and thrombotic events (non-cardiac, non-CNS);
●
Hepatic;
●
Renal; 
●
Herpes Zoster infection; 
●
CPK increases considered by the investigator to be an AE.
●
COVID-19
Supplemental study case report forms should be completed in the event of COVID-19 
related missed/virtual visits, study drug interruptions or discontinuations, or adverse 
events (including documentation of specific signs/symptoms of infection and testing 
results).
COVID-19 infections should be captured as adverse events.  If the event meets the criteria 
for a serious adverse event (SAE), then follow the SAE reporting directions per the 
protocol and above. 
The following COVID-19 related supplemental eCRFs should be completed (for both 
serious and non-serious events):
●
COVID-19 Supplemental Signs/Symptoms
abbvie 


Upadacitinib
M15-925 Protocol Amendment 6
EudraCT 2016-000933-37
107
●
COVID-19 Status Form
6.1.5
Adverse Event Reporting
In the event of an SAE, whether associated with study drug or not, the Investigator will 
notify Clinical Pharmacovigilance within 24 hours of the site being made aware of the 
SAE by entering the SAE data into the electronic data capture (EDC) system (RAVE®).  
SAEs that occur prior to the site having access to the RAVE system, or if RAVE is not 
operable, should be documented on the SAE Non-CRF forms and emailed (preferred 
route) or faxed to Clinical Pharmacovigilance within 24 hours of the site being made 
aware of the SAE.
Email:  PPDINDPharmacovigilance@AbbVie.com
FAX to:  +1 (847) 938-0660
For safety concerns, contact the Immunology Safety Team at:
Immunology Safety Team
1 North Waukegan Road
North Chicago, IL  60064
Toll Free: +1 (833) 942-2226
Email:
GPRD_SafetyManagement_Immunology@abbvie.com
abbvie 




Upadacitinib
M15-925 Protocol Amendment 6
EudraCT 2016-000933-37
109
of the first dose through 98 days (Period 1)/30 days (Period 2) following the last dose of 
study drug and the pregnancy will be followed to outcome.
Pregnancy in a study subject is not considered an AE.  The medical outcome for either 
mother or infant, meeting any serious criteria including an elective or spontaneous 
abortion, is considered an SAE and must be reported to AbbVie within 24 hours of the 
site becoming aware of the event.
Subjects should avoid pregnancy throughout the course of the study, starting with the 
Screening Visit through 98 days (Period 1)/30 days (Period 2) after the last study drug 
administration. Results of a positive pregnancy test or confirmation of a pregnancy will 
be assessed starting with the Screening Visit through the final study visit.  
6.1.7
Toxicity Management
The toxicity management of the AEs including AEs of special interest consists of safety 
monitoring (review of AEs on an ongoing basis, and periodical/ad hoc review of safety 
issues by a safety data monitoring committee), interruption of study drug dosing with 
appropriate clinical management if applicable, and discontinuation of the subjects from 
study drug.  The management of specific AEs and laboratory parameters is described 
below.
For subjects who discontinued study drug but continued study participation and are on 
standard of care therapies, these toxicity management requirements do not apply 
(including alerts from the central lab) and any intolerability to standard of care therapies 
should be managed by the prescribing physician.
Infusion Reactions (according to package insert for Abatacept):  Acute infusion-
related events (adverse reactions occurring within 1 hour of the start of the infusion) were 
more common in the abatacept-treated patients than placebo-treated patients (9.4% for 
abatacept, 7.2% for placebo).  The most frequently reported events with abatacept (1 –
2%) were dizziness, headache, and hypertension.  Acute infusion-related events that were 
reported in > 0.1% and ≤ 1% of patients treated with abatacept included cardiopulmonary 
abbvie 


Upadacitinib
M15-925 Protocol Amendment 6
EudraCT 2016-000933-37
110
symptoms such as hypotension, increased blood pressure, decreased blood pressure, and 
dyspnea; other symptoms included nausea, flushing, urticaria, cough, hypersensitivity, 
pruritus, rash, and wheezing.  Most of these reactions were mild to moderate.  The 
occurrence of anaphylaxis remained rare between the double blind and long-term open-
label experience.  Hypersensitivity was reported uncommonly.  Other reactions potentially 
associated with hypersensitivity to the medicinal product, such as hypotension, urticaria, 
and dyspnea, that occurred within 24 hours of abatacept infusion, were uncommon.  If any 
serious allergic or anaphylactic reaction occurs, intravenous abatacept therapy should be 
discontinued immediately and appropriate therapy initiated, and the use of abatacept 
should be permanently discontinued.
Serious Infections:  Subjects should be closely monitored for the development of signs 
and symptoms of infection during and after treatment with study drug.  Study drug should 
be interrupted if a subject develops a serious infection or an opportunistic infection.  A 
subject who develops a new infection during treatment with study drug should undergo 
prompt diagnostic testing appropriate for an immunocompromised subject.  As 
appropriate, antimicrobial therapy should be initiated, and the subject should be closely 
monitored.  Study drug may be restarted once the infection has been successfully treated.  
Subjects who develop active TB or experience Hepatitis B reactivation must be 
discontinued from study drug.
COVID-19:  Interrupt study drug in subjects with a confirmed diagnosis of COVID-19. 
Consider interrupting study drug in subjects with signs and/or symptoms and suspicion of 
COVID-19.  The COVID-19 eCRF must be completed.
Herpes zoster:  If a subject develops herpes zoster, consider temporarily interrupting 
study drug until the episode resolves.
Gastrointestinal Perforation:  If a diagnosis of gastrointestinal perforation is confirmed 
(other than appendicitis or penetrating injury), the subject must be permanently 
discontinued from study drug.
abbvie 


Upadacitinib
M15-925 Protocol Amendment 6
EudraCT 2016-000933-37
111
Cardiovascular Events (MACE):  Subjects presenting with potential cardiovascular 
events should be carefully monitored.  These events will be reviewed and adjudicated by 
an independent Cardiovascular Adjudication Committee in a blinded manner.
Thrombosis Events: Subjects who develop symptoms of thrombosis should be promptly 
evaluated and treated appropriately.  If the diagnosis of deep vein thrombosis, pulmonary 
embolus or non-cardiac, non-neurologic arterial thrombosis is confirmed, the subject 
should be discontinued from study drug.
Malignancy:  Subjects who develop malignancy other than NMSC or carcinoma in situ 
of the cervix must be discontinued from study drug.  Information including 
histopathological results should be queried for the confirmation of the diagnosis.  Periodic 
skin examination is recommended for subjects who are at increased risk of skin cancer.
ECG Abnormality:  Subjects must be discontinued from study drug for an ECG change 
considered clinically significant and with reasonable possibility of relationship to study 
drug OR a confirmed absolute QTcF value > 500 msec.
Management of Select Laboratory Abnormalities:  For any given laboratory 
abnormality, the Investigator should assess the subject, apply the standard of care for 
medical evaluation and treatment following any local guidelines.  Specific toxicity 
management guidelines for abnormal laboratory values are described in Table 4 and may 
require an appropriate supplemental eCRF be completed.  All abnormal laboratory tests 
that are considered clinically significant by the Investigator will be followed to a 
satisfactory resolution.  If a repeat test is required per Table 4, the repeat testing must 
occur as soon as possible.
abbvie 


Upadacitinib
M15-925 Protocol Amendment 6
EudraCT 2016-000933-37
112
Table 4.
Specific Toxicity Management Guidelines for Abnormal 
Laboratory Values
Laboratory Parameter
Toxicity Management Guideline
Hemoglobin

If hemoglobin < 8 g/dL interrupt study drug dosing and confirm by 
repeat testing with a new sample.

If hemoglobin decreases ≥ 3.0 g/dL from baseline without an 
alternative etiology, interrupt study drug dosing and confirm by repeat 
testing with new sample.

If hemoglobin decreases ≥ 3.0 g/dL from baseline and an alternative 
etiology is known, the subject may remain on study drug at the 
investigator's discretion.

If confirmed, continue to withhold study drug until hemoglobin value 
returns to normal reference range or its baseline value.
Absolute neutrophil count 
(ANC)

If confirmed < 1000 cells/µL by repeat testing with new sample, 
interrupt study drug dosing until ANC value returns to normal 
reference range or its baseline value.

Discontinue study drug if confirmed < 500 cells/µL by repeat testing 
with new sample.
Absolute lymphocyte 
counts (ALC)

If confirmed < 500 cells/µL by repeat testing with new sample, 
interrupt study drug dosing until ALC returns to normal reference 
range or its baseline value.
Total white blood cell 
count

If confirmed < 2000 cells/µL by repeat testing with new sample, 
interrupt study drug dosing until white blood cell count returns to 
normal reference range or its baseline value.
Platelet count

If confirmed < 50,000 cells/µL by repeat testing with new sample, 
interrupt study drug dosing until platelet count returns to normal 
reference range or its baseline value.
abbvie 


Upadacitinib
M15-925 Protocol Amendment 6
EudraCT 2016-000933-37
113
Table 4.
Specific Toxicity Management Guidelines for Abnormal 
Laboratory Values (Continued)
Laboratory Parameter
Toxicity Management Guideline
AST or ALT

Interrupt study drug immediately if confirmed ALT or AST > 3 × ULN 
by repeat testing with new sample and either a total bilirubin 
> 2 × ULN or an international normalized ratio > 1.5.
o
INR will only need to be measured in subjects with ALT or AST 
> 3 × ULN by the central lab.  A repeat test of INR is not needed 
for determination if above toxicity management criteria are met.

Interrupt study drug immediately if confirmed ALT or AST > 3 × ULN 
by repeat testing with new sample along with appearance of fatigue, 
nausea, vomiting, right upper quadrant pain or tenderness, fever, rash, 
and/or eosinophilia (> 5%). 

Interrupt study drug immediately if confirmed ALT or AST > 5 × ULN 
by repeat testing with new sample for more than 2 weeks.

If ALT or AST > 8 × ULN, interrupt study drug immediately, confirm
by repeat testing with a new sample, and contact the TA MD.
Subjects who meet any of the above criteria should be evaluated for an 
alternative etiology of the ALT or AST elevation and managed as medically 
appropriate.  If applicable, the alternative etiology should be documented in 
the eCRF.  If ALT or AST values return to the normal reference range or its 
Baseline value, study drug may be restarted.  If restarting study drug, 
documentation should include reason that rechallenge is expected to be 
safe.  If after clinically appropriate evaluation, no alternative etiology for 
ALT or AST elevation is found or the ALT or AST elevation has not 
resolved or is not trending down toward normal, the subject should be 
discontinued from study drug.
For any confirmed ALT or AST elevations > 3 ULN, complete 
supplemental hepatic eCRF.

Subjects with HBc Ab+ (irrespective of HBs Ab status) and negative 
HBV DNA at screening who develop the following should have HBV 
DNA by PCR testing performed within one week:
o
ALT > 5 × ULN OR
o
ALT or AST > 3 × ULN if an alternative cause is not readily
identified.
A positive result for HBV DNA PCR testing in these subjects will require 
immediate interruption of study drug and a hepatologist consultation should 
occur within one week for recommendation regarding subsequent treatment.
abbvie 


Upadacitinib
M15-925 Protocol Amendment 6
EudraCT 2016-000933-37
114
Table 4.
Specific Toxicity Management Guidelines for Abnormal 
Laboratory Values (Continued)
Laboratory Parameter
Toxicity Management Guideline
Serum Creatinine

If serum creatinine is > 1.5 × the baseline value and > ULN, repeat the 
test for serum creatinine (with subject in an euvolemic state) to confirm 
the results.  If the results of the repeat testing still meet this criterion 
then interrupt study drug and re-start study drug once serum creatinine 
returns to ≤ 1.5 × baseline value and ≤ULN.

If confirmed serum creatinine ≥ 2 mg/dL interrupt study drug, and re-
start study drug once serum creatinine returns to normal reference 
range or its baseline value.
For the above serum creatinine elevation scenarios, complete supplemental 
renal eCRF.
Creatine Phosphokinase

If confirmed CPK value ≥4 × ULN (if symptomatic or asymptomatic), 
complete supplemental CPK eCRF.

If confirmed CPK ≥4 × ULN accompanied by symptoms suggestive of 
myositis or rhabdomyolysis, interrupt study drug, complete 
supplemental CPK eCRF, and contact AbbVie Therapeutic Area 
Medical Director. 
For allowed study drug interruption, the following rules apply:
Period 1
●
Allow study drug interruption up to 7 consecutive days for AEs and 
emergency surgery.  Elective surgery will not be allowed during this 24-week 
period.
●
If the subject must undergo emergency surgery, the study drug should be 
interrupted at the time of the surgery.  After emergency surgery, allow 
reintroduction of study drug once the physician has examined the surgical site 
and determined that it has healed and there is no sign of infection.
Period 2
●
Allow study drug interruption up to 30 consecutive days.  The Investigator will 
make determination if study drug should be restarted for interruptions 
> 30 days. 
abbvie 


Upadacitinib
M15-925 Protocol Amendment 6
EudraCT 2016-000933-37
115
●
If the subject undergoes elective surgery, the study drug should be interrupted 
1 week prior to the planned surgery.  Allow reintroduction of study drug once 
the physician has examined the surgical site and determined that it has healed 
and there is no sign of infection.
●
If the subject must undergo emergency surgery, the study drug should be 
interrupted at the time of surgery.  Allow reintroduction of study drug once the 
physician has examined the surgical site and determined that it has healed and 
there is no sign of infection.
6.1.8
Data Monitoring Committee
An external DMC will review unblinded safety data.  See Section 5.5.5.2 for details.
6.1.9
Cardiovascular Adjudication Committee
An independent committee of physician experts in cardiovascular adjudication will be 
utilized to assess potential cardiovascular AEs in a blinded manner as defined by the 
Cardiovascular Adjudication Committee charter.
6.2
Product Complaint
6.2.1
Definition
A Product Complaint is any Complaint (see Section 6.0 for the definition) related to the 
biologic or drug component of the product.
For a product this may include, but is not limited to, damaged/broken product or 
packaging, product appearance whose color/markings do not match the labeling, labeling 
discrepancies/inadequacies in the labeling/instructions (example:  printing illegible), 
missing components/product, or packaging issues.
Any information available to help in the determination of causality to the events outlined
directly above should be captured.
abbvie 


Upadacitinib
M15-925 Protocol Amendment 6
EudraCT 2016-000933-37
116
6.2.2
Reporting
Product Complaints concerning the investigational product must be reported to the 
Sponsor within 24 hours of the study site's knowledge of the event via the Product 
Complaint form.  Product Complaints occurring during the study will be followed-up to a 
satisfactory conclusion.  All follow-up information is to be reported to the Sponsor (or an 
authorized representative) and documented in source as required by the Sponsor.  Product 
Complaints associated with adverse events will be reported in the study summary.  All 
other complaints will be monitored on an ongoing basis.
Product Complaints may require return of the product with the alleged complaint 
condition.  In instances where a return is requested, every effort should be made by the 
Investigator to return the product within 30 days.  If returns cannot be accommodated 
within 30 days, the site will need to provide justification and an estimated date of return.
The description of the complaint is important for AbbVie in order to enable AbbVie to 
investigate and determine if any corrective actions are required.
7.0
Protocol Deviations
AbbVie does not allow intentional/prospective deviations from the protocol unless when 
necessary to eliminate an immediate hazard to study subjects.  The Principal Investigator 
is responsible for complying with all protocol requirements, and applicable global and 
local laws regarding protocol deviations.  If a protocol deviation occurs (or is identified, 
including those that may be due to the COVID-19 or any pandemic or any state of 
emergency situation) after a subject has been enrolled, the Principal Investigator is 
responsible for notifying IEC/IRB regulatory authorities (as applicable), and the following 
AbbVie Clinical Contacts:
abbvie 




Upadacitinib
M15-925 Protocol Amendment 6
EudraCT 2016-000933-37
118
The statistical analysis described in this section applies to subjects who are enrolled under 
Amendment 4 or 3.01 or later.  For the subjects enrolled under Amendment 3, no formal 
statistical analysis is intended.  
Starting with Amendment 5, all subjects in Period 2 will receive open-label upadacitinib 
15 mg QD, including those currently on upadacitinib 30 mg QD. The details for handling 
the dose adjustment in analysis will be described in the Statistical Analysis Plan (SAP) for 
final reporting.
Completed and specific details of the statistical analysis will be described and fully 
documented in the Statistical Analysis Plan (SAP).  The SAP will be finalized prior to the 
Week 24 analysis database lock.  The statistical analyses will be performed using SAS 
(SAS Institute Inc., Cary, NC, USA).
8.1.1
Analysis Populations
8.1.1.1
Full Analysis Set
The Full Analysis Set (FAS) includes all randomized subjects who received at least 
one dose of study drug.  The FAS will be used for all efficacy and baseline analyses.
8.1.1.2
Per Protocol Analysis Set
The Per Protocol Analysis Set represents a subset of the FAS and consists of all FAS 
subjects who did not meet any major protocol violations during the study.  Definitions of 
major protocol violations will be detailed in the SAP.  Additional analysis may be 
conducted on the Per Protocol analysis set, in order to evaluate the impact of major 
protocol violations.
8.1.1.3
Safety Analysis Set
The Safety Analysis Set consists of all subjects who received at least one dose of study 
drug.  For the Safety Analysis Set, subjects are assigned to a treatment group based on the 
treatment actually received, regardless of the treatment randomized.
abbvie 


Upadacitinib
M15-925 Protocol Amendment 6
EudraCT 2016-000933-37
119
8.1.2
Subject Accountability, Disposition and Study Drug 
Exposure
8.1.2.1
Subject Accountability
The following will be summarized by site and by treatment group as well as overall, 
separately for Period 1 and Period 2:  number of subjects randomized, the number of 
subjects who received at least one dose of study drug, the number of subjects who 
completed, the number of subjects who prematurely discontinued study drug, and the 
number of subjects who prematurely discontinued study participation.
8.1.2.2
Subject Disposition
Separately for Period 1 and Period 2, the number and percentage of subjects who are 
randomized, received at least one dose of study drug, prematurely discontinued study 
drug, prematurely discontinued study participation, and completed will be summarized by 
treatment group and overall.  Reasons for premature discontinuation of study drug and 
study participation will be summarized separately for all randomized subjects by 
treatment group and overall, with frequencies and percentages by reason for 
discontinuation.
8.1.2.3
Study Drug Exposure
Exposure to study drug will be summarized for the Safety Analysis Set for Period 1 alone 
as well as for Period 1 and Period 2 combined.  The exposure to study drug (days) will be 
summarized with the mean, standard deviation, median, and range for each treatment 
group.
Study drug compliance will be summarized for each treatment group for Period 1.  The 
compliance is defined as the number of tablets taken (i.e., the difference between the 
number of tablets dispensed and the number of tablets returned) during the subject's 
participation in Period 1 divided by the number of tablets a subject is supposed to take 
each day times the length of time that the subject was in the Treatment Phase of Period 1.
abbvie 


Upadacitinib
M15-925 Protocol Amendment 6
EudraCT 2016-000933-37
120
8.1.3
Analysis of Demographic and Baseline Characteristics
Demographic and baseline characteristics will be summarized by treatment group and 
overall for the FAS.  For the purpose of this analysis, baseline data for each subject will 
be the data collected immediately prior to the first dose of study drug in Period 1.
Summary statistics for continuous variables will include the number of observations, 
mean, standard deviation, median, and range.  For discrete variables, frequencies and 
percentages for each category will be summarized.
Medical history will be presented by counts and percentages of subjects, broken down by 
Body System and Diagnosis.
Prior therapy and medication will be summarized by treatment group.  Prior therapy and 
medication will include all therapies and medications with a start date prior to the date of 
first dose of study drug.
Concomitant medications will also be summarized with frequencies and percentages for 
each treatment group.  All medications administered during study drug exposure will be 
included.
8.1.4
Efficacy Analyses
All efficacy analyses will be carried out using the FAS population, which includes all 
randomized subjects who receive at least one dose of study drug.
8.1.4.1
Efficacy Analysis for Period 1
8.1.4.1.1
Primary Efficacy Variable
The primary endpoint is the non-inferiority comparison of upadacitinib to abatacept on 
change from baseline in DAS28 (CRP) at Week 12.
abbvie 


Upadacitinib
M15-925 Protocol Amendment 6
EudraCT 2016-000933-37
121
Analysis of the primary endpoint will be conducted on the FAS based on treatment as 
randomized.  The mean, standard deviation, median, and range will be reported for each 
treatment group.
Between-group comparison of upadacitinib and abatacept will be performed using the 
analysis of covariance (ANCOVA) model with treatment as the fixed factor, and the 
corresponding baseline value and the main stratification factors as the covariates.  The 
non-inferiority of upadacitinib to abatacept on change from baseline in DAS28(CRP) at 
Week 12 will be evaluated against a non-inferiority margin of 0.6 using the 95% 
confidence interval (CI) of treatment difference from the ANCOVA model.  The margin 
of 0.6 was derived considering both the meta-analysis of placebo-subtracted effect of 
biologics in DAS28 on biologic-inadequate responder populations as well as the EULAR 
response criteria of "no response" for no clinically meaningful change.
For the primary analysis, multiple imputation will be used.  The analysis will be repeated 
using Observed Cases (OC).  Supportive analysis will also be conducted on the Per 
Protocol Analysis Set.
Treatment difference together with its 95% CI on the primary endpoint will be 
summarized in demographic subgroups including age, gender, weight, body mass index, 
race, and geographical region to assess the consistency of the treatment effect.  Additional 
subgroup summaries based on baseline disease characteristics and stratification factors 
will also be conducted.  However, no formal non-inferiority comparison will be 
performed at subgroup level.
8.1.4.1.2
Key Secondary Efficacy Variables
Key secondary endpoints are listed in Section 5.3.3.1.2.
For the binary endpoint proportion of subjects achieving Clinical Remission (CR), 
frequencies and percentages will be reported for each treatment group.  Comparison of 
upadacitinib to abatacept will be conducted using the Cochran-Mantel-Haenszel test 
adjusting for main stratification factors.
abbvie 


Upadacitinib
M15-925 Protocol Amendment 6
EudraCT 2016-000933-37
122
For the continuous endpoint change from baseline in DAS28(CRP), the mean, standard 
deviation, median, and range will be reported for each treatment group.  Superiority of 
upadacitinib to abatacept on change from baseline in DAS28(CRP) at Week 12 will also 
be evaluated based on the same ANCOVA model as in the non-inferiority comparison.
See Section 8.1.4.1.5 for imputation methods.
8.1.4.1.3
Other Efficacy Variables
Additional efficacy variables are listed in Section 5.3.3.1.3 and will be summarized for all 
visits, including visits beyond Week 24.  For binary endpoints, frequencies and 
percentages will be reported for each treatment group.  For continuous endpoints, the 
change from baseline mean, standard deviation, median, and range will be reported for 
each treatment group.
8.1.4.1.4
Multiplicity Control for Primary and Key Secondary 
Endpoints
In order to preserve Type I error, a step-down approach will be used to test the primary 
and key secondary endpoints where statistical significance can be claimed for a lower 
ranked endpoint only if the previous endpoint in the sequence meets the requirements of 
significance.  
8.1.4.1.5
Imputation Methods
The following methods will be used for missing data imputation:
Observed Cases (OC):  The OC analysis will not impute values for missing evaluations, 
and thus a subject who does not have an evaluation on a scheduled visit will be excluded 
from the OC analysis for that visit.
Multiple Imputation (MI):  The MI analysis imputes missing data multiple times under 
appropriate random variation and thus generates multiple imputed "pseudo-complete"
abbvie 


Upadacitinib
M15-925 Protocol Amendment 6
EudraCT 2016-000933-37
123
datasets.  Results will be aggregated across the multiple imputed datasets, overcoming 
drawbacks of the single imputation methods.
Non-Responder Imputation (NRI):  NRI applies to binary endpoints only.  In NRI 
analysis, subjects who prematurely discontinue study drug will be considered 
non-responders after discontinuation.
The NRI approach will serve as the primary analysis approach for key binary endpoints.  
The MI approach will serve as the primary analysis approach for key continuous 
endpoints.  Sensitivity analyses based on OC will also be conducted for key endpoints.
8.1.4.2
Long-Term Efficacy Analysis for Period 1 and Period 2 
Combined
The efficacy endpoints of long-term efficacy analysis are listed in Section 5.3.3.2 and will 
be summarized for all visits.
Long-term efficacy by time point will be summarized using descriptive statistics.  For 
binary endpoints, frequencies and percentages will be summarized.  For continuous 
endpoints, the mean and standard deviation will be reported.
8.1.5
Safety Analyses
8.1.5.1
General Considerations
Safety analyses will be carried out using the Safety Analysis Set.  Analyses will be 
conducted for Period 1 alone, as well as for Period 1 and Period 2 combined.
Safety analyses are based on treatments actually received.  Safety will be assessed by 
AEs, physical examination, laboratory assessments, ECG, and vital signs.  Frequency 
tables and lists of subjects with treatment-emergent AEs by preferred term as in the 
Medical Dictionary for Regulatory Activities (MedDRA) dictionary, by system organ 
class, by severity, and by relationship to the study drug as assessed by the Investigator 
will be provided.  The changes from baseline in vital signs, physical examination results, 
abbvie 


Upadacitinib
M15-925 Protocol Amendment 6
EudraCT 2016-000933-37
124
and clinical laboratory values will be analyzed in a descriptive manner.  Shift of 
laboratory values from baseline to defined time points will be tabulated.
Missing safety data will not be imputed.
8.1.5.2
Analysis of Adverse Events
Unless otherwise specified, the following conventions apply for both the Period 1 safety 
analysis and the combined safety analysis of Period 1 and Period 2.
8.1.5.2.1
Treatment-Emergent Adverse Events (TEAE)
AEs will be coded using MedDRA.  A TEAE is defined as AE that began or worsened in 
severity after initiation of study drug.
AEs starting more than 70 days following the last dose of study drug for subjects on 
abatacept and AEs starting more than 30 days following the last dose of study drug for 
subjects on upadacitinib will not be included in summaries of TEAEs.  For subjects who 
continued into Period 2, AEs that are reported in Period 2 will be captured in the 
combined safety analysis of Period 1 and Period 2.  
As a general safety summary, the number and percentage of subjects experiencing TEAEs 
will be summarized for each treatment group for the following AE categories:
●
All AEs;
●
All severe AEs;
●
All reasonably possibly related AEs;
●
All SAEs;
●
Frequent AEs (reported in 2% of subjects or more in any treatment group);
●
Frequent reasonably possibly related AEs (reported in 2% of subjects or more 
in any treatment group);
●
Discontinuations due to AEs;
●
Death.
abbvie 


Upadacitinib
M15-925 Protocol Amendment 6
EudraCT 2016-000933-37
125
Additional AEs may be considered for tabulation/summary based on recommendations 
from Clinical and Safety as deemed appropriate.
TEAEs will be summarized and presented by system organ classes (SOCs) and preferred 
terms (PTs) using MedDRA.  The SOCs will be presented in alphabetical order, and the 
PTs will be presented in alphabetical order within each SOC.
TEAE will also be summarized by maximum severity and by maximum relationship.
The AEs of special interest (including but not limited to serious infection, opportunistic 
infection, herpes zoster, TB, gastrointestinal perforations, malignancies, MACE, renal 
dysfunction, anemia, increased CPK, and drug-related hepatic disorders) will be 
summarized.  Event rate (per 100 patient years) for AEs of special interest will also be 
summarized for the combined safety analysis of Period 1 and Period 2.
All AEs leading to discontinuation of study drug will be presented in listing format.  A 
listing by treatment group of TEAEs grouped by SOC and MedDRA preferred term with 
subject identification numbers will be generated.
8.1.5.2.2
Serious Adverse Events and Death
All treatment-emergent SAEs and AEs leading to death will also be presented in listing 
format.  In addition, SAEs will be summarized by SOC and MedDRA PT.
8.1.5.3
Analysis of Laboratory, Vital Sign, and ECG Data
Changes from baseline by visit, and changes from baseline to minimum value, maximum 
value, and final values in continuous laboratory data, and vital signs will be summarized 
by treatment group.
Baseline values are defined as the last non-missing measurements recorded on or before 
the date of the first dose of study drug in Period 1.
abbvie 


Upadacitinib
M15-925 Protocol Amendment 6
EudraCT 2016-000933-37
126
The laboratory data will be categorized as Grade 1, Grade 2, Grade 3, and Grade 4 
according to OMERACT criteria (Rheumatology Common Toxicity Criteria v.2.0).  For 
creatinine phosphokinase, serum creatinine, and parameters that are not covered in the 
OMERACT criteria, NCI CTC criteria will be used.  The shift tables will tabulate the 
number and percentage of subjects with baseline and post-baseline values by grade levels.
Listings will be provided for potentially clinically significant laboratory values and vital 
signs.
8.1.6
Pharmacokinetic and Exposure-Response Analyses
Individual upadacitinib plasma concentrations at each study visit will be tabulated and 
summarized with appropriate statistical methods.
Data from this study may be combined with data from other studies for the population PK 
and exposure-response analyses.  Population PK and exposure-response analyses of only 
data from this study may not be conducted.  The following general methodology will be 
used for the population PK and exposure-response analyses.
Population PK analyses will be performed using the actual sampling time relative to 
dosing.  PK models will be built using a non-linear mixed-effects modeling approach with 
non-linear mixed-effects modeling (NONMEM) software (Version 7, or a higher version).  
The structure of the starting PK model will be based on the PK analysis of data from 
previous studies.  The CL/F and V/F of upadacitinib will be the PK parameters of major 
interest in the analyses.  If necessary, other parameters, including the parameters 
describing absorption characteristics, may be fixed if useful in the analysis.
The evaluation criteria described below will be used to examine the performance of 
different models.
1.
The objective function of the best model is significantly smaller than the alternative 
model(s).
abbvie 


Upadacitinib
M15-925 Protocol Amendment 6
EudraCT 2016-000933-37
127
2.
The observed and predicted concentrations from the preferred model are more 
randomly distributed across the line of unity (a straight line with zero intercept and 
a slope of one) than the alternative model(s).
3.
Visual inspection of model fits, standard errors of model parameters and change in 
inter-subject and intra-subject error.
Once an appropriate base PK model (including inter- and intra-subject error structure) is 
developed, empirical Bayesian estimates of individual model parameters will be 
calculated by the posterior conditional estimation technique using non-linear 
mixed-effects modeling.  The relationship between these conditional estimates CL/F and 
V/F values with only potentially physiologically relevant or clinically meaningful 
covariates (such as subject age, sex, body weight, concomitant medications, laboratory 
markers of hepatic of renal function, etc.) will be explored using stepwise forward 
selection method, or another suitable regression/smoothing method at a significance level 
of 0.05.  After identification of all relevant covariates, a stepwise backward elimination of 
covariates from the full model will be employed to evaluate the significance (at P < 0.005, 
corresponding to a decrease in objective function > 7.88 for one degree of freedom) of 
each covariate in the full model.
Linear or non-linear relationships of primary PK parameters with various covariates will 
be explored.
Relationships between upadacitinib exposure and clinical observations (primary efficacy 
variable) will be explored.  Exposure-response relationships for secondary efficacy 
variables and/or some safety measures of interest may also be explored.  The relationship 
between exposure (e.g., population PK model predicted average concentrations, area 
under the curve, trough concentrations, the individual model-predicted PK profiles, or 
some other appropriate measure of exposure) and drug effect will be explored.  Several 
classes of models (e.g., linear, log-linear, exponential, Emax, sigmoid Emax, etc.) will be 
evaluated to characterize the exposure-response relationship based on observed data.
abbvie 


Upadacitinib
M15-925 Protocol Amendment 6
EudraCT 2016-000933-37
128
Results of the PK and exposure-response analyses may be summarized in a separate report 
prior to regulatory filing of upadacitinib for the treatment of RA, rather than in the CSR.
Additional analyses will be performed if useful and appropriate.
8.1.7
Statistical Analysis of Biomarker Data
If the optional exploratory research variables including an additional panel of prognostic, 
and predictive biomarkers are evaluated, then those data may be analyzed as follows.  The 
association of biomarkers to the efficacy and safety endpoints may be explored for each 
biomarker one at a time, and also for combinations of biomarkers via some multivariate 
predictive modeling algorithms.  Optimal multivariate combinations of biomarkers that 
associate with efficacy endpoints, subject response/non-response (with respect to 
appropriate clinical endpoints), and also with safety endpoints may be explored via a 
variety of statistical predictive modeling algorithms.  Also cut-points for individual 
biomarkers and optimal combinations of biomarkers that differentiate the subject response 
with respect to efficacy/safety endpoints may be explored.  The significance of these 
multivariate combinations of biomarkers may be assessed via at least 20 iterations of 5-
fold cross-validation.
8.2
Determination of Sample Size
The planned total sample size of 550 (N = 275 per arm) can provide more than 90% 
power for the non-inferiority assessment on the primary endpoint using a non-inferiority 
margin of 0.6 at two-sided significance level of 0.05, assuming true difference between 
upadacitinib and abatacept in change from baseline in DAS28 (CRP) is 0.5 with an 
assumed standard deviation of 2.0 and accounting for a 10% drop rate.  Under the planned 
sample size, superiority comparison of upadacitinib to abatacept in change from baseline 
in DAS28 (CRP) is powered at approximately 80%.  The planned sample size can also 
provide approximately 80% power for superiority comparison of upadacitinib to abatacept 
in DAS CR at two-sided significance level of 0.05 and accounting for a 10% dropout rate, 
where the assumed DAS CR response rate is 31% for upadacitinib and 20% abatacept.
abbvie 


Upadacitinib
M15-925 Protocol Amendment 6
EudraCT 2016-000933-37
129
8.3
Randomization Methods
Subjects will be randomly assigned in a 1:1 ratio to one of the two treatment groups:
●
Group 1:  Upadacitinib 15 mg QD, N = 275 (Period 1) 
●
Group 2:  Abatacept, N = 275 (Period 1)
Randomization will be stratified by number of prior bDMARD use (stratum 1:  failed 1 or 
2 biologics of the same class; stratum 2:  failed ≥ 3 biologics of the same class or failed 
biologics of multiple classes) and geographic region.  Once 35% of the total subjects have 
been randomized in stratum 2, further screening of subjects who meet stratum 2 criteria 
may be suspended.  Once 20% of total subjects have been randomized who have not 
completed > 3 months of methotrexate, further screening of such methotrexate 
inexperienced subjects may be suspended.
See Section 5.5.3 for details.
9.0
Ethics
9.1
Independent Ethics Committee (IEC) or Institutional Review 
Board (IRB)
Good Clinical Practice requires that the clinical protocol, any protocol amendments, the 
Investigator's Brochure, the informed consent, and all other forms of subject information 
related to the study (e.g., advertisements used to recruit subjects) and any other necessary 
documents be reviewed by an IEC/IRB.  The IEC/IRB will review the ethical, scientific 
and medical appropriateness of the study before it is conducted.  IEC/IRB approval of the 
protocol, informed consent, and subject information and/or advertising, as relevant, will 
be obtained prior to the authorization of drug shipment to a study site.
Any amendments to the protocol will require IEC/IRB approval and approval by 
Regulatory Authority(ies), if required by local law regulations, prior to implementation of 
any changes made to the study design.  The investigator will be required to submit, 
abbvie 


Upadacitinib
M15-925 Protocol Amendment 6
EudraCT 2016-000933-37
130
maintain and archive study essential documents according to International Conference on 
Harmonization (ICH) GCP and all other applicable regulatory requirements.
Any SAEs that meet the reporting criteria, as dictated by local regulations, will be 
reported to both responsible Ethics Committees and Regulatory Agencies, as required by 
local regulations.  During the conduct of the study, the Investigator should promptly 
provide written reports (e.g., ICH Expedited Reports, and any additional reports required 
by local regulations) to the IEC/IRB of any changes that affect the conduct of the study 
and/or increase the risk to subjects.  Written documentation of the submission to the 
IEC/IRB should also be provided to AbbVie.
9.2
Ethical Conduct of the Study
The study will be conducted in accordance with the protocol, ICH guidelines, applicable 
regulations and guidelines governing clinical study conduct and the ethical principles that 
have their origin in the Declaration of Helsinki.  Responsibilities of the clinical 
investigator are specified in Appendix A.
In the event a significant disaster/crisis (e.g., epidemic/pandemic, natural disaster, 
conflict/combat) occurs leading to difficulties in performing protocol-specified 
procedures, AbbVie may engage with study site personnel in efforts to ensure the safety 
of subjects, maintain protocol compliance, and minimize risks to the integrity of the study 
while trying to best manage subject continuity of care.  This may include alternative 
methods for assessments (e.g., virtual site visits), alternative locations for data collection 
(e.g., use of a local lab instead of a central lab), and shipping investigational product 
and/or supplies direct to subjects to ensure continuity of treatment where allowed.  In all 
cases, these alternative measures must be allowed by local regulations and permitted by 
IRB/IEC.  Investigators should notify AbbVie if any urgent safety measures are taken to 
protect the subjects against any immediate hazard.
abbvie 


Upadacitinib
M15-925 Protocol Amendment 6
EudraCT 2016-000933-37
131
9.3
Subject Information and Consent
The Investigator or his/her representative will explain the nature of the study to the 
subject, and answer all questions regarding this study.  Prior to any study-related 
screening procedures being performed on the subject, the informed consent statement will 
be reviewed and signed and dated by the subject, the person who administered the 
informed consent, and any other signatories according to local requirements.  A copy of 
the informed consent will be given to the subject and the original will be placed in the 
subject's medical record.  An entry must also be made in the subject's dated source 
documents to confirm that informed consent was obtained prior to any study-related 
procedures and that the subject received a signed copy.
Information regarding incentives for subjects and information regarding provisions for 
treating and/or compensating subjects who are harmed as a consequence of participation 
in the study can be found in the informed consent.
Samples for exploratory research/validation studies will only be collected if the subject 
has voluntarily signed and dated the separate written consent for exploratory 
research/validation studies, approved by an IRB/IEC, after the nature of the testing has 
been explained and the subject has had an opportunity to ask questions.  The separate 
written consent must be signed before the exploratory research/validation studies samples 
are collected and testing is performed.  If the subject does not consent to the exploratory 
research/validation studies, it will not impact the subject's participation in the study.
In the event a subject withdraws from the main study, optional exploratory 
research/validation samples will continue to be stored and analyzed unless the subject 
specifically withdraws consent for the optional samples.  If consent is withdrawn for the 
optional sampling, the subject must inform their study doctor, and once AbbVie is 
informed, the optional samples will be destroyed.  However, if the subject withdraws 
his/her consent and the samples have already been tested, those results will still remain as 
part of the overall research data.
abbvie 


Upadacitinib
M15-925 Protocol Amendment 6
EudraCT 2016-000933-37
132
Due pandemic situation like COVID-19 or state of emergency, it is possible that 
additional protocol modifications not outlined in this protocol may become necessary.  If 
this situation arises, in addition to the study informed consent, additional verbal consent 
may be obtained prior to these adaptations or substantial changes in study conduct in 
accordance with local regulations.
10.0
Source Documents and Case Report Form 
Completion
10.1
Source Documents
Source documents are defined as original documents, data, and records.  This may include 
joint evaluation form, hospital records, clinical and office charts, laboratory 
data/information, subjects' diaries or evaluation checklists, pharmacy dispensing and other 
records, recorded data from automated instruments, microfiches, photographic negatives, 
microfilm or magnetic media, and/or x-rays.  Data collected during this study must be 
recorded on the appropriate source documents.  The Investigator Awareness Date (SAE 
CRF) may serve as the source for this data point.  This adverse event data point required 
for eCRF completion can be entered directly in the eCRF.
The Investigator(s)/Institution(s) will permit study-related monitoring, audits, IEC/IRB 
review, and regulatory inspection(s), providing direct access to source data documents.
During the COVID-19 pandemic or any pandemic/state of emergency, remote monitoring 
of data may be employed if allowed by the local regulatory authority, IRB/IEC, and the 
study site.
10.2
Case Report Forms
Case report forms (CRFs) must be completed for each subject screened/enrolled in this 
study.  These forms will be used to transmit information collected during the study to 
AbbVie and regulatory authorities, as applicable.  The CRF data for this study are being 
collected with an EDC system called Rave® provided by the technology vendor Medidata 
Solutions Incorporated, NY, USA.  The EDC system and the study-specific eCRFs will 
abbvie 


Upadacitinib
M15-925 Protocol Amendment 6
EudraCT 2016-000933-37
133
comply with Title 21 CFR Part 11.  The documentation related to the validation of the 
EDC system is available through the vendor, Medidata, while the validation of the 
study-specific eCRFs will be conducted by AbbVie and will be maintained in the Trial 
Master File at AbbVie.
The Investigator will document subject data in his/her own subject files.  These subject 
files will serve as source data for the study.  All eCRF data required by this protocol will 
be recorded by investigative site personnel in the EDC system.  All data entered into the 
eCRF will be supported by source documentation.
The Investigator or an authorized member of the investigator's staff will make any 
necessary corrections to the eCRF.  All change information, including the date and person 
performing the corrections, will be available via the audit trail, which is part of the EDC 
system.  For any correction, a reason for the alteration will be provided.  The eCRFs will 
be reviewed periodically for completeness, legibility, and acceptability by AbbVie 
personnel (or their representatives).  AbbVie (or their representatives) will also be allowed 
access to all source documents pertinent to the study in order to verify eCRF entries.  The 
Principal Investigator will review the eCRFs for completeness and accuracy and provide 
his or her electronic signature and date to eCRFs as evidence thereof.
Medidata will provide access to the EDC system for the duration of the study through a 
password-protected method of internet access.  Such access will be removed from 
investigator sites at the end of the site's participation in the study.  Data from the EDC 
system will be archived on appropriate data media (CD-ROM, etc.) and provided to the 
Investigator at that time as a durable record of the site's eCRF data.  It will be possible for 
the Investigator to make paper printouts from that media.
Patient and site reported data must be completed for each subject screened/enrolled in this 
study.
●
The following data are being collected with an Electronic Patient-Reported 
Outcome (ePRO) system called Trialmax, provided by the technology vendor 
CRF Health of Plymouth Meeting, PA, USA:
abbvie 


Upadacitinib
M15-925 Protocol Amendment 6
EudraCT 2016-000933-37
134
○
Completed by Patient:
●
Patient Global Assessment of Disease Activity VAS
●
Patient's Assessment of Severity and Duration of Morning Stiffness
●
Patient's Assessment of Pain VAS
●
HAQ-DI
●
SF-36
●
EQ-5D-5L
●
WPAI RA
●
FACIT-F
○
Completed by Site:
●
Physician Global Assessment of Disease Activity VAS
The ePRO system is in compliance with Title 21 CFR Part 11.  The documentation related 
to the system validation of the ePRO system is available through the vendor, CRF Health, 
while the user acceptance testing of the study-specific PRO design will be conducted and 
maintained at AbbVie.
The subject will be entering the data on an electronic device; these data will be uploaded 
to a server.  The data on the server will be considered source and will be maintained and 
managed by CRF Health.
Internet access to the ePRO data will be provided by CRF Health for the duration of the 
trial.  This access will be available for the duration of the trial to the site investigator, as 
well as delegated personnel.  Such access will be removed from investigator sites 
following the receipt of the study archive.  Data from the ePRO system will be archived 
on appropriate data media (CD-ROM, etc.) and provided to the investigator at that time as 
a durable record of the site's ePRO data.  It will be possible for the investigator to make 
paper print-outs from that media.
The ePRO data will be collected by the following method:
abbvie 


Upadacitinib
M15-925 Protocol Amendment 6
EudraCT 2016-000933-37
135
Tablet Based
●
The instrument/scale will be collected electronically via a tablet device into 
which the subject will directly enter the required pieces of information.  The 
electronic device will be programmed to allow data entry for only the visits 
specified in the protocol and will not allow for subjects to complete more than 
one of the same assessment at any one visit.  All data entered on the device 
will be immediately stored to the device itself and automatically uploaded to a 
central server administrated by CRF Health.  The Investigator and delegated 
staff will be able to access all uploaded subject entered data via a password 
protected website, up until the generation, receipt and confirmation of the 
study archive.
11.0
Data Quality Assurance
Prior to the initiation of the study, a meeting will be held with AbbVie personnel, the 
investigators and appropriate site personnel.  This meeting will include a detailed 
discussion of the protocol, performance of study procedures, CRF, subject dosing diary, 
and specimen collection methods.  Another alternative of site training may include 
module training via a study portal.
To ensure data integrity and subject safety, a study monitor will continuously and 
throughout the study, verify that all subjects sign the informed consent prior to any study 
specific procedures being conducted, that the protocol procedures are being followed 
appropriately, and that the information provided in the eCRF is complete, accurate, and 
supported by information in the source documents.
The AbbVie monitor will monitor each site throughout the study.  Source document 
review will be performed against entries on the CRF and a quality assurance check will be 
performed to ensure that the Investigator is complying with the protocol and regulations.
Data hand entered in the database will be verified at AbbVie.  Any discrepancies will be 
reviewed against the CRF and corrected on-line.  After completion of the entry process, 
abbvie 


Upadacitinib
M15-925 Protocol Amendment 6
EudraCT 2016-000933-37
136
computer logic and manual checks will be created by AbbVie to identify items such as 
inconsistent study dates.  Any necessary corrections will be made by the site to the eCRF.
Routine hematology, serum chemistry and serology, and urinalysis, and other tests such as 
rheumatoid factor, anti-CCP, and HBV/HCV testing, will be conducted using a central 
laboratory (refer to Appendix D and Appendix F).  The data from these analyses will be 
electronically transferred from the central laboratory to the study database.
Laboratory tests including, but not limited to, urine pregnancy testing and ESR, will be 
conducted locally by each study site (refer to Appendix D and Appendix F).  Sites will 
provide AbbVie with laboratory certifications and normal ranges for each local laboratory 
used.  The full name, address, phone number and fax number for each local laboratory 
will also be included.
12.0
Use of Information
Any research that may be done using optional exploratory research/validation samples 
from this study will be experimental in nature and the results will not be suitable for 
clinical decision making or patient management.  Hence, the subject will not be informed 
of individual results, should analyses be performed, nor will anyone not directly involved 
in this research.  Correspondingly, researchers will have no access to subject identifiers.  
Individual results will not be reported to anyone not directly involved in this research 
other than for regulatory purposes.  Aggregate data from optional exploratory 
research/validation studies may be provided to investigators and used in scientific 
publications or presented at medical conventions.  Exploratory research/validation 
information will be published or presented only in a way that does not identify any 
individual subject.
13.0
Completion of the Study
The Investigator will conduct the study in compliance with the protocol and complete the 
study within the timeframe specified in the contract between the Investigator and AbbVie.  
Continuation of this study beyond this date must be mutually agreed upon in writing by 
abbvie 


Upadacitinib
M15-925 Protocol Amendment 6
EudraCT 2016-000933-37
137
both the Investigator and AbbVie.  The Investigator will provide a final report to the 
IEC/IRB following conclusion of the study, and will forward a copy of this report to 
AbbVie or their representative.
The Investigator must submit, maintain, and archive any records related to the study 
according to ICH GCP and all other applicable regulatory requirements.  If the 
Investigator is not able to retain the records, he/she must notify AbbVie to arrange 
alternative archiving options.
AbbVie will select the signatory Investigator from the Investigators who participate in the 
study.  Selection criteria for this Investigator will include level of participation as well as 
significant knowledge of the clinical research, investigational drug, and study protocol.  
The signatory Investigator for the study will review and sign the final study report in 
accordance with the European Agency for the Evaluation of Medicinal Products Guidance 
on Investigator's Signature for Study Reports.
The end-of-study is defined as the date of the last subject's last visit.
abbvie 


Upadacitinib
M15-925 Protocol Amendment 6
EudraCT 2016-000933-37
138
14.0
Investigator's Agreement
1.
I have received and reviewed the Investigator's Brochure for upadacitinib.
2.
I have read this protocol and agree that the study is ethical.
3.
I agree to conduct the study as outlined and in accordance with all applicable 
regulations and guidelines.
4.
I agree to maintain the confidentiality of all information received or developed in 
connection with this protocol.
5.
I agree that all electronic signatures will be considered the equivalent of a 
handwritten signature and will be legally binding.
Protocol Title: 
A Phase 3, Randomized, Active-Controlled, Double-Blind Study 
Comparing Upadacitinib (ABT-494) to Abatacept in Subjects with 
Moderately to Severely Active Rheumatoid Arthritis with 
Inadequate Response or Intolerance to Biologic DMARDs 
(bDMARDs) on Stable Conventional Synthetic Disease Modifying 
Anti-Rheumatic Drugs (csDMARDs)
Protocol Date:
04 December 2020
Signature of Principal Investigator
Date
Name of Principal Investigator (printed or typed)
abbvie 


Upadacitinib
M15-925 Protocol Amendment 6
EudraCT 2016-000933-37
139
15.0
Reference List
1.
Grigor C, Capell H, Stirling A, et al.  Effect of treatment strategy of tight control 
for rheumatoid arthritis (the TICORA study):  a single-blind randomised controlled 
trial.  Lancet.  2004;364(9430):263-9.
2.
Vermeer M, Kuper HH, Bernelot Moens HJ, et al.  Adherence to a treat-to-target 
strategy in early rheumatoid arthritis:  results of the DREAM remission induction 
cohort.  Arthritis Res Ther.  2012;14(6):R254.
3.
Verstappen SM, Jacobs JW, van der Veen MJ, et al.  Intensive treatment with 
methotrexate in early rheumatoid arthritis:  aiming for remission.  Computer 
assisted management in early rheumatoid arthritis (CAMERA, an open-label 
strategy trial).  Ann Rheum Dis.  2007;66(11):1143-9.
4.
Aletaha D, Neogi T, Silman AJ, et al.  2010 rheumatoid arthritis classification 
criteria:  an American College of Rheumatology/European League against 
Rheumatism collaborative initiative.  Ann Rheum Dis.  2010;69(9):1580-8.
5.
Vaddi K, Luchi M.  JAK inhibition for the treatment of rheumatoid arthritis:  a new 
era in oral DMARD therapy.  Expert Opin Investig Drugs.  2012;21(7):961-73.
6.
Murray PJ.  The Jak-STAT signaling pathway:  input and output integration.  
J Immunol.  2007;178(5):2623-9.
7.
Xeljanz® (tofacitinib) [package insert].  New York, NY; Pfizer Labs, 2015.
8.
Lawendy N, Krishnaswai S, Wang R, et al.  Effect of CP-690,550, an orally active 
janus kinase inhibitor, on renal function in healthy adult volunteers.  J Clin 
Pharmacol.  2009;49(4):423-9.
9.
Greenwald MK, Fidelus-Gort R, Levy R, et al.  A randomized dose-ranging, 
placebo-controlled study of INCB028050, a selective JAK1 and JAK2 inhibitor in 
subjects with active rheumatoid arthritis [abstract].  Arthritis Rheum.  
2010;62 (Suppl 10):2172.
abbvie 


Upadacitinib
M15-925 Protocol Amendment 6
EudraCT 2016-000933-37
140
10.
Dougados M, van der Heijde D, Chen YC, et al.  Baricitinib, an oral janus kinase 
(JAK)1/JAK2 inhibitor, in patients with active rheumatoid arthritis (RA) and an 
inadequate response to CDMARD therapy:  results of the phase 3 RA-build study.  
Ann Rheum Dis.  2015;74 (Suppl 2):79.
11.
Genovese MC, Kremer J, Zamani O, et al.  Baricitinib in patients with refractory 
rheumatoid arthritis.  N Engl J Med.  2016;374(13):1243-52.
12.
Burmester GR, Feist E, Dorner T.  Emerging cells and cytokine targets in 
rheumatoid arthritis.  Nat Rev Rheumatol.  2014;10(2):77-88.
13.
Emery P.  Why is there persistent disease despite biological therapy?  Importance 
and early intervention.  Arthritis Res Ther.  2014;16(3):115.
14.
Meier FM, McInnes IB.  Small-molecule therapeutics in rheumatoid arthritis:  
scientific rationale, efficacy and safety.  Best Pract Res Clin Rheumatol.  
2014;28(4):605-24.
15.
Fleischmann R, Kremer J, Cush J, et al.  Placebo-controlled trial of tofacitinib 
monotherapy in rheumatoid arthritis.  N Engl J Med.  2012;367(6):495-507.
16.
van Vollenhoven RF, Fleischmann R, Cohen S, et al.  Tofacitinib or adalimumab 
versus placebo in rheumatoid arthritis.  N Engl J Med.  2012;367(6):508-19.
17.
Abatacept [Summary of Product Characteristics].  Uxbridge, United Kingdom; 
Bristol-Myers Squibb Pharma EEIG, 2012.
18.
Kremer J, Li ZG, Hall S, et al.  Tofacitinib in combination with nonbiologic 
disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis:  
a randomized trial.  Ann Intern Med.  2013;159(4):253-61.
19.
van der Heijde D, Tanaka Y, Fleischmann R, et al.  Tofacitinib (CP-690,550) in 
patients with rheumatoid arthritis receiving methotrexate:  twelve-month data from 
a twenty-four-month phase III randomized radiographic study.  Arthritis Rheum.  
2013;65(3):559-70.
20.
Galapagos [press release].  14 April 2015.  Available from:  
http://www.glpg.com/files/1314/2904/2940/PR_Darwin1_April_14_2015_FINAL.
pdf.  Accessed on:  02 September 2015.
abbvie 


Upadacitinib
M15-925 Protocol Amendment 6
EudraCT 2016-000933-37
141
21.
Galapagos [press release].  27 April 2015.  Available from:  
http://www.glpg.com/files/3514/3016/6234/PR_Darwin2_FINAL.pdf.  Accessed 
on:  02 September 2015.
22.
Woodworth T, Furst DE, Alten R, et al.  Standardizing assessment and reporting of
adverse effects in rheumatology clinical trials II:  the Rheumatology Common 
Toxicity Criteria v.2.0.  J Rheumatol.  2007;34(6):1401-14.
abbvie 


Upadacitinib
M15-925 Protocol Amendment 6
EudraCT 2016-000933-37
142
Appendix A.
Responsibilities of the Clinical Investigator
Clinical research studies sponsored by AbbVie are subject to the International Council for 
Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) 
Good Clinical Practices (GCP) and local regulations and guidelines governing the study at 
the site location.  In signing the Investigator Agreement in Section 14.0 of this protocol, 
the investigator is agreeing to the following:
1.
Conducting the study in accordance with the relevant, current protocol, making 
changes in a protocol only after notifying AbbVie, except when necessary to 
protect the safety, rights or welfare of subjects.
2.
Personally conducting or supervising the described investigation(s).
3.
Informing all subjects, or persons used as controls, that the drugs are being used for 
investigational purposes and complying with the requirements relating to informed 
consent and ethics committees (e.g., independent ethics committee [IEC] or 
institutional review board [IRB]) review and approval of the protocol and 
amendments.
4.
Reporting adverse experiences that occur in the course of the investigation(s) to 
AbbVie and the site director.
5.
Reading the information in the Investigator's Brochure/safety material provided, 
including the instructions for use and the potential risks and side effects of the 
investigational product(s).
6.
Informing all associates, colleagues, and employees assisting in the conduct of the 
study about their obligations in meeting the above commitments.
7.
Maintaining adequate and accurate records of the conduct of the study, making 
those records available for inspection by representatives of AbbVie and/or the 
appropriate regulatory agency, and retaining all study-related documents until 
notification from AbbVie.
abbvie 


Upadacitinib
M15-925 Protocol Amendment 6
EudraCT 2016-000933-37
143
8.
Maintaining records demonstrating that an ethics committee reviewed and 
approved the initial clinical investigation and all amendments.
9.
Reporting promptly, all changes in the research activity and all unanticipated 
problems involving risks to human subjects or others, to the appropriate individuals 
(e.g., coordinating investigator, institution director) and/or directly to the ethics 
committees and AbbVie.
10.
Following the protocol and not make any changes in the research without ethics 
committee approval, except where necessary to eliminate apparent immediate 
hazards to human subjects.
abbvie 


Upadacitinib
M15-925 Protocol Amendment 6
EudraCT 2016-000933-37
144
Appendix B.
List of Protocol Signatories
Name
Title
Functional Area
Executive Medical Director
Immunology Clinical Development
Medical Director
Therapeutic Area
Senior Medical Director
Pharmacovigilance and Patient Safety
Director
Statistics
Senior Director, Statistics TA Head
Statistics
 
Assistant Director, Clinical 
Pharmacology
Clinical Pharmacokinetics and 
Pharmacodynamics
Study Project Manager I
Clinical Program Development
abbvie 


Upadacitinib
M15-925 Protocol Amendment 6
EudraCT 2016-000933-37
145
Appendix C.
Local Requirements
Canada
Section 5.2.1 Inclusion Criteria
10.
If female of childbearing potential, subject must be practicing two forms of 
contraception (one highly effective method combined with one effective method, 
refer to Contraception Recommendations for Females below) that are effective 
from Study Day 1 through at least 98 days (Period 1)/30 days (Period 2) after the 
last dose of study drug.
11.
Male subjects who are sexually active with female partner(s) of childbearing 
potential must agree from Study Day 1 through 30 days after the last dose of study 
drug to practice the protocol-specified contraception (refer to Contraception 
Recommendations for Males below).
Section 5.2.4 Contraception Recommendations
Contraception Recommendation for Females
A woman who is postmenopausal or permanently surgically sterile (bilateral 
oophorectomy, bilateral salpingectomy or hysterectomy) is not considered to be a woman 
of childbearing potential and is not required to follow contraception recommendations.  
Postmenopausal is defined as:
●
Age ≥ 55 years with no menses for 12 or more months without an alternative 
medical cause; or
●
Age < 55 years with no menses for 12 or more months without an alternative 
medical cause AND an FSH level > 40 mIU/mL.
abbvie 


Upadacitinib
M15-925 Protocol Amendment 6
EudraCT 2016-000933-37
146
If the female subject is < 55 years of age:
AND has had no menses for ≥ 12 months AND has no history of permanent surgical 
sterilization (defined above), FSH should be tested at Screening.
●
If FSH is not tested, it is assumed that the subject is of childbearing potential 
and protocol-specified contraception is required.
●
If the FSH is tested and the result is consistent with post-menopausal status, 
contraception is not required.
●
If the FSH is tested and the result is consistent with pre-menopausal status, 
contraception is required.
For a female subject at any age:
●
Female subject with menses within the past 12 months are of childbearing 
potential and FSH is therefore not required but contraception is required.
●
Female subjects who are surgically sterile (defined above) are not of 
childbearing potential and therefore no FSH testing or contraception is 
required.
A woman who does not meet the definition of postmenopausal or permanently surgically 
sterile is considered of childbearing potential and is required to use two forms of 
contraception.  This includes one form of highly effective contraception and one effective 
method of contraception that are effective from Study Day 1 (or earlier) through at least 
98 days (Period 1)/30 days (Period 2) after the last dose of study drug.
●
Highly effective methods:
○
Hormonal contraceptives started at least 2 months prior to randomization 
(e.g., combined [estrogen and progestogen containing] oral contraceptives, 
patch, vaginal ring, injectables, and implants);
○
Intrauterine device (IUD) or intrauterine system (IUS);
○
Vasectomy and tubal ligation.
abbvie 


Upadacitinib
M15-925 Protocol Amendment 6
EudraCT 2016-000933-37
147
●
Effective methods:
○
Barrier methods of contraception (e.g., male condom, female condom, 
cervical cap, diaphragm, contraceptive sponge).
○
Note:  The proper use of diaphragm or cervical cap includes use of 
spermicide and is considered one barrier method.  The cervical cap and 
contraceptive sponge are less effective in parous women.  The use of 
spermicide alone is not considered a suitable barrier method for 
contraception.  When used consistently and correctly, "double barrier"
methods of contraception (e.g., male condom with diaphragm, male 
condom with cervical cap) can be used as an effective alternative to the 
highly effective contraception methods described above.  Male and female 
condoms should not be used together as they can tear of become damaged.
Contraception Recommendation for Males
For a male subject who has a female partner who is postmenopausal or permanently 
sterile, no contraception is required.
A male subject who is sexually active with female partner(s) of childbearing potential 
must agree from Study Day 1 through 30 days after the last dose of study drug to practice 
contraception with:
●
Condom use and female partner(s) using at least one of the highly effective 
contraceptive methods as defined in the protocol for female study subjects of 
childbearing potential.
Additionally, male subjects must agree not to donate sperm from Study Day 1 through 
30 days after the last dose of study drug.
Male subjects are responsible for informing his partner(s) of the risk of becoming 
pregnant and for reporting any pregnancy to the study doctor.  If a pregnancy occurs, a 
partner authorization form requesting pregnancy outcome information will be requested 
from the pregnant partner.
abbvie 


Upadacitinib
M15-925 Protocol Amendment 6
EudraCT 2016-000933-37
148
Korea
Section 5.2.1 Inclusion Criteria
10.
If female, subject must be either postmenopausal, OR permanently surgically sterile 
OR for women of childbearing potential practicing at least one protocol specified 
method of birth control (refer to Contraception Recommendations for Females, 
below), that is effective from Study Day 1 through at least 98 days (Period 1)/30 
days (Period 2) after the last dose of study drug. 
11.
If the male subject is sexually active with female partner(s) of childbearing 
potential, he must agree, from Study Day 1 through 30 days after the last dose of 
study drug, to practice the protocol-specified contraception (refer to Contraception 
Recommendations for Males below).
Section 5.2.4 Contraception Recommendations
Contraception Recommendation for Females
A woman who is postmenopausal or permanently surgically sterile (bilateral 
oophorectomy, bilateral salpingectomy or hysterectomy) is not considered to be a woman 
of childbearing potential and is not required to follow contraception recommendations.  
Postmenopausal is defined as:
●
Age ≥ 55 years with no menses for 12 or more months without an alternative 
medical cause; or
●
Age < 55 years with no menses for 12 or more months without an alternative 
medical cause AND an FSH level > 40 mIU/mL.
If the female subject is < 55 years of age:
AND has had no menses for ≥ 12 months AND has no history of permanent surgical 
sterilization (defined above), FSH should be tested at Screening.
abbvie 


Upadacitinib
M15-925 Protocol Amendment 6
EudraCT 2016-000933-37
149
●
If FSH is not tested, it is assumed that the subject is of childbearing potential 
and protocol-specified contraception is required.
●
If the FSH is tested and the result is consistent with post-menopausal status, 
contraception is not required.
●
If the FSH is tested and the result is consistent with pre-menopausal status, 
contraception is required.
For a female subject at any age:
●
Female subjects with menses within the past 12 months are of childbearing 
potential and FSH is therefore not required but contraception is required.
●
Female subjects who are surgically sterile (defined above) are not of 
childbearing potential and therefore no FSH testing or contraception is 
required.
A woman who does not meet the definition of postmenopausal or permanently surgically 
sterile is considered of childbearing potential and is required to practice at least one of the 
following highly effective methods of birth control that is effective from Study Day 1 (or 
earlier) through at least 98 days (Period 1)/30 days (Period 2) after the last dose of study 
drug.
●
Combined (estrogen and progestogen containing) hormonal contraception 
(oral, intravaginal, transdermal, injectable) associated with the inhibition of 
ovulation, initiated at least 1 month prior to Study Day 1.
●
Progestogen-only hormonal contraception (oral, injectable, implantable) 
associated with inhibition of ovulation, initiated at least 30 days prior to Study 
Day 1.
●
Bilateral tubal occlusion/ligation.
●
Vasectomized partner(s), provided the vasectomized partner has received 
medical confirmation of the surgical success and is the sole sexual partner of 
the women of childbearing potential trial participant.
●
Intrauterine device (IUD).
●
Intrauterine hormone-releasing system (IUS).
abbvie 


Upadacitinib
M15-925 Protocol Amendment 6
EudraCT 2016-000933-37
150
If required per local practices, male or female condom with or without spermicide OR 
cap, diaphragm or sponge with spermicide should be used in addition to one of the highly 
effective birth control methods listed above.
Contraception Recommendation for Males
There are no contraception requirements for male subjects receiving upadacitinib or their 
female partner(s.)
The concomitant csDMARDs (i.e., methotrexate, sulfasalazine, etc.) have been prescribed 
per standard of care prior to study entry and are allowed to be continued during the study.  
Contraception should continue while the subject is on the concomitant csDMARD(s) and 
that duration of contraception and the requirement not to donate sperm after 
discontinuation of the csDMARD(s) should be based on the local label.
abbvie 


Upadacitinib
M15-925 Protocol Amendment 6
EudraCT 2016-000933-37
151
Appendix D.
Study Activities (Period 1)
Activity
Screening
BL
Wk 2
Wk 4
Wk 8
Wk 12
Wk 16
Wk 20
Wk 24/PDa
30-Day 
F/U 
Visitb
70-Day 
F/U 
Visitb
D –35 to D –1
D1c
D15
D29
D57
D85
D113
D141
D169
Informed consentd
Xd
Inclusion/exclusion criteria
X
X
Medical/surgical historye
X
X
Alcohol and nicotine use
X
Adverse event assessmentf
Only SAEs and 
protocol-related 
nonserious AEs
X
X
X
X
X
X
X
X
X
X
Prior/concomitant therapy
X
X
X
X
X
X
X
X
X
X
X
Patient questionnairesg
PtGA
Pain (VAS)
HAQ-DI 
Morning Stiffness 
X
X
X
X
X
X
X
X
Patient questionnairesg
WPAI RA
X
X
X
X
X
Patient questionnairesg
EQ-5D-5L 
SF-36
X
X
X
X
Patient questionnaireg
FACIT-F
X
X
X
X
X
X
Latent TB risk assessment formh
X
Central lab QuantiFERON-TB Gold 
testh (and/or local PPD skin test)
X
abbvie 


Upadacitinib
M15-925 Protocol Amendment 6
EudraCT 2016-000933-37
152
Activity
Screening
BL
Wk 2
Wk 4
Wk 8
Wk 12
Wk 16
Wk 20
Wk 24/PDa
30-Day 
F/U 
Visitb
70-Day 
F/U 
Visitb
D –35 to D –1
D1c
D15
D29
D57
D85
D113
D141
D169
Chest x-rayi
X
12-lead ECG
Xj
Xk
Height (screening only) and weight
X
X
X
X
X
X
X
X
X
X
X
Vital signsl
X
X
X
X
X
X
X
X
X
X
X
Physical examm
X
X
X
Physician Global Assessment (PhGA)
X
X
X
X
X
X
X
X
TJC68/SJC66
X
X
X
X
X
X
X
X
X
20% joint assessment (TJC and SJC)
Xn
Xn
Xn
Xn
Serum pregnancy test at central labo
X
Local urine pregnancy testp
X
X
X
X
X
X
X
X
X
X
Central Lab Tests
hsCRPq
Blood chemistryr
Hematology (CBC)
Urinalysiss
X
X
X
X
X
X
X
X
X
X
X
ESR (local lab)
X
X
X
X
X
X
X
X
X
Other Central Lab Tests
Rheumatoid factor
Anti-CCP autoantibodies
HIVt/HBV/HCV screening
FSH (as applicable)u
X
Blood samples for upadacitinib PK 
assay
Xv
Xw
Xw
Xw
Xw
Xw
Xw
abbvie 


Upadacitinib
M15-925 Protocol Amendment 6
EudraCT 2016-000933-37
153
Activity
Screening
BL
Wk 2
Wk 4
Wk 8
Wk 12
Wk 16
Wk 20
Wk 24/PDa
30-Day 
F/U 
Visitb
70-Day 
F/U 
Visitb
D –35 to D –1
D1c
D15
D29
D57
D85
D113
D141
D169
Blood samples for exploratory 
research and validation studies 
(optional – see Appendix Ex)
X
X
X
X
X
Randomization/Drug assignment
X
Dispense study drug 
X
X
X
X
X
X
X
Xy
IV study drug infusion (abatacept or 
matching placebo)
X
X
X
X
X
X
X
Dispense subject dosing diary
X
Review and copy subject dosing diary 
and perform drug reconciliation
X
X
X
X
X
X
X
BL = Baseline Visit; CBC = complete blood count; CCP = cyclic citrullinated peptide; D = Day; ECG = electrocardiogram; EQ-5D-5L = EuroQoL-5D; ESR = erythrocyte 
sedimentation rate; F/U = Follow-up; HAQ-DI = Health Assessment Questionnaire – Disability Index; HBV = hepatitis B virus; HCV = hepatitis C virus; HIV = human 
immunodeficiency virus; hsCRP = high-sensitivity C-reactive protein; NRS = numerical rating scale; PD = Premature Discontinuation (completely from study [withdrawal of 
consent]); PhGA = Physician's Global Assessment of Disease Activity; PK = pharmacokinetics; PPD = purified protein derivative; PtGA = Patient's Global Assessment of Disease 
Activity; SAE = serious adverse event; SJC = Swollen Joint Count; SF-36 = 36-Item Short Form Health Survey; TB = tuberculosis; TJC = Tender Joint Count; VAS = visual 
analog scale; Wk = Week
a.
If a subject prematurely discontinues study participation (withdrawal of informed consent), the procedures outlined for the Premature Discontinuation visit (PD visit) should 
be completed as soon as possible, preferably within 2 weeks of study drug discontinuation.
b.
These visits are 30 and 70 days after last dose of study drug for those subjects who complete Period 1 and do NOT enter Period 2.  The 30 and 70-day follow-up phone call to 
determine the status of any ongoing AEs/SAEs or the occurrence of any new AEs/SAEs may be allowed for subjects who prematurely discontinue from study and have 
completed the PD visit.
c.
The Baseline visit procedures will serve as the reference for all subsequent visits with the exception of the ECG, which will be obtained at Screening only and used as the 
baseline reference.
d.
Informed consent should be obtained at Screening prior to performing any study related procedures.
e.
Document herpes zoster and hepatitis B vaccination status in medical history.
abbvie 


Upadacitinib
M15-925 Protocol Amendment 6
EudraCT 2016-000933-37
154
f.
Collect serious adverse events and protocol-related nonserious AEs that occur after a subject signs the informed consent, prior to the first dose of study drug.
g.
Prior to other procedures.  For morning stiffness, duration will be captured only if NRS rating is > 0.
h.
Refer to Section 5.3.1.1 Study Procedures TB Testing for specific requirements for TB testing and TB prophylaxis.
i.
The chest x-ray will not be required if a subject had a previous normal chest-x-ray within 90 days of Screening, provided that all source documentation is available at the site 
(refer to Section 5.3.1.1 Chest X-Ray for specific requirements).
j.
For subjects with a normal ECG taken within 90 days of Screening, a repeat ECG at Screening will not be required, provided all source documentation is available.  Refer to 
Section 5.3.1.1 12-Lead ECG for additional details.
k.
For subjects who do not enter Period 2 or prematurely discontinue from the study, an ECG will be performed.
l.
Blood pressure, pulse rate, body temperature, and respiratory rate should be performed before blood draws are performed.
m.
A full physical exam is required at the visits indicated.  A symptom-directed physical exam may be performed when necessary.
n.
Starting at Week 12 and thereafter, subjects who do not achieve ≥ 20% improvement in both TJC and SJC compared to baseline at 2 consecutive visits, should receive rescue 
medication as described in Section 5.2.3.3.  Starting at Week 12 and thereafter, subjects who demonstrate worsening of joint count (SJC or TJC) from baseline at 
2 consecutive visits should be discontinued from study drug and treated according to standard of care and at the discretion of the clinician.
o.
For all women of childbearing potential, collect serum for pregnancy test only at Screening.  If serum pregnancy test comes back borderline, a repeat test is necessary 
(pregnancy is an exclusion criterion).  Refer to Section 5.3.1.1 Study Procedures Pregnancy Test for additional details.
p.
For all women of childbearing potential, collect urine for pregnancy test at Baseline and all subsequent visits.  If urine pregnancy test (which is performed at the site) is 
negative, begin or continue dosing.  If urine pregnancy test is positive, withhold dosing and perform a serum pregnancy test.  Pregnant subjects must permanently discontinue 
study drug.  Refer to Section 5.3.1.1 Study Procedures Pregnancy Test for additional details.
q.
In Period 1, the central lab hsCRP results starting from Baseline (Day 1) will not be reported to the Sponsor, Investigator, study site personnel, and the subject.  Results of 
hsCRP may be blunted in subjects taking a JAK inhibitor, thereby limiting its clinical utility in the setting of a possible safety assessment or adverse event management.  Any 
local hsCRP or CRP tests should not be reported to the investigator until treatment allocation is unblinded or subject is known to be receiving upadacitinib.  In Period 2, the 
central lab hsCRP results will remain blinded to the Investigator, study site personnel, and the subject.  Starting with Amendment 5, at a timepoint specified by the Sponsor in 
Period 2, central laboratory hsCRP results will be reported to the Investigator/study site personnel.  After treatment assignment is unblinded, local hsCRP or CRP tests are 
allowed.
r.
Minimum 8-hour fast.  If a subject is not able to fast when necessary, due to unforeseen circumstances, the non-fasting status will be recorded in study source documentation.
s.
A urine dipstick macroscopic urinalysis will be completed by the central laboratory at all required visits.  A microscopic analysis will be performed in the event the dipstick 
results show leukocytes, nitrite, protein, ketones, or blood greater than negative or glucose greater than normal.
abbvie 


Upadacitinib
M15-925 Protocol Amendment 6
EudraCT 2016-000933-37
155
t.
HIV testing will be performed at Screening, unless prohibited by local regulations.  The Investigator must discuss any local reporting requirements to local health agencies 
with the subject.  The site will report confirmed positive results to their health agency per local regulations, if necessary.  If the result is confirmed as positive, then the 
Investigator will discuss with the subject potential implications to the subject's health and next steps.  If a subject has a confirmed positive result, the Investigator must discuss 
with the subject the potential implications to the subject's health and subject should receive or be referred for clinical care promptly.  A subject will not be eligible for study 
participation if test results indicate a positive HIV infection.  AbbVie will not receive results from the testing and will not be made aware of any positive result.
u.
FSH should be tested at Screening if the female subject is < 55 years of age AND has had no menses ≥ 12 months AND has no history of permanent surgical sterilization 
(defined in Section 5.2.4).
v.
At Week 2 visits, PK samples should be collected prior to dosing and the subjects should take the study drug dose at the clinic after collecting the PK blood sample.  
However, if the subject normally takes the study drug dose at a time that is after the time of the scheduled study visit, the subject should follow the regular dosing schedule 
and the PK sample should be collected at any time during the visit.
w.
PK samples should be collected at any time during the visit.  Subject should follow the regular dosing schedule.
x.
Samples only collected if subject provides written consent.
y.
For subjects entering Period 2 only.  Each subject will be dispensed one (1) bottle containing 100 tablets (a 12-week supply).  One (1) bottle of 100 tablets will be dispensed 
every 12 weeks for the remaining Period 2 visits.
Note:
Visit window is ± 3 days for Period 1.  Any of the procedures may be performed at an unscheduled visit at the discretion of the Investigator.  Subjects who 
choose to discontinue study drug treatment, but continue to participate in the study should follow the regular visit schedule and adhere to all study procedures 
except for dispensing study drug, PK sample collection, and blood sample collection for optional exploratory research and validation studies.
abbvie 


Upadacitinib
M15-925 Protocol Amendment 6
EudraCT 2016-000933-37
156
Appendix E.
Study Activities – Optional Samples for Exploratory Research and Validation Studies (Period 1 Only) 
Activity
Screening
BL
Wk 2
Wk 4
Wk 8
Wk 12
Wk 16
Wk 20
Wk 24/PD
30 or 
70-Day F/U 
Visit
D –35 to D –1
D1
D15
D29
D57
D85
D113
D141
D169
Pharmacogenetic samplesa,b
--
X
--
--
--
--
--
--
--
--
Epigenetic samplesb
--
X
X
X
--
X
--
--
X
--
Transcriptomic and epigenetic 
samplesb
--
X
X
X
--
X
--
--
X
--
Plasma samples for proteomic 
and targeted protein 
investigationsb
--
X
X
X
--
X
--
--
X
--
Serum samples for proteomic 
and targeted protein 
investigationsb
--
X
X
X
--
X
--
--
X
--
BL = Baseline Visit; D = Day; F/U = Follow-up; PD = Premature Discontinuation; Wk = Week
a.
The sample is preferred to be collected at BL, but can be drawn at any time during the subject's participation.
b.
Based on the value of the different technologies, samples may also be used to assess other biomarker signatures, including but not limited to metabolomics, lipidomics, and 
other approaches.
Notes:
Collections to be performed only if subject provides separate written consent to collect the exploratory research/validation studies samples; if the separate consent is not 
signed, no samples can be collected.  The separate written consent may be part of the main consent form.
It is preferred that the subject is fasting prior to sample collection, however it is not required.  It must be recorded whether subject is fasting or non-fasting at the time of 
collection.
abbvie 


Upadacitinib
M15-925 Protocol Amendment 6
EudraCT 2016-000933-37
157
Appendix F.
Study Activities (Period 2)
Activity
Wk 
28
Wk 
32
Wk 
36
Wk 
48
Monthly
Every 12 Weeksa
Every 24 Weeksa
Every 48 Weeksa
Final 
(Week 
216)/PD 
Visit
30-Day 
F/U 
Visitb
CDAI Calculationc
X
X
X
X
X
SJC/TJCc
X
X
X
X
Xc
X
Adverse event assessment
X
X
X
X
X
X
X
Concomitant therapy
X
X
X
X
X
X
X
Patient questionnairesd
PtGA 
Pain (VAS) 
HAQ-DI  
Morning Stiffness 
X
X
X
X
X
X
Patient questionnairesd
EQ-5D-5L 
SF-36 
FACIT-F 
WPAI RA
X
X
Latent TB risk assessment form
X
X
Central lab QuantiFERON-TB Gold teste
(and/or local PPD skin test)
Xe
Xe
Chest x-rayf
Xf
Xf
12-lead ECGg
X
X
X
Vital signs and body weighth
X
X
X
X
X
X
X
Physical exami
X
X
X
Physician Global Assessment (PhGA)
X
X
X
X
X
X
abbvie 


Upadacitinib
M15-925 Protocol Amendment 6
EudraCT 2016-000933-37
158
Activity
Wk 
28
Wk 
32
Wk 
36
Wk 
48
Monthly
Every 12 Weeksa
Every 24 Weeksa
Every 48 Weeksa
Final 
(Week 
216)/PD 
Visit
30-Day 
F/U 
Visitb
Local urine pregnancy testj
X
X
X
X
X
X
X
At home urine pregnancy testj
Xj
Central lab tests 
hsCRPk
Blood chemistryl
Hematology (CBC) 
Urinalysism
X
X
X
X
X
X
X
ESR (local lab)
X
X
X
X
X
X
Dispense study drug 
X
X
X
Review and copy subject dosing diary and 
perform drug reconciliation
X
X
X
X
X
X
BL = Baseline Visit; CBC = complete blood count; csDMARD = conventional synthetic disease-modifying anti-rheumatic drug; ECG = electrocardiogram; F/U = Follow-up; 
HAQ-DI = Health Assessment Questionnaire – Disability Index; hsCRP = high-sensitivity C-reactive protein; NRS = numerical rating scale; PD = Premature Discontinuation; 
PhGA = Physician's Global Assessment of Disease Activity; PPD = purified protein derivative; PtGA = Patient's Global Assessment of Disease Activity; SAE = serious adverse 
event; SJC = Swollen Joint Count; TB = tuberculosis; TJC = Tender Joint Count; VAS = visual analog scale; Wk = Week
a.
Every 12, 24, or 48 weeks from the Week 48 visit through Week 216.
b.
This visit is 30 days after last dose of study drug for those subjects who complete Period 2.  A 30-day follow-up phone call may be allowed for subjects who have completed 
PD visit to determine the status of any ongoing AEs/SAEs or the occurrence of any new AEs/SAEs.
c.
Starting at Week 28 and thereafter, study drug should be discontinued for subjects who fail to show at least 20% improvement in TJC and SJC compared to baseline at 
2 consecutive visits despite optimization of background RA therapies.  Starting at Week 28 and thereafter, subjects who achieve ≥ 20% improvement in both TJC and SJC but 
fail to achieve CDAI ≤ 10 at two consecutive visits will be given the option, at the discretion of the investigator, whether to continue study or discontinue study drug and be 
treated with standard of care at the discretion of the investigator.
d.
Prior to other procedures.  For morning stiffness, duration will be captured only if NRS rating is > 0.
e.
TB testing should be performed every 48 weeks after Week 48 in subjects with previous negative TB test.  Subjects with new evidence of latent TB must initiate prophylactic 
treatment immediately per local guidelines.  Refer to Section 5.3.1.1 TB Testing/TB Prophylaxis for additional details.
abbvie 


Upadacitinib
M15-925 Protocol Amendment 6
EudraCT 2016-000933-37
159
f.
Obtain chest x-ray every 48 weeks after Week 48 for subjects with newly identified TB risk factors as determined by the TB risk assessment form, or for subjects living in 
areas endemic for TB, or for subjects with a newly positive TB test after baseline.
g.
In addition to ECG assessments as indicated above, an ECG may be performed at any visit if deemed necessary by the Investigator.
h.
Blood pressure, pulse rate, body temperature, and respiratory rate should be performed before blood draws are performed.
i.
A full physical exam is required every 24 weeks after Week 48.  A symptom-directed physical exam may be performed when necessary.
j.
For all women of childbearing potential, a urine pregnancy test will be performed at all visits and monthly at home between scheduled study visits.  The results of the monthly 
at home tests will be communicated to the site.  If a urine pregnancy test is positive, the subject must stop dosing, come in to the clinic and have blood drawn for a serum 
pregnancy test that will be analyzed at the central laboratory.  Pregnant subjects must permanently discontinue study drug.  Refer to Section 5.3.1.1 Study Procedures 
Pregnancy Test for additional details.
k.
In Period 1, the central lab hsCRP results starting from Baseline (Day 1) will not be reported to the Sponsor, Investigator, study site personnel, and the subject.  Results of 
hsCRP may be blunted in subjects taking a JAK inhibitor, thereby limiting its clinical utility in the setting of a possible safety assessment or adverse event management.  Any 
local hsCRP or CRP tests should not be reported to the investigator until treatment allocation is unblinded or subject is known to be receiving upadacitinib.  In Period 2, the 
central lab hsCRP results will remain blinded to the Investigator, study site personnel, and the subject.  Starting with Amendment 5, at a timepoint specified by the Sponsor in 
Period 2, central laboratory hsCRP results will be reported to the Investigator/study site personnel.  After treatment assignment is unblinded, local hsCRP or CRP tests are 
allowed.
l.
Minimum 8-hour fast.  If a subject is not able to fast when necessary, due to unforeseen circumstances, the non-fasting status will be recorded in study source documentation.
m.
Dipstick urinalysis will be completed by the central lab at all required visits.  Specified abnormal macroscopic urinalyses defined as leukocytes, nitrite, protein, ketones, or 
blood greater than negative, or glucose greater than normal will be followed up with a microscopic analysis at the central laboratory.
Note:
Visit window is ± 7 days for Period 2.  Any of the procedures may be performed at an unscheduled visit at the discretion of the Investigator.  Subjects who 
choose to discontinue study drug treatment, but continue to participate in the study should complete a Premature Discontinuation Visit (PD Visit) as soon as 
possible, preferably within 2 weeks.  Refer to Section 5.1 Discontinuation of Study Drug and Continuation of Study Participation (Period 1 and Period 2) for 
additional details.
abbvie 


Upadacitinib
M15-925 Protocol Amendment 6
EudraCT 2016-000933-37
160
Appendix G.
Physician's Global Assessment of Disease Activity Example
Visual Analog Scale (VAS)
VAS will be used to assess the physician's global assessment of disease activity.  The 
VAS consists of a horizontal 100 mm line anchored at either end by opposite adjectives 
reflecting the spectrum/severity of the parameters assessed:
●
Physician's global assessment of disease activity (current status).  The 
Physician will rate global assessment of subject's current disease activity 
ranging from 0 to 100 (see example below).
Mark the line below to indicate the subject's rheumatoid arthritis disease activity 
(independent of the subject's self-assessment).
0
100
Very Low
Very High
abbvie 




Upadacitinib
M15-925 Protocol Amendment 6
EudraCT 2016-000933-37
162
JOINT EVALUATION
JOINT
(Tick Correct Answer)
Subject Right
Subject Left
0 = Absent
1 = Present
9 = 
Replaced 
NA = No 
Assessment
0 = Absent
1 = Present
9 = 
Replaced 
NA = No 
Assessment
Pain/ 
Tenderness
Swelling
Joint
Pain/ 
Tenderness
Swelling
Joint
27.  Metatarsophalangeal III
0
1
0
1
9
NA
0
1
0
1
9
NA
28.  Metatarsophalangeal IV
0
1
0
1
9
NA
0
1
0
1
9
NA
29.  Metatarsophalangeal V
0
1
0
1
9
NA
0
1
0
1
9
NA
30.  Great Toe/Hallux
0
1
0
1
9
NA
0
1
0
1
9
NA
31.  Interphalangeal II
0
1
0
1
9
NA
0
1
0
1
9
NA
32.  Interphalangeal III
0
1
0
1
9
NA
0
1
0
1
9
NA
33.  Interphalangeal IV
0
1
0
1
9
NA
0
1
0
1
9
NA
34.  Interphalangeal V
0
1
0
1
9
NA
0
1
0
1
9
NA
TOTAL Joint Count
abbvie 


Upadacitinib
M15-925 Protocol Amendment 6
EudraCT 2016-000933-37
163
Appendix I.
Latent TB Risk Assessment Form Example
1.
Have you or an immediate family member or other close contact ever been 
diagnosed or treated for tuberculosis?
2.
Have you lived in or had prolonged travels to countries in the following regions:
●
Africa
●
Eastern Europe
●
Asia
●
Latin America
●
Caribbean Islands
●
Russia
3.
Have you lived or worked in a prison, homeless shelter/refugee camp, immigration 
center, health care worker in a hospital or nursing home?
4.
Have you, or an immediate family member, had any of the following problems for 
the past 3 weeks or longer:
●
Chronic Cough
●
Chest pain, or pain with breathing or coughing
●
Blood-Streaked Sputum (coughing up blood)
●
Unexplained Weight Loss
●
Fever
●
Fatigue/Tiredness
●
Night Sweats
●
Shortness of Breath
From:  http://www.mayoclinic.org/diseases-conditions/tuberculosis/symptoms-causes/dxc-20188557 
http://www.in.gov/fssa/files/Tuberculosis_Questionnaire.pdf.
abbvie 


Upadacitinib
M15-925 Protocol Amendment 6
EudraCT 2016-000933-37
164
Appendix J.
Patient's Global Assessment of Disease Activity Example
Visual Analog Scale (VAS)
VAS will be used to assess the subject's global assessment of disease activity.  Each VAS 
consists of a horizontal 100 mm line anchored at either end by opposite adjectives 
reflecting the spectrum/severity of the parameters assessed:
●
Subject's global assessment of disease activity (within last 24 hours)
The subject will rate the severity of the RA symptoms and how he/she is doing from 0 to 
100.  This assessment will be used for the DAS28 (CRP) calculation in this study (see 
example below):
Please place a vertical mark on the line below to indicate how well your rheumatoid 
arthritis has been doing during THE LAST 24 HOURS:
0
Very Well 
100 
Very Poorly
abbvie 


Upadacitinib
M15-925 Protocol Amendment 6
EudraCT 2016-000933-37
165
Appendix K.
Patient's Assessment of Pain Example
Visual Analog Scale (VAS)
VAS will be used to assess the subject's assessment of pain.  Each VAS consists of a 
horizontal 100 mm line anchored at either end by opposite adjectives reflecting the 
spectrum/severity of the parameters assessed:
How much pain have you had because of your condition within the previous week?
Place a mark on the line below to indicate how severe your pain has been.
NO PAIN
WORST 
POSSIBLE PAIN
abbvie 


Upadacitinib
M15-925 Protocol Amendment 6
EudraCT 2016-000933-37
166
Appendix L.
Health Assessment Questionnaire (HAQ-DI) Example
HEALTH ASSESSMENT QUESTIONNAIRE
In this section we are interested in learning how your illness affects your ability to 
function in daily life.
Please check the response which best describes your usual abilities OVER THE PAST WEEK:
WITHOUT ANY
DIFFICULTY
WITH SOME
DIFFICULTY
WITH MUCH
DIFFICULTY
UNABLE
TO DO
DRESSING AND GROOMING
Are you able to:
Dress yourself, including tying 
shoelaces and doing buttons?
Shampoo your hair?
ARISING
Are you able to:
Stand up from a straight chair?
Get in and out of bed?
EATING
Are you able to:
Cut your own meat?
Lift a full cup or glass to your 
mouth?
Open a new milk carton?
WALKING
Are you able to:
Walk outdoors on flat ground?
Climb up five steps?
Please check any AIDS OR DEVICES that you usually use for any of these activities:
  Cane
  Devices used for dressing (button hook, zipper pull, long 
handled shoe horn, etc.)
  Walker
  Built up or special utensils
  Crutches
  Special or built up chair
  Wheelchair
  Other (Specify:  __________________)
abbvie 


Upadacitinib
M15-925 Protocol Amendment 6
EudraCT 2016-000933-37
167
Please check any categories for which you usually need HELP FROM ANOTHER PERSON:
  Dressing and Grooming
  Eating
  Arising
  Walking
Please check the response which best describes your usual abilities OVER THE PAST WEEK:
WITHOUT ANY
DIFFICULTY
WITH SOME
DIFFICULTY
WITH MUCH
DIFFICULTY
UNABLE
TO DO
HYGIENE
Are you able to:
Wash and dry your body?
Take a tub bath?
Get on and off the toilet?
REACH
Are you able to:
Reach and get down a 5-pound 
object (such as a bag of sugar) 
from just above your head?
Bend down to pick up clothing 
from the floor?
GRIP
Are you able to:
Open car doors?
Open jars which have been 
previously opened?
Turn faucets on and off?
ACTIVITIES
Are you able to:
Run errands and shop?
Get in and out of a car?
Do chores such as vacuuming 
or yard work?
Please check any AIDS OR DEVICES that you usually use for any of these activities:
  Raised toilet seat
  Bathtub bar
  Bathtub seat
  Long-handled appliances for reach
  Jar opener (for jars previously opened)
  Long-handled appliances in bathroom
  Other (Specify: ___________________)
abbvie 


Upadacitinib
M15-925 Protocol Amendment 6
EudraCT 2016-000933-37
168
Please check any categories for which you usually need HELP FROM ANOTHER PERSON:
  Hygiene
  Gripping and opening things
  Reach
  Errands and chores
HAQ – United States/English
HAQ-DI_AU1.0-eng-USori.doc
© Stanford University
abbvie 


Upadacitinib
M15-925 Protocol Amendment 6
EudraCT 2016-000933-37
169
Appendix M.
Patient's Assessment of Severity and Duration of Morning Stiffness 
Example
Instructions:
Please clearly mark an 'x' in the box (☒) that best describes your experience with 
morning stiffness on awakening in the past 7 days.
When you experience morning stiffness, how long does it take to get as limber as 
possible:  _____ hours ______ minutes
abbvie 
o morumg 
Worst pos.si.'bte morning 
.;tiffui!,., 
S?tiffu~s~ 
' 
' 
0 
1 
2 
3 
4 
5 
6 
8 
9 
10 
I 
I 
I 
I 
I 
I 
I 
I 
I 
I 
I 


Upadacitinib
M15-925 Protocol Amendment 6
EudraCT 2016-000933-37
170
Appendix N.
EuroQoL-5D-5L Example
Under each heading, please check the ONE box that best describes your health TODAY:
Mobility
I have no problems walking                                                                        ☐
I have slight problems walking                                                                   ☐
I have moderate problems walking                                                             ☐
I have severe problems walking                                                                  ☐
I am unable to walk                                                                                     ☐
Self-Care
I have no problems washing or dressing myself                                        ☐
I have slight problems washing or dressing myself                                   ☐
I have moderate problems washing or dressing myself                             ☐
I have severe problems washing or dressing myself                                  ☐
I am unable to wash or dress myself                                                          ☐
Usual Activities (e.g., work, study, housework, family or leisure activities)
I have no problems with doing my usual activities                                    ☐
I have slight problems with doing my usual activities                               ☐
I have moderate problems with doing my usual activities                         ☐
I have severe problems with doing my usual activities                             ☐
I am unable to do my usual activities                                                         ☐
abbvie 


Upadacitinib
M15-925 Protocol Amendment 6
EudraCT 2016-000933-37
171
Pain/Discomfort
I have no pain or discomfort                                                                      ☐
I have slight pain or discomfort                                                                 ☐
I have moderate pain or discomfort                                                           ☐
I have severe pain or discomfort                                                                ☐
I have extreme pain or discomfort                                                             ☐
Anxiety/Depression
I am not anxious or depressed                                                                    ☐
I am slightly anxious or depressed                                                             ☐
I am moderately anxious or depressed                                                       ☐
I am severely anxious or depressed                                                           ☐
I am extremely anxious or depressed                                                         ☐
abbvie 


Upadacitinib
M15-925 Protocol Amendment 6
EudraCT 2016-000933-37
172
abbvie 
W e \'IO'u'la lik e to know how good or baa your health is 
TODAY. 
Th is s cale is numbered fro m Oto 100. 
100 means the best health you ,can imag ine. 
0 means the 'l'to rst health y ou c an imag ine. 
Mar'k an X on the scale to indicate how y our health is 
TODAY. 
f\J ow, p I eas e ,•,rite the number you mark ea on the s cale in 
the box below. 
YO UR HEAL TIH TODAY = D 
TIiie !Jest liea'ltll 
yo u earn iima1j i11e 
mo 
95 
90 
85 
80 
75 
70 
65 
60 
5S 
50 
415 
410 
35 
30 
25 
20 
15 
'10 
The wo rst he.a.Ith 
you can iima1l·i 11e 
5 
0 


Upadacitinib
M15-925 Protocol Amendment 6
EudraCT 2016-000933-37
173
Appendix O.
Short Form-36 (SF-36™) Health Status Survey Questionnaire 
Example
Your Health and Well-Being
This survey asks for your views about your health.  This information will help keep 
track of how you feel and how well you are able to do your usual activities.  Thank 
you for completing this survey!
For each of the following questions, please mark an ☒in the box that best describes 
your answer.
1.
In general, would you say your health is:
Excellent
Very good
Good
Fair
Poor
1
2
3
4
5
2.
Compared to 1 year ago, how would you rate your health in general now?
Much better now 
than one year ago
Somewhat better 
now than one year 
ago
About the same as 
one year ago
Somewhat worse 
now than one year 
ago
Much worse now 
than one year ago
1
2
3
4
5
abbvie 
T 
T 
T 
T 
T 
T 
T 
T 
T 
T 


Upadacitinib
M15-925 Protocol Amendment 6
EudraCT 2016-000933-37
174
3.
The following questions are about activities you might do during a typical day.  
Does your health now limit you in these activities?  If so, how much?
Yes,
limited
a lot
Yes,
limited
a little
No, not
limited
at all
a
Vigorous activities, such as running, lifting 
heavy objects, participating in strenuous 
sports
1
2
3
b
Moderate activities, such as moving a table, 
pushing a vacuum cleaner, bowling, or playing golf
1
2
3
c
Lifting or carrying groceries
1
2
3
d
Climbing several flights of stairs
1
2
3
e
Climbing one flight of stairs
1
2
3
f
Bending, kneeling, or stooping
1
2
3
g
Walking more than a mile
1
2
3
h.
Walking several hundred yards
1
2
3
i
Walking one hundred yards
1
2
3
j
Bathing or dressing yourself
1
2
3
abbvie 


Upadacitinib
M15-925 Protocol Amendment 6
EudraCT 2016-000933-37
175
4.
During the past 4 weeks, how much of the time have you had any of the following 
problems with your work or other regular daily activities as a result of your 
physical health?
All of the 
time
Most of 
the time
Some 
of the 
time
A little 
of the 
time
None of the 
time
a   Cut down on the amount of time you 
spent on work or other activities
1
2
3
4
5
b   Accomplished less than you would like
1
2
3
4
5
c   Were limited in the kind of work or 
other activities
1
2
3
4
5
d   Had difficulty performing the work or 
other activities (for example, it took extra
effort) 
1
2
3
4
5
abbvie 


Upadacitinib
M15-925 Protocol Amendment 6
EudraCT 2016-000933-37
176
5.
During the past 4 weeks, how much of the time have you had any of the following 
problems with your work or other regular daily activities as a result of any 
emotional problems (such as feeling depressed or anxious)?
All of 
the 
time
Most of 
the 
time
Some 
of the 
time
A little 
of the 
time
None 
of the 
time
a   Cut down on the amount of time you spent 
on work or other activities
1
2
3
4
5
b   Accomplished less than you would like
1
2
3
4
5
c   Did work or other activities less carefully 
than usual
1
2
3
4
5
6.
During the past 4 weeks, to what extent has your physical health or emotional 
problems interfered with your normal social activities with family, friends, 
neighbors, or groups?
Not at all
Slightly
Moderately
Quite a bit
Extremely
1
2
3
4
5
7.
How much bodily pain have you had during the past 4 weeks?
None
Very mild
Mild
Moderate
Severe
Very Severe
1
2
3
4
5
6
abbvie 
T 
T 
T 
T 
T 
T 
T 
T 
T 
T 
T 
T 
T 


Upadacitinib
M15-925 Protocol Amendment 6
EudraCT 2016-000933-37
177
8.
During the past 4 weeks, how much did pain interfere with your normal work 
(including both work outside the home and housework)?
Not at all
A little bit
Moderately
Quite a bit
Extremely
1
2
3
4
5
9.
These questions are about how you feel and how things have been with you during 
the past 4 weeks.  For each question, please give the one answer that comes closest 
to the way you have been feeling.  How much of the time during the past 4 weeks:
All of the 
time
Most of 
the time
Some of 
the time
A little of 
the time
None of 
the time
a   Did you feel full of life?
1
2
3
4
5
b   Have you been very nervous?
1
2
3
4
5
c   Have you felt so down in the dumps 
that nothing could cheer you up?
1
2
3
4
5
d   Have you felt calm and peaceful?
1
2
3
4
5
e   Did you have a lot of energy?
1
2
3
4
5
f   Have you felt downhearted and
depressed?
1
2
3
4
5
g   Did you feel worn out?
1
2
3
4
5
h   Have you been happy?
1
2
3
4
5
i   Did you feel tired?
1
2
3
4
5
abbvie 
T 
T 
T 
T 


Upadacitinib
M15-925 Protocol Amendment 6
EudraCT 2016-000933-37
178
10.
During the past 4 weeks, how much of the time has your physical health or 
emotional problems interfered with your social activities (like visiting friends, 
relatives, etc.)?
All of the
time
Most of the
time
Some of the
time
A little of the 
time
None of the
time
1
2
3
4
5
11.
How TRUE or FALSE is each of the following statements for you?
Definitely 
true
Mostly 
true
Don't 
know
Mostly 
false
Definitely 
false
a  I seem to get sick a little easier 
than other people
1
2
3
4
5
b  I am as healthy as anybody I know
1
2
3
4
5
c  I expect my health to get worse
1
2
3
4
5
d  My health is excellent
1
2
3
4
5
THANK YOU FOR COMPLETING THESE QUESTIONS
SF-36v2™ Health Survey© 1996, 2000 by QualityMetric Incorporated and Medical Outcomes Trust.  All Rights 
Reserved.
SF-36® is a registered trademark of Medical Outcomes Trust
(SF-36v2 Standard, US Version 2.0)
abbvie 


Upadacitinib
M15-925 Protocol Amendment 6
EudraCT 2016-000933-37
179
Appendix P.
Functional Assessment of Chronic Illness Therapy – Fatigue 
(FACIT-F) Scale Example
Below is a list of statements that other people with your illness have said are important.  
Please circle or mark one number per line to indicate your response as it applies to 
the past 7 days.
abbvie 
I £eel fatigued ....................................................... 
0 
I foel weak all over ........... .. .. .. ... .. .. .. .. .. .. ... .. .. .. .. .. .. 
0 
I foel list!lecss: ( ''washed out") ................................. 
0 
I £eel tir,ed............................................................ 
0 
I have trouble startin!il ruin.gs because I am tired... 
0 
I hav,etrouble finishing things because I am tir,ed . 
0 
I have at<!rgy ........................................................ 
0 
i\d1 
I am ablet,o do my u&ualactivitics ........................ 
0 
I ne,ed t,o slee,p during lli.e day ............... .. .. .... .. .. .. .. .. 
0 
A<,] 
I am too tir,ed to ,eat.................................................. 
0 
A<il4 
I need help doing my usual xti ,;i tie$ .......... ... .. .. .. . 
0 
I am f:rustra ted by being too tir-e,d t,o do lli.e ruin.gs 
I want t,o ............ ... .. .. .. .. .. .. ... .. .. .. .. .. .. .. ... .. .. .. .. .. .. ... . 
O 
A<,]6 
I have t,o limit my social a,ctivity because I am 
0 
tired ..................................................................... . 
A little 
Some-
bit 
what 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
Quite 
a bit 
3 
3 
3 
3 
3 
3 
3 
3 
3 
3 
3 
3 
3 
\ery 
much 
4 
4 
4 
4 
4 
4 
4 
4 
4 
4 
4 
4 
4 
15N01·e~:r 'l«f1 
Pa 1~
· I of ! 


Upadacitinib
M15-925 Protocol Amendment 6
EudraCT 2016-000933-37
180
Appendix Q.
Work Productivity and Activity Impairment Questionnaire:  
Rheumatoid arthritis V2.0 (WPAI:RA)
The following questions ask about the effect of your rheumatoid arthritis on your ability 
to work and perform normal daily activities.  Please fill in the blanks or circle a number, 
as indicated. 
1.
Are you currently employed (working for pay)? _____ NO ___ YES
If 'NO,' tick "NO" and skip to question 6.
The next questions refer to the past seven days, not including today.
2.
During the past 7 days, how many hours did you miss from work because of 
problems associated with your rheumatoid arthritis?  Include hours you missed on 
sick days, times you went in late, left early, etc., because of your rheumatoid 
arthritis.  Do not include time you missed to participate in this study.
______ HOURS
3.
During the past 7 days, how many hours did you miss from work because of any 
other reason, such as annual leave, holidays, time off to participate in this study?
______ HOURS
4.
During the past 7 days, how many hours did you actually work?
______ HOURS (If "0," skip to question 6.)
5.
During the past 7 days, how much did your rheumatoid arthritis affect your 
productivity while you were working?
Think about days you were limited in the amount or kind of work you could do, days you 
accomplished less than you would like, or days you could not do your work as carefully as 
usual.  If rheumatoid arthritis affected your work only a little, choose a low number.  
Choose a high number if rheumatoid arthritis affected your work a great deal. 
abbvie 


Upadacitinib
M15-925 Protocol Amendment 6
EudraCT 2016-000933-37
181
Consider only how much rheumatoid arthritis affected productivity while you were 
working.
Rheumatoid 
arthritis had no 
effect on my 
work
Rheumatoid 
arthritis
completely 
prevented me 
from working
0
1
2
3
4
5
6
7
8
9
10
CIRCLE A NUMBER
6.
During the past 7 days, how much did your rheumatoid arthritis problems affect 
your ability to perform your regular daily activities, other than work at a job?
By regular activities, we mean the usual activities you perform, such as working 
around the house, shopping, childcare, exercising, studying, etc.  Think about times 
you were limited in the amount or kind of activities you could perform and times 
you accomplished less than you would like.  If rheumatoid arthritis affected your 
activities only a little, choose a low number.  Choose a high number if rheumatoid 
arthritis affected your activities a great deal. 
Consider only how much rheumatoid arthritis affected your ability to perform your 
regular daily activities, other than work at a job.
abbvie 


Upadacitinib
M15-925 Protocol Amendment 6
EudraCT 2016-000933-37
182
Rheumatoid 
arthritis had no 
effect on my 
daily activities
Rheumatoid 
arthritis
completely 
prevented me 
from performing 
my daily activities
0
1
2
3
4
5
6
7
8
9
10
CIRCLE A NUMBER
WPAI:RA V2.0 (US English)
abbvie 


Upadacitinib
M15-925 Protocol Amendment 6
EudraCT 2016-000933-37
183
Appendix R.
Rheumatology Common Toxicity Criteria v.2.0 Example
For designation of adverse event terms not shown in the Rheumatology Common Toxicity 
Criteria v.2.0 table, the approach described in Row 1 should be used.
abbvie 


Upadacitinib
M15-925 Protocol Amendment 6
EudraCT 2016-000933-37
184
Rheumatology Common Toxicity Criteria v.2.0
Based on Woodworth TG, et al.  Standardizing assessment of adverse effects in rheumatology clinical trials II.  Status of OMERACT Drug Safety Working Group 
May 2006:  OMERACT 8.  Standardizing Assessment and Reporting of Adverse Effects in Rheumatology Clinical Trials:  Enabling Description of Comparative 
Safety Profiles for Anti-Rheumatic Therapies
1 – Mild
No medication or OTC
Asymptomatic, or transient
Short duration (< 1 week)
No change in life style
2 – Moderate
Symptomatic
Duration (1 – 2 weeks)
Alter lifestyle occasionally
Meds relieve.  (may be 
prescription)
Study drug continued
3 – Severe
Prolonged symptoms, reversible, 
major functional impairment
Prescription meds/partial relief
May be hospitalized < 24 hr
Temporary study drug 
discontinuation, or/and dose reduced
4 – Includes Life Threatening
At risk of death
Substantial disability, especially if 
permanent.
Multiple meds
Hospitalised > 24 hr
Study drug discontinued
A.  Allergic/Immunologic
A1.  Allergic 
reaction/ 
hypersensitivity 
(includes drug fever)
Transient rash:  drug fever 
< 38°C:  transient, asymptomatic 
bronchospasm
Generalised urticaria responsive to 
meds; or drug fever > 38°C, or 
reversible bronchospasm
Symptomatic bronchospasm 
requiring meds; symptomatic 
urticaria persisting with meds, 
allergy related oedema/angioedema
Anaphylaxis, laryngeal/pharyngeal 
oedema, requiring resuscitation
A2.  Autoimmune 
reaction
Seriologic or other evidence of 
autoimmune reaction, but patient 
asymptomatic:  all organ function 
normal and no treatment is 
required (e.g., vitiligo)
Evidence of autoimmune reaction 
involving a non-essential organ or 
functions, requiring treatment 
other than immunosuppressive 
drugs (e.g., hypothyroidism)
Reversible autoimmune reaction 
involving function of a major organ 
or toxicity requiring short term 
immunosuppressive treatment 
(e.g., transient colitis or anaemia)
Causes major organ dysfunction, or 
progressive, not reversible, or 
requires long term administration 
of high dose immunosuppressive 
therapy
A3.  Rhinitis 
(includes sneezing, 
nasal stuffiness, post 
nasal discharge)
Transient, non-prescription meds 
relieve
Prescription med. required, slow
Corticosteroids or other prescription 
med. with persistent disabling 
symptoms such as impaired exercise 
tolerance
NA
A4.  Serum sickness
Transient, non-prescription meds 
relieve
Symptomatic, slow response to 
meds (e.g., oral corticosteroids)
Prolonged; symptoms only partially 
relieved by meds; parenteral 
corticosteroids required
Major organ dysfunction, requires 
long-term high-dose 
immunosuppressive therapy
abbvie 


Upadacitinib
M15-925 Protocol Amendment 6
EudraCT 2016-000933-37
185
A.  Allergic/Immunologic (continued)
A5.  Vasculitis
Localised, not requiring 
treatment; or rapid response to 
meds; cutaneous
Symptomatic, slow response to 
meds (e.g., oral corticosteroids)
Generalised, parenteral 
corticosteroids required or/and short 
duration hospitalisation
Prolonged, hospitalisation, 
ischemic changes, amputation
B.  Cardiac
B1.  Arrhythmia
Transient, asymptomatic
Transient, but symptomatic or 
recurrent, responds to meds
Recurrent/persistent; maintenance 
prescription
Unstable, hospitalisation required, 
parenteral meds
B2.  Cardiac function 
decreased
Asymptomatic decline in resting 
ejection fraction by > 10%, but 
< 20% of baseline value
Asymptomatic decline of resting 
ejection fraction ≥ 20% of baseline 
value
CHF responsive to treatment
Severe or refractory CHF
B3.  Edema
Asymptomatic
(e.g., 1 + feet/calves), self-limited, 
no therapy required
Symptomatic
(e.g., 2 + feet/calves), requires 
therapy
Symptoms limiting function 
(e.g., 3 + feet/calves, 2 + thighs), 
partial relief with treatment 
prolonged
Anasarca; no response to treatment
B4.  Hypertension 
(new onset or 
worsening)
Asymptomatic, transient increase 
by > 20 mmHg (diastolic) or to 
> 150/100 if previously normal, 
no therapy required
Recurrent or persistent increase 
> 150/100 or by > 10 mmHg 
(diastolic), requiring and 
responding readily to treatment
Symptomatic increase > 150/100, 
> 20 mmHg, persistent, requiring 
multi agency therapy, difficult to 
control
Hypertensive crisis
B5.  Hypotension 
(without underlying 
diagnosis)
Transient, intermittent, 
asymptomatic, orthostatic 
decrease in blood pressure 
> 20 mmHg
Symptomatic, without interference 
with function, recurrent or 
persistent > 20 mmHg decrease, 
responds to treatment
Syncope or symptomatic, interferes 
with function, requiring therapy and 
sustained medical attention, dose 
adjustment or drug discontinuation
Shock
B6.  Myocardial 
ischaemia
Transient chest pain/ECG 
changes; rapid relief with nitro
Recurring chest pain, transient 
ECG ST-T changes; treatment 
relieves
Angina with infarction, no or 
minimal functional compromise, 
reduce dose or discontinue study 
drug
Acute myocardial infarction, 
arrthymia or/and CHF
abbvie 


Upadacitinib
M15-925 Protocol Amendment 6
EudraCT 2016-000933-37
186
B.  Cardiac (continued)
B7.  Pericarditis/ 
pericardial effusion
Rub heard, asymptomatic
Detectable effusion by 
echocardiogram, symptomatic 
NSAID required
Detectable on chest x-ray, 
dyspnoea; or pericardiocentesis; 
requires corticosteroids
Pulsus alternates with low cardiac 
output; requires surgery
B8.  
Phlebitis/thrombosis/ 
Embolism (excludes 
injection sites)
Asymptomatic, superficial, 
transient, local, or no treatment 
required
Symptomatic, recurrent, deep vein 
thrombosis, no anticoagulant 
therapy required
Deep vein thrombosis requiring 
anticoagulant therapy
Pulmonary embolism
C.  General (Constitutional)
C1.  Fatigue/malaise 
(asthenia)
Increase over baseline; most usual 
daily functions maintained, short 
term
Limits daily function intermittently 
over time
Interferes with basic ADL, 
persistent
Unable to care for self, bed or 
wheelchair bound > 50% of day 
debilitating, hospitalisation
C2.  Fever (pyrexia) 
(note:  fever due to 
drug allergy should 
be coded as allergy)
Transient, few symptoms
37.7 – 38.5°C
Symptomatic, recurrent
38.6 – 39.9°C.  Relieved by meds
≥ 40°C; ≤ 24 h, persistent 
symptoms; partial response to meds.
≥ 40°C, debilitating, > 24 h, 
hospitalisation; no relief with meds
C3.  Headache
Transient or intermittent, no meds 
or relieved with OTC
Persistent, recurring, non-narcotic 
analgesics relieve
Prolonged with limited response to 
narcotic medicine
Intractable, debilitating, requires 
parenteral meds.
C4.  Insomnia
Difficulty sleeping, short term, no 
interfering with function
Difficulty sleeping interfering with 
function, use of prescription med.
Prolonged symptoms, with limited 
response to narcotic meds
Debilitating, hospitalisation; no 
relief with meds
C5.  Rigors, chills
Asymptomatic, transient, no 
meds, or non-narcotic meds 
relieve
Symptomatic, narcotic meds 
relieve.
Prolonged symptoms, with limited 
response to narcotic meds
Debilitating, hospitalisation; no 
relief with meds
C6.  Sweating 
(diaphoresis)
Episodic, transient
Frequent, short term
Frequent, drenching, disabling
Dehydration, requiring IV 
fluids/hospitalization > 24 hrs
C7.  Weight gain
5% – 9.9%
10% – 19.9%
20% – 30%
NA
C8.  Weight loss
5% – 9.9%
10% – 19.9%
20% – 30%
NA
abbvie 


Upadacitinib
M15-925 Protocol Amendment 6
EudraCT 2016-000933-37
187
D.  Dermatologic
D1.  Alopecia
Subjective, transient
Objective, fully reversible
Patchy, wig used, partly reversible
Complete, or irreversible even if 
patchy
D2.  Bullous eruption
Localised, asymptomatic
Localised, symptomatic, requiring 
treatment
Generalised, responsive to 
treatment; reversible
Prolonged, generalised, or 
requiring hospitalisation for 
treatment
D3.  Dry skin
Asymptomatic, controlled with 
emollients
Symptoms eventually (1 – 2 wks) 
controlled with emollients
Generalised, interfering with ADL 
> 2 wks, persistent pruritis, partially 
responsive to treatment
Disabling for extended period, 
unresponsive to ancillary therapy 
and requiring study drug 
discontinuation for relief
D4.  Injection site 
reaction
Local erythema, pain, pruritis, 
< few days
Erythema, pain, oedema, may 
include superficial phlebitis,
1 – 2 wks
Prolonged induration, superficial 
ulceration; includes thrombosis
Major ulceration necrosis requiring 
surgery
D5.  Petechiae 
(without vasculitis)
Few, transient asymptomatic
Dependent areas, persistent up to 
2 wks
Generalised, responsive to 
treatment; reversible
Prolonged, irreversible, disabling
D6.  Photosensitivity
Transient erythema
Painful erythema and oedema 
requiring topical treatment
Blistering or desquamation, requires 
systematic corticosteroids
Generalised exfoliation or 
hospitalisation
D7.  Pruritis
Localised, asymptomatic, 
transient, local treatment
Intense, or generalised, relieved by 
systematic medication
Intense or generalised; poorly 
controlled despite treatment
Disabling, irreversible
D8.  Rash (not 
bullous)
Erythema, scattered 
macular/popular eruption; pruritis 
transient; TOC or no meds
Diffuse macular/popular eruption 
or erythema with pruritus; dry 
desquamation; treatment required
Generalised, moist desquamation, 
requires systemic corticosteroids; 
responsive to treatment; reversible
Exfoliative or ulcerating; or 
requires hospitalisation; or 
parenteral corticosteroids
D9.  Indurartion/ 
fibrosis/Thickening 
(not sclerodermal)
Localized, high density on 
palpation, reversible, no effect on 
ADL and not disfiguring
Local areas < 50% body surface, 
not disfiguring, transient 
interference with ADL, reversible
Generalized, disfiguring, interferes 
with ADL, reversible
Disabling, irreversible, systemic 
symptoms
E.  Ear/Nose/Throat
E1.  Hearing loss
Transient, intermittent, no 
interference with function
Symptomatic, treatment required, 
reversible
Interferes with function; incomplete 
response to treatment
Irreversible deafness
E2.  Sense of smell
Slightly altered
Markedly altered
Complete loss, reversible
Complete loss, without recovery
abbvie 


Upadacitinib
M15-925 Protocol Amendment 6
EudraCT 2016-000933-37
188
E.  Ear/Nose/Throat (continued)
E3.  Stomatitis
Asymptomatic
Painful, multiple, can eat
Interferes with nutrition, slowly 
reversible
Requires enteral support; residual 
dysfunction
E4.  Taste 
disturbance 
(dysgeusia)
Transiently altered; metallic
Persistently altered; limited effect 
on eating
Disabling, effect on nutrition
NA
E5.  Tinnitus
Intermittent, transient, no 
interference with function
Requires treatment, reversible
Disabling, or associated with 
hearing loss
Irreversible deafness
E6.  Voice changes 
(includes hoarseness, 
loss of voice, 
laryngitis)
Intermittent hoarseness, able to 
vocalise
Persistent hoarseness, able to 
vocalise
Whispered speech, slow return of 
ability to vocalise
Unable to vocalize for extended
E7.  Xerostomia (dry 
mouth)
Transient dryness
Relief with meds
Interferes with nutrition, slowly 
reversible
Extended duration interference 
with nutrition, requires parenteral 
nutrition
F.  Eye/Ophthalmologic
F1.  Cataract
Asymptomatic, no change in 
vision, non-progressive
Symptomatic, partial visual loss, 
progressive
Symptoms impairing function, 
vision loss requiring treatment, 
including surgery
NA
F2.  Conjunctivitis
Asymptomatic, transient, rapid 
response to treatment
Symptomatic, responds to 
treatment, changes not interfering 
with function
Symptoms prolonged, partial 
response to treatment, interferes 
with function
NA
F3.  Lacrimation 
increased (tearing, 
watery eyes)
Symptoms not requiring 
treatment, transient
Symptomatic, treatment required, 
reversible
Unresponsive to treatment with 
major effect on function
NA
F4.  Retinopathy
Asymptomatic, non-progressive, 
no treatment
Reversible change in vision; 
readily responsive to treatment
Disabling change in vision 
ophthalmological findings 
reversible, sight improves over time
Loss of sight
abbvie 


Upadacitinib
M15-925 Protocol Amendment 6
EudraCT 2016-000933-37
189
F.  Eye/Ophthalmologic (continued)
F5.  Vision changes 
(e.g., blurred, 
photophobia, night 
blindness, vitreous 
floaters)
Asymptomatic, transient, no 
treatment required
Symptomatic, vision changes not 
interfering with function, 
reversible
Symptomatic, vision changes 
interfering with function
Loss of sight
F6.  Xerophtalmia 
(dry eyes)
Mild scratchiness
Symptomatic without interfering 
with function, requires artificial 
tears
Interferes with vision/function, 
corneal ulceration
Loss of sight
G.  Gastrointestinal
G1.  Anorexia
Adequate food intake, minimal 
weight loss
Symptoms requiring oral 
nutritional supplementation
Prolonged, requiring iv support
Requires hospitalization for 
nutritional support
G2.  Constipation
Asymptomatic, transient, 
responds to stool softener, OTC 
laxatives
Symptomatic, requiring 
prescription laxatives, reversible
Obstipation requiring medical 
intervention
Bowel obstruction.  Surgery 
required.
G3.  Diarrhea
Transient, increase of
2 – 3 stools/day over 
pre-treatment (no blood or 
mucus), OTC agents relieve
Symptomatic, increase
4 – 6 stools/day, nocturnal stools, 
cramping, requires treatment with
prescription meds.
Increase > 6 stools/day, associated 
with disabling symptoms, 
e.g., incontinence, severe cramping, 
partial response to treatment.
Prolonged, dehydration, 
unresponsive to treatment, requires 
hospitalization.
G4.  Dyspepsia 
(heartburn)
Transient, intermittent, responds 
to OTC antacids, H-2 blockers
Prolonged, recurrent, requires 
prescription meds, relieved by 
meds
Persistent despite treatment, 
interferes with function, associated 
with GI bleeding
NA
G5.  GI bleed 
(gastritis, gastric or 
duodenal ulcer 
diagnosed-define 
aetiology)
Asymptomatic, endoscopic 
finding, haemocult + stools, no 
transfusion, responds rapidly to 
treatment
Symptomatic, transfusion ≤ 2 units 
needed; responds to treatment
Haematemesis, transfusion
3 – 4 units, prolonged interference 
with function
Recurrent, transfusion > 4 units, 
perforation, requiring surgery, 
hospitalisation
G6.  Haematochezia 
(rectal bleeding)
Haemorrhodial, asymptomatic, no 
transfusion
Symptomatic, transfusion
≤ 2 units, reversible
Recurrent, transfusion > 3 – 4 units
> 4 units, hypotension, requiring 
hospitalization
abbvie 


Upadacitinib
M15-925 Protocol Amendment 6
EudraCT 2016-000933-37
190
G.  Gastrointestinal (continued)
G7.  Hepatitis
Laboratory abnormalities, 
asymptomatic, reversible
Symptomatic laboratory 
abnormalities, not interfering with 
function, slowly reversible
Laboratory abnormalities persistent 
> 2 wks, symptoms interfere with 
function
Progressive, hepato-renal, anasarca, 
pre-coma or coma
G8.  Nausea, or 
nausea/vomiting (use 
diagnostic term)
Transient, intermittent, minimal 
interference with intake, rapid 
response to meds.
Persistent, recurrent, requires 
prescription meds, intake 
maintained
Prolonged, interferes with daily 
function and nutritional intake, 
periodic iv fluids
Hypotensive, hospitalization, 
parenteral nutrition, unresponsive 
to out-patient management
G9.  Pancreatitis
Anylase elevation, intermittent 
nausea/vomiting, transient, 
responds rapidly to treatment
Amylase elevation with abdominal 
pain, nausea, occasional vomiting, 
responsive to treatment
Severe, persistent abdominal pain 
with pancreatitic enzyme elevation, 
incomplete or slow response to 
treatment
Complicated by shock, 
haemorrhage (acute circulatory 
failure)
G10.  Proctitis
Perianal pruritus, haemorrhoids 
(new onset), transient, or 
intermittent, relieved by OTC 
meds
Tenesmus or ulcerations, anal 
fissure, responsive to treatment, 
minimal interference with function
Unresponsive to treatment, marked 
interference with function
Mucosal necrosis with 
haemorrhage, infection, surgery 
required.
H.  Musculoskeletal
H1.  Avascular 
necrosis
Asymptomatic MRI changes, 
non-progressive
MRI changes and symptoms 
responsive to rest and analgesia
MRI changes, symptoms requiring 
surgical intervention
Wheelchair bound; surgical repair 
not possible
H2.  Arthralgia
Intermittent transient symptoms, 
no meds or relieved by OTC meds
Persistent or recurrent symptoms, 
resolve with meds, little effect on 
function
Severe symptoms despite meds 
impairs function
Debilitating, hospitalisation 
required for treatment
H3.  Leg cramps
Transient, intermittent, does not 
interfere with function
Recurrent symptoms, minimally 
interferes with function or sleep, 
responds to meds
Persistent, prolonged interference 
with function or sleep, partial or no 
response to meds
NA
H4.  Myalgia
Occasional; does not interfere 
with function
Frequent, requires meds 
(non-narcotic); minor effects on 
function
Major change in function/lifestyle, 
narcotic pain meds
Debilitating, profound weakness, 
requires wheelchair, unresponsive 
to meds
abbvie 


Upadacitinib
M15-925 Protocol Amendment 6
EudraCT 2016-000933-37
191
I.  Neuropsychiatric
I1.  Anxiety or 
Depression (mood 
alteration)
Symptomatic, does not interfere 
with function; no meds
Frequent symptoms, responds to 
meds; interferes with ADL at times
Persistent, prolonged symptoms, 
partial or no response to meds, 
limits daily function
Suicidal ideation or danger to self
I2.  Cerebrovascular 
ischaemia
NA
Single transient ischaemic event, 
responsive to treatment
Recurrent transient ischaemic events
Cerebrovascular vascular accident 
with permanent disability
I3.  Cognitive 
disturbance
Subjective symptoms, transient, 
intermittent, not interfering with 
function
Objective symptoms, persisting, 
interferes with daily function 
occasionally
Persistent, or worsening objective 
symptoms; interferes with routine 
daily routine
Debilitating/disabling and 
permanent; toxic psychosis
I4.  Depressed 
consciousness 
(somnolence)
Observed, transient, intermittent, 
not interfering with function
Somnolence or sedation, 
interfering with function
Persistent, progressive, obundation, 
stupor
Coma
I5.  Inability to 
concentrate
Subjective symptoms, does not 
interfere with function
Objective findings, interferes with 
function
Persistent, prolonged objective 
findings or organic cause
NA
I6.  Insomnia (in 
absence of pain)
Occasional difficulty sleeping, 
transient intermittent, not 
interfering with function
Recurrent difficulty sleeping; 
requires meds for relief; occasional 
interference with function
Persistent or worsening difficulty 
sleeping; severely interferes with 
routine daily function
NA
I7.  Libido decreased
Decrease in interest
Loss of interest; influences 
relationship
Persistent, prolonged interfering 
with relationship
NA
I8.  Peripheral motor 
neuropathy
Subjective or transient loss of 
deep tendon reflexes; function 
maintained
Objective weakness, persistent, no 
significant impairment of daily 
function
Objective weakness with substantial 
impairment of function
Paralysis
I9.  Peripheral 
sensory neuropathy 
(sensory disturbance)
Subjective symptoms without 
objective findings, transient, not 
interfering with function
Objective sensory loss, persistent, 
not interfering with function
Prolonged sensory loss or 
paraethesias interfering with 
function
NA
I10.  Seizure
NA
Recurrence of old seizures, 
controlled with adjustment of 
medication
Recurrence/exacerbation with 
partial response to medication
Recurrence not controlled, 
requiring hospitalization; new 
seizures
abbvie 


Upadacitinib
M15-925 Protocol Amendment 6
EudraCT 2016-000933-37
192
I.  Neuropsychiatric (continued)
I11.  Vertigo 
(dizziness)
Subjective symptoms, transient, 
intermittent, no treatment
Objective findings, recurrent, meds 
relieve, occasionally interfering 
with function
Persistent, prolonged, interfering 
with daily function; partial response 
to medication
Debilitating without response to 
medication, hospitalization
J.  Pulmonary
J1.  Asthma
Occasional wheeze, no 
interference with activities
Wheezing, requires oral meds, 
occasional interference with 
function
Debilitating, requires nasal O2
Requires ventilator assistance
J2.  Cough
Transient, intermittent, occasional 
OTC meds relieve
Persistent, requires narcotic or 
other prescription meds for relief
Recurrent, persistent coughing 
spasms without consistent relief by 
meds, interferes with function
Interferes with oxygenation; 
debilitating
J3.  Dyspnea
Subjective, transient, no 
interference with function
Symptomatic, intermittent or 
recurring, interferes with 
exertional activities
Symptomatic during daily routine 
activities, interferes with function, 
treatment with intermittent nasal O2
relieves
Symptomatic at rest, debilitating, 
requires constant nasal O2
J4.  Pleuritic pain 
(pleurisy)
Transient, intermittent symptoms, 
no treatment or OTC meds relieve
Persistent symptoms, requires 
prescription meds for relief
Prolonged symptoms, interferes 
with function, requires frequent 
narcotic pain relief
Debilitation, requiring 
hospitalisation
J5.  Pneumonitis 
(pulmonary 
infiltrates)
Asymptomatic radiographic 
changes, transient, no treatment 
required
Symptomatic, persistent, requiring 
corticosteroids
Symptomatic, requiring treatment 
including O2
Debilitating, not reversible; or 
requiring assisted ventilation
J6.  Pulmonary 
function decreased 
(FVC or carbon 
monoxide diffusion 
capacity – DLCO)
76% – 90% of pre-treatment value
51% – 75% of pre-treatment value
26% – 50% of pre-treatment value
≤ 25% of pre-treatment value
abbvie 


Upadacitinib
M15-925 Protocol Amendment 6
EudraCT 2016-000933-37
193
Laboratory Data
K.  Haematology
K1.  Hgb (g/dl) 
decrease from 
pre-treatment
1.0 – 1.4
1.5 – 2.0
2.1 – 2.9, or Hgb < 8.0, > 7.0
≥ 3.0; or Hgb < 7.0
K2.  Leukopenia 
(total WBC) × 1000
3.0 – 3.9
2.0 – 2.9
1.0 – 1.9
< 1.0
K3.  Neutropenia 
(× 1000)
1.5 – 1.9
1.0 – 1.4
0.5 – 0.9
< 0.5
K4.  Lymphopenia 
(× 1000)
1.5 – 1.9
1.0 –1.4
0.5 – 0.9
< 0.5
K5.  Platelets 
(× 1000)
75 – LLN
50 – 74.9
20 – 49.9; platelet transfusion 
required
< 20; recurrent platelet transfusions
L.  Chemistry
L1.  Hypercalcaemia 
(mg/dl)
1.1 × ULN – 11.5
11.6 – 12.5
12.6 – 13.5; or symptoms present
> 13.5; or associated coma
L2.  Hyperglycemia 
(mg/dl) Fasting
140 – 160
161 – 250
251 – 500
> 500, or associated with 
ketoacidosis
L3.  Hyperkalaemia 
(mg/dl)
5.5 – 5.9
6.0 – 6.4
6.5 – 7.0 or any ECG change
> 7.0 or any arrhythmia
L5.  Hypocalcaemia 
(mg/dl)
0.9 × LLN – 7.8
7.7 – 7.0
6.9 – 6.5; or associated with 
symptoms
< 6.5 or occurrence of tetany
L6.  Hypoglycemia 
(mg/dl)
55 – 64 (no symptoms)
40 – 54 (or symptoms present)
30 – 39 (symptoms impair function)
< 30 or coma
L7.  Hyponatraemia 
(mg/dl)
--
125 – 129
120 – 124
< 120
L8.  Hypokalaemia 
(mg/dl)
--
3.0 – 3.4
2.5 – 2.9
< 2.5
abbvie 


Upadacitinib
M15-925 Protocol Amendment 6
EudraCT 2016-000933-37
194
L.  Chemistry (continued)
L9.  CPK (also if 
polymyositis-
disease)*
1.2 – 1.9 × ULN
2.0 – 4.0 × ULN
4.0 × ULN with weakness but 
without life-threatening signs or 
symptoms
> 4.0 × ULN with signs or 
symptoms of rhabdomyolysis or 
life-threatening
L10.  Serum uric acid
1.2 – 1.6 × ULN
1.7 – 2.9 × ULN
3.0 – 5.0 × ULN or gout
NA
L11.  Creatinine 
(mg/dL)*
1.1 – 1.3 × ULN
1.3 – 1.8 × ULN
1.9 – 3.0 × ULN
> 3.0 × ULN
L12.  SGOT (AST)
1.2 – 1.5 × ULN
1.6 – 3.0 × ULN
3.1 – 8.0 × ULN
> 8.0 × ULN
L13.  SGPT (ALT)
1.2 – 1.5 × ULN
1.6 – 3.0 × ULN
3.0 – 8.0 × ULN
> 8.0 × ULN
L14.  Alkaline 
phosphatase
1.1 – 2.0 × ULN
1.6 – 3.0 × ULN
3.0 – 5.0 × ULN
> 5.0 × ULN
L15.  T. bilirubin
1.1 – 1.4 × ULN
1.5 – 1.9 × ULN
2.0 – 3.0 × ULN
> 3.0 × ULN
L16.  LDH
1.3 – 2.4 × ULN
2.5 – 5.0 × ULN
5.1 – 10 × ULN
> 10 × ULN
M.  Urinalysis
M1.  Haematuria
Micro only
Gross, no clots
Clots, transfusion < 2 units 
Transfusion required
M2.  Proteinuria (per 
24 h)
300 – 500 mg (tr/1+)
501 – 1999 mg (2+)
2 – 5.0 g (3+) nephrotic syndrome
5.0 g (4+) anasarca
M3.  WBC in urine
NA
NA
Indicating acute interstitial nephritis
Associated with acute renal failure
M4.  Uric acid 
crystals
Present without symptoms
NA
With stones or symptoms of stones 
(e.g., renal colic)
Causing renal outflow obstruction 
and hospitalization
OTC = over-the-counter medication; ADL = activities of daily living; IV = intravenous; ECG = electrocardiogram; CHF = congestive heart failure; MRI = magnetic resonance 
imaging; Hb = haemglobin; LLN = lower limit of normal; ULN = upper limit of normal; WBC = white blood cells; SLE = systemic lupus erythematosus; ANA = antinuclear 
antibodies; H-2 blockers = histamine-2 blockers; FVC = forced vital capacity
*
For CPK and Creatinine NCI CTC grading will be used.  For CPK therefore the following gradings apply:  Grade 1:  > ULN – 2.5 × ULN; Grade 2:  > 2.5 – 5.0 × ULN; 
Grade 3:  > 5.0 – 10.0 × ULN; Grade 4:  > 10.0 × ULN; For Creatinine the following gradings apply:  Grade 1:  > 1 – 1.5 × Baseline; > ULN – 1.5 × ULN; Grade 2:  > 1.5 –
3.0 × Baseline; > 1.5 – 3.0 × ULN; Grade 3:  > 3.0 baseline; > 3.0 – 6.0 × ULN; Grade 4:  > 6.0 × ULN.
abbvie 

SAP_005.pdf: 
Upadacitinib
M15-925 – Statistical Analysis Plan
Version 2.0 – 17 Dec 2020
1
1.0
Title Page
Statistical Analysis Plan
Study M15-925
A Phase 3, Randomized, Active-Controlled, Double-
Blind Study Comparing Upadacitinib to Abatacept in 
Subjects with Moderately to Severely Active 
Rheumatoid Arthritis with Inadequate Response or 
Intolerance to Biologic DMARDs (bDMARDs) on 
Stable Conventional Synthetic Disease Modifying 
Anti-Rheumatic Drugs (csDMARDs)
Date:  17 Dec 2020
Version 2.0
 
NCT03086343


Upadacitinib
M15-925 – Statistical Analysis Plan
Version 2.0 – 17 Dec 2020
2
2.0
Table of Contents
1.0
Title Page..................................................................................1
2.0
Table of Contents.....................................................................2
3.0
Introduction .............................................................................7
4.0
Study Objectives, Design and Procedures.............................7
4.1
Study Objectives ........................................................................................7
4.2
Overall Study Design and Plan..................................................................7
4.3
Study Design History...............................................................................11
4.4
Sample Size..............................................................................................12
4.5
Interim Analysis and Date Base Lock......................................................13
4.6
Data Monitoring Committee (DMC) Activities.......................................13
5.0
Analysis Populations and Analysis Windows .....................13
5.1
Analysis Populations................................................................................13
5.2
Analysis Windows ...................................................................................14
6.0
Demographics, Baseline Characteristics, Medical 
History, and Previous/Concomitant Medications ..............17
6.1
Demographics and Baseline Characteristics............................................17
6.2
Medical History .......................................................................................20
6.3
Prior Treatment and Concomitant Medications.......................................21
6.4
Protocol Deviations..................................................................................21
7.0
Patient Disposition.................................................................22
8.0
Study Drug Exposure and Compliance...............................23
8.1
Study Drug Exposure...............................................................................23
8.2
Compliance ..............................................................................................24
9.0
Efficacy Analysis....................................................................25
9.1
General Considerations............................................................................25
9.1.1
Efficacy Analysis at Different Phases of the Study.................................25
9.1.2
Definition of Missing Data Imputation....................................................25
9.2
Efficacy Analysis for Period 1.................................................................27
9.2.1
Primary Efficacy Analysis .......................................................................27
9.2.2
Sensitivity Analysis of Primary Efficacy Variables ................................28
9.2.3
Key Secondary Efficacy Analyses...........................................................28
 


Upadacitinib
M15-925 – Statistical Analysis Plan
Version 2.0 – 17 Dec 2020
3
9.2.4
Exploratory Efficacy Analyses ................................................................29
9.2.5
Handling of Multiplicity ..........................................................................30
9.2.6
Efficacy Subgroup Analysis ....................................................................30
9.3
Long-Term Efficacy Analysis..................................................................31
9.4
Efficacy Variables Definitions and Conventions.....................................32
9.4.1
ACR Criteria ............................................................................................32
9.4.2
Joint Evaluation .......................................................................................35
9.4.3
Patient's Global Assessment of Disease Activity Visual Analog 
Scale (VAS) .............................................................................................36
9.4.4
Physician's Global Assessment of Disease Activity Visual Analog 
Scale (VAS) .............................................................................................37
9.4.5
Patient's Global Assessment of Pain........................................................37
9.4.6
Disease Activity Score (DAS28) .............................................................37
9.4.7
Simplified Disease Activity Index (SDAI) ..............................................38
9.4.8
Clinical Disease Activity Index (CDAI)..................................................38
9.4.9
Clinical Remission (CR) and Low Disease Activity (LDA)....................39
9.4.10
ACR/EULAR Boolean Remission...........................................................39
9.4.11
Disability Index of Health Assessment Questionnaire (HAQ DI)...........39
9.4.12
EuroQoL-5D (EQ-5D-5L) .......................................................................40
9.4.13
Functional Assessment of Chronic Illness Therapy-Fatigue 
(FACIT-F)................................................................................................40
9.4.14
Form SF-36v2 ..........................................................................................41
9.4.15
Work Productivity and Activity Impairment (WPAI) .............................41
9.4.16
Systemic Corticosteroid Dose..................................................................42
10.0
Safety Analysis.......................................................................42
10.1
General Considerations............................................................................42
10.2
Analysis of Adverse Events.....................................................................43
10.2.1
Analysis of Adverse Events for Period 1.................................................44
10.2.1.1
Adverse Events Overview........................................................................44
10.2.1.2
Adverse Events by System Organ Class and Preferred Term..................45
10.2.1.3
TEAEs by Maximum Severity.................................................................45
10.2.1.4
TEAEs by Relationship............................................................................46
 


Upadacitinib
M15-925 – Statistical Analysis Plan
Version 2.0 – 17 Dec 2020
4
10.2.1.5
Frequent (≥ 2%) Adverse Events and Reasonably Possibly 
Related Adverse Events by System Organ Class and Preferred 
Term.........................................................................................................46
10.2.1.6
Adverse Events of Special Interest ..........................................................46
10.2.2
Analysis of Long-Term Adverse Event Rates .........................................48
10.2.2.1
Overview of Adverse Events Rates per 100 Patient-Years of 
Study Drug Exposure...............................................................................49
10.2.2.2
Adverse Events Rates per 100 Patient-Years of Study Drug 
Exposure by SOC and PT ........................................................................50
10.2.2.3
Adverse Events of Special Interest Rates per 100 Patient Years of 
Study Drug Exposure...............................................................................50
10.2.2.4
Listing of Serious Adverse Events (Including Deaths) and 
Adverse Events Leading to Study Drug Discontinuation ........................50
10.3
Analysis of Laboratory Data....................................................................50
10.3.1
Variables and Units..................................................................................50
10.3.2
Analysis of Laboratory Data for Period 1................................................52
10.3.2.1
Assessment of Mean Change from Baseline and Percentage 
Change from Baseline in Clinical Laboratory Variables.........................53
10.3.2.2
Assessment of Shift from Baseline in Clinical Laboratory 
Variables ..................................................................................................53
10.3.2.3
Assessment of Potentially Clinical Significant Laboratory Values .........54
10.3.2.4
Assessment of Liver Elevations...............................................................54
10.3.3
Analysis of Long-Term Laboratory Data.................................................55
10.3.3.1
Assessment of Mean Change from Baseline and Percentage 
Change from Baseline in Clinical Laboratory Variables.........................55
10.3.3.2
Assessment of Potentially Clinically Significant Laboratory 
Values ......................................................................................................55
10.3.3.3
Assessment of Liver Elevations...............................................................56
10.4
Analysis of Vital Signs ............................................................................56
10.4.1
Variables and Criteria Defining Abnormality..........................................56
10.4.2
Analysis of Vital Sign for Period 1..........................................................57
10.4.3
Analysis of Long-Term Vital Sign...........................................................57
11.0
Summary of Changes ............................................................58
 


Upadacitinib
M15-925 – Statistical Analysis Plan
Version 2.0 – 17 Dec 2020
5
11.1
Summary of Changes between the Previous Version and the 
Current Version........................................................................................58
12.0
Version History......................................................................59
13.0
Appendix.................................................................................59
List of Tables
Table 1.
Analysis Windows for Efficacy Analysis for Period 1 (for ACR 
Components and Morning Stiffness) and Safety Analysis for 
Period 1 (for Labs and Vital Signs) .........................................................15
Table 2.
Analysis Windows for Efficacy Analysis for Period 1 (for EQ 5D 
5L and SF-36) ..........................................................................................16
Table 3.
Analysis Windows for Efficacy Analysis for Period 1 (for FACIT-
F)..............................................................................................................16
Table 4.
Analysis Windows for Efficacy Analysis for Period 1 (for WPAI) ........16
Table 5.
Insert Table Title Here.............................................................................31
Table 6.
Anatomical Joints Assessed for Calculation of Tender and 
Swollen Joint Counts (TJC68 and SJC66)...............................................36
Table 7.
Anatomical Joints for DAS28 (CRP) Calculation ...................................38
Table 8.
AESI for Upadacitinib with SMQs/CMQs/PTs Searches........................47
Table 9.
List of Laboratory Variables....................................................................51
Table 10.
Criteria for Potentially Clinically Significant Vital Sign Findings..........57
Table 11.
SAP Version History Summary...............................................................59
List of Figures
Figure 1.
Period 1 Study Design .............................................................................10
Figure 2.
Period 2 Study Design .............................................................................11
List of Appendices
Appendix A.
Statistical Analysis for the 30 mg Cohort ................................................60
Appendix B.
Statistical Analysis to Account for Impact of COVID-19 
Pandemic..................................................................................................63
 


Upadacitinib
M15-925 – Statistical Analysis Plan
Version 2.0 – 17 Dec 2020
6
Appendix C.
OMERACT Criteria.................................................................................65
 


Upadacitinib
M15-925 – Statistical Analysis Plan
Version 2.0 – 17 Dec 2020
7
3.0
Introduction
This statistical analysis plan (SAP) describes the statistical analyses to be completed by 
the Data and Statistical Science Department for Upadacitinib Study M15-925.  It provides 
details to further elaborate statistical methods as outlined in the protocol.  
Pharmacokinetic and biomarker analyses will be performed separately and the 
corresponding analysis plan is documented separately.
Unless noted otherwise, all analyses will be performed using SAS version 9.2 or later 
(SAS Institute Inc., Cary, NC 27513) under the UNIX operating system.
4.0
Study Objectives, Design and Procedures
4.1
Study Objectives
Period 1
To compare the safety and efficacy of upadacitinib 15 mg once daily (QD) versus 
abatacept intravenous (IV) for the treatment of signs and symptoms of rheumatoid 
arthritis (RA) in bDMARD-inadequate response (bDMARD-IR) or bDMARD-intolerant 
subjects on stable conventional synthetic DMARDs with moderately to severely active 
RA.
Period 2
To evaluate the long-term safety, tolerability, and efficacy of Upadacitinib 15 mg QD in 
subjects with RA who have completed Period 1.
4.2
Overall Study Design and Plan
This is a Phase 3, multicenter study that includes two periods.  Period 1 is a 24-week 
randomized, double-blind, parallel-group, active-controlled treatment period designed to 
compare the safety and efficacy of upadacitinib 15 mg QD versus abatacept IV for the 
treatment of signs and symptoms of subjects with moderately to severely active RA who 
have an inadequate response to or intolerance to bDMARD therapies other than abatacept 
 


Upadacitinib
M15-925 – Statistical Analysis Plan
Version 2.0 – 17 Dec 2020
8
and are currently on a stable dose of csDMARDs.  Period 2 is an open-label extension to 
evaluate the long-term safety, tolerability, and efficacy of upadacitinib 15 mg QD in 
subjects with RA who have completed Period 1.  Starting with Amendment 5, all subjects 
will receive open-label upadacitinib 15 mg QD, including those currently on upadacitinib 
30 mg QD.
The study is designed to enroll approximately 550 subjects at approximately 200 study 
centers worldwide to meet scientific and regulatory objectives without enrolling an undue 
number of subjects in alignment with ethical considerations.  Therefore, if the target 
number of subjects has been enrolled, there is a possibility that additional subjects in 
screening may not be enrolled.
The study duration will include a 35-day maximum screening period; a 24-week 
randomized, double blind, parallel-group, active controlled treatment period, with 30-day 
and 70-day follow-ups if subjects are discontinued earlier or choose not to enter Period 2 
(Period 1); and a 192-week open-label long term extension period with a 30-day follow-
up call or site visit (Period 2).
Subjects who meet eligibility criteria will be randomized in a 1:1 ratio to one of two 
treatment groups:
●
Group 1:  Upadacitinib 15 mg QD, N = 275 (Period 1) →Upadacitinib 15 mg 
QD (Period 2)
●
Group 2:  Abatacept IV, N = 275 (Period 1) →Upadacitinib 15 mg QD 
(Period 2)
Randomization will be stratified by number of prior bDMARD use (stratum 1:  failed 1 or 
2 biologics of the same class; stratum 2:  failed ≥ 3 biologics of the same class or failed 
biologics of multiple classes) AND geographic region.
Subjects must have been on stable csDMARD(s) treatment for ≥ 4 weeks prior to the 
first dose of study drug and must remain on a stable dose until Week 12; the csDMARD 
dose may be decreased only for safety reasons.  Starting at Week 12 (after Week 12 
 


Upadacitinib
M15-925 – Statistical Analysis Plan
Version 2.0 – 17 Dec 2020
9
assessments have been performed), initiation of or change in corticosteroids, non-steroidal 
anti-inflammatory drugs (NSAIDs), acetaminophen, or adding or increasing doses for up 
to 2 csDMARDs (concomitant use of up to 2 csDMARDs except the combination of 
MTX and leflunomide) is allowed as per local label.
Rescue therapy will be offered to subjects who meet the following criteria:
●
Starting at Week 12, subjects who do not achieve ≥ 20% improvement in both 
TJC and SJC at two consecutive visits will be rescued with optimizing (initiate 
or increase) background RA medications:  NSAIDs, corticosteroids, low-
potency analgesics, acetaminophen or adding or increasing doses in up to 
2 csDMARDs (concomitant use of up to 2 csDMARDs except the combination 
of MTX and leflunomide) and, if necessary, a burst of systemic corticosteroids 
(prednisone equivalent ≤ 0.5 mg/kg/day for 3 consecutive days), intra-articular, 
intramuscular, intravenous, trigger point or tender point, intra-bursa, and intra-
tendon sheath injections of corticosteroids, dosage and frequency per standard 
of care, are allowed.
Subjects who complete the Week 24 visit (end of Period 1) will enter the open-label long 
term extension portion of the study, Period 2 (192 weeks).  Subjects who are assigned to 
upadacitinib 15 mg QD treatment group in Period 1 will continue to receive upadacitinib 
15 mg QD per original randomization assignment.  Subjects who are assigned to abatacept 
IV in Period 1 will be switched to receive upadacitinib 15 mg QD.
An unblinded analysis will be conducted after all subjects have completed Period 1 
(Week 24).  Period 2 is open-label.
Study design schematics of Period 1 and Period 2 are shown in Figure 1 and Figure 2, 
respectively.
 


Upadacitinib
M15-925 – Statistical Analysis Plan
Version 2.0 – 17 Dec 2020
10
Figure 1.
Period 1 Study Design
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
  
 
 
 
   
 
  
 
 
  
 
 
  
 
 
 
 
  
 
 
 
 
 
 
 
  
 
 
 
  
 
  
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 


Upadacitinib
M15-925 – Statistical Analysis Plan
Version 2.0 – 17 Dec 2020
11
Figure 2.
Period 2 Study Design
4.3
Study Design History
The study was originally designed to compare upadacitinib dose of 30 mg QD versus 
abatacept IV.  In October 2017, the study protocol was amended (Amendment 4) to 
replace the upadacitinib 30 mg arm with the upadacitinib dose of 15 mg QD.  This 
decision was made based on data from the initial, placebo controlled periods of the 
upadacitinib Phase 3 RA Studies M13-549 (csDMARD-IR) and M13-542 (bDMARD-
IR).  The data from these studies showed that both the 15 and 30 mg QD doses achieved 
superior responses to placebo for all primary and ranked secondary endpoints at Week 12 
 
 
 
  
  
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
  
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 


Upadacitinib
M15-925 – Statistical Analysis Plan
Version 2.0 – 17 Dec 2020
12
and 30 mg dose provided no incremental benefit over the 15 mg dose.  Safety results from 
these studies showed that upadacitinib 15 mg and 30 mg QD doses were well-tolerated.
In Period 1, subjects randomized to upadacitinib arm under Amendment 3 received 30 mg 
QD dose.  As such, 44 subjects in total were enrolled under Amendment 3.  Starting with 
Amendment 4, new subjects randomized to upadacitinib arm will receive 15 mg QD dose.  
In Period 2, subjects who enrolled under Amendment 3, including subjects randomized to 
both Upadacitinib 30 mg QD and Abatacept IV, will receive open-label upadacitinib 30 
mg QD; all subjects who enroll under Amendment 4 or thereafter will receive open-label 
upadacitinib 15 mg QD.  Starting with Amendment 5, all subjects will receive open label 
upadacitinib 15 mg QD dose, including those currently on upadacitinib 30 mg QD.
The subjects enrolled before and after Protocol Amendment 4 form two separate cohorts 
and the cohort from Protocol Amendment 4 is considered the main cohort for the study.  
The statistical analyses for these two cohorts will be conducted differently as described in 
Section 5.1.
4.4
Sample Size
The planned total sample size of 550 (N = 275 per arm) is applied to the cohort of 
upadacitinib 15mg QD vs abatacept IV that is enrolled after Protocol Amendment 4.  This 
sample size can provide more than 90% power for the non-inferiority assessment on the 
primary endpoint using a non-inferiority margin of 0.6 at two-sided significance level of 
0.05, assuming true difference between upadacitinib 15 mg QD and abatacept in change 
from baseline in DAS28 (CRP) at Week 12 is 0.5 with an assumed standard deviation of 
2.0 and accounting for a 10% dropout rate.  Under the planned sample size, superiority 
comparison of upadacitinib 15 mg QD to abatacept in change from baseline in DAS28 
(CRP) is powered at approximately 80%.  The planned sample size can also provide 
approximately 80% power for superiority comparison of upadacitinib 15 mg QD to 
abatacept in DAS28 (CRP) Clinical Remission (DAS28 (CRP) < 2.6) at two-sided 
significance level of 0.05 and accounting for a 10% dropout rate, where the assumed 
 


Upadacitinib
M15-925 – Statistical Analysis Plan
Version 2.0 – 17 Dec 2020
13
DAS28 (CRP) CR response rate is 31% for upadacitinib 15 mg QD and for 20% 
abatacept.
4.5
Interim Analysis and Date Base Lock
An unblinded analysis will be conducted after all subjects have completed Period 1 
(Week 24).
4.6
Data Monitoring Committee (DMC) Activities
An independent external Data Monitoring Committee (DMC) is used to review unblinded 
safety data at regular intervals during the conduct of the study as described in the DMC 
charter.  The DMC will provide recommendation to an AbbVie Point of Contact on 
whether to continue, modify, or terminate studies after each review.  When needed, high-
level unblinded efficacy data may also be requested by the DMC and be reviewed so that 
the DMC can assess benefit:risk of any emerging safety differences.
5.0
Analysis Populations and Analysis Windows
5.1
Analysis Populations
The study contains two cohorts of subjects:  the "30 mg Cohort" which includes the 
subjects randomized to Upadacitinib 30 mg QD vs Abatacept IV, and the "15 mg Cohort" 
which includes the subjects randomized to Upadacitinib 15 mg QD vs Abatacept IV.  The 
15 mg Cohort is the main cohort for statistical analysis.  For the 30 mg Cohort, the full 
analysis set and safety analysis set are defined.  For 15 mg Cohort, the full analysis set, 
per protocol analysis set and safety analysis set are defined.
For the 30 mg Cohort, no formal statistical analysis is planned.  The scope of data 
reporting and the statistical methods for descriptive summary are provided in Appendix A.
The statistical analysis described in Chapters 6 to 10 applies to the 15 mg Cohort.
 


Upadacitinib
M15-925 – Statistical Analysis Plan
Version 2.0 – 17 Dec 2020
14
Full Analysis Set (FAS)
The Full Analysis Set (FAS) includes all randomized subjects who received at least 
one dose of study drug.  The FAS will be used for all efficacy and baseline analyses.
Per Protocol Analysis Set
The Per Protocol Analysis Set represents a subset of the FAS and consists of all FAS 
subjects who did not meet any major protocol deviations that can potentially impact the 
Week 12 efficacy assessment.  Additional analysis of the primary efficacy endpoint will 
be conducted on the Per Protocol analysis set, in order to evaluate the impact of major 
protocol deviations.
Major protocol deviations (ICH deviations and other clinically significant non-ICH 
deviations) will be identified prior to database lock.
Safety Analysis Set
The Safety Analysis Set consists of all subjects who received at least one dose of study 
drug.  For the Safety Analysis Set, subjects are assigned to a treatment group based on the 
"as treated" treatment group, regardless of the treatment randomized.  The "as treated" is 
determined by the treatment the subject received during the majority of the subject's drug 
exposure time in the analysis period.
5.2
Analysis Windows
Definition of Study Days (Days Relative to the First Dose of Study Drug)
Study Days are calculated for each collection date relative to the date of the first dose of 
study drug.  It is defined as the number of days between the date of the first dose of study 
drug and the collection date.  Study days are negative values when the collection date of 
interest is prior to the first study drug dose date.  Study days are positive values when the 
collection date of interest is on or after the first study drug dose date.  The day of the first 
dose of study drug is defined as Study Day 1, while the day prior to the first study drug 
 


Upadacitinib
M15-925 – Statistical Analysis Plan
Version 2.0 – 17 Dec 2020
15
dose is defined as Study Day –1 (there is no Study Day 0).  Study days are used to map 
actual study visits to the protocol-specified study visits.
Definition of Analysis Windows
The following rules will be applied to assign actual subject visits to protocol-specified 
visits.  For each protocol-specified study visit, a target study day will be identified to 
represent the corresponding visit along with a window around the target day.  Windows 
will be selected in a non-overlapping fashion so that a collection date does not fall into 
multiple visit windows.  If a subject has two or more actual visits in one visit window, the 
visit closest to the target day will be used for analysis.  If two visits are equidistant from 
the target day, then the later visit will be used for analysis. 
The visit window and the target study day for each protocol-specified visit in Period 1 are 
displayed in Table 1, Table 2, Table 3, and Table 4 (depending on the different visit 
schedules of different endpoints).  Visit windows for protocol-specified visits in Period 2 
are defined similarly.
Table 1.
Analysis Windows for Efficacy Analysis for Period 1 (for ACR 
Components and Morning Stiffness) and Safety Analysis for
Period 1 (for Labs and Vital Signs)
Protocol Specified Visit Week
Lower Bound
Target Day
Upper Bound
Baseline
–99
1a
1
2
2
15
22
4
23
29
43
8
44
57
71
12
72
85
99
16
100
113
127
20
128
141
155
24
156
169
first dose date of Period 2
a.
Day of first dose of study drug.
 


Upadacitinib
M15-925 – Statistical Analysis Plan
Version 2.0 – 17 Dec 2020
16
Table 2.
Analysis Windows for Efficacy Analysis for Period 1 (for EQ 5D 5L 
and SF-36)
Protocol Specified Visit Week
Lower Bound
Target Day
Upper Bound
Baseline
–99
1a
1
4
2
29
57
12
58
85
127
24
128
169
first dose date of Period 2
a.
Day of first dose of study drug.
Table 3.
Analysis Windows for Efficacy Analysis for Period 1 (for FACIT-F)
Protocol Specified Visit Week
Lower Bound
Target Day
Upper Bound
Baseline
–99
1a
1
4
2
29
43
8
44
57
71
12
72
85
99
16
100
113
141
24
142
169
first dose date of Period 2
a.
Day of first dose of study drug.
Table 4.
Analysis Windows for Efficacy Analysis for Period 1 (for WPAI)
Protocol Specified Visit Week
Lower Bound
Target Day
Upper Bound
Baseline
–99
1a
1
4
2
29
43
8
44
57
71
12
72
85
127
24
128
169
first dose date of Period 2
a.
Day of first dose of study drug.
 


Upadacitinib
M15-925 – Statistical Analysis Plan
Version 2.0 – 17 Dec 2020
17
6.0
Demographics, Baseline Characteristics, Medical 
History, and Previous/Concomitant Medications
6.1
Demographics and Baseline Characteristics
Demographic and baseline characteristics information will be collected at the Baseline 
visit of the study and will be summarized for the FAS.  The number of observations, 
mean, standard deviation, median, minimum and maximum will be summarized for 
continuous variables.  Categorical or discrete variables will be summarized via 
frequencies and percentages.  Summary statistics will be computed for each treatment 
group and overall.
Main Demographic and Baseline Characteristics
●
Sex (male, female)
●
Age (years)
●
Age Categories (< 40, [40, 65], ≥ 65 years)
●
Race (White, Black or African American, American Indian or Alaska Native, 
Native Hawaiian or Other Pacific Islander, Asian, Other)
●
Geographic Region (North America, South/Central America, Western Europe, 
Eastern Europe, Asia, Other)
●
Ethnicity (Hispanic or Latino, Not Hispanic or Latino) 
●
Weight (kg)
●
Weight Categories (< 60 kg, ≥ 60 kg)
●
Height (cm)
●
Body Mass Index (BMI) (kg/m2)
●
Body Mass Index (BMI) Category (kg/m2) (BMI < 25, BMI ≥ 25)
RA Medical History and Characteristics
●
Duration of RA Symptoms in years
●
Duration of RA Diagnosis in years
 


Upadacitinib
M15-925 – Statistical Analysis Plan
Version 2.0 – 17 Dec 2020
18
●
Duration of RA Symptoms Categories (< 10 year, ≥ 10 year)
●
Duration of RA Diagnosis Categories (< 10 year, ≥ 10 year)
●
Number of prior bDMARD received (1, 2, ≥ 3)
●
Prior failed bDMARD (stratum 1:  failed 1 or 2 biologics with the same 
mechanism of action; stratum 2:  failed ≥ 3 biologics with the same mechanism 
of action and/or multiple mechanisms of action)
●
Failed at least one prior bDMARD due to lack of efficacy (yes, no)
●
Failed at least one anti-TNF (yes, no)
●
Oral steroid dose at baseline (yes, no)
●
Oral steroid dose (prednisone equivalent) at baseline 
●
Concomitant csDMARD at baseline (MTX alone, MTX plus other csDMARD, 
csDMARD other than MTX)
ACR and/or DAS Components at Baseline
●
Tender joint count (TJC68) defined as the number of tender joints out of 
68 assessed joints
●
Swollen joint count (SJC66) defined as the number of swollen joints out of 
66 assessed joints
●
Tender joint count (TJC28) defined as the number of tender joints out of 
28 assessed joints used for DAS28 calculation
●
Swollen joint count (SJC28) defined as the number of swollen joints out of 
28 assessed joints used for DAS28 calculation
●
Physician's global assessment of disease activity (mm on a 100-mm horizontal 
visual analogue scale [VAS])
●
Patient's assessment of pain within last week (mm on a 100-mm horizontal 
VAS)
●
Patient's global assessment of disease activity within last 24 hours (mm on a 
100-mm horizontal VAS)
●
Health Assessment Questionnaire Disability Index of the (HAQ – DI) 
(range:  0 to 3)
 


Upadacitinib
M15-925 – Statistical Analysis Plan
Version 2.0 – 17 Dec 2020
19
●
High sensitivity C-reactive protein (hsCRP) (mg/L)
●
Erythrocyte sedimentation rate (ESR) (mm/hr)
Other Baseline RA Disease Characteristics
●
Anti-cyclic citrullinated peptide (Anti-CCP) (units)
●
Anti-CCP status:  Positive or Negative
●
Rheumatoid Factor (RF) (units)
●
Rheumatoid Factor (RF) status:  Positive or Negative
●
RF and Anti-CCP both positive vs. at least one negative
●
RF and Anti-CCP both negative vs. at least one positive
●
DAS28 [hsCRP]
●
DAS28 [ESR]
●
DAS28 Categories:
○
DAS28 > 5.1 (High Disease Activity)
○
DAS28 ≤ 5.1
●
Clinical Disease Activity Index (CDAI)
●
CDAI categories:
○
CDAI > 22 (High Disease Activity)
○
CDAI ≤ 22
●
Simplified Disease Activity Index (SDAI)
●
SDAI categories:
○
SDAI > 26 (High Disease Activity)
○
SDAI ≤ 26
Patient Report Outcomes at Baseline
●
Morning stiffness (severity and duration)
●
EQ-5D-5L
●
FACIT-F
 


Upadacitinib
M15-925 – Statistical Analysis Plan
Version 2.0 – 17 Dec 2020
20
●
36-Item Short Form Health Survey (SF-36) Version 2:  physical component 
summary, mental component summary and the 8 sub-domain scores
●
WPAI
Clinical Tests at Screening
●
Chest x-ray
●
ECG
●
Tuberculin PPD skin test, QuantiFERON TB Gold test
●
Hepatitis Testing
●
Serum pregnancy test
Immunization History
●
BCG immunization
●
Herpes Zoster immunization
●
Hepatitis B immunization
Tobacco/Nicotine and Alcohol Use
●
Tobacco/Nicotine Use [user, ex-user, non-user, unknown]
●
Alcohol Use [drinker, ex-drinker, non-drinker, unknown]
6.2
Medical History
Medical history data will be summarized and presented for FAS population using body 
systems and conditions/diagnoses as captured on the CRF.  The body systems will be 
presented in alphabetical order and the conditions/diagnoses will be presented in 
alphabetical order within each body system.  The number and percentage of subjects with 
a particular condition/diagnosis will be summarized for each randomized treatment group 
as well as overall.  Subjects reporting more than one condition/diagnosis within a body 
 


Upadacitinib
M15-925 – Statistical Analysis Plan
Version 2.0 – 17 Dec 2020
21
system will be counted only once for that body system.  No statistical comparison will be 
performed for medical history reporting.
6.3
Prior Treatment and Concomitant Medications
Prior and concomitant medications will be summarized by each randomized treatment 
group as well as overall for FAS.  Prior medications are those medications taken prior to 
the first dose of study drug.  This includes medications with a start date before the 
first study drug administration date, regardless of the end date of these medications.  
Medications taken on the day of the first dose of study drug are not counted as prior 
medications.  Concomitant medications are those medications, other than study drug, 
taken after the first dose of study drug and within 28 days of the last dose of study drug.  
This includes medications with a start date between first study drug administration and 
last study drug administration + 28 days, as well as, medications with a start date prior to 
first dose of study drug and which are ongoing after first dose of study drug.  Medications 
taken on the day of the first dose of study drug are counted as concomitant medications.
The number and percentage of subjects who received a prior medication and the number 
and percentage of subjects who received a concomitant medication will be tabulated 
separately by the generic name assigned by the most current version of the World Health 
Organization (WHO) Drug Dictionary.
6.4
Protocol Deviations
Protocol deviations based on ICH deviation criteria are categorized as follows:
1.
Those who entered the study even though they did not satisfy the entry criteria
2.
Those who developed withdrawal criteria during the study and were not 
withdrawn
3.
Those who received the wrong treatment or incorrect dose, and
4.
Those who received an excluded or prohibited concomitant medication.
 


Upadacitinib
M15-925 – Statistical Analysis Plan
Version 2.0 – 17 Dec 2020
22
The protocol deviations listed above will be summarized and listed by treatment group.
7.0
Patient Disposition
The following will be summarized by randomized treatment group as well as overall:
●
number of subjects randomized,
●
number of subjects included in key analysis populations (Full Analysis Set, Per 
Protocol Analysis Set for primary efficacy analysis, Safety Analysis Set for 
Period 1),
●
number of subjects who completed Period 1 study participation,
●
number of subjects who entered Period 2,
●
number of subjects who completed overall study (Period 1 and Period 2) 
participation (if applicable).
This summary will be repeated by site.
Premature discontinuation details will be further summarized separately for Period 1 and 
Period 2 as follows.
Period 1
The number and percentage of subjects completed Period 1 and prematurely discontinued 
in Period 1 will be summarized by randomized treatment group, separately by study drug 
and study participation completion/discontinuation, with the primary reason for 
discontinuation collected from CRF by the following categories:
●
Adverse event (AE)
●
Withdrew consent
●
Lost to follow-up
●
Lack of efficacy (this option is collected as a reason for study drug 
discontinuation, not for study participation discontinuation)
●
Other
 


Upadacitinib
M15-925 – Statistical Analysis Plan
Version 2.0 – 17 Dec 2020
23
Subjects may have more than one reason for discontinuing, but only the primary reason 
will be summarized.
In addition, the number and percentage of subjects who entered Period 2 will also be 
summarized by randomized treatment group.
Period 2
Period 2 patient dispositions and reason for discontinuation will be summarized for the 
single treatment group Upadacitinib 15 mg QD in Period 2.
Among the subjects who entered Period 2 participation (regardless of whether subject is 
on study drug in Period 2), the number and percentage of subjects completed and 
prematurely discontinued study participation in Period 2 will be summarized.  Among the 
subjects who entered Period 2 on study drug, the number and percentage of subjects 
completed and prematurely discontinued study drug in Period 2 will be summarized.
For subjects who prematurely discontinued study drug or study participation, the primary 
reason as well as all reasons for discontinuation will be summarized with the same 
categories as given above for Period 1.
8.0
Study Drug Exposure and Compliance
8.1
Study Drug Exposure
The duration of exposure to study drug will be summarized for the safety analysis set by 
the following groups.
1.
Upadacitinib 15 mg QD
This includes Upadacitinib 15 mg QD exposure from subjects starting on 
Upadacitinib 15 mg QD and subjects switching from abatacept IV to Upadacitinib 
15 mg QD.
2.
Abatacept IV
 


Upadacitinib
M15-925 – Statistical Analysis Plan
Version 2.0 – 17 Dec 2020
24
The duration of exposure to study drug will be summarized for each group as specified 
above, with the number of subjects, mean, standard deviation, median, minimum and 
maximum values.  In addition, the number and percentage of subjects exposed to study 
drug will be summarized for the following cumulative duration intervals.
●
≥ 2 weeks
●
≥ 1 month
●
≥ 3 months
●
≥ 6 months
●
≥ 9 months
●
≥ 12 months
●
≥ 18 months
●
≥ 2 years
●
≥ 2.5 years
●
≥ 3 years
●
≥ 4 years
8.2
Compliance
Study drug compliance for upadacitinib 15 mg QD/PBO and for abatacept/PBO will be 
summarized separately for each treatment group for Period 1.  Upadacitinib 15 mg 
QD/PBO compliance is defined as the number of upadacitinib 15 mg QD/PBO tablets 
taken (i.e., the difference between the number of tablets dispensed and the number of 
tablets returned) during Period 1divided by the number of days that the subject was in the 
Treatment Phase in Period 1.  Abatacept/PBO compliance is defined as the number of 
injections administered during the subject's participation in Period 1 divided by the 
number of injections planned during the subject's participation in the Treatment Phase in 
Period 1.
 


Upadacitinib
M15-925 – Statistical Analysis Plan
Version 2.0 – 17 Dec 2020
25
9.0
Efficacy Analysis
9.1
General Considerations
There are two sets of planned efficacy analysis:  efficacy analysis for Period 1 and long-
term efficacy analysis.  All efficacy analyses will be carried out using the FAS population.
9.1.1
Efficacy Analysis at Different Phases of the Study
Efficacy Analysis for Period 1
Standard efficacy analysis by randomized treatment groups (Upadacitinib 15 mg QD and 
Abatacept IV) will be performed on efficacy data for Period 1 (up to Week 24).  No 
protocol-defined treatment switching will occur prior to the time point.  Formal statistical 
inference will be generated, and results from this set of analysis will be used as the key 
efficacy findings of this study.
Long-Term Efficacy Analysis
Long-term efficacy analysis will be performed on As Observed data (defined in 
Section 9.1.2) by randomized treatment group sequence as described below:
1.
Upadacitinib 15 mg QD 
2.
Abatacept IV →Upadacitinib 15 mg QD
There will be no statistical testing; only descriptive statistics and confidence intervals will 
be provided.
9.1.2
Definition of Missing Data Imputation
Non-Responder Imputation (NRI) Approach
The NRI approach will categorize any subject who has a missing value for categorical 
variables at a specific visit as non-responder for that visit.  In addition, subjects who 
 


Upadacitinib
M15-925 – Statistical Analysis Plan
Version 2.0 – 17 Dec 2020
26
prematurely discontinue from study drug will be considered as non-responders for all 
subsequent visits after discontinuation.
Observed Cases (OC)
The OC analysis will not impute values for missing evaluations.  In addition, the OC will 
not use values after premature discontinuation of study drug.  This sensitivity analysis will 
only be applied to the analysis in Period 1.
As Observed (AO)
The AO analysis will not impute values for missing evaluations.  Regardless of treatment 
switching or premature discontinuation of study drug, all observed data will be used in the 
analysis.  The AO analysis will be applied to long-term efficacy analysis.
Multiple Imputation (MI)
The MI analysis will impute missing data multiple times under appropriate random 
variation and thus generate multiple imputed "pseudo-complete" datasets.  Results will be 
aggregated across the multiple imputed datasets, overcoming drawbacks of the single 
imputation methods.  PROC MI will be used to generate 5 datasets using the fully 
conditional specification (FCS) method.  Specifically, treatment group is included in the 
FCS imputation model to enable sampling stratified by treatment groups.  Additionally, 
the imputation model includes demographics variables and baseline disease 
characteristics, as well as longitudinal response observed at any other visits.  An 
ANCOVA model will first be performed on each of the multiple imputed datasets 
adjusting for treatment, stratification factor and baseline value.  PROC MIANALYZE will 
then be used to aggregate the results for the final statistical inference using Rubin's 
method.  The imputation is based on the assumption of data being missing at random.  
The missing at random assumption is considered reasonable given the high placebo 
response rate typically seen in RA trials.  Additionally in RA trials, the proportion of 
discontinuation is relatively small (10 – 15% only) and the rate of discontinuation due to 
lack of efficacy is generally low (< 5%).
 


Upadacitinib
M15-925 – Statistical Analysis Plan
Version 2.0 – 17 Dec 2020
27
Mixed Effect Model Repeat Measurement (MMRM) and Generalized Linear Mixed 
Model (GLMM) for Long-Term Analysis
The repeated measure analysis will be conducted using mixed model including As 
Observed measurements at all visits.  MMRM will be used for continuous endpoints and 
GLMM will be used for binary endpoints.  The mixed models will include the categorical 
fixed effects of treatment, visit and treatment-by-visit interaction, and main stratification 
factor prior bDMARD use.  For the MMRM analysis of change from baseline in 
continuous endpoints, the baseline measurement will be included as a continuous fixed 
covariate.  The categorical fixed effect of subject's discontinuation status may also be 
included in the model as appropriate.  Unstructured, Toeplitz, compound symmetry, or 
other covariance structures may be considered.
9.2
Efficacy Analysis for Period 1
9.2.1
Primary Efficacy Analysis
The primary endpoint is the non-inferiority comparison of upadacitinib 15 mg QD to 
abatacept on change from baseline in DAS28 (CRP) at Week 12.
Analysis of the primary endpoint will be conducted on the FAS based on randomized 
treatment groups (Upadacitinib 15 mg QD and Abatacept IV).  Statistical inference will 
be conducted using analysis of covariance (ANCOVA) coupled with MI for missing data 
handling.  Specifically, the ANCOVA model will include treatment as the fixed factor, 
and the corresponding baseline value and the stratification factor of prior bDMARD use 
as the covariates.  The LS mean and 95% CI will be reported for each randomized 
treatment group; the LS mean treatment difference and associated 95% CI will be reported 
comparing Upadacitinib 15 mg QD group and Abatacept IV group.  The non-inferiority of 
Upadacitinib 15 mg QD versus Abatacept will be tested using the 95% confidence interval 
(CI) of treatment difference against a non-inferiority margin of 0.6.
 


Upadacitinib
M15-925 – Statistical Analysis Plan
Version 2.0 – 17 Dec 2020
28
9.2.2
Sensitivity Analysis of Primary Efficacy Variables
A sensitivity analysis will be conducted using ANCOVA based on Observed Cases 
without any imputation.  This will be conducted on the FAS based on randomized 
treatment groups.
The primary analysis will be repeated on the Per Protocol Analysis Set as a supportive 
analysis.
9.2.3
Key Secondary Efficacy Analyses
Ranked key secondary endpoints (at Week 12) are:
1.
Change from baseline in DAS28 (CRP) at Week 12 (superiority)
2.
Proportion of subjects achieving DAS28 (CRP) Clinical Remission (CR) at 
Week 12 (superiority)
For the continuous endpoint change from baseline in DAS28 (CRP), the mean, standard 
deviation, median, and range will be reported for each randomized treatment group 
(Upadacitinib 15 mg QD and Abatacept IV).  Statistical inference will be derived from the 
same analysis as the primary endpoint of the non-inferiority assessment using analysis of 
covariance (ANCOVA) coupled with MI for missing data handling, and p-value will be 
reported for the superiority comparison of Upadacitinib 15 mg QD versus Abatacept IV.
For the binary endpoint proportion of subjects achieving DAS28 (CRP) Clinical 
Remission (CR), frequencies and percentages will be reported for each randomized 
treatment group (Upadacitinib 15 mg QD and Abatacept IV).  Point estimate and 95% CI 
using normal approximation will be provided for the response rate for each randomized 
treatment group.  Point estimate, 95% CI and p-value will be provided for the treatment 
comparison between Upadacitinib 15 mg QD and Abatacept IV using the Cochran-
Mantel-Haenszel test adjusting for the stratification factor of prior bDMARD use.  NRI 
will be used as primary analysis and OC will be used as sensitivity analysis.
 


Upadacitinib
M15-925 – Statistical Analysis Plan
Version 2.0 – 17 Dec 2020
29
9.2.4
Exploratory Efficacy Analyses
Additional efficacy analysis includes the following endpoints at all visits in Period 1 
unless specified otherwise:
●
Proportion of subjects achieving DAS28 (CRP) LDA at Week 12 (non-
inferiority with 10% margin);
●
ACR20/50/70 response rates;
●
Change from baseline in individual components of ACR response;
●
Change from baseline in DAS28 (CRP) and DAS28 (erythrocyte sedimentation 
rate [ESR]);
●
Change from baseline in SF-36 at Weeks 4, 12 and 24;
●
Change from baseline in morning stiffness (severity and duration);
●
Proportion of subjects achieving LDA or CR based on DAS28 (CRP), DAS28 
(ESR), Simplified Disease Activity Index (SDAI), and Clinical Disease 
Activity Index (CDAI) criteria;
●
Change from baseline in EQ-5D-5L at Weeks 4, 12 and 24;
●
Change from baseline in Functional Assessment of Chronic Illness Therapy –
fatigue (FACIT-F) at Weeks 4, 8, 12, 16 and 24;
●
Change from baseline in Work Productivity and Activity Impairment (WPAI) 
at Weeks 4, 8, 12 and 24;
●
Change from baseline in CDAI and SDAI;
●
Proportion of subjects achieving change from baseline in HAQ-DI ≤ –0.3 and ≤ 
–0.22, respectively;
●
ACR/EULAR Boolean remission;
●
Systemic corticosteroid dose from Week 12 to 24 (see Section 9.4.16 for 
details).
For binary endpoints, point estimate and 95% CI using normal approximation will be 
provided for the response rate for each randomized treatment group.  Point estimate, 95% 
CI and p-value will be provided for the treatment comparison between Upadacitinib 
15 mg QD and Abatacept IV using the Cochran-Mantel-Haenszel test adjusting for 
 


Upadacitinib
M15-925 – Statistical Analysis Plan
Version 2.0 – 17 Dec 2020
30
stratification factor prior bDMARD use.  The non-inferiority of Upadacitinib 15 mg QD 
versus Abatacept in DAS28 (CRP) LDA at Week 12 will be tested using the 95% 
confidence interval for treatment comparison against a non-inferiority margin of 10%.  
NRI will be used as primary analysis and OC will be used as sensitivity analysis.
For continuous endpoints, analysis will be conducted using ANCOVA based on Observed 
Cases without any imputation.  The ANCOVA model will include treatment as the fixed 
factor, and the corresponding baseline value and the main stratification factors as the 
covariates.  The LS mean and 95% CI will be reported for each randomized treatment 
group.  The LS mean treatment difference and associated 95% CI and p-values between 
Upadacitinib 15 mg QD and Abatacept IV will be provided.
9.2.5
Handling of Multiplicity
In order to preserve the overall Type I error, a step-down approach will be used to test the 
primary and ranked key secondary endpoints where statistical significance can be claimed 
for a lower ranked endpoint only if the previous endpoint in the sequence meets the 
requirements of significance.  Specifically, the testing will utilize the endpoint sequence 
of primary endpoint followed by ranked key secondary endpoints in the order as specified 
in Section 9.2.3, using two-sided α of 0.05.
9.2.6
Efficacy Subgroup Analysis
The primary efficacy endpoint will be examined in the subgroups listed in Table 5 below.  
Treatment difference between Upadacitinib 15 mg QD and Abatacept IV will be 
presented with point estimate and 95% confidence interval using ANCOVA based on 
Observed Cases without imputation.  No formal non-inferiority or superiority comparison 
will be performed at subgroup level.  If any of the resulting subgroups has fewer than 10% 
of the planned study size (i.e., < 55 subjects), the subgroup analyses for that variable will 
not be presented.
 


Upadacitinib
M15-925 – Statistical Analysis Plan
Version 2.0 – 17 Dec 2020
31
Table 5.
Insert Table Title Here
Subgroup Factor
Categories
Age
< 40, 40 – < 65, ≥ 65
Sex
Male or Female
Weight
< 60 kg or ≥ 60 kg
BMI
< 25 or ≥ 25
Race
White, non-white
Geographic Region
North America, South/Central America, Western 
Europe, Eastern Europe, Asia, Other
Duration of RA diagnosis
< 10 year or ≥ 10 year
Baseline Rheumatoid Factor Status
Positive or Negative
Baseline Anti-CCP Antibody Status
Positive or Negative
Baseline both RF positive and Anti-CCP positive
Yes or No
Baseline both RF negative and Anti-CCP negative
Yes or No
Baseline DAS28 (CRP)
≤ 5.1 or > 5.1
Prior failed bDMARD 
stratum 1:  failed 1 or 2 biologics with the same 
mechanism of action; stratum 2:  failed
≥ 3 biologics with the same mechanism of action 
and/or multiple mechanisms of action
Failed at least one Prior bDMARD due to lack of 
efficacy
Yes or No
Failed anti-IL6 due to lack of efficacy
Yes or No
9.3
Long-Term Efficacy Analysis
Assessments to evaluate long-term efficacy will be analyzed for the following measures at 
each visit through Week 216 unless specified otherwise:
●
ACR20/50/70 response rates;
●
Change from baseline in individual ACR components;
●
Change from baseline in DAS28 (CRP) and DAS28 (ESR);
●
Change from baseline in SF-36 up to Week 48 only;
●
Change from baseline in morning stiffness;
 


Upadacitinib
M15-925 – Statistical Analysis Plan
Version 2.0 – 17 Dec 2020
32
●
Proportion of subjects achieving LDA based on DAS28 (CRP), DAS28 (ESR), 
SDAI, and CDAI criteria;
●
Proportion of subjects achieving CR based on DAS28 (CRP), DAS28 (ESR), 
SDAI, and CDAI criteria;
●
Change from baseline in EQ-5D-5L up to Week 48 only;
●
Change from baseline in Functional Assessment of Chronic Illness Therapy –
fatigue (FACIT-F) up to Week 48 only;
●
Change from baseline in Work Productivity and Activity Impairment (WPAI) 
at Week 48 only;
●
Change from baseline in CDAI and SDAI;
●
Proportion of subjects achieving a change from baseline in HAQ-DI ≤ –0.3;
●
Proportion of subjects achieving a change from baseline in HAQ-DI ≤ –0.22;
●
ACR/EULAR Boolean remission;
●
Proportion of subjects with no concomitant corticosteroid use
Analyses will be based on As Observed (AO) data.  Descriptive statistics will be provided 
for each randomized treatment group sequence as defined in Section 9.1.1.  These include 
the number of observations, mean, standard deviation, and 95% CI for continuous 
endpoints; and frequencies and percentages with 95% CI using normal approximation for 
binary endpoints.  In addition, longitudinal analysis will be performed using MMRM or 
GLMM as described in Section 9.1.2 for all endpoints except proportion of subjects with 
no concomitant corticosteroid use.  Point estimates and 95% CI from the model will be 
provided for each treatment group sequence.  Plot for each randomized treatment group 
sequence over time will be provided.  
9.4
Efficacy Variables Definitions and Conventions
9.4.1
ACR Criteria
ACR criteria are a commonly used standard criteria set mentioned in the guidance of 
American College of Rheumatology to evaluate the effectiveness of investigation drug in 
 


Upadacitinib
M15-925 – Statistical Analysis Plan
Version 2.0 – 17 Dec 2020
33
RA clinical trials.  It is a composite measurement calculated based on the improvement 
over a set of core measurements.
ACR20 is defined as at least 20% improvement (compared to baseline values) in tender 
and swollen joint counts and at least 20% improvement in 3 of the remaining 5 core set 
measures (subject global assessment of pain, subject global assessment of disease activity, 
physician global assessment of disease activity, subject assessment of physical function 
and acute phase reactant hsCRP).
ACR50 and ACR70 are similarly defined with at least 50% and 70% improvement, 
respectively.
A subject will be classified as an ACR20 (ACR50, ACR70) responder, if the following 
conditions are met:
1.
≥ 20% (50%, 70%) improvement from baseline in tender joint count (TJC68) and
2.
≥ 20% (50%, 70%) improvement from baseline in swollen joint count (SJC66) and
3.
≥ 20% (50%, 70%) improvement from baseline in at least 3 of the following 5:
●
patient's assessment of pain
●
patient's global assessment of disease activity (PGA)
●
physician's global assessment of disease activity (PhGA)
●
patient's self-assessment of physical function (i.e., measured by Health 
Assessment Questionnaire HAQ-DI score)
●
Acute-phase reactant value CRP
There are seven components to be evaluated to define an ACR response.  Missing values 
for each component can occur due to a missed visit or due to dropout from the study.  
Depending on the pattern of the missing components, ACR responses may be or may not 
be determined using observed values only.
 


Upadacitinib
M15-925 – Statistical Analysis Plan
Version 2.0 – 17 Dec 2020
34
To maximize the utilization of observed information at certain visits and be scientifically 
as robust as possible, the principle to calculate ACR response is to minimize imputation 
whenever possible.  Observed ACR response will be calculated first based on a derived 
visit window instead of the nominal visit identifier (e.g., Week 6 visit) collected from the 
CRF.
To calculate observed ACR responses:
●
Identify the observed component xx% improvement indicator (0/1/missing), 1 
means achieving ≥ xx% improvement from baseline and 0 means < xx% 
improvement from baseline (e.g., xx% representing 20%/50%/70%).
●
ACRxx = 0 if TJC indicator = 0 OR SJC indicator = 0 OR at least 3 out of 5 
components improvement indicators = 0.
●
ACRxx = 1 if TJC indicator = 1 AND SJC indicator = 1 AND at least 3 out of 5 
components improvement indicators = 1.
●
For all other cases, ACRxx = missing since ACRxx cannot be determined.
The following table illustrates examples for ACR calculations.
Example
TJC 
68
SJC 
66
Component 
1
Component 
2
Component 
3
Component 
4
Component 
5
ACR20-
Response?
A
1
1
1
1
1
.
.
Yes
B
1
0
1
1
1
1
1
No
C
.
0
.
.
.
.
.
No
D
1
.
1
1
1
1
1
.
E
1
1
0
0
0
1
1
No
F
.
.
0
0
0
.
.
No
G
1
1
1
1
0
0
.
.
Legend:  1 = ≥ 20% improved compared to baseline; 0 = < 20% improved compared to baseline; "." = Missing
Windowing Rule for ACR Response Calculation:
●
ACR component values will first be determined at each date within a visit 
window.
 


Upadacitinib
M15-925 – Statistical Analysis Plan
Version 2.0 – 17 Dec 2020
35
●
ACR component values at each date will be combined to determine the 
observed ACR composite score at each date in each window.
●
After this calculation, if multiple non-missing ACR composite scores are 
available within a given visit window, the non-missing ACR composite score 
closest to the target day will be used.  If two composite scores have the same 
distance from the target day, the later one will be used.  The corresponding date 
will be used as the observed ACR response date in the derived efficacy dataset.
●
If a non-missing ACR composite score is not available for any day within a 
given visit window, the windowed component values for that visit will be used 
to calculate the ACR composite score for that visit window (component value 
windowing follow the same rules as in steps described above).  The date of 
observed ACR composite score will be determined by the first available ACR 
component date, in the order of TJC, SJC, Pain, PGA, PhGA, HAQ-DI, 
CRP/ESR, in the derived efficacy dataset.
When observed ACR xx response for a given visit is missing, imputation methods will be 
used to calculate "imputed" ACRxx response.
●
Non-Responder Imputation (NRI) for ACR response:
○
Step 1:  all missing components will be imputed using LOCF, and then the 
ACR composite score can be calculated.
○
Step 2:  if the ACR composite score cannot be determined by step 1, the 
ACR composite score will be imputed as 0.  In addition, subjects who 
prematurely discontinue from the study drug will be considered as non-
responders (ACR = 0) for all subsequent visits after the discontinuation 
date.
9.4.2
Joint Evaluation
Anatomical joints are evaluated for swelling and tenderness at every study visit.  The 
34 anatomical joints in Table 6 are assessed in this study for both the left and right side of 
the body.
 


Upadacitinib
M15-925 – Statistical Analysis Plan
Version 2.0 – 17 Dec 2020
36
Table 6.
Anatomical Joints Assessed for Calculation of Tender and Swollen 
Joint Counts (TJC68 and SJC66)
Temporomandibular
Sternoclavicular
Acromio-clavicular
Shoulder
Elbow
Wrist
Metacarpophalangeal I
Metacarpophalangeal II 
Metacarpophalangeal III
Metacarpophalangeal IV
Metacarpophalangeal V
Thumb Interphalangeal
Proximal Interphalangeal 
II
Proximal Interphalangeal 
III
Proximal Interphalangeal 
IV
Proximal Interphalangeal 
V
Distal
Interphalangeal II
Distal
Interphalangeal III
Distal
Interphalangeal IV
Distal
Interphalangeal V
Hipa
Knee
Ankle
Tarsus
Metatarsophalangeal I
Metatarsophalangeal II 
Metatarsophalangeal III
Metatarsophalangeal IV
Metatarsophalangeal V
Great Toe/Hallux
Interphalangeal II
Interphalangeal III
Interphalangeal IV
Interphalangeal V
a.
Hip joints are not assessed for swelling.
At each study visit, a joint evaluator assessed whether a particular joint was "tender or 
painful" where presence of tenderness was scored as "1" and the absence of tenderness 
was scored as "0," provided the joint was not replaced ("9") or could not be assessed 
("NA") due to other reasons (e.g., post-corticosteroid joint injection).  The total tender 
joint count (TJC68), which is based on 68 joints, will be derived as the sum of all "1s" and 
proportional extrapolation will be used to impute joint counts for the joints that are
replaced or not assessed.  A similar method will be followed for the derivation of total 
swollen joint count (SJC66), which is based on 66 joints as the hip joints are excluded.  
Thus, the range for TJC68 will be 0 to 68 and 0 to 66 for SJC66.
9.4.3
Patient's Global Assessment of Disease Activity Visual 
Analog Scale (VAS)
The subject will assess his/her disease activity for the past 24 hours using a Patient's 
Global Assessment of Disease VAS.  The range is 0 to 100 mm with no activity being 
indicated by 0 and severe activity by 100.
 


Upadacitinib
M15-925 – Statistical Analysis Plan
Version 2.0 – 17 Dec 2020
37
9.4.4
Physician's Global Assessment of Disease Activity Visual 
Analog Scale (VAS)
The physician will assess Patient's disease activity at the time of visit using a Physician's 
Global Assessment of Disease VAS.  The range is 0 to 100 mm with no activity being 
indicated by 0 and severe activity by 100.
9.4.5
Patient's Global Assessment of Pain
The subject will assess his/her pain in the previous week using a Patient's Global 
Assessment Pain VAS.  The range is 0 to 100 mm with no pain being indicated by 0 and 
severe pain by 100.
9.4.6
Disease Activity Score (DAS28)
DAS28 (CRP) and DAS28 (ESR) are composite indices to assess disease activity in RA 
patients using hsCRP or ESR measurement respectively.  The DAS provides a score 
between 0 and 10, indicating how active the rheumatoid arthritis is at the time of 
measurement.
DAS28 (CRP) and DAS28 (ESR) can be calculated based on Tender Joint Count, Swollen 
Joint Count, Patient's Global Assessment of Disease Activity (PtGA) (in mm), and hsCRP 
(in mg/L) or ESR (mm/hr).
DAS28 (CRP) = 0.56 × √(TJC28*) + 0.28 × √(SJC28**) + 0.36 × ln(hsCRP& + 1) + 
0.014 × PtGA» + 0.96
DAS28 (ESR) = 0.56 × √(TJC28*) + 0.28 × √(SJC28**) + 0.70 × ln(ESR#) + 0.014 
× PtGA»
*
TJC28 refers to the Subject's total Tender Joint Count out of the provided 28 evaluated joints.
**
SJC28 refers to the Subject's total Swollen Joint Count out of the provided 28 evaluated joints.
&
hsCRP refers to the high-sensitivity c-reactive protein lab value.  hsCRP unit in the DAS28 (CRP) equation is 
expressed as mg/L.
#
ESR refers to the Erythrocyte sedimentation rate.  ESR unit in the DAS28 (ESR) equation is expressed as mm/hr.
»
PtGA refers to the Patient's Global Assessment of Disease Activity.
 


Upadacitinib
M15-925 – Statistical Analysis Plan
Version 2.0 – 17 Dec 2020
38
where √is square root and ln is natural log.
Table 7.
Anatomical Joints for DAS28 (CRP) Calculation
Shoulder
Elbow
Wrist
Thumb Interphalangeal
Metacarpophalangeal I
Metacarpophalangeal II
Metacarpophalangeal III
Metacarpophalangeal IV
Metacarpophalangeal V
Proximal Interphalangeal
II
Proximal Interphalangeal 
III
Proximal Interphalangeal 
IV
Proximal Interphalangeal 
V
Knee
To calculate observed DAS28 scores, the observed component value will be calculated 
first.  Then the components will be included in the calculation per the DAS formula 
selected.  If any observed component is missing in a window, then the observed DAS28 
score will be missing.
9.4.7
Simplified Disease Activity Index (SDAI)
SDAI is a composite continuous index to assess disease activity based on TJC28, SJC28, 
Patient's Global Assessment of Disease Activity (PtGA) (in cm, 0 – 10), Physician's 
Global Assessment of Disease Activity (PhGA) (in cm, 0 – 10) and hsCRP (mg/dL).  It 
can be derived as follows:
SDAI = TJC28 + SJC28 + PtGA (cm) + PhGA (cm) + hsCRP (mg/dL).
To calculate observed SDAI scores, the observed component value will be calculated first.  
Then the components will be included in the calculation per the SDAI formula selected.  
If any observed component is missing in a window, then the observed SDAI score will be 
missing.
9.4.8
Clinical Disease Activity Index (CDAI)
CDAI is a composite continuous index to assess disease activity without using hsCRP 
measurement.  It can be calculated based on TJC28, SJC28, Patient's Global Assessment 
of Disease Activity (PtGA) (in cm, 0 – 10) and Physician's Global Assessment of Disease 
Activity (PhGA) (in cm, 0 – 10).  It can be derived as follows:
 


Upadacitinib
M15-925 – Statistical Analysis Plan
Version 2.0 – 17 Dec 2020
39
CDAI = TJC28 + SJC28 + PtGA (cm) + PhGA (cm).
To calculate observed CDAI scores, the observed component value will be calculated 
first.  Then the components will be included in the calculation per the CDAI formula 
selected.  If any observed component is missing in a window, then the observed CDAI 
score will be missing.
9.4.9
Clinical Remission (CR) and Low Disease Activity (LDA)
Clinical remission (CR) and low disease activity (LDA) based on DAS28 (CRP), 
DAS28(ESR), SDAI and CDAI are defined as follows:
DAS28 (CRP) and DAS28 (ESR)
SDAI
CDAI
LDA
≤ 3.2
≤ 11.0
≤ 10
CR
< 2.6
≤ 3.3
≤ 2.8
9.4.10
ACR/EULAR Boolean Remission
ACR/EULAR Boolean remission is defined based on the following four criteria:
●
Tender joint count ≤ 1 (based on 28 joints)
●
Swollen joint count ≤ 1 (based on 28 joints)
●
CRP ≤ 1 mg/dL
●
Patient global assessment of disease activity ≤ 10 (mm)
All four criteria must be satisfied at a visit for a subject to be classified as achieving 
ACR/EULAR Boolean remission.
9.4.11
Disability Index of Health Assessment Questionnaire
(HAQ DI)
HAQ-DI is a self-reported patient outcome measurement.  It is calculated as the mean of 
the scores from 8 following categories with a range 0 – 3:  Dressing and Grooming, 
Rising, Eating, Walking, Hygiene, Reach, Grip, and Activities.  The higher the score, the 
more likely to associate with morbidity and mortality for the RA patient.
 


Upadacitinib
M15-925 – Statistical Analysis Plan
Version 2.0 – 17 Dec 2020
40
The maximum score for all the questions in each category is considered as the score for 
the category.  The Standard disability index (HAQ-DI) takes into account the subject's use 
of aids or devices or assistance in the scoring algorithm for a disability category.  For each 
of the eight disability categories there is an AIDS OR DEVICES companion variable(s) 
that is used to record the type of assistance, if any, a subject uses for his/her usual 
activities.  If aids or devices and/or assistance from another person are checked for a 
disability category, the score for this category is set to 2 (much difficulty), if the original 
score is 0 (no difficulty) or 1 (some difficulty).  The HAQ-DI is then calculated by 
summing the adjusted categories scores and dividing by the number of categories 
answered.  The HAQ-DI cannot be calculated if the patient does not have scores for at 
least 6 categories.
9.4.12
EuroQoL-5D (EQ-5D-5L)
EQ-5D is a standardized measure of health status developed by the EuroQol Group in 
order to provide a simple, generic measure of health for clinical and economic appraisal.  
The EQ-5D consists of 2 pages.  The first page measures 5 dimensions of the health status 
(mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) with 
5 levels per dimension (no problems, slight problems, moderate problems, severe 
problems, and extreme problems corresponding to Level 1 to Level 5 respectively).  The 
second page is an EQ Visual Analogue Scale (EQ VAS).  EQ-5D health states, defined by 
the EQ-5D-5L descriptive system on the first page, may be converted into a single index 
value.  The change from baseline of the index value and EQ VAS will be analyzed and 
reported.  UK scoring algorithm will be used.
9.4.13
Functional Assessment of Chronic Illness Therapy-Fatigue 
(FACIT-F)
Fatigue is one of the most frequent complaints of the elderly and is strongly associated 
with loss of independence and decreased physical activity and functional decline.  
One validated tool to measure fatigue is FACIT Fatigue Scale v4.  The FACIT Fatigue 
Scale is a short, 13-item, easy to administer tool that measures an individual's level of 
fatigue during their usual daily activities over the past week.  Each of the fatigue and 
 


Upadacitinib
M15-925 – Statistical Analysis Plan
Version 2.0 – 17 Dec 2020
41
impact of fatigue items are measured on a four point Likert scale.  The FACIT Fatigue 
Scale is ranged from 0 to 52 and the higher the score, the better the quality of life.  Score 
for each item is calculated by either subtracted from 4 or adding 0 depending on whether 
it is a reversal item or not.  FACIT Fatigue Scale is then calculated by adding up all item 
scores, multiplied by 13 and divided by the number of items answered.  It is essentially a 
prorated subscale if there are missing values for some items.  If less than or equal to 50% 
of the items are answered (e.g., 6 out of 13), the proration is not acceptable and the scale 
will not be computed.
9.4.14
Form SF-36v2
The 36-Item Short Form, Version 2 (SF-36v2) Questionnaire with 4 week recall will be 
completed by the subject at Baseline, Weeks 4, 8 and at study completion (Week 12 or at 
PD).  The SF-36v2 health survey consists of 36 general health questions and this study is 
using the form for 4 weeks recall period (standard form).  It has 2 components:  physical 
and mental.  For each component, a transformed summary score is calculated using 8 sub 
domains:  physical functioning, role-physical, bodily pain, general health, vitality, social 
functioning, role-emotional, and mental health.
The coding and scoring for the SF-36 will use the software provided by QualityMetrics.
9.4.15
Work Productivity and Activity Impairment (WPAI)
The Work Productivity and Activity Impairment (WPAI) questionnaire is a validated, 
self-administered tool used to assess the impact of disease on productivity.  It measures 
time missed from work and impairment of work and activities due to a specific health 
problem.  The questionnaire consists of 6 questions concerning a patient's ability to work 
and perform regular activities.  Unemployed patients only answer select WPAI questions 
relating to their employment status and ability to perform daily activities other than work.  
WPAI scores are expressed as percent impairment based on six items.  The four main 
impairment measures or scores are absenteeism, presenteeism, percent overall work 
impairment and percent activity impairment.
 


Upadacitinib
M15-925 – Statistical Analysis Plan
Version 2.0 – 17 Dec 2020
42
9.4.16
Systemic Corticosteroid Dose
This endpoint is to assess for differential corticosteroid use between treatment groups 
during the period between Week 12 and Week 24, due to Week 12 rescue criteria 
allowing dose changes with regard to corticosteroids.  Systemic corticosteroid dose 
standardized by the duration of treatment phase, represented as average dose per day 
between Week 12 and Week 24, is calculated.  The change from baseline dose to this 
average daily dose will be analyzed.
10.0
Safety Analysis
10.1
General Considerations
Safety analyses will be carried out using the Safety Analysis Set.  There are two sets of 
planned safety analysis:  safety analysis for Period 1, and long-term safety analysis.
Safety Analysis For Period 1
Standard safety analysis by the "as treated" treatment groups of Upadacitinib 15 mg QD 
and Abatacept IV will be performed on safety data up to Week 24.  No protocol-defined 
treatment switching will occur prior to Week 24.
The standard safety analyses will include reporting of adverse events (AEs), laboratory, 
and vital signs measurements.  Frequency tables of subjects with treatment-emergent 
adverse events (TEAEs) by system organ class (SOC) and by preferred term (PT) as in the 
Medical Dictionary for Regulatory Activities (MedDRA) dictionary will be provided by 
treatment group.  Mean changes from baseline in all continuous laboratory parameters and 
vital signs variables at each visit will be summarized by "as treated" treatment group.  
Frequency tables of subjects meeting criteria for potentially clinically significant vital sign 
values and for potentially clinically significant laboratory values will be provided by 
treatment group.  Missing safety data will not be imputed.
 


Upadacitinib
M15-925 – Statistical Analysis Plan
Version 2.0 – 17 Dec 2020
43
Long-Term Safety Analysis
Long-term safety analyses for upadacitinib 15 mg QD include reporting of AE rate 
adjusted by cumulative exposure, mean change from baseline in laboratory parameters 
and vital sign variables, and rate of potentially clinically significant laboratory and vital 
signs values.  The treatment-emergent adverse event (TEAE) rate per 100 patient-years of 
exposure will be presented.  Listing of subjects with TEAEs by SOC and PT will be 
provided.  Mean changes from baseline in all continuous laboratory parameters and vital 
signs variables at each visit will be summarized by "as treated" treatment group sequences 
defined as follows.  Frequency tables and listings of subjects meeting criteria for 
potentially clinically significant vital sign values and for potentially clinically significant 
laboratory values will be provided.  Missing safety data will not be imputed.
"As treated" treatment group sequences are defined as follows:
1.
Upadacitinib 15 mg QD 
2.
Abatacept IV →Upadacitinib 15 mg QD
10.2
Analysis of Adverse Events
A treatment-emergent Adverse Event (TEAE) is defined as an adverse event with an onset 
date that is after the first dose of study drug, and no more than 30 days or 5 half-lives of 
the drug, whichever is larger, after the last dose of study drug.  Specifically, 30 days will 
be used for Upadacitinib 15mg QD, and 70 days will be used for abatacept.
Events where the onset date is the same as the study drug start date are assumed to be 
treatment-emergent, unless the study drug start time and the adverse event start time are 
collected and the adverse event start time is prior to the study drug start time.  If an 
incomplete onset date was collected for an adverse event, the event will be assumed to be 
treatment-emergent unless there is other evidence that confirms that the event was not 
treatment-emergent (e.g., the event end date was prior to the study drug start date).
 


Upadacitinib
M15-925 – Statistical Analysis Plan
Version 2.0 – 17 Dec 2020
44
Adverse event data will be presented by SOCs and PTs using MedDRA Version 21.0 or 
most up to date version, in which adverse events will be sorted in alphabetical order by 
SOC and PT.
10.2.1
Analysis of Adverse Events for Period 1
10.2.1.1
Adverse Events Overview
The number and percentage of subjects experiencing TEAEs will be summarized by "as 
treated" treatment group for the following AE categories.
●
All TEAEs
●
Treatment-emergent serious adverse events (SAEs)
●
Treatment-emergent severe adverse events
●
TEAEs reasonably possibly related to study drug
●
TEAEs of special interest
●
TEAEs leading to discontinuation of study drug
●
TEAE leading to death
In the AE overview summary, any event with an unknown severity will be considered as 
severe and any AE with an unknown relationship will be considered as having 
"reasonable possibility" of being related to study drug.
Additional AEs may be considered for tabulation/summary based on recommendations 
from Clinical and Safety as deemed appropriate.
For TEAEs of special interest, the point estimate and 95% CI (using normal 
approximation) will be provided for the treatment difference in AE percentage.
As a sensitivity analysis, the AE overview summary and AE of special interest overview 
summary will be repeated in which all AEs with an onset date after the first dose of study 
drug will be included, regardless of whether the AE occurred more than 30 days (or 
70 days) after the last dose of study drug.
 


Upadacitinib
M15-925 – Statistical Analysis Plan
Version 2.0 – 17 Dec 2020
45
10.2.1.2
Adverse Events by System Organ Class and Preferred Term
The number and percentage of subjects experiencing adverse events will be tabulated by 
SOC and MedDRA PT by "as treated" treatment group.  The SOCs will be presented in 
alphabetical order, and the PTs will be presented in alphabetical order within each SOC.
The following summaries of adverse events will be generated:
●
All TEAEs
●
Treatment-emergent serious adverse events (SAEs)
●
Treatment-emergent severe adverse events
●
TEAEs reasonably possibly related to study drug
●
TEAEs leading to discontinuation of study drug
●
TEAE leading to death
●
Frequent AEs (reported in 2% of subjects or more in any treatment group)
Subjects reporting more than one adverse event for a given MedDRA preferred term will 
be counted only once for that term (most severe incident for the severity tables and most 
related incident for the relationship tables).  Subjects reporting more than one type of 
adverse event within a SOC will be counted only once for that SOC.  Subjects reporting 
more than one type of adverse event will be counted only once in the overall total.
As a sensitivity analysis, the AE summary by SOC and PT will be repeated, in which all 
AEs with an onset date after the first dose of study drug will be included, regardless of 
whether the AE occurred more than 30 days (or 70 days) after the last dose of study drug.
10.2.1.3
TEAEs by Maximum Severity
TEAEs will also be summarized by maximum severity by "as treated" treatment group.  If 
a subject has an AE with an unknown severity, then the subject will be counted in the 
severity category of unknown, even if the subject has another occurrence of the same 
event with a severity present.  The only exception is that if the subject has another 
 


Upadacitinib
M15-925 – Statistical Analysis Plan
Version 2.0 – 17 Dec 2020
46
occurrence of the same AE with the most extreme severity – severe.  In this case, the 
subject will be counted under the severe category.
10.2.1.4
TEAEs by Relationship
TEAEs will also be summarized by relationship to study drug, as assessed by the 
investigator, by "as treated" treatment group.  If a subject has a TEAE with an unknown 
relationship, then the subject will be counted in the relationship category of "unknown," 
even if the subject has another occurrence of the same event with a relationship present.  
The only exception is if the subject has another occurrence of the same TEAE with a 
relationship assessment of "reasonable possibility."  In this case, the subject will be 
counted under the "reasonable possibility" category.
10.2.1.5
Frequent (≥ 2%) Adverse Events and Reasonably Possibly 
Related Adverse Events by System Organ Class and 
Preferred Term
TEAEs and reasonably possibly related AEs occurring for more than 2% of the subjects in 
any of the "as treated" treatment groups will be summarized by MedDRA PT in 
decreasing frequency separately.
10.2.1.6
Adverse Events of Special Interest
The Adverse Events of Special Interest (AESI) categories will be summarized and 
presented by "as treated" treatment group using SOC and MedDRA PT.  The AESI 
categories will be identified by the following search criteria per Standard MedDRA 
Queries (SMQs)/Company MedDRA Queries (CMQs) in Table 8 below.  Adjudicated 
cardiovascular events will be summarized and presented by treatment group using the 
CAC adjudicated categories.
 


Upadacitinib
M15-925 – Statistical Analysis Plan
Version 2.0 – 17 Dec 2020
47
Table 8.
AESI for Upadacitinib with SMQs/CMQs/PTs Searches
AESI
Type of 
MedDRA 
Query
Broad or 
Narrow 
Search
SMQ/CMQ Search Criteria
Serious Infections
CMQ
"Infections" – Subset for SAEs
Opportunistic Infection
excluding Tuberculosis and 
Herpes Zoster
CMQ
"Opportunistic Infection excluding 
Tuberculosis and Herpes Zoster"
Possible Malignancy
SMQ
Narrow
"Malignancies"
Malignancy
SMQ
"Malignant tumours"
Non-Melanoma Skin Cancer 
(NMSC)
SMQ
Narrow
Skin Malignant tumours (Narrow SMQ) 
removing Melanoma CMQ
Malignancy excluding NMSC
"Malignant tumours" SMQ removing 
NMSC output
Lymphoma
SMQ
"Malignant Lymphomas"
Hepatic Disorder
SMQ
Narrow
"Drug Related Hepatic Disorders"
Adjudicated Gastrointestinal 
Perforations
Output from 
adjudication
Anemia
CMQ
"Non-Hemolytic and Non-Aplastic 
Anemias"
Neutropenia
CMQ
"Hematological Toxicity – Neutropenia"
Lymphopenia
CMQ
"Hematological Toxicity – Lymphopenia"
Herpes Zoster
CMQ
"Herpes Zoster"
Creatine Phosphokinase (CPK) 
Elevation
PT
Search only for the PT of "Blood creatine 
phosphokinase increased"
Renal Dysfunction
SMQ
Narrow
"Acute Renal, Failure"
Active Tuberculosis
CMQ
"Active Tuberculosis"
Adjudicated Cardiovascular 
Events
Output from 
CAC
MACE*
Cardiovascular Death
Non-fatal Myocardial 
Infarction
Non-fatal Stroke
 


Upadacitinib
M15-925 – Statistical Analysis Plan
Version 2.0 – 17 Dec 2020
48
Table 8.
AESI for Upadacitinib with SMQs/CMQs/PTs Searches 
(Continued)
AESI
Type of 
MedDRA 
Query
Broad or 
Narrow 
Search
SMQ/CMQ Search Criteria
Undetermined/Unknown 
Cause of Deaths
Other Cardiovascular events
Adjudicated Thrombotic Events
Output From 
CAC
Venous Thromboembolic 
Events**
Deep Vein Thrombosis
Pulmonary Embolism
Other Venous Thrombosis
Arterial Thromboembolic 
Events (non-cardiac, non-
neurologic)
CAC = Cardiovascular Adjudication Committee; CMQ = company MedDRA query; PT = preferred term; 
SMQ = standard MedDRA query
*
MACE; Major Adverse Cardiovascular Events, defined as cardiovascular death, non-fatal myocardial infarction 
and non-fatal stroke.
**
Venous thromboembolic events (VTE) include deep vein thrombosis (DVT) and pulmonary embolism (PE) (fatal 
and non-fatal).
Additional AEs may be considered for tabulation/summary based on recommendations 
from Clinical and Safety as deemed appropriate.
10.2.2
Analysis of Long-Term Adverse Event Rates
Long-term adverse event rates for upadacitinib 15 mg QD will be analyzed using event 
rates adjusted by cumulative exposure.  This includes TEAEs occurred under 
Upadacitinib 15 mg QD exposure from subjects starting on Upadacitinib 15 mg QD and 
subjects switching from Abatacept IV to Upadacitinib 15 mg QD.
For this event rate calculation, 1 year will be considered to be 365.25 days.  For each 
treatment group, the numerator of the overall rate will be the total number of TEAEs 
 


Upadacitinib
M15-925 – Statistical Analysis Plan
Version 2.0 – 17 Dec 2020
49
reported for the event; that is, a subject can contribute more than one event to the 
numerator.  The denominator of the rates will be the total number of days exposed to 
upadacitinib 15 mg QD summed across all treated subjects divided by 365.25.  The TEAE 
rate per 100 patient-years of exposure will be calculated as 
([numerator/denominator])*100.  The number of TEAEs reported (numerator), the total 
number of years of study drug exposure (denominator), and the TEAE rate per 
100 patient-years will be presented.
10.2.2.1
Overview of Adverse Events Rates per 100 Patient-Years of 
Study Drug Exposure
An overview of AEs per 100 patient-years of study exposure will be presented for the 
following AE categories.
●
All TEAEs 
●
Treatment-emergent serious adverse events (SAEs)
●
Treatment-emergent severe adverse events 
●
TEAEs reasonably possibly related to study drug
●
TEAEs of special interest
●
TEAEs leading to discontinuation of study drug
●
TEAE leading to death
In the AE overview summary, any event with an unknown severity will be considered as 
severe and any AE with an unknown relationship will be considered as having 
"reasonable possibility" of being related to study drug.
Additional AEs may be considered for tabulation/summary based on recommendations 
from Clinical and Safety as deemed appropriate.
 


Upadacitinib
M15-925 – Statistical Analysis Plan
Version 2.0 – 17 Dec 2020
50
10.2.2.2
Adverse Events Rates per 100 Patient-Years of Study Drug 
Exposure by SOC and PT
The TEAE rate per 100 patient-years of exposure will be calculated overall, for each SOC 
and each PT, for each of the following events:
●
All TEAEs
●
Treatment-emergent serious adverse events (SAEs)
●
Treatment-emergent severe adverse events
●
TEAEs reasonably possibly related to study drug
●
TEAEs leading to discontinuation of study drug
●
TEAE leading to death
10.2.2.3
Adverse Events of Special Interest Rates per
100 Patient Years of Study Drug Exposure
The Adverse Events of Special Interest (AESI) rate per 100 patient-years of exposure as 
outlined in Section 10.2.2 will be calculated overall, for each SOC and each PT, for each 
of the AESI listed in Section 10.2.1.6.  Adjudicated cardiovascular events will be 
summarized and presented using the CAC adjudicated categories.
10.2.2.4
Listing of Serious Adverse Events (Including Deaths) and 
Adverse Events Leading to Study Drug Discontinuation
All serious adverse events (SAEs), deaths, and adverse events leading to discontinuation 
of study drug will be listed.
10.3
Analysis of Laboratory Data
10.3.1
Variables and Units
All laboratory parameters to be collected in this study are listed below.  Laboratory 
parameters will be reported using the standard international (SI) units.
 


Upadacitinib
M15-925 – Statistical Analysis Plan
Version 2.0 – 17 Dec 2020
51
Table 9.
List of Laboratory Variables
Laboratory Variables
Hematology
White Blood Cell (WBC) Count
Red Blood Cell (RBC) Count
Hemoglobin
Hematocrit
Platelets count
Neutrophils
Basophils
Eosinophils
Lymphocytes
Monocytes
Bands
Chemistry
Total Bilirubin
Alkaline Phosphatase (ALP)
Serum glutamic oxaloacetic transaminase/aspartate aminotransferase (SGOT/AST)
Serum glutamic pyruvic transaminase/alanine aminotransferase (SGPT/ALT)
Total Protein
Albumin
Glucose
Triglycerides
Blood Urea Nitrogen (BUN)
Creatinine
Uric acid
Sodium
Potassium
Calcium
Inorganic Phosphorus
Creatine Phosphokinase (CPK)
Chloride
Bicarbonate
 


Upadacitinib
M15-925 – Statistical Analysis Plan
Version 2.0 – 17 Dec 2020
52
Table 9.
List of Laboratory Variables (Continued)
Laboratory Variables
Chemistry (Continued)
Cholesterol (TC)
LDL cholesterol (LDL-C)
HDL cholesterol (HDL-C)
LDL-C/HDL-C ratio
TC/HDL-C ratio
Urinalysis
Specific Gravity
pH
Protein
Glucose
Ketones
Blood
Microscopic Examination (if needed)
Urobilinogen
Bilirubin
Leukocytes
Nitrites
Other
hs-CRP
QuantiFERON-TB Golda
IgG and IgM
ESR
a.
For annual follow-up QFT is captured only for those with negative QFT at Screening.
10.3.2
Analysis of Laboratory Data for Period 1
The laboratory data will be summarized by the "as treated" treatment groups 
(Upadacitinib 15 mg QD and Abatacept IV).
 


Upadacitinib
M15-925 – Statistical Analysis Plan
Version 2.0 – 17 Dec 2020
53
10.3.2.1
Assessment of Mean Change from Baseline and Percentage 
Change from Baseline in Clinical Laboratory Variables
Analyses of mean change from baseline in continuous hematology, chemistry, and 
urinalysis variables which are measured longitudinally will be performed by visits and by 
"as treated" treatment group.  For each change from baseline analysis, the following 
summary statistics will be presented for each treatment group:  sample size, baseline 
mean, visit mean, and the mean, standard deviation, and median of the changes from 
baseline.
In addition, similar analyses will be conducted for percentage change from baseline in 
LDL-C, HDL-C, total cholesterol, triglycerides, and hemoglobin.
10.3.2.2
Assessment of Shift from Baseline in Clinical Laboratory 
Variables
The baseline and post-baseline laboratory observations will be categorized as Grade 1, 
Grade 2, Grade 3, and Grade 4 according to OMERACT criteria (Rheumatology Common 
Toxicity Criteria v.2.0).  For creatine phosphokinase and creatinine, NCI CTC criteria will 
be used.
For each laboratory variable, shift tables will be generated that cross tabulate the subjects' 
as deemed appropriate by "as treated" treatment group:
●
Category of the baseline value versus category of the final value.
●
Category of the baseline value versus maximum category.
●
Category of the baseline value versus minimum category.
Note that the minimum/maximum category is used, rather than the category of the 
minimum/maximum value.  The two may be different due to variation in the reference 
range.
No statistical tests will be performed for this analysis.
 


Upadacitinib
M15-925 – Statistical Analysis Plan
Version 2.0 – 17 Dec 2020
54
10.3.2.3
Assessment of Potentially Clinical Significant Laboratory 
Values
The criteria for potentially clinically significant laboratory values will be determined by 
OMERACT criteria of Grade 3 or 4.  For creatine phosphokinase and creatinine, NCI 
CTC criteria will be used.
The number and percentage of subjects meeting the criteria for potentially clinically 
significant laboratory values will be summarized by "as treated" treatment group.  Only 
subjects with worsening in grade compared to baseline grade will be captured.
10.3.2.4
Assessment of Liver Elevations
According to FDA's Guidance for Industry "Drug-Induced Liver Injury:  Premarketing 
clinical evaluation" (July 2009), when aminotransferase (AT) abnormalities indicating 
hepatocellular injury are accompanied by evidence of impaired hepatic function (bilirubin 
elevation > 2 × ULN), in the absence of evidence of biliary obstruction (i.e., significant 
elevation of ALP) or some other explanation of the injury (e.g., viral hepatitis, alcohol 
hepatitis), the combined finding (i.e., Hy's Law cases) represents a signal of a potential for 
the drug to cause severe DILI.
For the purpose of assessing for potential Hy's law cases, the frequencies and percentages 
of subjects with post baseline liver specific function test values that meet the following 
criteria of potential clinical interest will be summarized by "as treated" treatment group:
●
ALT ≥ 3 × ULN
●
ALT ≥ 5 × ULN
●
ALT ≥ 10 × ULN
●
ALT ≥ 20 × ULN
●
AST ≥ 3 × ULN
●
AST ≥ 5 × ULN
●
AST ≥ 10 × ULN
●
AST ≥ 20 × ULN
 


Upadacitinib
M15-925 – Statistical Analysis Plan
Version 2.0 – 17 Dec 2020
55
●
TBL ≥ 2 × ULN
●
Alkaline phosphatase ≥ 1.5 × ULN
●
ALT and/or AST ≥ 3 × ULN and concurrent TBL ≥ 1.5 × ULN
●
ALT and/or AST ≥ 3 × ULN and concurrent TBL ≥ 2 × ULN
10.3.3
Analysis of Long-Term Laboratory Data
10.3.3.1
Assessment of Mean Change from Baseline and Percentage 
Change from Baseline in Clinical Laboratory Variables
Analyses of mean change from baseline in continuous hematology, chemistry, and 
urinalysis variables which are measured longitudinally will be performed by visits and by 
"as treated" treatment group sequences as described in Section 10.1.  For each change 
from baseline analysis, the following summary statistics will be presented for each 
treatment group sequence:  sample size, baseline mean, visit mean, and the mean, standard 
deviation, and median of the changes from baseline.
In addition, similar analyses will be performed for percentage change from baseline in 
LDL-C, HDL-C, triglycerides and hemoglobin.
10.3.3.2
Assessment of Potentially Clinically Significant Laboratory 
Values
Long-term laboratory data will be summarized based on the number and percentage of 
subjects meeting the criteria for potentially clinically significant laboratory values for 
upadacitinib 15 mg QD.
In the evaluation of potentially clinically significant laboratory values, the baseline value 
will be determined by the last non-missing measurement recorded on or before the date of 
the first dose of upadacitinib 15mg QD (which may be different than the first dose of 
study drug in the study).  For example, for a subject who started on abatacept and 
switched to upadacitinib 15 mg QD, lab values under upadacitinib 15 mg QD exposure 
 


Upadacitinib
M15-925 – Statistical Analysis Plan
Version 2.0 – 17 Dec 2020
56
would be evaluated against the baseline value defined as the last non-missing 
measurement recorded on or before the date of the first dose of upadacitinib 15 mg QD.
A listing of all subjects with any laboratory determination meeting OMERACT criteria of 
Grade 3 or 4 will be provided.  For creatine phosphokinase and creatinine, NCI CTC 
criteria will be used.  Only subjects with worsening in grade compare to baseline grade 
will be captured.  For each of these subjects, the whole course of the respective parameter 
will be listed.
10.3.3.3
Assessment of Liver Elevations
The frequencies and percentages of subjects with post-baseline liver-specific function test 
values that meet the criteria of potential clinical interest (as described in Section 10.3.2.4) 
will be summarized for upadacitinib 15 mg QD, similarly as described in Section 10.2.2.
A listing of potentially clinically significant liver elevations based on criteria specified 
above will be provided.  For each of these subjects, the whole course of the respective 
parameter will be listed.
10.4
Analysis of Vital Signs
10.4.1
Variables and Criteria Defining Abnormality
Vital sign variables include sitting systolic blood pressure, sitting diastolic blood pressure, 
pulse rate, respiratory rate, body temperature, and weight.  The criteria for potentially 
clinically significant vital sign findings are presented in Table 10.
 


Upadacitinib
M15-925 – Statistical Analysis Plan
Version 2.0 – 17 Dec 2020
57
Table 10.
Criteria for Potentially Clinically Significant Vital Sign Findings
Vital Sign
Category
Criteria for Potential Clinically Significant Vital Signs
Systolic blood pressure
Low
Value ≤ 90 mmHg and decrease ≥ 20 mmHg from Baseline
High
Value ≥ 160 mmHg and increase ≥ 20 mmHg from Baseline
Diastolic blood pressure
Low
Value ≤ 50 mmHg and decrease ≥ 15 mmHg from Baseline
High
Value ≥ 105 mmHg and increase ≥ 15 mmHg from Baseline
Weight
High
> 7% increase from baseline
Low
> 7% decrease from baseline
10.4.2
Analysis of Vital Sign for Period 1
Analyses of mean change from baseline in continuous vital sign variables which are 
measured longitudinally will be performed by visits and by the "as treated" treatment 
groups of Upadacitinib 15 mg QD and Abatacept IV.  For each change from baseline 
analysis, the following summary statistics will be presented for each treatment group:  
sample size, baseline mean, visit mean, and the mean, standard deviation, and median of 
the changes from baseline.
The number and percentage of subjects meeting the criteria for potentially clinically 
significant vital sign values will be summarized by "as treated" treatment group.
10.4.3
Analysis of Long-Term Vital Sign
Analyses of mean change from baseline in continuous vital signs variables which are 
measured longitudinally will be performed by visits and by "as treated" treatment group 
sequences as described in Section 10.1.  For each change from baseline analysis, the 
following summary statistics will be presented for each treatment group sequence:  
sample size, baseline mean, visit mean, and the mean, standard deviation, and median of 
the changes from baseline.
Long-Term Vital Sign will also be summarized based on the number and percentage of 
subjects meeting the criteria for potentially clinical significant vital sign for upadacitinib 
15 mg QD.  In the evaluation of potentially clinically significant vital sign values, the 
 


Upadacitinib
M15-925 – Statistical Analysis Plan
Version 2.0 – 17 Dec 2020
58
baseline value will be determined by the last non-missing measurement recorded on or 
before the date of the first dose of upadacitinib 15 mg QD, similarly as described in 
Section 10.3.3.2.
A listing of all subjects with any vital sign values meeting the criteria for potentially 
clinically significant vital signs will be provided.  For each of these subjects, the whole 
course of the respective parameter will be listed.
11.0
Summary of Changes
11.1
Summary of Changes between the Previous Version and the 
Current Version
The primary efficacy analysis and Period 1 reporting have been completed under the SAP 
version 1.0.  The current SAP update applies only to future reporting of long-term 
analysis.
1.
Updated to align with Protocol Amendment 5 and 6, including handling of dose 
switch from upadacitinib 30 mg QD to 15 mg QD for the 30 mg Cohort 
(Appendix A) and change of study length from 260 to 216 weeks.
2.
Updated Section 9.1.2 to describe the missing data handling approach for the 
additional sensitivity analysis using longitudinal models for long-term efficacy.
3.
Updated Section 9.3 to incorporate the additional sensitivity analysis for long-term 
efficacy.
4.
Added language to clarify analysis details in Section 10.2.1.1, and Section 10.2.2.1.
5.
Updated Section 10.2.1.6 and Section 10.4.1 to align with the latest upadacitinib 
AESI definitions in PSSAP V4.0.
6.
Added Appendix B to describe analysis accounting for impact of COVID-19 
pandemic.
7.
Added Section 11.0 for summary of changes and Section 12.0 for SAP version 
history summary.
 


Upadacitinib
M15-925 – Statistical Analysis Plan
Version 2.0 – 17 Dec 2020
59
12.0
Version History
Table 11.
SAP Version History Summary
Version
Date
Summary
1.0
04 Jun 2019
Original version.  Version 1.0 was used for the primary analysis.
2.0
17 Dec 2020
Updated to align with Protocol Amendment 5 and 6, including 
handling of dose switch from upadacitinib 30 mg QD to 15 mg 
QD for the 30 mg Cohort and change of study length from 5 
years to 216 weeks. Included additional sensitivity analysis for 
long-term efficacy, and analyses due to COVID-19 impact. 
13.0
Appendix
Appendix A
Statistical Analysis for 30 mg Cohort
Appendix B
Statistical Analysis to Account for Impact of COVID-19 Pandemic
Appendix C
OMERACT Criteria
 


Upadacitinib
M15-925 – Statistical Analysis Plan
Version 2.0 – 17 Dec 2020
60
Appendix A.
Statistical Analysis for the 30 mg Cohort
For subjects in the 30 mg Cohort, descriptive summaries will be provided as follows.
Patient Disposition
For subject accountability, by-site summary will be provided for each randomized 
treatment group (i.e., Upadacitinib 30 mg QD and Abatacept IV) for all the items 
described in the first paragraph of Section 7.0.  Premature discontinuation details will be 
further summarized separately for Period 1 and Period 2, similar to as described in 
Section 7.0.
Summary of Dose Switch from Upadacitinib 30 mg QD to 15 mg QD
Starting with Amendment 5, all subjects will receive open-label upadacitinib 15 mg QD, 
including those currently on upadacitinib 30 mg QD.  The visit at which dose switch 
occurs could be different for each subject.  For subjects in the 30 mg Cohort, the number 
and percentage of subjects switching to upadacitinib 15 mg QD at each visit will be 
summarized.
Efficacy Analysis
Descriptive summaries will be provided for DAS28 (CRP) change from baseline and 
Clinical Remission (CR) based on DAS28 (CRP) by randomized treatment group for 
Period 1 or by randomized treatment sequence for long term analysis as described below.  
Other efficacy data will be reported as collected in CSR 16.2 listings.
1.
Randomized treatment group sequence for long term analysis for the 30 mg 
Cohort:Abatacept IV →Upadacitinib 30 mg QD
2.
Upadacitinib 30 mg QD
Starting with Amendment 5, all subjects will receive open-label upadacitinib 15 mg QD, 
including those currently on upadacitinib 30 mg QD.  For long-term efficacy analysis, 
 


Upadacitinib
M15-925 – Statistical Analysis Plan
Version 2.0 – 17 Dec 2020
61
subjects will continue to be summarized under the treatment sequences as described 
above, regardless of dose switch – i.e., data collected after dose switch will continue to be 
summarized under the same treatment sequences.  The visit at which dose switch occurs 
could be different for each subject.  The first and last visits at which dose switch occurs 
will be noted in the summary.
Safety Analysis
Safety analysis for the 30 mg Cohort includes Period 1 safety analysis and long-term 
safety analysis.
Period 1 safety analysis by the "as treated" treatment groups of Upadacitinib 30 mg QD 
and Abatacept IV will be performed up to Week 24.  Period 1 safety analyses include the 
overview of treatment emergent adverse events (TEAE), overview of treatment emergent 
AESI and the TEAE summary by SOC and PT (similar to as described in Section 10.2.1.1
and Section 10.2.1.2).
For long-term safety analysis, adverse event rates for upadacitinib 30 mg QD will be 
summarized using event rates adjusted by cumulative exposure.  Starting with 
Amendment 5, all subjects will receive open-label upadacitinib 15 mg QD, including 
those currently on upadacitinib 30 mg QD.  For subjects who previously received 
upadacitinib 30 mg QD, adverse events and exposure to upadacitinib 30 mg QD will be 
censored at the time of dose switch; subsequent adverse events and exposure starting the 
day of first dose of upadacitinib 15 mg QD will be summarized under a separate group:  
1.
Upadacitinib 30 mg QD 
This includes AEs occurred under Upadacitinib 30 mg QD exposure from subjects 
starting on Upadacitinib 30 mg QD and subjects switching from Abatacept IV to 
Upadacitinib 30 mg QD.  Exposure is censored at time of dose switch from 
Upadacitinib 30 mg QD to Upadacitinib 15 mg QD.
2.
Upadacitinib 15 mg QD switched from any Upadacitinib 30mg QD
 


Upadacitinib
M15-925 – Statistical Analysis Plan
Version 2.0 – 17 Dec 2020
62
This includes Upadacitinib 15 mg QD exposure from subjects who switched dose 
from Upadacitinib 30 mg QD to Upadacitinib 15 mg QD
Long term safety analysis will only include overview of TEAE rates per 100 patient-years 
of study drug exposure, overview of treatment emergent AESI event rates per 
100 patient-years of study drug exposure, and the TEAE rate per 100 patient-years 
summary by SOC and PT (similar to as described in Section 10.2.2.1 and Section 
10.2.2.2).
Additional long-term safety analysis for the any abatacept group, including abatacept 
subjects in both 15 mg Cohort and 30 mg Cohort, will be conducted.  Specifically, 
overview of TEAE rates per 100 patient-years of study drug exposure, overview of 
treatment emergent AESI event rates per 100 patient-years of study drug exposure, and 
the TEAE rate per 100 patient-years summary by SOC and PT will be conducted.
 


Upadacitinib
M15-925 – Statistical Analysis Plan
Version 2.0 – 17 Dec 2020
63
Appendix B.
Statistical Analysis to Account for Impact of COVID-19 Pandemic
1.0
Overview
The COVID-19 pandemic is interfering with the conduct of many ongoing trials, with 
potential impacts on treatment duration and collection, analysis and the interpretation of 
clinical trial data.  Some protocol-specified visits in the clinical trials may be impacted 
due to COVID-19 infection or logistical restrictions during the pandemic.  For example, 
some scheduled visits may be missed due to self-quarantine or local government 
restrictions on travel; some visits may also be delayed or canceled due to healthcare 
resource constraints during the pandemic.  Impacted visits due to COVID-19 will be 
recorded in the database.
This appendix describes the additional analyses and updates to existing analyses due to 
COVID-19 impact.  At the time of COVID-19 pandemic, all study subjects are in Period 2 
of the study.  The primary efficacy analysis and Period 1 reporting have been completed 
in 2019 and are not affected by the COVID-19 pandemic.  The analyses described in this 
appendix are only applicable to Period 2 and future reporting of the long-term analyses.
2.0
Patient Disposition
Period 2 patient disposition and reason for discontinuation will be summarized as 
described in Section 7.0.  For subjects who prematurely discontinued study drug or study 
participation, the reasons for discontinuation will be summarized with two additional 
categories capturing discontinuation due to COVID-19 infection or logistical restrictions 
related to the COVID-19 pandemic (as collected in CRF):
●
Adverse event (AE)
●
Withdrew consent
●
Lost to follow-up
●
Lack of efficacy
●
COVID-19 infection
●
COVID-19 logistical restrictions
 


Upadacitinib
M15-925 – Statistical Analysis Plan
Version 2.0 – 17 Dec 2020
64
●
Other
In addition, the number and percentage of subjects with scheduled study visits affected by 
COVID-19 pandemic will be summarized by treatment group sequences.  The impact on 
study visits will be summarized by the following categories (as collected in CRF) by visit:
●
Missed visit
●
Virtual visit
●
In person, partial assessments done
3.0
Long Term Efficacy Analysis
Missing data could occur due to various reasons, including missing visits/assessments, 
early withdrawal from the study, or missing due to COVID-19 infection or logistic 
restriction.  The probability of having missed visits and missing data due to COVID-19 
infection or logistical restrictions related to the COVID-19 pandemic can be reasonably 
assumed to be unrelated to the unobserved values.  Therefore, for the purpose of statistical 
analysis, it is reasonable to assume that these missing data are missing at random (MAR) 
and the statistical models that require MAR assumption are appropriate.
As described in Section 9.1.2, longitudinal analysis models MMRM and GLMM will be 
used for long term efficacy analysis and will be maintained for long term efficacy analysis 
in the presence of missing data due to COVID-19.
4.0
Safety Analysis
In listings of adverse events and deaths, a flag indicating whether the event or death was 
related to COVID-19 infection will be presented.  A listing of COVID-19 related adverse 
events may be provided.
 


Upadacitinib
M15-925 – Statistical Analysis Plan
Version 2.0 – 17 Dec 2020
65
Appendix C.
OMERACT Criteria
Rheumatology Common Toxicity Criteria v.2.0
Based on Woodworth TG, et al.  Standardizing assessment of adverse effects in rheumatology clinical trials II.  Status of OMERACT Drug Safety Working Group 
May 2006:  OMERACT 8.  Standardizing Assessment and Reporting of Adverse Effects in Rheumatology Clinical Trials:  Enabling Description of Comparative 
Safety Profiles for Antirheumatic Therapies
1 – Mild
Asymptomatic, or transient
Short duration (< 1 week)
No change in life style
No medication or OTC
2 – Moderate
Symptomatic
Duration (1 – 2 weeks)
Alter lifestyle occasionally
Meds relieve.  (may be 
prescription),
Study drug continued
3 – Severe
Prolonged symptoms, reversible, 
major functional impairment
Prescription meds/partial relief
May be hospitalized < 24 hr
Temporary study drug 
discontinuation, or/and dose reduced
4 – Includes Life Threatening
At risk of death
Substantial disability, especially if 
permanent.
Multiple meds
Hospitalised > 24 hr
Study drug discontinued
A.  Allergic/Immunologic
A1.  Allergic 
reaction/ 
hypersensitivity 
(includes drug fever)
Transient rash:  drug fever 
< 38°C:  transient, asymptomatic 
bronchospasm
Generalised urticaria responsive to 
meds; or drug fever > 38°C, or 
reversible bronchospasm
Symptomatic bronchospasm 
requiring meds; symptomatic 
urticaria persisting with meds, 
allergy related oedema/angioedema
Anaphylaxis, laryngeal/pharyngeal 
oedema, requiring resuscitation
A2.  Autoimmune 
reaction
Seriologic or other evidence of 
autoimmune reaction, but patient 
asymptomatic:  all organ function 
normal and no treatment is 
required (e.g., vitiligo)
Evidence of autoimmune reaction 
involving a non-essential organ or 
functions, requiring treatment 
other than immunosuppressive 
drugs (e.g., hypothyroidism)
Reversible autoimmune reaction 
involving function of a major organ 
or toxicity requiring short term 
immunosuppressive treatment 
(e.g., transient colitis or anaemia)
Causes major organ dysfunction, or 
progressive, not reversible, or 
requires long-term administration 
of high dose immunosuppressive 
therapy
A3.  Rhinitis 
(includes sneezing, 
nasal stuffiness, post-
nasal discharge)
Transient, non-prescription meds 
relieve
Prescription med. required, slow
Corticosteroids or other prescription 
med. with persistent disabling 
symptoms such as impaired exercise 
tolerance
NA
 


Upadacitinib
M15-925 – Statistical Analysis Plan
Version 2.0 – 17 Dec 2020
66
A4.  Serum sickness
Transient, non-prescription meds 
relieve
Symptomatic, slow response to 
meds (e.g., oral corticosteroids)
Prolonged; symptoms only partially 
relieved by meds; parenteral 
corticosteroids required
Major organ dysfunction, requires 
long-term high-dose 
immunosuppressive therapy
A5.  Vasculitis
Localised, not requiring 
treatment; or rapid response to 
meds; cutaneous
Symptomatic, slow response to 
meds (e.g., oral corticosteroids)
Generalised, parenteral 
corticosteroids required or/and short 
duration hospitalisation
Prolonged, hospitalisation, 
ischemic changes, amputation
B.  Cardiac
B1.  Arrhythmia
Transient, asymptomatic
Transient, but symptomatic or 
recurrent, responds to meds
Recurrent/persistent; maintenance 
prescription
Unstable, hospitalisation required, 
parenteral meds
B2.  Cardiac function 
decreased
Asymptomatic decline in resting 
ejection fraction by > 10%, but 
< 20% of baseline value
Asymptomatic decline of resting 
ejection fraction ≥ 20% of baseline 
value
CHF responsive to treatment
Severe or refractory CHF
B3.  Edema
Asymptomatic
(e.g., 1 + feet/calves), self-limited, 
no therapy required
Symptomatic
(e.g., 2 + feet/calves), requires 
therapy
Symptoms limiting function 
(e.g., 3 + feet/calves, 2 + thighs), 
partial relief with treatment 
prolonged
Anasarca; no response to treatment
B4.  Hypertension 
(new onset or 
worsening)
Asymptomatic, transient increase 
by > 20 mmHg (diastolic) or to 
> 150/100 if previously normal, 
no therapy required
Recurrent or persistent increase 
> 150/100 or by > 10 mmHg 
(diastolic), requiring and 
responding readily to treatment
Symptomatic increase > 150/100, 
> 20 mmHg, persistent, requiring 
multi agency therapy, difficult to 
control
Hypertensive crisis
B5.  Hypotension 
(without underlying 
diagnosis)
Transient, intermittent, 
asymptomatic, orthostatic 
decrease in blood pressure 
> 20 mmHg
Symptomatic, without interference 
with function, recurrent or 
persistent > 20 mmHg decrease, 
responds to treatment
Syncope or symptomatic, interferes 
with function, requiring therapy and 
sustained medical attention, dose 
adjustment or drug discontinuation
Shock
B6.  Myocardial 
ischaemia
Transient chest pain/ECG 
changes; rapid relief with nitro
Recurring chest pain, transient 
ECG ST-T changes; treatment 
relieves
Angina with infarction, no or 
minimal functional compromise, 
reduce dose or discontinue study 
drug
Acute myocardial infarction, 
arrthymia or/and CHF
 


Upadacitinib
M15-925 – Statistical Analysis Plan
Version 2.0 – 17 Dec 2020
67
B7.  Pericarditis/ 
pericardial effusion
Rub heard, asymptomatic
Detectable effusion by 
echocardiogram, symptomatic 
NSAID required
Detectable on chest x-ray, 
dyspnoea; or pericardiocentesis; 
requires corticosteroids
Pulsus alternates with low cardiac 
output; requires surgery
B8.  
Phlebitis/thrombosis/ 
Embolism (excludes 
injection sites)
Asymptomatic, superficial, 
transient, local, or no treatment 
required
Symptomatic, recurrent, deep vein 
thrombosis, no anticoagulant 
therapy required
Deep vein thrombosis requiring 
anticoagulant therapy
Pulmonary embolism
C.  General (constitutional)
C1.  Fatigue/malaise 
(asthenia)
Increase over baseline; most usual 
daily functions maintained, short 
term
Limits daily function intermittently 
over time
Interferes with basic ADL, 
persistent
Unable to care for self, bed or 
wheelchair bound > 50% of day 
debilitating, hospitalisation
C2.  Fever (pyrexia) 
(note:  fever due to 
drug allergy should 
be coded as allergy)
Transient, few symptoms 37.7 –
38.5°C
Symptomatic, recurrent 38.6 –
39.9°C.  Relieved by meds
≥ 40°C; ≤ 24 h, persistent 
symptoms; partial response to meds
≥ 40°C, debilitating, > 24 h, 
hospitalisation; no relief with meds
C3.  Headache
Transient or intermittent, no meds 
or relieved with OTC
Persistent, recurring, non-narcotic 
analgesics relieve
Prolonged with limited response to 
narcotic medicine
Intractable, debilitating, requires 
parenteral meds
C4.  Insomnia
Difficulty sleeping, short term, no 
interfering with function
Difficulty sleeping interfering with 
function, use of prescription med
Prolonged symptoms, with limited 
response to narcotic meds
Debilitating, hospitalisation; no 
relief with meds
C5.  Rigors, chills
Asymptomatic, transient, no 
meds, or non-narcotic meds 
relieve
Symptomatic, narcotic meds 
relieve
Prolonged symptoms, with limited 
response to narcotic meds
Debilitating, hospitalisation; no 
relief with meds
C6.  Sweating 
(diaphoresis)
Episodic, transient
Frequent, short term
Frequent, drenching, disabling
Dehydration, requiring IV 
fluids/hospitalization > 24 hrs
C7.  Weight gain
5% – 9.9%
10% – 19.9%
20% – 30%
NA
C8.  Weight loss
5% – 9.9%
10% – 19.9%
20% – 30%
NA
 


Upadacitinib
M15-925 – Statistical Analysis Plan
Version 2.0 – 17 Dec 2020
68
D.  Dermatologic
D1.  Alopecia
Subjective, transient
Objective, fully reversible
Patchy, wig used, partly reversible
Complete, or irreversible even if 
patchy
D2.  Bullous eruption
Localised, asymptomatic
Localised, symptomatic, requiring 
treatment
Generalised, responsive to 
treatment; reversible
Prolonged, generalised, or 
requiring hospitalisation for 
treatment
D3.  Dry skin
Asymptomatic, controlled with 
emollients
Symptoms eventually (1 – 2 wks) 
controlled with emollients
Generalised, interfering with ADL 
> 2 wks, persistent pruritis, partially 
responsive to treatment
Disabling for extended period, 
unresponsive to ancillary therapy 
and requiring study drug 
discontinuation for relief
D4.  Injection site 
reaction
Local erythema, pain, pruritis, 
< few days
Erythema, pain, oedema, may 
include superficial phlebitis,
1 – 2 wks
Prolonged induration, superficial 
ulceration; includes thrombosis
Major ulceration necrosis requiring 
surgery
D5.  Petechiae 
(without vasculitis)
Few, transient asymptomatic
Dependent areas, persistent up to 
2 wks
Generalised, responsive to 
treatment; reversible
Prolonged, irreversible, disabling
D6.  Photosensitivity
Transient erythema
Painful erythema and oedema 
requiring topical treatment
Blistering or desquamation, requires 
systematic corticosteroids
Generalised exfoliation or 
hospitalisation
D7.  Pruritis
Localised, asymptomatic, 
transient, local treatment
Intense, or generalised, relieved by 
systematic medication
Intense or generalised; poorly 
controlled despite treatment
Disabling, irreversible
D8.  Rash (not 
bullous)
Erythema, scattered 
macular/popular eruption; pruritis 
transient; TOC or no meds
Diffuse macular/popular eruption 
or erythema with pruritus; dry 
desquamation; treatment required
Generalised, moist desquamation, 
requires systemic corticosteroids; 
responsive to treatment; reversible
Exfoliative or ulcerating; or 
requires hospitalisation; or 
parenteral corticosteroids
D9.  
Induration/fibrosis/ 
Thickening (not 
sclerodermal)
Localized, high density on 
palpation, reversible, no effect on 
ADL and not disfiguring
Local areas < 50% body surface, 
not disfiguring, transient 
interference with ADL, reversible
Generalized, disfiguring, interferes 
with ADL, reversible
Disabling, irreversible, systemic 
symptoms
E.  Ear/Nose/Throat
E1.  Hearing loss
Transient, intermittent, no 
interference with function
Symptomatic, treatment required,
reversible
Interferes with function; incomplete 
response to treatment
Irreversible deafness
 


Upadacitinib
M15-925 – Statistical Analysis Plan
Version 2.0 – 17 Dec 2020
69
E2.  Sense of smell
Slightly altered
Markedly altered
Complete loss, reversible
Complete loss, without recovery
E3.  Stomatitis
Asymptomatic
Painful, multiple, can eat
Interferes with nutrition, slowly 
reversible
Requires enteral support; residual 
dysfunction
E4.  Taste 
disturbance 
(dysgeusia)
Transiently altered; metallic
Persistently altered; limited effect 
on eating
Disabling, effect on nutrition
NA
E5.  Tinnitus
Intermittent, transient, no 
interference with function
Requires treatment, reversible
Disabling, or associated with 
hearing loss
Irreversible deafness
E6.  Voice changes 
(includes hoarseness, 
loss of voice, 
laryngitis)
Intermittent hoarseness, able to 
vocalise
Persistent hoarseness, able to 
vocalise
Whispered speech, slow return of 
ability to vocalise
Unable to vocalize for extended
E7.  Xerostomia (dry 
mouth)
Transient dryness
Relief with meds
Interferes with nutrition, slowly 
reversible
Extended duration interference 
with nutrition, requires parenteral 
nutrition
F.  Eye/Ophthalmologic
F1.  Cataract
Asymptomatic, no change in 
vision, non-progressive
Symptomatic, partial visual loss, 
progressive
Symptoms impairing function, 
vision loss requiring treatment, 
including surgery
NA
F2.  Conjunctivitis
Asymptomatic, transient, rapid 
response to treatment
Symptomatic, responds to 
treatment, changes not interfering 
with function
Symptoms prolonged, partial 
response to treatment, interferes 
with function
NA
F3.  Lacrimation 
increased (tearing, 
watery eyes)
Symptoms not requiring 
treatment, transient
Symptomatic, treatment required, 
reversible
Unresponsive to treatment with 
major effect on function
NA
F4.  Retinopathy
Asymptomatic, non-progressive, 
no treatment
Reversible change in vision; 
readily responsive to treatment
Disabling change in vision 
ophthalmological findings 
reversible, sight improves over time
Loss of sight
 


Upadacitinib
M15-925 – Statistical Analysis Plan
Version 2.0 – 17 Dec 2020
70
F5.  Vision changes 
(e.g., blurred, 
photophobia, night 
blindness, vitreous 
floaters)
Asymptomatic, transient, no 
treatment required
Symptomatic, vision changes not 
interfering with function, 
reversible
Symptomatic, vision changes 
interfering with function
Loss of sight
F6.  Xerophtalmia 
(dry eyes)
Mild scratchiness
Symptomatic without interfering 
with function, requires artificial 
tears
Interferes with vision/function, 
corneal ulceration
Loss of sight
G.  Gastrointestinal
G1.  Anorexia
Adequate food intake, minimal 
weight loss
Symptoms requiring oral 
nutritional supplementation
Prolonged, requiring iv support
Requires hospitalization for 
nutritional support
G2.  Constipation
Asymptomatic, transient, 
responds to stool softener, OTC 
laxatives
Symptomatic, requiring 
prescription laxatives, reversible
Obstipation requiring medical 
intervention
Bowel obstruction.  Surgery 
required
G3.  Diarrhea
Transient, increase of 2 –
3 stools/day over pre-treatment 
(no blood or mucus), OTC agents 
relieve
Symptomatic, increase 4 –
6 stools/day, nocturnal stools, 
cramping, requires treatment with 
prescription meds
Increase > 6 stools/day, associated 
with disabling symptoms, 
e.g., incontinence, severe cramping, 
partial response to treatment
Prolonged, dehydration, 
unresponsive to treatment, requires 
hospitalization
G4.  Dyspepsia 
(heartburn)
Transient, intermittent, responds 
to OTC antacids, H-2 blockers
Prolonged, recurrent, requires 
prescription meds, relieved by 
meds
Persistent despite treatment, 
interferes with function, associated 
with GI bleeding
NA
G5.  GI bleed
(gastritis, gastric or 
duodenal ulcer 
diagnosed-define 
aetiology)
Asymptomatic, endoscopic 
finding, haemocult + stools, no 
transfusion, responds rapidly to 
treatment
Symptomatic, transfusion ≤ 2 units 
needed; responds to treatment
Haematemesis, transfusion 3 –
4 units, prolonged interference with 
function
Recurrent, transfusion > 4 units, 
perforation, requiring surgery, 
hospitalisation
G6.  Haematochezia 
(rectal bleeding)
Haemorrhodial, asymptomatic, no 
transfusion
Symptomatic, transfusion
≤ 2 units, reversible
Recurrent, transfusion > 3 – 4 units
> 4 units, hypotension, requiring 
hospitalization
 


Upadacitinib
M15-925 – Statistical Analysis Plan
Version 2.0 – 17 Dec 2020
71
G7.  Hepatitis
Laboratory abnormalities, 
asymptomatic, reversible
Symptomatic laboratory 
abnormalities, not interfering with 
function, slowly reversible
Laboratory abnormalities persistent 
> 2 wks, symptoms interfere with 
function
Progressive, hepato-renal, anasarca, 
pre-coma or coma
G8.  Nausea, or 
nausea/vomiting (use 
diagnostic term)
Transient, intermittent, minimal 
interference with intake, rapid 
response to meds
Persistent, recurrent, requires 
prescription meds, intake 
maintained
Prolonged, interferes with daily 
function and nutritional intake, 
periodic iv fluids
Hypotensive, hospitalization, 
parenteral nutrition, unresponsive 
to out-patient management
G9.  Pancreatitis
Anylase elevation, intermittent 
nausea/vomiting, transient, 
responds rapidly to treatment
Amylase elevation with abdominal 
pain, nausea, occasional vomiting, 
responsive to treatment
Severe, persistent abdominal pain 
with pancreatitic enzyme elevation, 
incomplete or slow response to 
treatment
Complicated by shock, 
haemorrhage (acute circulatory 
failure)
G10.  Proctitis
Perianal pruritus, haemorrhoids 
(new onset), transient, or 
intermittent, relieved by OTC 
meds
Tenesmus or ulcerations, anal 
fissure, responsive to treatment, 
minimal interference with function
Unresponsive to treatment, marked 
interference with function
Mucosal necrosis with 
haemorrhage, infection, surgery 
required
H.  Musculoskeletal
H1.  Avascular 
necrosis
Asymptomatic MRI changes, non-
progressive
MRI changes and symptoms 
responsive to rest and analgesia
MRI changes, symptoms requiring 
surgical intervention
Wheelchair bound; surgical repair 
not possible
H2.  Arthralgia
Intermittent transient symptoms, 
no meds or relieved by OTC meds
Persistent or recurrent symptoms, 
resolve with meds, little effect on 
function
Severe symptoms despite meds 
impairs function
Debilitating, hospitalisation 
required for treatment
H3.  Leg cramps
Transient, intermittent, does not 
interfere with function
Recurrent symptoms, minimally 
interferes with function or sleep, 
responds to meds
Persistent, prolonged interference 
with function or sleep, partial or no 
response to meds
NA
H4.  Myalgia
Occasional; does not interfere 
with function
Frequent, requires meds (non-
narcotic); minor effects on 
function
Major change in function/lifestyle, 
narcotic pain meds
Debilitating, profound weakness, 
requires wheelchair, unresponsive 
to meds
 


Upadacitinib
M15-925 – Statistical Analysis Plan
Version 2.0 – 17 Dec 2020
72
I.  Neuropsychiatric
I1.  Anxiety or 
Depression (mood 
alteration)
Symptomatic, does not interfere 
with function; no meds
Frequent symptoms, responds to 
meds; interferes with ADL at times
Persistent, prolonged symptoms, 
partial or no response to meds, 
limits daily function
Suicidal ideation or danger to self
I2.  Cerebrovascular 
ischaemia
NA
Single transient ischaemic event, 
responsive to treatment
Recurrent transient ischaemic events
Cerebrovascular vascular accident 
with permanent disability
I3.  Cognitive 
disturbance
Subjective symptoms, transient, 
intermittent, not interfering with 
function
Objective symptoms, persisting, 
interferes with daily function 
occasionally
Persistent, or worsening objective 
symptoms; interferes with routine 
daily routine
Debilitating/disabling and 
permanent; toxic psychosis
I4.  Depressed 
consciousness 
(somnolence)
Observed, transient, intermittent, 
not interfering with function
Somnolence or sedation, 
interfering with function
Persistent, progressive, obundation, 
stupor
Coma
I5.  Inability to 
concentrate
Subjective symptoms, does not 
interfere with function
Objective findings, interferes with 
function
Persistent, prolonged objective 
findings or organic cause
NA
I6.  Insomnia (in 
absence of pain)
Occasional difficulty sleeping, 
transient intermittent, not 
interfering with function
Recurrent difficulty sleeping; 
requires meds for relief; occasional 
interference with function
Persistent or worsening difficulty 
sleeping; severely interferes with 
routine daily function
NA
I7.  Libido decreased
Decrease in interest
Loss of interest; influences 
relationship
Persistent, prolonged interfering 
with relationship
NA
I8.  Peripheral motor 
neuropathy
Subjective or transient loss of 
deep tendon reflexes; function 
maintained
Objective weakness, persistent, no 
significant impairment of daily 
function
Objective weakness with substantial 
impairment of function
Paralysis
I9.  Peripheral 
sensory neuropathy 
(sensory disturbance)
Subjective symptoms without 
objective findings, transient, not 
interfering with function
Objective sensory loss, persistent, 
not interfering with function
Prolonged sensory loss or 
paraethesias interfering with 
function
NA
I10.  Seizure
NA
Recurrence of old seizures, 
controlled with adjustment of 
medication
Recurrence/exacerbation with 
partial response to medication
Recurrence not controlled, 
requiring hospitalization; new 
seizures
 


Upadacitinib
M15-925 – Statistical Analysis Plan
Version 2.0 – 17 Dec 2020
73
I11.  Vertigo 
(dizziness)
Subjective symptoms, transient, 
intermittent, no treatment
Objective findings, recurrent, meds 
relieve, occasionally interfering 
with function
Persistent, prolonged, interfering 
with daily function; partial response 
to medication
Debilitating without response to 
medication, hospitalization
J.  Pulmonary
J1.  Asthma
Occasional wheeze, no 
interference with activities
Wheezing, requires oral meds, 
occasional interference with 
function
Debilitating, requires nasal O2
Requires ventilator assistance
J2.  Cough
Transient, intermittent, occasional 
OTC meds relieve
Persistent, requires narcotic or 
other prescription meds for relief
Recurrent, persistent coughing 
spasms without consistent relief by 
meds, interferes with function
Interferes with oxygenation; 
debilitating
J3.  Dyspnea
Subjective, transient, no 
interference with function
Symptomatic, intermittent or 
recurring, interferes with 
exertional activities
Symptomatic during daily routine 
activities, interferes with function, 
treatment with intermittent nasal O2
relieves
Symptomatic at rest, debilitating, 
requires constant nasal O2
J4.  Pleuritic pain 
(pleurisy)
Transient, intermittent symptoms, 
no treatment or OTC meds relieve
Persistent symptoms, requires 
prescription meds for relief
Prolonged symptoms, interferes 
with function, requires frequent 
narcotic pain relief
Debilitation, requiring 
hospitalisation
J5.  Pneumonitis 
(pulmonary 
infiltrates)
Asymptomatic radiographic 
changes, transient, no treatment 
required
Symptomatic, persistent, requiring 
corticosteroids
Symptomatic, requiring treatment 
including O2
Debilitating, not reversible; or 
requiring assisted ventilation
J6.  Pulmonary 
function decreased 
(FVC or carbon 
monoxide diffusion 
capacity – DLCO)
76% – 90% of pre-treatment value
51% – 75% of pre-treatment value
26% – 50% of pre-treatment value
≤ 25% of pre-treatment value
 


Upadacitinib
M15-925 – Statistical Analysis Plan
Version 2.0 – 17 Dec 2020
74
Laboratory Data
K.  Haematology
K1.  Hgb (g/dl) 
decrease from pre-
treatment
1.0 – 1.4
1.5 – 2.0
2.1 – 2.9, or Hgb < 8.0, > 7.0
≥ 3.0; or Hgb < 7.0
K2.  Leukopenia 
(total WBC) × 1000
3.0 – 3.9
2.0 – 2.9
1.0 – 1.9
< 1.0
K3.  Neutropenia 
(× 1000)
1.5 – 1.9
1.0 – 1.4
0.5 – 0.9
< 0.5
K4.  Lymphopenia 
(× 1000)
1.5 – 1.9
1.0 – 1.4
0.5 – 0.9
< 0.5
K5.  Platelets 
(× 1000)
75 – LLN
50 – 74.9
20 – 49.9; platelet transfusion 
required
< 20; recurrent platelet transfusions
L.  Chemistry
L1.  Hypercalcaemia 
(mg/dl)
1.1 × ULN – 11.5
11.6 – 12.5
12.6 – 13.5; or symptoms present
> 13.5; or associated coma
L2.  Hyperglycemia 
(mg/dl) Fasting
140 – 160
161 – 250
251 – 500
> 500, or associated with 
ketoacidosis
L3.  Hyperkalaemia 
(mmol/l)***
5.5 – 5.9
6.0 – 6.4
6.5 – 7.0 or any ECG change
> 7.0 or any arrhythmia
L5.  Hypocalcaemia
(mg/dl)
0.9 × LLN – 7.8
7.7 – 7.0
6.9 – 6.5; or associated with 
symptoms
< 6.5 or occurrence of tetany
L6.  Hypoglycemia 
(mg/dl)
55 – 64 (no symptoms)
40 – 54 (or symptoms present)
30 – 39 (symptoms impair function)
< 30 or coma
L7.  Hyponatraemia
(mmol/l)***
-
125 – 129
120 – 124
< 120
 


Upadacitinib
M15-925 – Statistical Analysis Plan
Version 2.0 – 17 Dec 2020
75
L8.  Hypokalaemia 
(mg/dl)***
-
3.0 – 3.4
2.5 – 2.9
< 2.5
L9.  CPK (also if 
polymyositis-disease)
1.2 – 1.9 × ULN
2.0 – 4.0 × ULN
4.0 × ULN with weakness but 
without life-threatening signs or 
symptoms
> 4.0 × ULN with signs or 
symptoms of rhabdomyolysis or 
life-threatening
L10.  Serum uric acid
1.2 – 1.6 × ULN
1.7 – 2.9 × ULN
3.0 – 5.0 × ULN or gout
NA
L11.  Creatinine 
(mg/dl)
1.1 – 1.3 × ULN
1.4* – 1.8 × ULN
1.9 – 3.0 × ULN
> 3.0 × ULN
L12.  SGOT (AST)
1.2 – 1.5 × ULN
1.6 – 3.0 × ULN
3.1 – 8.0 × ULN
> 8.0 × ULN
L13.  SGPT (ALT)
1.2 – 1.5 × ULN
1.6 – 3.0 × ULN
3.0 – 8.0 × ULN
> 8.0 × ULN
L14.  Alkaline 
phosphatase
1.1 – 1.5** × ULN
1.6 – 3.0 × ULN
3.0 – 5.0 × ULN
> 5.0 × ULN
L15.  T. bilirubin
1.1 – 1.4 × ULN
1.5 – 1.9 × ULN
2.0 – 3.0 × ULN
> 3.0 × ULN
L16.  LDH
1.3 – 2.4 × ULN
2.5 – 5.0 × ULN
5.1 – 10 × ULN
> 10 × ULN
M.  Urinalysis
M1.  Haematuria
Micro only
Gross, no clots
Clots, transfusion < 2 units 
Transfusion required
M2.  Proteinuria (per 
24 h)
300 – 500 mg (tr/1+)
501 – 1999 mg (2+)
2 – 5.0 g (3+) nephrotic syndrome
5.0 g (4+) anasarca
M3.  WBC in urine
NA
NA
Indicating acute interstitial nephritis
Associated with acute renal failure
M4.  Uric acid 
crystals
Present without symptoms
NA
With stones or symptoms of stones 
(e.g., renal colic)
Causing renal outflow obstruction 
and hospitalization
*
In L11, 1.5 – 1.8 × ULN is changed to 1.4 – 1.8 × ULN.
**
In L14, 1.1 – 2.0 × ULN is changed to 1.1 – 1.5 × ULN.
***
In L3, L7 and L8, mg/dl is changed to mmol/l.
****
For CPK and Creatinine NCI CTC grading will be used.  For CPK therefore the following gradings apply:  Grade 1:  > ULN – 2.5 × ULN; Grade 2:  > 2.5 – 5.0 × ULN; 
Grade 3:  > 5.0 – 10.0 × ULN; Grade 4:  > 10.0 × ULN; For Creatinine the following gradings apply:  Grade 1:  > 1 – 1.5 × Baseline; > ULN – 1.5 × ULN; Grade 2:  > 1.5 
– 3.0 × Baseline; > 1.5 – 3.0 × ULN; Grade 3:  > 3.0 baseline; > 3.0 – 6.0 × ULN; Grade 4:  > 6.0 × ULN.